Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

ABSTRACT

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4  and R 7  are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the National Stage of International Application No.PCT/US03/16888, filed May 28, 2003, which claims the benefit of U.S.Provisional Application No. 60/383,130, filed May 28, 2002, thedisclosure of which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is in the field of medicinal chemistry. Inparticular, the invention is directed to novel heterocyclic amidines andtheir use for inhibiting the enzyme C1s, a protease in the classicalpathway of the complement system; and the use of this inhibition totreat or ameliorate acute or chronic disorders in mammals.

2. Related Art

The immune system of the human body is equipped with several defensemechanisms to respond to bacterial, viral, or parasitic infection andinjury. One such defense mechanism involves the complement system.Complement consists of a complex series of approximately 30 plasma andmembrane protein components, many of which are proteinases. Onceactivated, this system of enzymes non-specifically complements theimmunologically specific effects of antibody by modulating the immuneresponse, lysing target cells, stimulating vascular and other smoothmuscle cells, facilitating the transport of immune complexes, producinganaphylatoxins which cause degranulation of mast cells and release ofhistamine, stimulating chemotaxis (migration) of leukocytes toward thearea of complement activity, activating B lymphocytes and macrophages,and inducing phagocytosis and lysis of cells (Eisen, H. N., Immunology,Harper & Row Publishers, Inc., Hagerstown, Md., p. 512 (1974); Roitt, I.et al., Immunology, Gower Medical Publishing, London, N.Y., pp. 7.1–7.14(1985); U.S. Pat. Nos. 5,472,939 and 5,268,363).

The complement system functions as a “cascade.” The enzyme cascades areinitiated when inactive enzyme precursor molecules are activated,through limited proteolysis, by membrane-bound enzymes. A small fragmentis lost from the enzyme precursor and a nascent membrane binding site isrevealed. The major fragment then binds to the membrane as the nextfunctionally active enzyme of the complement cascade. Since each enzymeis able to activate many enzyme precursors, the system forms anamplifying cascade, resembling the reactions seen in blood clotting andfibrinolysis (Roitt, I. et al., Immunology, Gower Medical Publishing,London, N.Y., pp. 7.1–7.14 (1985)).

The proteins of the complement system form two inter-related enzymecascades, termed the classical and alternative pathways. The classicalpathway is usually initiated by antigen-antibody complexes, while thealternative pathway is activated by specific polysaccharides, oftenfound on bacterial, viral, and parasitic cell surfaces. The classicalpathway consists of components C1–C9, while the alternative pathwayconsists of components C3–C9 (excluding C4) and several factors, such asFactor B, Factor D, and Factor H.

The sequence of events comprising the classical complement pathwayconsists of three stages: recognition, enzymatic activation, andmembrane attack leading to cell death. The first phase of complementactivation begins with C1. C1 is made up of three distinct proteins: arecognition subunit, C1q, and the serine proteinase subcomponents, C1rand C1s, which are bound together in a calcium-dependent tetramericcomplex, C1r₂s₂. An intact C1 complex is necessary for physiologicalactivation of C1 to result. Activation occurs when the intact C1 complexbinds to immunoglobulin complexed with antigen. This binding activatesC1s which then cleaves both the C4 and C2 proteins to generate C4a andC4b, as well as C2a and C2b. The C4b and C2a fragments combine to formthe C3 convertase, which in turn cleaves C3 to form C3a and C3b(Makrides, Pharmacol. Rev. 50:59–87 (1998); and U.S. Pat. No.5,268,363). Both the classical and alternative pathways are capable ofindividually inducing the production of the C3 convertase to convert C3to C3b, the generation of which is the central event of the complementpathway. C3b binds to C3b receptors present on neutrophils, eosinophils,monocytes and macrophages, thereby activating the terminal lyticcomplement sequence, C5–C9 (Roitt, I. et al., Immunology, Gower MedicalPublishing, London, N.Y., pp. 7.1–7.14 (1985)).

Complement is designed to fight infection and injury; however, this samemechanism, if inappropriately activated, can cause a significant amountof inflammation and tissue damage as a result of the rapid andaggressive enzyme activity. Complement-induced inflammation and tissuedamage has been implicated in a number of disease states, including: theintestinal inflammation of Crohn's disease which is characterized by thelymphoid infiltration of mononuclear and polymorphonuclear leukocytes(Ahrenstedt et al., New Engl. J. Med. 322:1345–9 (1990)), thermal injury(burns, frostbite) (Gelfand et al., J. Clin. Invest. 70:1170 (1982);Demling et al., Surgery 106:52–9(1989)), hemodialysis (Deppisch et al.,Kidney Inst. 37:696–706 (1990); Kojima et al., Nippon Jenzo Gakkai Shi31:91–7 (1989)), post pump syndrome in cardiopulmonary bypass (Chenowethet al., Complement. Inflamm. 3:152–165 (1981); Chenoweth et al.,Complement 3:152–165 (1986); Salama et al., N. Engl. J. Med. 318:408–14(1988)), and ischaemia (Huang et al., Science 285:595 (1999); Naka etal., Transplantation 64:1248 (1997); Pemberton et al., J. Immunol.150:5104 (1993); Chavez-Cartaya et al., Transplantation 59:1047 (1995);Hill et al., J. Immunol. 149:1723 (1992); Weisman et al., Science249:146 (1990)). Both complement and leukocytes are reported to beimplicated in the pathogenesis of adult respiratory distress syndrome(Zilow et al., Clin. Exp. Immunol. 79:151–57 (1990); Langlois et al.,Heart Lung 18:71–84 (1989)). Activation of the complement system issuggested to be involved in the development of fatal complications insepsis (Hack et al., Am. J. Med. 86:20–26 (1989)) and causes tissueinjury in animal models of autoimmune diseases such asimmune-complex-induced vasculitis (Cochrane, Springer SeminarImmunopathol. 7:263 (1984)), glomerulonephritis (Couser et al., KidneyInst. 29:879 (1985)), type II collagen-induced arthritis (Watson &Townes, J. Exp. Med. 162:1878 (1985)), and experimental allergicneuritis (Feasby et al., Brain Res. 419:97 (1987)). The complementsystem is also involved in hyperacute allograft and hyperacute xenograftrejection (Knechtle et al., J. Heart Transplant 4(5):541 (1985);Guttman, Transplantation 17:383 (1974); Adachi et al., Trans. Proc.19(1):1145 (1987)). Complement activation during immunotherapy withrecombinant IL-2 appears to cause the severe toxicity and side effectsobserved from IL-2 treatment (Thijs et al., J. Immunol. 144:2419(1990)).

Complement fragments generated by the classical portion of thecomplement cascade have been found to be present in the immune complexesformed against indigenous tissue in autoimmune diseases. Such diseasesinclude, but are not limited to: Hashimoto's thyroiditis,glomerulonephritis and cutaneous lesions of systemic lupuserythematosus, other glomerulonephritides, bullous pemphigoid,dermatitis herpetiformis, Goodpasture's syndrome, Graves' disease,myasthenia gravis, insulin resistance, autoimmune hemolyic anemia,autoimmune thrombocytopenic purpura, and rheumatoid arthritis (Bieseckeret al., J. Exp. Med. 154: 1779 (1981); Biesecker et al., N. Engl. J.Med. 306: 264 (1982); Falk et al., Clin. Research 32:503A (Abstract)(1984); Falk et al., J. Clin. Invest. 72:560 (1983); Dahl et al., J.Invest. Dermatol. 82:132 (1984); Dahl et al., Arch. Dermatol. 121:70(1985); Sanders et al., Clin. Research 33:388A (Abstract) (1985); andU.S. Pat. Nos. 5,268,363 and 4,722,890).

Compounds that potently and selectively inhibit complement will havetherapeutic applications in several acute and chronic immunological andnon-immunological disorders, and a variety of neurodegenerativediseases. Evidence from both human and animal studies shows thatactivation of the classical complement pathway is primarily involved inneurodegenerative diseases of the central nervous system (CNS).Autoimmune diseases in which these inhibitors of the complement cascadesystem will be therapeutically useful include myasthenia gravis (MG),rheumatoid arthritis, and systemic lupus erythematosus.Neurodegenerative diseases in which inhibitors of the complement cascadesystem will be therapeutically useful include the demyelinating disordermultiple sclerosis (MS), the neuropathies Guillain-Barré syndrome (GBS)and Miller-Fisher syndrome (MFS), Alzheimer's disease (AD), andprion-related disease (variant Creutzfeld Jacob disease). Other diseasesand conditions include hereditary and acquired angioedema (in which adeficiency in complement inhibitory protein leads to an activecomplement consumption and repeated episodes of life-threateningangiodema), septic shock, paroxysmal nocturnal hemoglobinuria, organrejection (transplantation), burns (wound healing), brain trauma, softtissue trauma, asthma, platelet storage, hemodialysis,ischemia-reperfusion injury, and cardiopulnonary bypass equipment(Nakrides, Pharmacol. Rev. 50:59–87 (1998); Spiegel et al., Strategiesfor Inhibition of Complement Activation in the Treatment ofNeurodegenerative Diseases in: Neuroinflammation: Mechanisms andManagement, Wood (ed.), Humana Press, Inc., Totowa, N.J., Chapter 5, pp.129–176; and U.S. Pat. No. 4,916,219).

A number of strategies have been proposed for the inhibition ofprimarily the classical complement pathway. Efforts to directly inhibitcomplement activation have focused on chemical compounds that inhibitcomplement components such as C1r and C1s. Small peptide inhibitors ofconvertases, such as the C3 and C5 convertases, have also been described(Liszewski and Atkinson, Exp. Opin. Invest. Drugs 7: 323–332 (1998). Sofar, the best studied ‘designer’ complement inhibitor for treatment ofCNS disorders is soluble recombinant human complement receptor Type 1(sCR1). sCR1 has proven effective in animal models of CNS diseases andis under investigation for use in man (Fearon, Clin. Exp. Immunol. 86(Suppl.1):43–46 (1991)). However, there are several drawbacks to the useof sCR1 in disorders of the CNS: the agent is expensive, must beadministered systemically, and has a short half-life in vivo. The nextgeneration of complement inhibitors are likely to solve many of thesedrawbacks (Spiegel et al., Strategies for Inhibition of ComplementActivation in the Treatment of Neurodegenerative Diseases in:Neuroinflammation: Mechanisms and Management, Wood (ed.), Humana Press,Inc., Totowa, N.J., Chapter 5, pp. 129–176).

A need continues to exist for non-peptidic compounds that are potentinhibitors of complement, specifically C1s, and which possess greaterbioavailability and fewer side-effects than currently available C1sinhibitors. Accordingly, novel C1s inhibitors, characterized by potentinhibitory capacity, are potentially valuable therapeutic agents for avariety of conditions.

SUMMARY OF THE INVENTION

The present invention provides a novel class of thienyl amidines. Thethienyl amides of Formula I inhibit the enzyme C1s, a protease in theclassical pathway of the complement system, and thus, can be used totreat or ameliorate complement-mediated acute or chronic disorders inmammals.

Thus, a first aspect of the present invention is directed to novelcompounds of Formula I.

In a second embodiment, the present invention provides a pharmaceuticalcomposition comprising a compound of Formula I and a pharmaceuticallyacceptable carrier or diluent.

The present invention further provides a method for treating acute andchronic disorders associated with activation of the classical pathway ofthe complement system by administering to a mammal in need of suchtreatment a therapeutically effective amount of a compound of Formula I.These acute and chronic conditions are caused either in whole or in partby inflammation and tissue damage that result from aberrant activationof the complement cascade.

In one embodiment, compounds of Formula I can be administered to amammal to treat complement-mediated inflammation and tissue damage.Examples of conditions that can be treated include intestinalinflammation of Crohn's disease, thermal injury (burns, frostbite), postpump syndrome in cardiopulmonary bypass, and ischaemia (stroke,myocardial infarction, ischaemic colitis, hemorrhagic shock, trauma,post-surgical tissue damage and delayed or impaired function of organ orgraft following transplant).

The complement system is activated in hyperacute allograft andhyperacute xenograft rejection, and in acute humoral rejection mediatedby donor-specific antibodies. Thus, in yet another embodiment, compoundsof Formula I can be administered to a mammal before, during or after thetransplant of an organ or a graft to ameliorate the rejection of suchorgan or graft by the mammal. Grafts can include an allograft orxenograft.

Complement activation during immunotherapy with recombinant IL-2 appearsto cause acute vascular leak syndrome that results in the severetoxicity and side effects observed from IL-2 treatment and otherconditions such as bone marrow transplantation and acute pancreatitis.In another embodiment of the present invention, a compound of Formula Iis administered to a mammal before, during or after treatment of saidmammal with IL-2, bone marrow transplantation, or onset of pancreatitis,in an amount effective to reduce the vascular leak syndrome that causestoxicity and side-effects associated with the treatment or disorders.

In another embodiment, compounds of Formula I can be administered to amammal to treat complement-mediated tissue injury associated withautoimmune diseases. Examples of autoimmune diseases that are treatableaccording to the present invention include Hashimoto's thyroiditis,Addison's disease, glomerulonephritis and cutaneous lesions of systemiclupus erythematosus, other glomerulonephritides, bullous pemphigoid,pemphigus, Goodpasture's syndrome, Graves' disease,immune-complex-induced vasculitis, hemolytic anemia, myasthenia gravis,allergic neuritis, myasthenia gravis, Type I diabetes mellitus,autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, typeII collagen-induced arthritis, and rheumatoid arthritis. Autoimmunediseases preferred for treatment by inhibitors of the present inventioninclude myasthenia gravis (MG), rheumatoid arthritis, and systemic lupuserythematosus.

Another embodiment of the present invention is directed to administeringa therapeutically effective amount of a compound of Formula I to amammal that has been diagnosed with a neurodegenerative disease.Neurodegenerative diseases in which inhibitors of the complement cascadesystem will be therapeutically useful include the demyelinating disordermultiple sclerosis (MS), the neuropathies Guillain-Barré syndrome (GBS)and Miller-Fisher syndrome (MFS), Alzheimer's disease (AD), and variantCreutzfeldt-Jakob disease.

In another embodiment, compounds of the present invention can beadministered to a mammal to treat complement-mediated complications insepsis, or symptoms of adult respiratory distress syndrome.

Other diseases and conditions that can be treated include hereditary andacquired angioedema, paroxysmal nocturnal hemoglobinuria, brain traumaand other soft tissue trauma, asthma and hemodialysis.

Compounds of Formula I can also be employed in vitro for human organ andgraft storage as well as platelet storage.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Compounds useful in the present invention have the general Formula I:

or a solvate, hydrate or pharmaceutically acceptable salt thereof;wherein:

Z is —S(O)— or —S(O₂)—;

R¹ is C₁₋₄ alkyl, halo, amino, C₁₋₆ alkylthio, C₂₋₆ alkenylthio, C₁₋₆alkoxy, trifluoromethyl, methylsulfonyl, or benzylthio; preferably halo,C₁₋₄ alkylthio or C₂₋₄ alkenylthio;

Ar is phenyl, naphthyl, pyridyl, imidazolyl, thiazolyl, furanyl,thienyl, benzothiazolyl, pyrazolyl, pyrimidinyl, benzimidazolyl,benzofuranyl, indolyl, benzothiophenyl or benzo[c]chromenyl, any ofwhich is optionally substituted;

R², R³ and R⁴ are independently hydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl, C₁₋₄hydroxyalkyl, C₁₋₄ aminoalkyl, mono(C₁₋₄)alkylamino(C₂₋₆)alkyl,di(C₁₋₄)alkylamino(C₂₋₆)alkyl, carboxy(C₁₋₄)alkyl, cyano, amino, nitro,C₁₋₄ alkoxy, or hydroxy, or —CO₂R^(w), where

-   -   R^(w) is hydrogen, hydroxy, C₁₋₄ alkoxy, cyano, C₁₋₄        alkoxycarbonyl, C₁₋₄ alkyl, C₃₋₈ cycloalkyl, phenyl, benzyl,

-   -   -   where R^(d) and R^(e) are independently hydrogen, C₁₋₆            alkyl, C₂₋₆ alkenyl or phenyl,        -   R^(f) is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl or phenyl,        -   R^(g) is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl or phenyl, and        -   R^(h) is C₆₋₁₀ ar(C₁₋₄)alkyl or C₁₋₆ alkyl; and

R⁷ is hydrogen, chloro, fluoro or amino.

A first preferred group of compounds falling within the scope of thepresent invention include compounds of Formula I wherein Ar is naphthylor phenyl substituted by one or two of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₄alkenyl, halo, hydroxy, phenyl, phenoxy, amino or phenylamino. Usefulvalues of Ar in this aspect of the invention include 2-phenylphenyl,naphth-2-yl, 2-methoxyphenyl, 4-methoxyphenyl, 4-chlorophenyl,2-bromophenyl, 3,4-dimethylphenyl, 3-methoxyphenyl, 3-bromophenyl,4-ethylphenyl, 4-bromophenyl, 4-phenylphenyl, 3,4-dimethoxyphenyl,2-isopropylphenyl, 3,5-dichlorophenyl, 3-hydroxyphenyl,2-methyl-5-t-butylphenyl, 4-t-butylphenyl, 3-bromo-5-t-butoxyphenyl,3-bromo-5-hydroxyphenyl, 3-bromo-5-methoxyphenyl,3-bromo-5-vinyloxyphenyl, 3-phenoxyphenyl, 5-bromo-3-methylphenyl and2-aminophenyl.

Another group of compounds falling within the scope of the presentinvention include compounds of Formula I wherein Ar is phenylsubstituted by one or two of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl,halo, hydroxy, phenyl, phenoxy, amino, phenylamino,hydroxytetrahydropyranyl, (C₁₋₄ alkoxy)-tetrahydropyranyl,hydroxypiperidinyl, hydroxy-N-(C₁₋₄ alkyl)-piperidinyl,hydroxy-pyridinyl-(C₁₋₄)alkyl or (C₁₋₄ alkoxy)carbonyl(C₂₋₆)alkenyl.Additional useful values of Ar in this aspect of the invention include4-amino-3-bromophenyl, 3-(4-hydroxytetrahydropyran-4-yl)-phenyl,3-(4-hydroxy-1-methylpiperidin-4-yl)-phenyl,3-(4-methoxytetrahydropyran-4-yl)-phenyl,3-(hydroxy-pyridin-2-yl-methyl)-phenyl,3-(1-ethoxycarbonyl-propen-2-yl)-phenyl, 3-chlorofluorophenyl and3-iodophenyl.

Another group of compounds falling within the scope of the presentinvention include compounds of Formula I wherein Ar is pyridyl,imidazolyl, furanyl, thienyl, thiazolyl, benzothiazolyl, benzofuranyl,benzothiophenyl, indolyl, benzimidazolyl or benzo[c]chromenyl, any ofwhich is optionally substituted by one or two of C₁₋₆ alkyl, C₁₋₆alkoxy, C₂₋₆ alkenyl, halo, hydroxy, amino, phenyl, phenoxy or tolyl.Useful values of Ar in this aspect of the invention include pyrid-2-yl,pyrid-3-yl, imidazol-2-yl, 1-methylimidazol-2-yl, 2-methylfuran-2-yl,thien-2-yl, thiazol-2-yl, 4-phenylthiazol-2-yl,5-ethoxybenzothiazol-2-yl, benzimidazol-2-yl,7-bromo-1-methyl-1H-benzoimidazolyl,4-bromo-1-methyl-1H-benzoimidazolyl,4-bromo-2-methyl-1H-benzoimidazolyl, 4-bromo-1H-benzoimidazolyl,6-bromo-benzimidazolyl, pyrrol-2-yl, and piperdin-2-yl. An additionaluseful value of Ar in this aspect of the invention is6H-benzo[c]chromen-2-yl.

Useful values of Ar in this aspect of the invention also include thoseof Formula IA:

wherein:

R^(x) is halo, or phenyl substituted by one or two of C₁₋₆ alkyl or(C₁₋₄ alkyl)oxy(C₁₋₄)alkyl wherein one of the C₁₋₄ alkyl portions isoptionally substituted by carboxy;

R^(y) is hydrogen, amino, halo, phenoxy or C₁₋₆ alkylamino wherein thealkyl portion is optionally substituted by one of phenyl, pyridyl,tetrahydrofuranyl, imidazolyl, morpholinyl, (C₁₋₄ haloalkyl)-pyridyl,sulfonamidophenyl, hydroxy, (C₁₋₄ alkyl)-thienyl or aminopyrimidinyl;and

R^(z) is hydrogen, halo or C₁₋₄ alkyl.

Useful values of R^(x) include 2-methylphenyl,2-carboxymethoxymethyl-6-methylphenyl and bromo.

Useful values of R^(y) include hydrogen, chloro, amino, phenoxy,benzylamino, isopropylamino, pyrid-3-ylmethylamino,pyrid-4-ylmethylamino, pyrid-2-ylmethylamino,tetrahydrofuran-2-ylmethylamino, 3-(imidazol-1-yl)-propylamino,2-methyl-2-(morpholinyl)-propylamino,6-trifluoromethyl-pyrid-3-ylmethylamino,2-(3H-imidazol-1-yl)-ethylamino, 4-sulfamoylbenzylamino,2,2-dimethyl-3-hydroxypropylamino, 3-methylthien-2-ylmethylamino and4-aminopyrimidin-5-ylmethylamino.

Useful values of R^(z) include hydrogen, methyl or ethyl.

Preferred values of R^(x) include bromo. Preferred values of R^(y)include optionally-substituted C₁₋₆ alkylamino. Preferred values ofR^(z) include hydrogen.

Useful values of Ar in this aspect of the invention also include thoseof Formula IB:

wherein:

R¹³ and R¹⁴ are independently hydrogen, halo or C₁₋₄ alkyl;

R¹⁵ is hydrogen, halo or tolyl;

R¹⁷ is hydrogen or C₁₋₄ alkyl; and

one of R¹⁶ and R¹⁸ is an electron pair and the other is hydrogen, C₁₋₆alkyl, C₂₋₆ alkenyl, cyclopropylmethyl, phenyl, benzyl, 1-phenylethyl,pyridylmethyl or isoxazolylmethyl optionally substituted with one or twomethyl groups, wherein said benzyl is unsubstituted or is substitutedwith one or two of halo, nitro, amino or(2-carboxyethyl)-sulfanylacetylamino.

Useful values of R¹³ and R¹⁴ include hydrogen, methyl and ethyl.

Useful values of R¹⁵ include hydrogen, bromo, chloro and o-tolyl.

Useful values of R¹⁷ include hydrogen, methyl and ethyl.

Useful values of R¹⁶ and R¹⁸, other than an electron pair, includehydrogen, methyl, cyclopropylmethyl, allyl, 3-methylbut-2-enyl,pyrid-2-ylmethyl, 3,5-dimethylisoxazol-4-ylmethyl, phenyl,1-phenylethyl, benzyl, 2,6-dichlorobenzyl, 2,5-difuorobenzyl,2,6-difluorobenzyl, 2-fluoro-5-nitrobenzyl, 2-fluoro-4-nitrobenzyl,2-fluoro-5-aminobenzyl and5-[(2-carboxyethyl)-sulfanylacetylamino]-2-fluorobenzyl.

Preferred R¹³ include hydrogen. Preferred R¹⁴ include hydrogen.Preferred R¹⁵ include bromo and chloro. More preferred is bromo.Preferred R¹⁷ include hydrogen. Preferred R¹⁶ and R¹⁸, other than anelectron pair, include hydrogen, phenyl, 1-phenylethyl, benzyl andbenzyl substituted with one or two, preferably two, of halo, amino ornitro. More preferred are benzyl and benzyl substituted with two offluoro, chloro, amino or nitro.

In yet another aspect of the invention, Ar is a substituted phenyl grouphaving a required substituent in the 3-position of the phenyl ring andan optional substituent on one of the remaining positions of the phenylring. Thus, this aspect of the invention is directed to compounds of theoverall Formula II:

or a solvate, hydrate or pharmaceutically acceptable salt thereof;wherein:

R¹, R², R³, R⁴, R⁷ and Z are defined as above, and

R⁵ is phenyl, naphthyl, thienyl, furanyl, imidazolyl, oxazolyl,isoxazolyl, pyridyl, pyrimidinyl, benzothienyl, benzofuranyl,benzimidazolyl, quinolinyl, isoquinolinyl, pyrazinyl, piperidinyl orpiperazinyl, any of which is optionally substituted; and

R⁶ is hydrogen, C₁₋₄ alkyl, hydroxy, C₁₋₄ alkoxy, C₂₋₄ alkenyloxy,phenoxy, benzyloxy, halo, amino or nitro.

In one embodiment R⁵ is naphthyl, phenyl or phenyl substituted by one tofive, preferably one or two groups independently selected from the groupconsisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄haloalkyl, C₂₋₄ alkenyl, (C₁₋₄ alkyl)carbonyl, cyano, amino,mono(C₁₋₄)alkylamino, di(C₁₋₄)alkylamino, formyl, (C₁₋₄ alkoxy)carbonyl,halo(C₁₋₄ alkoxy)carbonyl, phenyl, phenoxy, phenoxyphenyl, biphenyl,halo, C₁₋₄ haloalkoxy, carboxy, nitro, methylenedioxo (—O—CH₂—O—),ethylenedioxo, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylthio,hydroxy, aminocarbonyl, mono(C₁₋₄ alkyl)aminocarbonyl, di(C₁₋₄alkyl)aminocarbonyl and halogenated C₁₋₄ hydroxyalkyl.

Useful values of R⁵ in this embodiment include phenyl, 2-methoxyphenyl,2-methylphenyl, 2-vinylphenyl, 2-hydroxymethylphenyl,2-(1-hydroxyethyl)phenyl, 2-trifluoromethylphenyl, 2-formylphenyl,2-hydroxyphenyl, 2-chloromethylphenyl, 2-amino, 2-chlorophenyl,3-methoxyphenyl, 3-methylphenyl, 3-formylphenyl, 3-hydroxymethylphenyl,3-aminophenyl, 3-isopropylphenyl, 3-ethoxyphenyl,3-ethoxycarbonylphenyl, 3-methylcarbonylphenyl, 3-carboxyphenyl,3-hydroxyphenyl, 3-nitrophenyl, 3-dimethylaminocarbonylphenyl,3-trifluoromethylphenyl, 3-trifluoromethoxycarbonylphenyl,4-vinylphenyl, 4-trifluoromethoxyphenyl, 4-methoxycarbonylphenyl,4-methylphenyl, 4-hydroxymethylphenyl, 4-trifluoromethylphenyl,4-cyanophenyl, 4-ethoxyphenyl, 4-dimethylaminophenyl, biphenyl,4-phenoxyphenyl, 4-chloromethyl, 4-methylsulfonyl)phenyl,4-hydroxyphenyl, 4-fluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl,2,3-dimethylphenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl,3-hydroxy-4-phenylphenyl, 3,5-bistrifluoromethylphenyl,2-hydroxy-5-phenylphenyl, 4-methyl-3-nitrophenyl,3,4-methylenedioxophenyl, 3,5-dimethylphenyl, 2,4-dimethoxyphenyl,2-ethoxy-6-methylphenyl, 3-isopropoxycarbonyl-2-methylphenyl,3-fluoro-4-phenylphenyl, 4-formylphenyl, 2-carboxy-6-methylphenyl,3-formyl-2-methylphenyl, 3-hydroxy-6-methylphenyl,3-formyl-6-methylphenyl, 3-formyl-6-hydroxyphenyl,3-formyl-6-methoxyphenyl, 2-amino-6-methylphenyl, 3,4-dimethoxyphenyl,3-[(2,2,2-trifluoro-1-hydroxy)ethyl]phenyl, 4-nitrophenyl,2-fluoro-4-phenylphenyl, 2,4-dimethoxyphenyl, 4-hydroxy-3-formylphenyl,2-tolyl-5-morpholinephenyl, 4-methoxyphenyl, 3-hydroxyaminomethylphenyl, 4-phenyl-acetamide, 4-benzamide, 2,6-dimethylphenyl,phenoxyphenyl, 2-methyl-6-hydroxymethyl phenyl, 2-methyl-5-hydroxymethylphenyl, 2-hydroxy-3-phenylphenyl, naphthyl and 4-ethoxycarbonylphenyl.An additional useful value of R⁵ is 6-methyl-3,4-methylenedioxophenyl.

In another embodiment R⁵ is phenyl substituted by one to three groupsindependently selected from the group consisting of C₁₋₄ alkyl, C₁₋₄alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, (C₁₋₄alkyl)carbonyl, cyano, amino, mono(C₁₋₄)alkylamino, di(C₁₋₄)alkylamino,formyl, (C₁₋₄ alkoxy)carbonyl, halo(C₁₋₄ alkoxy)carbonyl, phenyl,phenoxy, phenoxyphenyl, biphenyl, halo, C₁₋₄ haloalkoxy, carboxy, nitro,methylenedioxo (—O—CH₂—O—), ethylenedioxo, C₁₋₄ alkylsulfonyl, C₁₋₄alkylsulfinyl, C₁₋₄ alkylthio, hydroxy, aminocarbonyl,mono(C₁₋₄alkyl)aminocarbonyl, di(C₁₋₄alkyl)aminocarbonyl, halogenatedC₁₋₄ hydroxyalkyl, carboxy(C₁₋₄)alkoxy(C₁₋₄)alkyl, carboxy(C₁₋₄)alkoxy,C₁₋₄ alkylthio(C₁₋₄)alkyl wherein the alkyl portion of C₁₋₄ alkylthio isoptionally substituted with one or two carboxy groups,phosphono(C₂₋₄)alkenyl, phosphono(C₁₋₄)alkylamino, C₁₋₄haloalkylsulfonylamino, phosphono(C₁₋₄)alkoxy, C₁₋₄ alkylsulfonylamino,carboxy(C₁₋₄)alkylamino, morpholinyl(C₁₋₄)alkyl, morpholinyl,morpholinyl(C₁₋₄)alkylaminocarbonyl, piperazinyl(C₁₋₄)alkyl orpiperazinyl wherein either of said piperazinyl(C₁₋₄)alkyl or piperazinylis optionally N-substituted with methyl or ethyl, formylamino,morpholinyl(C₁₋₄)alkylamino, optionally-substituted alkylcarbonylamino,optionally-substituted ureido and optionally-substituted guanidino.

Useful optionally-substituted alkylcarbonylamino groups have the formula—N(H)—C(O)—C(H)(W¹)—Y^(1a)—X¹—Y^(1b)-Z¹, wherein:

W¹ is hydrogen or amino;

Y^(1a) is a direct covalent bond or an α,β-diradical of a C₁₋₁₀ straightor branched alkane;

X¹ is O or S, or a direct covalent bond;

Y^(1b) is an α,β-diradical of a C₁₋₁₀ straight or branched alkane,optionally substituted with a carboxy group or an amino group; and

Z¹ is carbamoyl, carboxy, C₁₋₆ alkylsulfonyl, (C₁₋₆ alkoxy)carbonyl,C₂₋₆ alkanoylamino, sulfo, phosphono, phenyl, aminosulfonyl, amino, C₁₋₆haloalkylsulfonylamino, formylamino, C₁₋₄ alkylamino, C₁₋₆alkylaminosulfonyl, C₁₋₆ alkylsulfonylamino or2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl-(C₁₋₆ alkyl)carbonylamino;

or, W¹ is hydrogen and Y^(1a)—X¹—Y^(1b)-Z¹ represents hydrogen, halo,amino or tri-(C₁₋₄ alkyl)ammonio;

provided that, if Y^(1a) is a direct covalent bond and X is O or S, thenW¹ is hydrogen.

Useful optionally-substituted ureido groups have the formula—N(L¹)-C(O)—N(L²)-Y^(2a)—X²—Y^(2b)-Z² wherein:

L¹ and L² are both hydrogen, or L¹ and L² together represent ethylene ortrimethylene;

Y^(2a) is a direct covalent bond or an α,β-diradical of a C₁₋₁₀ straightor branched alkane;

X² is O or S, or a direct covalent bond;

Y^(2b) is an α,β-diradical of a C₁₋₁₀ straight or branched alkane,optionally substituted with a carboxy group; and

Z² is carboxy, (C₁₋₆ alkoxy)carbonyl, phenoxy, carboxyphenoxy, C₁₋₆alkylsulfonyl, phenyl, benzyloxycarbonylamino, amino, C₁₋₄ alkylamino,halophenyl, indolyl, diphenylmethyl, phenylsulfonylamino,N′-(carboxy(C₁₋₄)alkyl)ureido, tetrazolyl, phosphono or phenylamino;

or, Y^(2a)—X²—Y^(2b)-Z² represents C₁₋₄ alkylsulfonyl or—(CH₂CH₂—O—)_(m)—(CH₂)_(n)—C(O)OR wherein m is an integer from 2 to 6, nis an integer from 2 to 4, and R is hydrogen or C₁₋₄ alkyl.

Useful optionally-substituted guanidino groups have the formula—N(L³)-C(═NL⁴)-N(L⁵)-Z³, wherein:

L³ is hydrogen or C₁₋₄ alkyl;

L⁴ and L⁵ are both hydrogen, or L⁴ and L⁵ together represent ethylene;and

Z³ is hydrogen, C₁₋₆ alkyl, phenyl(C₁₋₆)alkyl, carboxy(C₁₋₆)allyl, C₁₋₄alkoxy, (C₁₋₄ alkyl)carbonyl or C₁₋₄ alkylsulfonyl(C₁₋₆)alkyl.

One group of preferred compounds in this embodiment includes thosewherein R⁵ is phenyl substituted at the 2′-position by methyl and at the4′-position by optionally-substituted guanidino. A more preferred groupof compounds in this embodiment includes those wherein R⁵ is phenylsubstituted at the 2′-position by methyl, at the 4′-position byoptionally-substituted guanidino, and at the 6′-position byoptionally-substituted alkylcarbonylamino or optionally-substitutedureido. Another group of preferred compounds in this embodiment includesthose wherein R⁵ is phenyl substituted at the 2′-position by methyl andat the 6′-position by optionally-substituted alkylcarbonylamino oroptionally-substituted ureido. Within these preferred groups, R¹ ispreferably methylthio, R², R³, R⁴, R⁶ and R⁷ are preferably hydrogen,and Z is preferably —SO₂—.

Useful values of R⁵ in this embodiment also include those of FormulaIIA:

wherein:

R⁸ is hydrogen or methyl;

R⁹ is hydrogen, formylamino or carbamoyl;

R¹⁰ is methoxy, hydroxy, carboxymethoxy, phosphonomethylamino,trifluoromethanesulfonylamino, phosphonomethoxy, carboxymethylamino,amino, chloro, fluoro, 2-(morpholinyl)-ethylamino, carboxy, carbamoyl,(1,2-dicarboxyethyl)-sulfanylacetylamino, carboxymethoxyacetylamino,4-amino-4-carboxybutyrylamino,6-[5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-hexanoylamino,bromoacetylamino, 2-amino-4-carboxybutyrylamino,triethylammonioacetylamino, 2-amino-4-methanesulfonylbutyrylamino,aminoacetylamino, carbamoylmethylsulfanylacetylamino,3-phosphonopropionylamino, ureido, N′-(5-carboxypentyl)-ureido,N′-(5-ethoxycarbonylpentyl)-ureido, N′-(3-methanesulfonylpropyl)-ureido,guanidino, N′-(3-phenylpropyl)-guanidino, N′-(2-phenylethyl)-guanidino,N′-(3-methylbutyl)-guanidino, N′-acetylguanidino,N′-(4-methanesulfonylbutyl)-guanidino,N′-(3-methanesulfonylpropyl)-guanidino,N′-(6-methanesulfonylhexyl)-guanidino,N′-(5-methanesulfonylpentyl)-guanidino, N′-methoxyguanidino,N-methylguanidino, N′-hexylguanidino, N′-(5-carboxypentyl)-guanidino or4,5-dihydro-1H-imidazol-2-ylamino;

R¹¹ is hydrogen, 3-(morpholin-4-yl)-propylaminocarbonyl orcarboxymethoxymethyl; and

R¹² is carboxymethoxymethyl, 2-carboxyethoxymethyl, nitro, amino,methyl, (1,2-dicarboxyethyl)-sulfanylmethyl, 2-phosphonovinyl,morpholin-4-ylmethyl, 4-methylpiperazin-1-ylmethyl, morpholin-4-yl,formylamino, methanesulfonylamino, carboxymethylamino,3-(morpholin-4-yl)-propylaminocarbonyl, chloro, acetylamino,carbamoylmethylsulfanylacetylamino,(2-carboxyethyl)-sulfanylacetylamino, 4-methanesulfonylbutyrylamino,(1,2-dicarboxyethyl)-sulfanylacetylamino,methoxycarbonylmethoxyacetylamino, carboxymethoxyacetylamino,bromoacetylamino, 4-carboxybutyrylamino, carbamoylmethoxyacetylamino,(2-acetylamino-2-carboxy-1,1-dimethylethyl)-sulfanylacetylamino,(2-sulfoethyl)-sulfanylacetylamino,(2-methoxycarbonylethyl)-sulfanylacetylamino,(2-acetylamino-2-carboxyethyl)-sulfanylacetylamino,methanesulfonylacetylamino, 6-methanesulfonylhexanoylamino,3-methanesulfonylpropionylamino, 2-methanesulfonylpropionylamino,benzylsulfanylacetylamino, 4-aminosulfonylbutyrylamino,11-aminoundecanoylamino, 4-trifluoromethanesulfonylaminobutyrylamino,5-carboxyvalerylamino, carboxyacetylamino, 3-carboxypropionylamino,11-carboxyundecanoylamino, 5-methoxycarbonylvalerylamino,N′-ethoxycarbonylmethylureido, N′-carboxymethylureido,N′-[5-(4-carboxyphenoxy)-pentyl]-ureido,N′-(2-methanesulfonylethyl)-ureido, N′-(5-carboxypentyl)-ureido,N′-(2-[2-{2-(2-carboxyethoxy)-ethoxy}-ethoxy]-ethoxyethyl)-ureido,N′-methanesulfonylureido, N′-(4-methanesulfonylbutyl)-ureido,N′-(3-phenylpropyl)-ureido, N′-benzylureido,N′-(1-carboxy-2-phenylethyl)-ureido,N′-(5-benzyloxycarbonylamino-5-carboxypentyl)-ureido,N′-(2-phenylethyl)-ureido, N′-(5-amino-5-carboxypentyl)-ureido,N′-[2-(4-bromophenyl)-ethyl]-ureido, N′-[2-(indol-3-yl)-ethyl]-ureido,N′-(3,3-diphenylpropyl)-ureido, N′-(2-phenylsulfonylaminoethyl)-ureido,N′-(2-methanesulfonylaminoethyl)-ureido,N′-[2-(N′-carboxymethylureido)-ethyl]-ureido,N′-[2-(2H-tetrazol-5-yl)-ethyl]-ureido,N′-[4-(2H-tetrazol-5-yl)-butyl]-ureido,N′-[5-(2H-tetrazol-5-yl)-pentyl]-ureido, N′-(5-phosphonopentyl)-ureido,N′-(5-ethoxycarbonylpentyl)-ureido, N′-(3-methanesulfonylpropyl)-ureido,N′-(2-phenylaminoethyl)-ureido or 2-oxo-imidazolidin-1-yl.

One preferred group of compounds in this embodiment includes thosewherein R⁸ is methyl, and R⁹ and R¹¹ are both hydrogen. Anotherpreferred group of compounds in this embodiment includes those whereinR⁸ is methyl, and R⁹, R¹¹ and R¹² are all hydrogen. Another preferredgroup of compounds in this embodiment includes those wherein R⁸ ismethyl, and R⁹, R¹⁰ and R¹¹ are all hydrogen.

In an additional embodiment, R⁵ is thienyl, furanyl, imidazolyl,oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, benzothienyl, benzofuranyl,dibenzofuranyl, benzimidazolyl, quinolinyl, isoquinolinyl, indolyl orpyrazinyl, optionally substituted by one or two groups independentlyselected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄ haloallyl, C₂₋₄ alkenyl, formyl, (C₁₋₄alkoxy)carbonyl, phenyl, C₁₋₄ alkylphenyl, phenoxy, halo, C₁₋₄haloalkoxy, carboxy, hydroxy, nitro, amino, C₁₋₄ alkylsulfonyl(C₁₋₄alkyl)ureido, sulfo(C₁₋₄)alkyl, trimethylsilanyl(C₁₋₄)alkoxy(C₁₋₄)alkyland C₁₋₄ alkoxy(C₁₋₄)alkyl.

Where R⁵ is a heteroaryl group, useful values include thien-3-yl,quinolin-7-yl, 3,5-dimethylisoxazol-4-yl, 5-chlorothien-2-yl,pyrid-3-yl, pyrimidin-4-yl, quinolin-3-yl, benzothien-2-yl,benzofuran-2-yl, furan-2-yl, furan-3-yl, 4-methylpyrid-3-yl,3-methyl-pyrid-2-yl, 6-methylbenzimidazol-5-yl, benzimidazol-6-yl,1-methyl-4-(2′-methylphenyl)benzimidazol-6-yl,2-methyl-4-(2′-methylphenyl)benzimidazol-6-yl, dibenzofuran-2-yl,2-methylimidazolyl, 6-ethoxy-benzothiazolyl, 6-methyl-pyrid-3-yl,6-chloro-pyrid-3-yl, and 3-chloro-pyrid-2-yl.

Where R⁵ is a heteroaryl group, useful values also include3-methyl-5-nitropyrid-2-yl, 5-amino-3-methylpyrid-2-yl,4-methylpyrimidin-5-yl, 3-methylpyrid-2-yl, 2-chloropyrid-3-yl,6-formylpyrid-2-yl,3-methyl-5-[N′-(3-methanesulfonylprop-1-yl)]-ureidopyrid-2-yl,3-methyl-pyrid-4-yl, 3-amino-5-methyl-pyrid-4-yl,3-chloro-5-trifluoromethylpyrid-2-yl, 1H-benzimidazol-2-yl,1-methyl-1H-benzimidazol-2-yl, 3-methyl-3H-imidazol-4-yl,1H-imidazol-2-yl, 1-methyl-1H-imidazol-2-yl,1-ethyl-1H-benzimidazol-2-yl, 2,5-dimethyl-1H-imidazolyl,1-(3-sulfoprop-1-yl)-1H-benzimidazol-2-yl, 3-methylpyrazin-2-yl,5-methyl-1-(2-trimethylsilanylethoxymethyl)-1H-benzimidazolyl,5-methyl-1H-benzimidazol-4-yl, 1-methyl-1H-benzimidazol-5-yl,2-methoxymethyl-6-methyl-1H-benzimidazol-5-yl,2,6-dimethyl-1H-benzimidazol-5-yl and 1,6-dimethyl-1H-benzimidazol-5-yl.

In an additional embodiment, R⁵ is —NR^(a)R^(b), wherein R^(a) and R^(b)are independently C₁₋₆ alkyl, or R^(a) and R^(b) together with thenitrogen atom to which they are attached form a ring selected from thegroup consisting of piperidinyl, pyrroldinyl, piperazinyl,imidazolidinyl, pyrazolidinyl and morpholinyl, wherein said ring isoptionally substituted by one or two C₁₋₄ alkyl groups. In thisembodiment, useful values of R⁵ include piperidin-1-yl and4-methylpiperazin-1-yl.

Useful values of R⁶ include hydrogen, methyl, halo, amino, methoxy,ethoxy, vinyloxy, hydroxy and benzyloxy.

For each embodiment above, preferred values of R¹ include bromo,methylthio, ethylthio or prop-2-en-1-ylthio, more preferably bromo ormethylthio, most preferably methylthio.

One useful value of Z is SO₂. An additional value of Z is SO.

Preferred values of R², R³ and R⁴ are independently hydrogen, C₁₋₆alkyl, amino, cyano, C₁₋₄ alkoxy or hydroxy, and are preferably allhydrogen. Useful values of R², R³ and R⁴ include hydrogen, methyl,ethyl, propyl, n-butyl, hydroxy, methoxy, and ethoxy.

Additional preferred values of R², R³ and R⁴ in Formula I also includeprodrugs such as —CO₂R^(w), where R^(w), in each instance, is preferablyone of C₁₋₄alkyl, C₄₋₇cycloalkyl or benzyl. Suitable values of R², R³and R⁴ include hydrogen, methyl, ethyl, propyl, n-butyl, hydroxy,methoxy, ethoxy, cyano, —CO₂CH₃, —CO₂CH₂CH₃ and —CO₂CH₂CH₂CH₃.

Also suitable at R², R³ and R⁴ is the group —CO₂R^(w), where R^(w) isone of

where R^(d)–R^(h) are defined as above. When R², R³ and R⁴ are—CO₂R^(w), where R^(w) is one of these moieties, the resulting compoundsare prodrugs that possess desirable formulation and bioavailabilitycharacteristics. A preferred value for each of R^(d), R^(e) and R^(g) ishydrogen, preferred R^(f) is methyl, and preferred values for R^(h)include benzyl and tert-butyl.

Specific compounds for use in the method of the invention include thecompounds described in the Examples, such as the following:

-   4-(4′-hydroxy-[1,1′;3′,1″]terphenyl-3″-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-methoxymethoxy-[1,1′;3′,1″]terphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-3-carboxylic    acid isopropyl ester trifluoroacetate,-   3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-carboxylic    acid trifluoroacetate,-   4-(6′-hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(5′-hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(5′-formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-[3-(4-methyl-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-[3-(2-chloro-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-[3-(3-methyl-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    bis-trifluoroacetate,-   4-(3-allyloxy-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3-bromo-5-methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(5-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    hydrochloride,-   4-(5-allyloxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(5-benzyloxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    hydrochloride,-   4-(2′-chloro-5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-chloro-5-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-bromo-4-(3′-formyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-amino-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-chloro-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-bromo-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-formyl-4′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   {[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamic    acid tert-butyl ester,-   5-methylsulfanyl-4-[3′-(2,2,2-trifluoro-1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-[3′-(2,2,2-trifluoro-acetyl)-biphenyl-3-sulfonyl]-thiophene-2-carboxamidine    trifluoroacetate,-   4-[3-(6-methyl-3H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    bis-trifluoroacetate,-   N-hydroxy-4-[3-(6-methyl-3H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-[2′-(1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-[4′-(1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-carboxylic    acid trifluoroacetate,-   4-(5′-formyl-2′-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(5′-formyl-2′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   N-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-yl]-formimidic    acid trifluoroacetate,-   4-(3′-formylamino-biphenyl-3-sulfonyl)-5-methyl-sulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4-tert-butyl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(1-methyl-1H-imidazole-2-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3,5-dichloro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-bromo-4-(2-methoxy-benzenesulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(naphthalene-2-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′,4′-dimethoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′,4′-dimethoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′,5′chloro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′,5′-dichloro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′,5′-bis-trifluoromethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3-benzofuran-2-yl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3-benzo[b]thiophen-2-yl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-methyl-3′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-chloro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(4′-trifluoromethyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(4′-trifluoromethoxy-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(4′-phenoxy-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-{imino-[4-(4′-methanesulfonyl-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamic    acid tert-butyl ester,-   4-(3-benzo[1,3]dioxol-5-yl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3-quinolin-7-yl-benzenesulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-formyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-amino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3′-trifluoromethyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-hydroxymethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-([1,1′;3′,1″]terphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3-dibenzofuran-4-yl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(2′-trifluoromethyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-hydroxymethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-chloro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3-pyridin-3-yl-benzenesulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3-pyrimidin-5-yl-benzenesulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3-furan-3-yl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3-quinolin-3-yl-benzenesulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-4-carboxylic    acid methyl ester,-   4-(3′,5′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3-furan-2-yl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3-thiophen-3-yl-benzenesulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3′-nitro-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-formyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-fluoro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-fluoro-[1,1′;4′,1″terphenyl-3″-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-hydroxymethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-cyano-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-acetyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-dimethylamino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(2′-vinyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(4′-ethoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-[3-(3,5-dimethyl-isoxazol-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3-naphthalen-1-yl-benzenesulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-[3-(5-chloro-thiophen-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′-formyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(4′-vinyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-ethoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′,6′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-isopropyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′,3′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2′,3′-dichloro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3′-acetyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-carboxylic    acid ethyl ester,-   3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-carboxylic    acid dimethylamide,-   3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-carboxylic    acid amide,-   N-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-yl]-acetamide,-   4-(2′-amino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-[3-(1H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(7-bromo-3-methyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(7-bromo-1-methyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(3-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(2-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidine    trifluoroacetate,-   4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(6-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(2-methyl-furan-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   5-methylsulfanyl-4-(4-phenyl-thiazole-2-sulfonyl)-thiophene-2-carboxamidine    hydrochloride,-   4-(6-ethoxy-benzothiazole-2-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    hydrochloride,-   4-(6-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,-   4-(3-methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    hydrochloride,-   5-methylsulfanyl-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxamidine    hydrochloride, and-   4-(3-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine    trifluoroacetate,    as well as pharmaceutically acceptable salts thereof, or a prodrug    thereof.    Definitions

The term “alkyl” as employed herein by itself or as part of anothergroup refers to both straight and branched chain radicals of up to 12carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl,isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl,2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl.

The term “alkenyl” is used herein to mean a straight or branched chainradical of 2–20 carbon atoms, unless the chain length is limitedthereto, wherein there is at least one double bond between two of thecarbon atoms in the chain, including, but not limited to, ethenyl,1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, andthe like. Preferably, the alkenyl chain is 2 to 10 carbon atoms inlength, more preferably 2 to 8 carbon atoms in length, most preferably 2to 4 carbon atoms in length.

In all instances herein where there is an alkenyl moiety as asubstituent group, the unsaturated linkage, i.e., the vinylene linkage,is preferably not directly attached to a nitrogen, oxygen or sulfurmoiety.

The term “allylthio” as employed herein by itself or as part of anothergroup refers to a straight or branched chain radical of 1 to 20 carbonatoms, unless the chain length is limited thereto, bonded to a sulfuratom, including, but not limited to, methylthio, ethylthio,n-propylthio, isopropylthio, and the like. Preferably the alkylthiochain is 1 to 10 carbon atoms in length, more preferably 1 to 8 carbonatoms in length.

The term “alkoxy” as employed herein by itself or as part of anothergroup refers to a straight or branched chain radical of 1 to 20 carbonatoms, unless the chain length is limited thereto, bonded to an oxygenatom, including, but not limited to, methoxy, ethoxy, n-propoxy,isopropoxy, and the like. Preferably the alkoxy chain is 1 to 10 carbonatoms in length, more preferably 1 to 8 carbon atoms in length.

The term “cycloalkyl” as employed herein by itself or as part of anothergroup refers to cycloalkyl groups containing 3 to 9 carbon atoms.Typical examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, cyclooctyl and cyclononyl.

The terms “halogen” or “halo” as employed herein by itself or as part ofanother group refers to chlorine, bromine, fluorine or iodine, withchlorine being preferred.

The term “monoalkylamine” as employed herein by itself or as part ofanother group refers to an amino group which is substituted with onealkyl group having from 1 to 6 carbon atoms.

The term “dialkylamine” as employed herein by itself or as part ofanother group refers to an amino group which is substituted with twoalkyl groups, each having from 1 to 6 carbon atoms.

The term “aryl” as employed herein by itself or as part of another grouprefers to monocyclic or bicyclic aromatic groups containing from 6 to 14carbons in the ring portion, preferably 6–10 carbons in the ringportion, such as phenyl, naphthyl or tetrahydronaphthyl.

The term “aralkyl” or “arylalkyl” as employed herein by itself or aspart of another group refers to C₁₋₆alkyl groups as discussed abovehaving an aryl substituent, such as benzyl, phenylethyl or2-naphthylmethyl.

The terms “heterocyclic,” “heterocyclo” or “heterocycle” as employedherein by themselves or as part of larger groups refer to a saturated orwholly or partially unsaturated 3–7 membered monocyclic, or 7–10membered bicyclic ring system, which consists of carbon atoms and fromone to four heteroatoms independently selected from the group consistingof O, N, and S, wherein the nitrogen and sulfur heteroatoms can beoptionally oxidized, the nitrogen can be optionally quaterized, andincluding any bicyclic group in which any of the above-definedheterocyclic rings is fused to a benzene ring, and wherein theheterocyclic ring can be substituted on carbon or on a nitrogen atom ifthe resulting compound is stable. Especially useful are rings containingone oxygen or sulfur, one to three nitrogen atoms, or one oxygen orsulfur combined with one or two nitrogen atoms. Examples of suchheterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl,2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl,4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl,imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl,pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl,morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl,isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl,thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl,tetrahydrofuryl, tetaahydropyranyl, benzofuranyl, thienyl, benzothienyl,thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, andoxadiazolyl. Morpholino is the same as morpholinyl.

The term “heteroatom” is used herein to mean an oxygen atom (“O”), asulfur atom (“S”) or a nitrogen atom (“N”). It will be recognized thatwhen the heteroatom is nitrogen, it may form an NR^(y)R^(z) moiety,wherein R^(y) and R^(z) are, independently from one another, hydrogen orC₁ to C₈ alkyl, or together with the nitrogen to which they are bound,form a saturated or unsaturated 5-, 6-, or 7-membered ring.

The term “heteroaryl” as employed herein refers to groups having 5 to 14ring atoms; 6, 10 or 14 π electrons shared in a cyclic array; andcontaining carbon atoms and 1, 2 or 3 oxygen, nitrogen or sulfurheteroatoms (where examples of heteroaryl groups are: thienyl,benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl,benzofuranyl, pyranyl, isobenzofuranyl, benzoxazolyl, chromenyl,xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl,pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl,3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl,quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl,pteridinyl, 4αH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl,acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl,phenothiazinyl, isoxazolyl, furazanyl and phenoxazinyl groups).

The expression “prodrug” denotes a derivative of a known direct actingdrug, which derivative has enhanced delivery characteristics andtherapeutic value as compared to the drug, and is transformed into theactive drug by an enzymatic or chemical process. Useful prodrugs arethose where R², R³ and/or R⁴ are —CO₂R^(w), where R^(w) is definedabove. See U.S. Pat. No. 5,466,811 and Saulnier et al., Bioorg. Med.Chem. Lett. 4:1985–1990 (1994).

The term “substituted,” as used herein, means that one or more hydrogensof the designated moiety are replaced with a selection from theindicated group, provided that no atom's normal valency is exceeded, andthat the substitution results in a stable compound. When a substituentis keto (i.e., ═O), then 2 hydrogens attached to an atom of the moietyare replaced.

By “stable compound” or “stable formula” is meant herein a compound thatis sufficiently robust to survive isolation to a useful degree of purityfrom a reaction mixture and formulation into an efficacious therapeuticagent.

When any variable occurs more than one time in any constituent or in anyFormula, its definition on each occurrence is independent of itsdefinition at every other occurrence. Also, combinations of substituentsand/or variables are permissible only if such combinations result instable compounds.

Methods of Use

The present invention provides a method for treating acute and chronicdisorders associated with activation of the classical pathway of thecomplement system by administering to a mammal in need of such treatmenta therapeutically effective amount of a compound of Formula I.

These acute and chronic conditions include inflammation and tissuedamage that arise as a result of rapid and aggressive enzyme activity ofthe complement cascade. Complement-mediated inflammation and theresultant tissue damage has been implicated in a number of diseasestates including: 1) ischaemia reperfusion damage, such as occurs postmyocardial infarction, post transplant, post surgery and in hemorrhagicshock; 2) antibody-mediated conditions, such as hyperacute allogralt andxenograft rejection, organ transplant rejection and auto-immunediseases; and 3) other disease states, such as thermal injury, trauma,adult respiratory distress syndrome (ARDS), sepsis and prion disease.

The compounds of the present invention are believed to inhibit thefunctioning of the protease activity of C1s. This protease-inhibitionactivity results in the inhibition or blocking of a variety ofcomplement-mediated immunological functions. Therefore, compounds ofFormula I can be used to ameliorate a number of disease states inducedby complement-mediated inflammation and tissue damage.

The term “treatment of inflammation” or “treating inflammation” isintended to include the administration of compounds of the presentinvention to a subject for purposes which can include prophylaxis,amelioration, prevention or cure of an inflammatory response. Suchtreatment need not necessarily completely ameliorate the inflammatoryresponse. Further, such treatment can be used in conjunction with othertraditional treatments for reducing the inflammatory condition known tothose of skill in the art.

By an “efficacious level” of a composition of the invention is meant alevel at which some relief is afforded to the patient who is therecipient of the treatment. By an “abnormal” host inflammatory conditionis meant a level of inflammation in the subject at a site which exceedsthe norm for the healthy medical state of the subject, or exceeds adesired level. By “secondary” tissue damage or toxic effects is meantthe tissue damage or toxic effects which occur to otherwise healthytissues, organs, and the cells therein, due to the presence of aninflammatory response, including as a result of a “primary” inflammatoryresponse elsewhere in the body.

The “animals” referred to herein are preferably mammals and mostpreferably humans, although the invention is not intended to be limitedto such.

In one embodiment, compounds of Formula I can be administered to amammal to treat complement-mediated inflammation and tissue damage thatis a consequence of ischaemia/reperfusion injury. Thus, the C1sinhibitors of the present invention can be employed to prevent, or atleast ameliorate, inflammation and tissue damage arising from a stroke,myocardial infarction, hemorrhagic shock, and surgery. In particular,compounds of Formula I can be employed to prevent inflammation oftransplanted tissue and organs.

The compounds of Formula I can also be provided as a “preventive”treatment before detection of an inflammatory state, so as to preventthe same from developing in patients at high risk for the same, such as,for example, transplant patients.

The compounds of Formula I can be used to treat chronic or acuteinflammation that is the result of an antibody-mediated reaction, suchas hyperacute allograft and xenograft rejection, organ transplantrejection and auto-immune diseases, which include arthritis, rheumatoidarthritis, multiple sclerosis (MS), type I diabetes, intestinalinflammation of Crohn's disease, systemic lupus erythematosus (lupus),immune-complex-induced vasculitis, restenosis and psoriasis.

The complement system is activated in hyperacute allograft andhyperacute xenograft rejection, and in acute humoral rejection mediatedby donor-specific antibodies. In another embodiment, compounds ofFormula I can be administered to a mammal before, during or after thetransplant of an organ or a graft to ameliorate the rejection of suchorgan or graft by the mammal.

Organ transplant and graft patients undergo concurrent immunotherapy.Complement activation during immunotherapy with recombinant IL-2 appearsto cause acute vascular leak syndrome that results in the severetoxicity and side effects observed from IL-2 treatment and otherconditions such as bone marrow transplantation and acute pancreatitis.Thus, in a further embodiment of the present invention, a compound ofFormula I is administered to a mammal before, during or after treatmentof said mammal with IL-2, bone marrow transplantation, or onset ofpancreatitis, in an amount effective to reduce the vascular leaksyndrome that causes toxicity and side-effects associated with thetreatment or disorders.

Another embodiment of the present invention is directed to administeringa therapeutically effective compound of Formula I to a mammal that hasbeen diagnosed with an autoimmune disease. Autoimmune diseases that aretreatable according to the present invention include Addison's disease,Type I diabetes mellitus, Hashimoto's thyroiditis, glomerulonephritisand cutaneous lesions of systemic lupus erythematosus, otherglomerulonephritides, bullous pemphigoid, dermatitis herpetiformis,Goodpasture's syndrome, Graves' disease, myasthenia gravis, insulinresistance, autoimmune hemolytic anemia, autoimmune thrombocytopenicpurpura, immune-complex-induced vasculitis glomerulonephritis, type IIcollagen-induced arthritis, rheumatoid arthritis, and allergic neuritis.Autoimmune diseases preferred for treatment by inhibitors of the presentinvention include myasthenia gravis (MG), rheumatoid arthritis, andsystemic lupus erythematosus.

Another embodiment of the present invention is directed to administeringa therapeutically effective amount of a compound of Formula I to amammal that has been diagnosed with a neurodegenerative disease.Neurodegenerative diseases in which inhibitors of the complement cascadesystem will be therapeutically useful include the demyelinating disordermultiple sclerosis (MS), the neuropathies Guillain-Barré syndrome (GBS)and Miller-Fisher syndrome (MFS), Alzheimer's disease (AD) and variantCreutzfeldt-Jakob disease (vCJD).

In another embodiment, efficacious levels of the C1s inhibitors of theinvention are administered so as to provide therapeutic benefits againstthe secondary harmful inflammatory effects of inflammation.

In an additional embodiment, compounds of the present invention can beadministered to a mammal suffering from the symptoms of ARDS. ARDS is acomplex pulmonary disorder affecting 150,000 people in the U.S. yearlywith a 50% mortality rate. Leukocytes, platelets and the proteolyticpathways of coagulation and complement mediate ARDS. ARDS involvesactivation of the contact activation pathway and depletion of C1inhibitor and may be induced by either sepsis or trauma. Sepsis-inducedARDS results in more severe Disseminated intravascular coagulation (DIC)and fibrinolysis, more fibrin degradation products and reduced ATIIIlevels compared to trauma-induced ARDS (Carvalho et al., J. Lab. Clin.Med. 112:270–277 (1988)).

In a further embodiment, compounds of Formula I can be administered to aperson in septic shock. Septic shock is the most common cause of deathof humans in intensive care units in the United States (Parillo et al.,Ann. Int. Med. 113:227–242 (1990); Schmeichel C. J. & McCormick D.,BioTechnol. 10:264–267 (1992)). In recent years aggressive fluidinfusion therapy has been accepted as a primary means of treatment forseptic shock.

The increase in cardiac output and vasodilation in septic shock isattributed to the action of inflammatory mediators. In septic shock,components of the kallikrein-kinin system are depleted, suggestingactivation of this system. This is not the case in cardiogenic shock,suggesting that the kallikrein-kinin system is a key player in septicshock (Martinez-Brotons F. et al., Thromb. Haemostas. 58:709–713(1987)). While the actual events leading to septic shock, DIC andhypotension have not been established, the known interactions amongvarious components of the many physiological systems suggest thatactivation of the contact pathway may lead to a state of septic shock,multi-organ failure, and death (Bone, R. C., Arch. Intern. Med.152:1381–1389 (1992); Colman, R. W., New Engl. J. Med. 320:1207–1209(1989)). The contact activation pathway is also involved in both fibrindeposition and lysis, as well as triggering neutrophil activation,activation of complement and modulation of blood pressure.

Inhibition of the complement cascade is expected to lead to downstreamutilities associated with the contact system of coagulation and thecomplement system. This interaction between components of the complementand coagulation systems at the surface of blood platelets andendothelium can generate inflammatory and chemotactic peptides at sitesof vascular thrombus formation and may contribute to the alteredhemostasis associated with immune disease states. In addition, immunereactions affecting blood platelets and endothelium can lead to plateletaggregation, the secretion of proteolytic enzymes and vasoactive aminesfrom platelet storage granules, and increase adherence of platelets andleukocytes to the endothelial lining of blood vessels.

Other diseases and conditions that can be treated with compounds ofFormula I include hereditary angioedema, paroxysmal nocturnalhemoglobinuria, wound healing, brain trauma, asthma, hemodialysis,infection, dermatosis, inflammatory bowel disease, osteoporosis,osteoarthritis, thermal injury (burns and frostbite), hemolytic anemiaand post pump syndrome in cardiopulmonary bypass.

It has been demonstrated that membrane-uptake of C3b and C5b-9 proteinscan occur spontaneously during incubation of platelets in citratedplasma. Complement activation can also occur during blood collection asa result of exposure to plastic surfaces supporting the C3-convertasereaction. While the implications of complement activation during bloodcollection and in vitro storage for transfusion have not been directlyaddressed, it is nevertheless known that plasma levels of coagulationfactors V and VIII rapidly decline in stored platelet concentrates at arate considerably faster than their decay in cell-free plasma,suggesting consumptive loss. Further, platelet collection and storage isassociated with an increase in vesicular plasma membrane microparticles,a product of C5b-9 initiated platelet secretion. These physiological andenzymatic changes greatly reduce the potential shelf life of storedplatelets, particularly platelet-rich plasma concentrates used fortransfusions, which is generally only 72 hours at best. Furthermore,this interaction of activated C5b-9, platelets, and coagulation factorsin stored platelet concentrates will adversely affect the hemostaticeffectiveness of these units when infused.

In vitro human organ and tissue storage and survival of the transplantedgraft is also adversely affected by the spontaneous activation of thecomplement system, resulting in membrane insertion of the C5b-9 proteinsinto vascular endothelium. Activation of C5 to C5a and C5b can becatalyzed by plastics and other synthetic membranes required to maintainperfusion of vascular beds during in vitro tissue and organ storage. Inaddition, membrane deposition of C5b-9 in vivo has been implicated inthe acute rejection of transplanted tissue due to immune activation ofthe recipient's plasma complement system against the endothelial cellswithin the donor's organ.

Platelet and endothelial cell activation by C5b-9 also has ramificationsin autoimmune disorders and other disease states. The importance ofspontaneous complement activation and the resulting exposure ofplatelets and endothelium to activated C5b-9 to the evolution ofvaso-occlusive disease is underscored by consideration that a) leukocyteinfiltration of the subendothelium, which is known to occur in regionsof atheromatous degeneration and suggests localized generation of C5a atthe vessel wall, is potentially catalyzed by adherent platelets; and b)local intravascular complement activation resulting in membranedeposition of C5b-9 complexes accompanies coronary vessel occlusion andmay affect the ultimate extent of myocardial damage associated withinfarction.

It is therefore an aspect of the present invention to provide a meansand method for the modulation and inhibition of complement-mediatedplatelet and endothelial cell activation in vivo and in vitro.

It is a further aspect of the present invention to provide a means andmethod for increasing the survival and therapeutic efficacy of plateletsand tissues or organs collected and stored in vitro.

Preferably, the treatment methods of the invention deliver the C1sinhibitor either by contacting cells of the animal with a C1s inhibitordescribed above or by administering to the animal a C1s inhibitordescribed above.

The inhibitors can be used in vitro or in vivo. They can be administeredby any number of known routes, including orally, intravenously,intramuscularly, subcutaneously, intrathecally, topically,transdermally, and by infusion (Platt et al., U.S. Pat. No. 4,510,130;Badalamente et al., Proc. Natl. Acad. Sci. U.S.A. 86:5983–5987 (1989);Staubli et al., Brain Research 444:153–158 (1988)) and will generally beadministered in combination with a physiologically acceptable carrier(e.g., physiological saline) or diluent. The effective quantity ofinhibitor given will be determined empirically and will be based on suchconsiderations as the particular inhibitor used, the condition of theindividual, and the size and weight of the individual. It is to beexpected that the general end-use application dose range will be about0.01 to 100 mg per kg per day, preferably 0.1 to 75 mg per kg per dayfor an effective therapeutic effect.

Amounts and regimens for the administration of C1s inhibitors andcompositions of the invention can be determined readily by those withordinary skill in the clinical art of treating inflammation-relateddisorders such as arthritis, tissue injury and tissue rejection.Generally, the dosage of the composition of the invention will varydepending upon considerations such as: type of pharmaceuticalcomposition employed; age; health; medical conditions being treated;kind of concurrent treatment, if any; frequency of treatment and thenature of the effect desired; extent of tissue damage; gender; durationof the symptoms; and contraindications, if any, and other variables tobe adjusted by the individual physician. A desired dosage can beadministered in one or more applications to obtain the desired results.Pharmaceutical compositions containing the C1s inhibitors of theinvention can be provided in unit dosage forms.

In one embodiment, dosing will be by intravenous injection or short-terminfusion. In a further embodiment, the C1s inhibitors of the presentinvention will be administered orally, in the form of a tablet, pill,lozenge, troche or capsule. To achieve optimal therapeutic effect,maintenance dosing may be required. Such maintenance dosing may be givenrepeatedly during the course of a day by, for instance, repeatedindividual injections, repeated oral dosing, or by introduction of acontinuous drip infusion. Effective dosages can be readily determined byone of ordinary skill in the art through routine trials establishingdose response curves.

Pharmaceutical Compositions

Pharmaceutical compositions for treating a complement-mediated diseasestate, comprising a compound of Formula I in an amount effective toinhibit C1s protease function in a mammal and a pharmaceuticallyacceptable carrier or diluent, are within the scope of the presentinvention.

Pharmaceutical compositions comprising an effective amount of the C1sinhibitors of the invention, in combination with any conventionalpharmaceutically acceptable carrier or diluent, are included in thepresent invention.

For medicinal use, the pharmaceutically acceptable acid addition salts,those salts in which the anion does not contribute significantly totoxicity or pharmacological activity of the organic cation, arepreferred. The acid addition salts are obtained either by reaction of anorganic base of Formula I with an organic or inorganic acid, preferablyby contact in solution, or by any of the standard methods detailed inthe literature available to any practitioner skilled in the art.Examples of useful organic acids are carboxylic acids such as maleicacid, acetic acid, tartaric acid, propionic acid, fumaric acid,isethionic acid, succinic acid, cyclamic acid, pivalic acid and thelike; useful inorganic acids are hydrohalide acids such as HCl, HBr, andHI; sulfuric acid; phosphoric acid and the like. Preferred acids forforming acid addition salts include HCl and acetic acid.

The pharmaceutical compositions of the invention can be administered toany animal that can experience the beneficial effects of the compoundsof the invention. Foremost among such animals are humans, although theinvention is not intended to be so limited.

The pharmaceutical compositions of the present invention can beadministered by any means that achieve their intended purpose. Forexample, administration can be by parenteral, subcutaneous, intravenous,intramuscular, intraperitoneal, transdermal, buccal, or ocular routes.Alternatively, or concurrently, administration can be by the oral route.The dosage administered will be dependent upon the age, health, andweight of the recipient, kind of concurrent treatment, if any, frequencyof treatment, and the nature of the effect desired.

In addition to the pharmacologically active compounds, the newpharmaceutical preparations can contain suitable pharmaceuticallyacceptable carriers comprising excipients and auxiliaries thatfacilitate processing of the active compounds into preparations that canbe used pharmaceutically.

The pharmaceutical preparations of the present invention aremanufactured in a manner that is, itself, known, for example, by meansof conventional mixing, granulating, dragee-making, dissolving, orlyophilizing processes. Thus, pharmaceutical preparations for oral usecan be obtained by combining the active compounds with solid excipients,optionally grinding the resulting mixture and processing the mixture ofgranules, after adding suitable auxiliaries, if desired or necessary, toobtain tablets or dragee cores.

Suitable excipients are, in particular, fillers such as saccharides, forexample, lactose or sucrose, mannitol or sorbitol, cellulosepreparations and/or calcium phosphates, for example, tricalciumphosphate or calcium hydrogen phosphate, as well as binders, such as,starch paste, using, for example, maize starch, wheat starch, ricestarch, potato starch, gelatin, tragacanth, methyl cellulose,hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/orpolyvinyl pyrrolidone. If desired, disintegrating agents can be added,such as, the above-mentioned starches and also carboxymethyl-starch,cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a saltthereof, such as, sodium alginate. Auxiliaries are, above all,flow-regulating agents and lubricants, for example, silica, talc,stearic acid or salts thereof, such as, magnesium stearate or calciumstearate, and/or polyethylene glycol. Dragee cores are provided withsuitable coatings that, if desired, are resistant to gastric juices. Forthis purpose, concentrated saccharide solutions can be used, which mayoptionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethyleneglycol, and/or titanium dioxide, lacquer solutions and suitable organicsolvents or solvent mixtures. In order to produce coatings resistant togastric juices, solutions of suitable cellulose preparations, such as,acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate,are used. Dye stuffs or pigments can be added to the tablets or drageecoatings, for example, for identification or in order to characterizecombinations of active compound doses.

Other pharmaceutical preparations which can be used orally includepush-fit capsules made of gelatin, as well as soft, sealed capsules madeof gelatin and a plasticizer, such as, glycerol or sorbitol. Thepush-fit capsules can contain the active compounds in the form ofgranules that may be mixed with fillers such as lactose, binders such asstarches, and/or lubricants such as talc or magnesium stearate and,optionally, stabilizers. In soft capsules, the active compounds arepreferably dissolved or suspended in suitable liquids, such as, fattyoils or liquid paraffin. In addition, stabilizers may be added.

Suitable formulations for parenteral administration include aqueoussolutions of the active compounds in water-soluble form, for example,water-soluble salts, alkaline solutions and cyclodextrin inclusioncomplexes. Especially preferred salts are hydrochloride and acetatesalts. One or more modified or unmodified cyclodextrins can be employedto stabilize and increase the water solubility of compounds of thepresent invention. Useful cyclodextrins for this purpose are disclosedin U.S. Pat. Nos. 4,727,064, 4,764,604, and 5,024,998.

In addition, suspensions of the active compounds as appropriate oilyinjection suspensions can be administered. Suitable lipophilic solventsor vehicles include fatty oils, for example, sesame oil, or syntheticfatty acid esters, for example, ethyl oleate or triglycerides orpolyethylene glycol-400 (the compounds are soluble in PEG-400). Aqueousinjection suspensions can contain substances that increase the viscosityof the suspension, for example, sodium carboxymethyl cellulose,sorbitol, and/or dextran. Optionally, the suspension may also containstabilizers.

When employed as thrombin inhibitors, the compounds of the presentinvention may be administered in an effective amount within the dosagerange of about 0.1 to about 500 mg/kg, preferably between about 0.1 andabout 10 mg/kg body weight, on a regimen in single or 2–4 divided dailydoses.

Methods of Making

Many synthetic methods used to form compounds of the present inventiongenerally involve the formation of an amidine from a carboxylic acidderivative, such as an ester. In the process a Lewis acid, such astrimethylaluminum, is added to a source of ammonia, such as ammoniumchloride, in an aprotic solvent, such as a toluene, under an inertatmosphere (e.g., under an atmosphere of nitrogen or argon gas) at atemperature between −15° C. and 5° C., preferably at 0° C. Anappropriate carboxylic acid derivative is added to the mixture and themixture is heated at reflux for a predetermined period of time,preferably between 1 hr. and 24 hrs., and most preferably between 1 hr.and 4 hrs. The resulting solution is allowed to cool to room temperatureand the amidine product is isolated by known methods.

Scheme 1 illustrates a general approach to compounds of Formula I whereX=O or S, and R¹=alkylthio, aralkylthio, arylthio, alkyloxy, aralkyloxyor aryloxy. Starting with the heterocycle where X=O or S appropriatelysubstituted by a leaving group, the leaving groups can be sequentiallydisplaced by an appropriate thiol to produce the 4-substitutedheterocycles. In some cases a disulfide and a reducing agent such astriphenylphosphine can be used for the in situ generation of the thiol.Examples of leaving groups include chlorine, bromine or iodine. Theresulting sulfide is oxidized, either to the sulfoxide or the sulfonewith an appropriate oxidizing agent such as meta-chloroperoxybenzoicacid or hydrogen peroxide in acetic acid. When the 4-substituent is asulfone, the nitro group can then be displaced by an appropriatenucleophile (preferably the anion of the group R¹ to be substituted) toproduce a 5-substituted heterocycle. Preferable nucleophiles includeanions of thiols or alcohols having as the counter ion an alkali oralkali earth metal such as sodium, lithium, potassium, magnesium orcesium.

Scheme 2 illustrates approaches to providing the amidine ((R₃R₄N)CNR₂)functionality of compounds of Formula I where X=O or S, and R¹=halo,alkyl, alkylthio, aralkylthio, arylthio, alkyloxy, aralkyloxy oraryloxy. Depending on the nature of the group W in 4, several methodsmay be employed in the transformation of W to (R₃R₄N)CNR₂.

When W in 4 is a cyano group (CN), primary amide (CONH₂) or ester(CO₂R⁹), direct conversion to an unsubstituted amidine 6 (i.e., FormulaI where R², R³, R⁴=H) can be effected by treatment with a reagentconsisting of a Lewis acid complexed to ammonia This complex is producedby treatment of ammonia or an ammonium salt, preferably an ammoniumhalide and most preferably ammonium chloride or bromide, with anappropriate Lewis acid, preferably a trialkylaluminum and mostpreferably trimethyl- or triethylaluminum in a solvent inert to theLewis acid employed. For example, when a trialkylaluminum Lewis acid isemployed with an ammonium halide, reaction occurs with loss of oneequivalent of alkane to produce the dialkylhaloaluminum complex ofammonia (see, for example, Sidler, D. R., et al., J. Org. Chem., 59:1231(1994)). Examples of suitable solvents include unsaturated hydrocarbonssuch as benzene, toluene, xylenes, or mesitylene, preferably toluene, orhalogenated hydrocarbons such as dichloroethane, chlorobenzene ordichlorobenzene. The amidination reaction is generally carried out atelevated temperatures, preferably 40–200° C., more preferably 80–140°C., and most preferably at the reflux temperature of a solvent in therange of 80–120° C. When W is a cyano group (CN), direct conversion to amono- or disubstituted amidine 6 is also possible by treatment with areagent consisting of a Lewis acid, preferably a trialkylaluminum,complexed to a mono- or disubstituted amine H₂NR³ or HNR³R⁴ (Garigipati,R., Tetrahedron Lett. 31: 1969 (1990)). Alternatively the same additionof a mono- or disubstituted amine may be catalyzed by a copper salt suchas Cu(I) chloride (Rousselet, G., et al., Tetrahedron Lett. 34: 6395(1993)).

When W in 4 is a carboxyl group (CO₂H), indirect conversion to anunsubstituted amidine 6 can be carried out by initial esterification to5 by any of a number of well-known dehydrating agents (for example,dicyclohexylcarbodiimide) with an alcohol (R⁸OH). More preferably 5 canbe made by initial formation of an acid chloride by treatment of 4 withany of a number of anhydrides of HCl and another acid, such as thionylchloride, POCl₃, PCl₃, PCl₅, or more preferably oxalyl chloride, with orwithout an added catalyst such as N,N-dimethylformamide (DMF), followedby the alcohol R⁸OH. Conversion to the unsubstituted amidine 6 (R², R³,R⁴=H) can be carried out by treatment with a Lewis acid complexed toammonia.

Amidines 6 can also be produced indirectly by conversion of 4 (W=CN) toiminoethers 7 by exposure to a strong acid such as a hydrogen halide,HBF₄ or other non-nucleophilic acid, preferably gaseous HCl in thepresence of an alcohol R⁸OH (R⁸=alkyl, branched alkyl or cycloalkyl,preferably Me or Et) and most preferably with the alcohol as solvent.Alternatively when W=CONH₂, conversion to an iminoether can be carriedout by treatment with a trialkyloxonium salt (Meerwein's salts). Ineither case, treatment of the iminoether with ammonia (R³, R⁴=H) or amono- or disubstituted amine (HNR³R⁴) provides the correspondingunsubstituted or substituted amidines 6 (i.e., via classical Pinnersynthesis: Pinner, A., Die Iminoaether und ihre Derivate, Verlag R.Oppenheim, Berlin (1892)).

Conversion to substituted amidine 6 (R², R³=H and, R⁴=OH) can beachieved by refluxing in ethanol the unsubstituted amidine 6 (R², R³,R⁴=H), hydroxylamine, and a base, preferably triethylamine.

Scheme 3 illustrates one approach to aryl thiols, which can be used inScheme 1 when such aryl thiols are not commercially available. Startingwith an aryl halide with sufficient stability to strong nucleophiles,the aryl halide can be reacted with an alkali earth metal in an inertethereal solvent such as diethyl ether under reflux, yielding a reactiveorganometallic species. Preferred metals include lithium, magnesium, andsodium, while the halide can be an aryl iodide or bromide.Alternatively, the aryl-metal species can be generated through ametal-halogen exchange with another organometallic reagent at lowtemperature in an ethereal solvent. Useful organometallic reagentsinclude any of the isomeric butyllithiums and isopropylmagnesium bromideor chloride. In this instance, the aryl halide must be an aryl bromideor iodide and stable to strong nucleophiles.

The aryl-metal reagent may then be reacted with elemental sulfur toprovide a mixture of the aryl thiol (12) and the disulfide oxidationproducts (11). The disulfide can be reacted with a reducing agent suchas sodium borohydride, dithiothreitol, or triphenylphosphine, to givethe aryl thiol (12).

Scheme 4 illustrates another approach to aryl thiols, which can be usedin Scheme 1 when such aryl thiols are not commercially available. Anarylamine 13 can be converted to the diazonium salt and reacted withO-ethylxanthic acid potassium salt (Aldrich Chemical Company) to give anO-ethyl-S-aryl dithiocarbonate, which can subsequently be hydrolyzed tothe aryl thiol 15. In some cases hydrolysis can provide a mixture of thearyl thiol (15) and the disulfide oxidation products (14). The disulfidecan be reacted with a reducing agent such as sodium borohydride,dithiothreitol, or triphenylphosphine, to give the aryl thiol (15).

Scheme 5 illustrates a general approach to compounds of Formula I whereX=O or S, and R¹=halo. The nitroheterocycle 3 obtained in the mannerdescribed in Scheme 1 is reduced to the aminoheterocycle 16. Appropriatereagents to effect reduction of the nitro functionality include hydrogengas in the presence of a catalyst such as palladium or platinum metaldeposited on carbon or barium sulfate in any number of solvents such asmethanol, ethanol, ethyl acetate, DMF, or THF. Tin(II) chloride may beemployed as a reductant in a solvent such as methanol or ethanol.Alternatively, metals such as zinc or iron (Stanetty, P. andKremslehner, M., Heterocycles 48: 259 (1998)) may also be used. Morepreferably, titanium(III) chloride in HCl (see Ho, Wong, Synthesis, 45(1974)) can be used as the reducing reagent. The aminoheterocycle 16 canthen be converted to the halide 17 by diazotization. When X=Cl or Br,this reaction is carried out by treating the aminoheterocycle 16 witht-butyl nitrite and copper(II) chloride or bromide as described in theSandmeyer reaction (see Doyle; Siegfried; Dellaria, J. Org. Chem. 42:2426 (1977)).

Scheme 6a illustrates approaches to providing the biaryl functionalitypresent in compounds of Formula II, where R⁵ can be a substitutedaromatic or heteroaromatic ring (aryl or heteroaryl). Starting witheither of two aryl bromides, the methyl carboxylate 18 or theBoc-amidine 20, a transition-metal catalyzed cross-coupling reaction cantake place using an appropriately substituted arylboronic acid,arylzincate, or arylstannane under Suzuki (Miyaura, N.; Suzuki, A.,Chem. Rev. 95:2457 (1995)), Negishi (Negishi, E. et al., J. Org. Chem.42:1821 (1977)), or Stille conditions (Stille, J. K. Angew. Chem., Int.Ed. Engl. 25: 508 (1986), and references contained therein),respectively.

The Stille-type cross-coupling reaction takes place under inertatmosphere between an arylstannane and an aryl halide mediated by acatalyst such as palladium tetrakis-triphenylphosphine. The reaction isusually performed at temperatures ranging from room temperature to 150°C. in an aprotic solvent of appropriate boiling point such astetrahydrofuran, toluene, or dimethylformamide. In some cases, additivessuch as lithium chloride (Curran, D. P. et al., J. Org. Chem. 61:6480(1996)) or copper iodide (Liebeskind, L. S.; Fengl, R. W., J. Org. Chem.55:5359 (1990)) can facilitate the cross-coupling reaction.

A more preferable cross-coupling reaction of aryl bromides 18 and 20takes place under Negishi conditions, utilizing an aryl zinc reagent.The aryl zinc reagent can be prepared by transmetalation of an arylgrignard or aryl lithium reagent with a zinc halide salt, or morepreferably, directly prepared from an aryl halide and activated zinc(Reike, R. D., Tetrahedron 53:1925 (1997). The cross-coupling reactiongenerally takes place at temperatures between 60 and 100° C. in THF orTHF/polar aprotic co-solvent mixtures. Palladiumtetrakis(triphenylphosphine) is the most widely used catalyst, althoughnew catalysts such as palladium di-tert-butylphosphine (Dai, C.; Fu, G.C., J. Am. Chem. Soc. 123:2719 (2001)) can offer enhanced reactivities.

The most preferable and widely applicable biaryl-forming reactionconditions for aryl bromides 18 and 20 take place under Suzukiconditions. Many sets of reaction conditions can be employed to promotethe Suzuki-type cross-coupling reactions. These include appropriatecombinations of anhydrous or water-containing solvents, appropriatebases such as metal carbonates, phosphates, and fluorides, and thetransition-metal catalyst. For the synthesis of biarylsulfones 21 and23, the most universal reaction conditions consisted of reacting arylbromide 18 or 20 with an arylboronic acid or an aryboronate ester (e.g.pinacolboronate) in a biphasic toluene/ethanol/aqueous sodium carbonatesolvent system. Palladium tetrakis-triphenylphosphine is used as thecatalyst under these aqueous conditions. Under anhydrous conditions, newcatalysts such as palladium di-tert-butylphosphine (Littke, A. F. etal., J. Am. Chem. Soc. 122:4020 (2000)) andbis(o-(dicyclohexylphosphino)biphenyl)palladium (Wolfe, J. P. et al., J.Am. Chem. Soc. 121: 9550 (1999)) can offer enhanced reactivity at lowercatalyst loadings.

Scheme 6b describes an alternate route to compounds of Formula II whereR⁵ is an aryl, or heteroaryl. Boc-protected amidine 20 is converted toan organoboron or organostannane 66, which is then reacted with asuitable halide or triflate in the presence of a palladium catalyst togive 21, which is converted to the amidine 22 as described in scheme 6a.The preferred method for the synthesis of 66 when E is a boron or tinspecies is to first treat 20 with a base such isopropylmagnesiumchloride, followed by lithiation with a suitable reagent such asn-butyllithium, followed by reaction with an electrophile such astrimethyl borate or tributyltin chloride.

Another approach to introduce heteroaromaties is to prepare 67. This isaccomplished by treatment of the organolithium species, prepared asoutlined above, with a suitable electrophile such asN,N-dimethylformamide. Conversion of 67 to 21 can then be accomplishedusing diamine reagents such as 1,2-phenyldiamine to give 2-substitutedbenzimidazoles or ammonium acetate and glyoxal to give 2-substitutedimidazoles, which is converted to the amidine 22 as described in scheme6a.

Scheme 6c describes methods for the introduction of alkyl groups to thephenyl ring of Formula I. Compound 20 is treated with a base such asisopropylmagnesium chloride, followed by lithiation with a suitablereagent such as n-butyllithium, followed by reaction with electrophilessuch as aldehydes and ketones to give 68 (Wakefield, B. J. The Chemistryof Organolithium Compounds; Pergamon: Oxford, 1974; Wakefield, B. J.Organolithium Methods; Academic: San Diego, 1990), which is converted tothe amidine 22 as described in scheme 6a.

Scheme 6d describes an approach to compounds of formula I, where the Arresidue is substituted with amines at the meta-position. Transitionmetal catalyzed coupling of the bromide 69 with amines is used tosynthesize arylamine 70. Examples of suitable transition metal catalystinclude palladium(0) or palladium(II) compounds such as Pd(II) acetate(Pd(OAc)₂), dipalladium tris(dibenzylidineacetone) (Pd₂(dba)₃),tetrakis(triphenylphosphine)palladium(0) (Ph₃P)₃Pd), nickel(II)bis(1,5-cyclooctadiene) (Ni(COD)₂), or(1,1′-bis(diphenylphosphino)ferrocenyl nickel dichloride, in thepresence or absence of coordinating ligand and in the presence of asuitable base and solvent. Preferred catalyst include Pd(OAc)₂ andPd₂(dba)₃. Examples of coordinating ligands includetri-t-butylphosphine, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl(BINAP), 2,2′-bis(ditolylphosphino)-1,1′binaphthyl (tol-BINAP),1,1′-bis(diphenylphosphino)ferrocene (DPPF),bis(2-diphenylphosphinophenyl)ether (DPEphos),2-(di-t-butylphosphino)biphenyl (DBPB),2-(di-cyclohexylphosphino)biphenyl (1)CPB),2-dicyclohexylphosphino-2,-(N,N-dimethylamino)biphenyl (DCDMB).Preferred ligands for palladium-catalyzed reactions include BINAP, DBPB,DCPB, and DCDMB. Preferred ligands for nickel-catalyzed reactionsinclude DPPF or 1,10-phenanthroline. Examples of suitable bases includesodium t-butoxiode, potassium t-butoxide, cesium carbonate, potassiumcarbonate, potassium phosphate or cesium fluoride, with sodiumt-butoxide, potassium phosphate or cesium carbonate preferred dependingon the other functionality present in 70 and the amine being coupled.Suitable solvents include aromatic hydrocarbons such as benzene,toluene, or xylenes; ethers such as dimethoxyethane (DME) or1,4-dioxane; or amides such as N,N-dimethylformamide,N,N-dimethylacetamide or N-methylpyrrolidinone. Preferred solventsinclude toluene, DME and 1,4-dioxane. The coupling reaction may becarried out at a temperature of 20–160 C, preferably 20–100 C, and mostpreferably at the lowest possible temperature that provides reactiontimes of less than 24 hours. For representative methodologies,catalysts, examples of conditions and reviews of these types ofpalladium-catalyzed coupling reactions see: J. P. Wolfe, et al., Acc.Chem. Res., 31:805–18(1998), C. G. Frost, et al., J. Chem. Soc., PerkinTrans 1, 2615–23 (1998) and J. P. Wolfe, J. Org. Chem., 65:1158–74(1998). For examples of nickel-catalyzed reactions see J. P. Wolfe andS. L. Buchwald, J. Am. Chem. Soc., 119:6054–58 (1997). The nitrile 70can be converted to the BOC-protected amidine by treating with lithiatedtert-butylcarbamate (Aldrich Chemical Company, WI, USA). The amidine 72is obtained by treating 71 with TFA.

After completion of the biaryl species, amidine 22 is completed eitherthrough amidination of the methyl carboxylate 23 (Scheme 2), or bydeprotection of Boc-amidine 21 with trifluoroacetic acid or hydrochloricacid in an organic solvent such as dioxane.

When not commercially available, arylboronic acids of formulas 25 and26, where Ar is phenyl, naphthyl, or heterocycle, any of which areoptionally substituted, can be synthesized by the methods illustrated inScheme 7. When Y is Br, I, or Cl and Ar is tolerant to strong basicand/or nucleophilic conditions, the preferred method involveslithium/halogen exchange with n-BuLi followed by treatment withtrimethyl borate, triisopropyl borate, or triethyl borate to givecompounds of formula 26 where R¹⁰ is Me, Et, iPr, or H. Alternatively,regioselective metalation of 24 can be directly achieved with n-BuLi ort-BuLi when Y is H and an ortho directing group is present in Ar. Insuch cases, treatment of the metalated species with trimethyl boratetriisopropyl borate, or triethyl borate gives rise to compounds offormula 26 where R¹⁰ is Me, Et, iPr or H. Examples of ortho directinggroups suitable for this transformation include but are not limited toOCH₂OCH₃, SO₂NR², CONR₂, CONHR, NHCOR, NHCO₂R, and CSNHR (Mark, R., etal, J. Org. Chem. 47: 2101 (1982); Townsend, C., et al., TetrahedronLett. 3923 (1981)). When Ar contains functional groups that aresensitive to base and/or nucleophiles, conversion of 24, where Y is Br,I, Cl, or OTf to arylboronic acids of formula 25 can be effected usingone of several methods involving palladium(0)-mediated boronation ofarylhalides (Ishiyama, T., et al., J. Org. Chem. 60: 7508 (1995)).Examples of this transformation include but are not limited to treatmentof 24 with: 1) Pd(PPh₃)₄, (PPh₃)₂PdCl₂, or PdCl₂(dppf), pinacolborane,and Et₃N in dioxane at 100° C. (Murata, M., et al., J. Org. Chem. 65:164(2000)); 2) Pd(OAc)₂,(2′-Dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine,bis(pinacolato)diboron, and K₃PO₄ in toluene at 95° C. (Old, D. W., etal., J. Am. Chem. Soc. 120:9722 (1998)); 3) PdCl₂(dppf),bis(pinacolato)diboron, and KOAc in DMSO (Ishiyama, T., et al., J. Org.Chem. 60:7508 (1995)). Suitable reaction times for this transformationare 12–24 hr.

Scheme 8 illustrates an alternate approach to compounds of Formula Iwhere X=O or S, and R¹=halo, alkylthio, aralkylthio, arylthio, alkyloxy,aralkyloxy or aryloxy. A heterocycle 27 appropriately substituted with aleaving group L may be substituted with an anion of R¹ to giveintermediate 28. When L=halo, the halide can be left alone to giveR¹=halo. The amine 29 is then derived from reduction of the nitro group.Appropriate reagents to effect reduction of the nitro functionalityinclude hydrogen gas in the presence of a catalyst such as palladium orplatinum metal deposited on carbon or barium sulfate in any number ofsolvents such as methanol, ethanol, ethyl acetate, DMF, or THF. Morepreferably, tin(II) chloride may be employed as a reductant in a solventsuch as methanol or ethanol. Alternatively, metals such as zinc or iron(Stanetty, P. and Kremslehner, M., Heterocycles 48: 259 (1998)) may alsobe used. When R¹ is halo, titanium(III) chloride in HCl (see Ho, Wong,Synthesis 45 (1974)) is the preferred reducing reagent. The amine 29 canthen be converted to the sulfonyl chloride 30 by diazotization in thepresence of sulfur dioxide and copper(II) chloride (Ramsay, G. C. etal., J. Am. Chem. Soc. 93:1166–1171 (1971), European Patent EP 983982).The sulfonyl chloride 30 can then be treated with sodium sulfite andsodium bicarbonate to afford the sodium sulfinate 31 (Field L. andClark. R. D., Organic Synthesis Collective Vol. IV, 674–677, John Wileyand Sons, Inc. 1963). The sulfinate 31 can be converted to sulfone 32 byreacting the sulfinate 31 with an alkyl or aryl group appropriatelysubstituted with a leaving group in a solvent such as ethanol (Field L.and Clark. R. D., Organic Synthesis Collective Vol. IV, 674–677, JohnWiley and Sons, Inc. 1963).

Scheme 9 illustrates a specific example of the method shown in Scheme 8.The sulfinate 33 can be obtained by treating4-nitro-5-bromo-thiophene-2-carboxylic acid methyl ester (Dell'Erba, C.and Spinelli, D., Tetrahedron 21: 1061 (1965); Dell'Erba, C. et al., J.Chem. Soc., Perkin Trans 2, 1779 (1989)) according to scheme 8. Thesulfinate 33, can be treated with 34 (Hazelton, C. J. et al.,Tetrahedron, 51:5597 (1995)) in a solvent such as aqueous ethanol withacetic acid as catalyst to give the sulfone 35. Sulfone 35 is treatedwith sodium dithionite in aqueous ethanol to afford 36 (Hazelton, C. J.et al., Tetrahedron, 51:5597 (1995)), which can be cross-coupled to anaryl residue using the methods described in Scheme 6 to give compoundsof formula 37. Both compound 36 and 37 can be treated with hot formicacid to give compounds 42 and 38 respectively. Benzimidazoles 38 and 42can then be alkylated to give 39–41 and 43–44 respectively. These esterscan be converted to their amidines by the methods described in Scheme 2.

Scheme 9b illustrates approaches to 1-alkyl-5-sulfonyl-benzimidazoles ofcompounds of Formula X, where R=H, halo, alkyl, alkyloxy, and R₁=alkylor aryl. Appropriately substituted sulfinate can be prepared from thecorresponding sulfonyl chloride in a manner similar to that described inscheme 11. Reaction of the appropriately substituted arylsulfinate 74with the bromo-nitro-thiophene, 1 yields a mixture of mono- andbis-sulfone adducts. Thiomethoxide addition at −78° C. chemoselectivelyoccurs at the 5-position of the thiophene for both adducts, giving theintermediate 75. The aniline 75 is converted to the arylhalide 76 underSandmeyer diazotization conditions (Doyle, M. P. et al., J. Org. Chem.42, 2426 (1977)). Heating this halo-nitroarene with an amine orarylamine at 60–80° C. in the presence of a base (NaOAc or DIEA) yieldsthe substituted aniline 77. Reduction of the nitro group (e.g. Fe/AcOHin ethanol) followed by heating in formic acid gives the benzimidazole78, which can be converted to the amidine 79 as described in Scheme 2.

The synthesis of compounds of formulas 48 and 49, having twometa-substitutions on the phenyl ring with respect to the sulfone aredescribed in Scheme 10. The tert-butyl phenol ether in compound 45 canbe deprotected using a strong acid treatment such as TFA or HCl in DCMor dioxane, respectively. The free phenol as in compound 46 can bealkylated under standard conditions with alkyl halide and a base,preferably Cs₂CO₃ in acetone, to furnish compounds described by formula47. Examples of alkylating agents (R¹¹) include but are not limited toallyl bromide, benzyl bromide, methyl iodide, 2-bromoacetate, and2-bromoacetamide. The carboxylic acid ester in formula 47 can bedirectly converted to the amidine or a masked amidine as described inScheme 2 to give compounds of formula 48. Alternatively, 47 can becross-coupled with a variety of arylboronic acids and heterocyclicboronic acids as shown in Scheme 6, followed by amidination aspreviously described to afford compounds contained in formula 49.

Scheme 11 illustrates yet another approach to compounds of Formula Iwhere X=O or S, R¹=halo, alkylthio, aralkylthio, arylthio, alkyloxy,aralkyloxy or aryloxy. A sulfonyl chloride 50, where Ar is aryl orheteroaryl, is treated with sodium sulfite and sodium bicarbonate toafford the sodium sulfinate 51 (Field L. and Clark. R. D., OrganicSynthesis Collective Vol. IV, pp. 674–677, John Wiley and Sons, Inc.(1963)). The sulfinate 51 can be converted to sulfone 3 by reacting thesulfinate 51 with 1. The sulfone 3 can then be treated as described inscheme 1 to give intermediate 4, which can be converted to an amidine bythe methods described in scheme 2.

Scheme 12 illustrates a specific example of the method shown in scheme11. Pyridylsulfonylchloride (Aldrich), 52 is converted to the sulfinicacid and reacted with thiophene ester 54 to give the sulfone, 55. Thesulfone (55) is then treated as described in scheme 1 to give theintermediate 56. Intermediate 56 can be treated with ammonia or zincdust in acetic acid (Krutosikova, A.; Sleziak, R. Collect. Czech. Chem.Commun. (1996) 61, 1627–1636) to give compounds 58 or 59 respectively.The amide 58 can be converted to the biaryl compound 60 using methodsdescribed in scheme 6. Compounds 56, 58, 59, and 60 can be converted tothe corresponding amidines 57, 61, 62, and 63 respectively, as describedin scheme 2.

Scheme 13 illustrates a general route to compounds of formula I where Aris substituted 3-pyridyl (when A=N) and compounds of formula II wherethe phenylsulfone moiety has an amino group at the 4-position (A=N, C).The sulfone 56 is prepared as described in scheme 12 and then treated asdescribed in scheme 1 to give the corresponding amidine, which isBOC-protected to give intermediate 64. The Cl group in intermediate 64can be displaced with an amine to give a substituted aminopyridine,which upon treatment with trifluoroacetic acid gives compound 65.Intermediate 56 can be treated with Zn dust (Krutosikova, A.; Sleziak, RCollect. Czech. Chem. Commun. (1996) 61, 1627–1636) to give thedehalogentaed product 59, which can also be converted to the amidine 63.The halogen Y in intermediate 56 (when A=N or C) can also be substitutedwith ammonia to give 58, which can be converted to the amidine 62.Alternatively, 58 can be converted to the biaryl compound 60 usingmethods described in scheme 6.

Scheme 14 illustrates the general approach to the synthesis of compoundsof formula II, where R⁵ is 2-aminophenyl or 2-amino-4-pyridyl and theamino groups are further substituted. The Biaryl-intermediate 80 can beprepared either by treating 20 with an appropriately substitutedarylboronate or boronic acid using conditions similar that described inscheme 6a or by treating 66 with an appropriately substituted arylhalideor triflate using conditions similar to that described in scheme 6b.Intermediate 2 can be converted to the corresponding substituted ureas81 using conditions such as p-nitrophenylchloroformate in the presenceof a base such as pyridine, followed by addition of a substituted amine,followed by treatment with an acid such as trifluoroacetic acid. In analternative approach intermediate 80 can be treated with reagents suchas substituted isocyanates in the presence of a base such astriethylamine, followed by treatment with an acid such astrifluoroacetic acid to give the corresponding substituted ureas 81. Theintermediate 2 can also be converted to the corresponding amides 82using reagents such as substituted acids in the presence of couplingreagents such as EDCI and HOBt, followed by treatment with an acid suchas trifluoroacetic acid. The intermediate 80 can also be converted tothe corresponding amides or sulfonamides 82 by treating with acidchlorides, sulfonyl chlorides, anhydrides, or activated esters in thepresence of a base such as triethylamine, followed by treatment with anacid such as trifluoroacetic acid.

Scheme 15 illustrates a general approach to the synthesis of compoundsof formula II, where R⁵ is 2,4-diaminophenyl and the amino groups arefurther substituted. Intermediate 83 can be synthesized in a mannersimilar to that described in scheme 14. When R²³ is a masked amine suchas nitro, or trimethylsilylethyl carbamate (Teoc), the ortho-aniline maybe functionalized with a variety of reagents such as acid chlorides,sulfonyl chlorides, activated carboxylic esters, and isocyanates to givecompound 84. When R²³ of compound 84 is a nitro-group it can be reducedto an amino-group under mild conditions using iron powder in ethanolicaqueous ammonium chloride (R¹=NO₂) and further reacted with reagentssuch as acid chlorides, sulfonyl chlorides, activated carboxylic esters,isocyanates, guanidinylating reagents, alkyl halides, and aldehydes(reductive amination) to give compound 86. When R²³ is a protectedaniline it can be deprotected. For example a Teoc group is removed bytreatment with a fluoride anion source such as tetrabutylammoniumfluoride in THF to give compound 85. This can be further functionalizedin the manner described above.

Scheme 16 illustrates approaches to providing the arylguanidinefunctionality of compounds of Formula II where R⁵ is a substitutedphenyl group with a 4-amino functionality. Depending on the nature ofthe group R, several methods may be employed in the guandinylation ofthe aniline 87 to compounds 89, 90 or 92. When R¹ is H or alkyl,unsubstituted or N,N′-bis-substituted arylguanidines 90, can besynthesized by the reaction of the aniline with a diprotected S-alkylisothiourea (e.g. bis-Boc-SMe-isothiourea). This reaction can generallybe promoted by either of two reaction conditions; 1) a mercury salt(e.g. HgCl₂) with triethylamine at 50° C. [WO-99/206208] or 2) aceticacid in methanol at 40° C. [Tetrahedron Lett., 43, 6563–6566 (2000)].When R¹ is a strong electron-withdrawing group (e.g. nitro), or containsother acid-sensitive functionality, the mercury reagent is preferred.When R³¹ is, or, contains an amino-group, selective guanidinylation atthe 4-amino group can be achieved using the acetic acid/methanolconditions. Monosubstituted N′-arylguanidines 89 can be synthesized byreaction of the aniline (R¹=H, alkyl) with a substituted diprotectedS-alkyl isothiourea (e.g. alkylN(Boc)-C(SMe)=NBoc). The acetic acid inmethanol reaction condition is the method of choice for thistransformation. The monoalkyl isothiourea starting materials can besynthesized via alkylation of the bis-Boc-SMe-isothiourea with a hydridebase/alkyl halide [J. Med. Chem., 36, 2956–2963 (1993)] or Mitsunobureaction [J. Med. Chem., 43, 2362–2370 (2000)].

Alternatively, arylguanidines can be prepared from correspondingthiourea intermediates 91 and 94. Preparation of 91 is achieved byreacting the aniline scaffold with an isothiocyanate. Alternatively, theaniline scaffold may be converted to the isothiocyanate [J. Org. Chem.,51, 2613–2615 (1986)] followed by reaction with an alkylamine, aniline,hydrazide, or alkoxylamine to give 94. The thiourea may then beconverted to the guanidine using mercuric oxide in the presence ofexcess amine (e.g. ammonia, methylamine, etc.) [J. Chem. Soc, 475, 479(1949)].

Scheme 17 illustrates the general approach to the synthesis of compoundsof formula II, represented by examples 213–214. The alcohol 95 can beconverted to the corresponding mesylate 98 in the presence of amethanesulfonyl chloride and a base such as triethylamine, in a solventsuch as dichloromethane. Mesylate 98 can be treated with a variety ofsubstituted nucleophiles in the presence of a base such as triethylaminein a solvent such as dichloromethane, followed by treatment with an acidsuch as trifluoroacetic acid to give the corresponding product 99.Alternatively, compound 95 can be converted to the correspondingaldehyde 96 in the presence of an oxidizing agent such as manganesedioxide. Aldehyde 96 can then be treated with a variety of phosphorusylides to give the corresponding olefin, (see Paterson, I., et al., Org.Lett. 5(1):35–38 (2003)), followed by treatment with an acid such astrifluoroacetic acid to give compound 100. For example, aldehyde 96 istreated with (diethoxy-phosphorylmethyl)-phosphonic acid diethyl esterin the presence of a base such as sodium hydride in a solvent such astetrahydrofuran, followed by treatment with trimethylsilyl iodide and asolvent such as dichloromethane to give compound 97 (see Ruzziconi, R.et al., J. Org. Chem. 68(3):736–742 (2003)).

The following examples are illustrative, but not limiting, of the methodand compositions of the present invention. Other suitable modificationsand adaptations of the variety of conditions and parameters normallyencountered and obvious to those skilled in the art are within thespirit and scope of the invention.

EXAMPLES Example 14-(4′-Hydroxy-[1,1′;3′,1′]terphenyl-3′-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 4-Methoxymethoxy-biphenyl

To an oven-dried flask containing a stirbar was added 4-hydroxybiphenyl(1.70 g, 10 mmol), toluenesulfonic acid (190 mg, 1.1 mmol),dichloromethane (DCM, 5 mL), and dimethoxypropane (5 mL). The solutionwas heated and stirred at 40° C. for 48 h. Solid NaHCO₃ (200 mg) wasadded, followed by EtOAc (100 mL) and NaOH (1N, 20 mL). The layers wereseparated and the organic layer was further extracted with NaOH (1N,12×20 mL), brine (30 mL), and was dried over sodium sulfate. Removal ofthe solvents in vacuo yielded the title compound (385 mg, 18%) which wasused without further purification. ¹H-NMR (CDCl₃): δ 7.56 (m, 4H), 7.44(m, 2H), 7.34 (m, 1H), 7.14 (m, 2H), 5.24 (s, 2H), 3.54 (s, 3H).

b) 4-Methoxymethoxy-biphenyl-3-yl-boronic acid

Butyllithium (2.5M, 1.44 mL, 3.6 mmol) was added over 5 min to a stirredsolution of 4-methoxymethoxy-biphenyl (from the previous step 385 mg,1.8 mmol) in Et₂O (18 mL) at 0° C. The reaction was allowed to warm tort and stirred for 2 h. The solution was cooled to −78° C. andtrimethylborate (1.23 mL, 10.8 mmol) in THF (10 mL) was quickly added.The reaction warmed to rt over 1 h and was stirred 1 h at rt, duringwhich it became cloudy and a gelatin-like residue appeared. EtOAc (70mL) and water (30 mL) were added along with HCl (1N, 1 mL). The biphasicsolution was stirred for 10 min and the layers were separated. Theorganic layer was further extracted with HCl (0.1N, 3×20 mL), brine (60mL), and was dried over sodium sulfate. Removal of the solvents in vacuofollowed by chromatography of the residue (20–40% EtOAc in hexanes)yielded the title compound (135 mg, 29%) as a light-brown solid. Thetitle compound exists as a mixture of boronic acids and anhydrides inCDCl₃, therefore the reported NMR signals represent pairs or groups ofrelated signals. ¹H-NMR (CDCl₃): δ 8.07 (d, 1H, J=2.6 Hz), 7.60 (m, 3H),7.42 (m, 2H), 7.31 (m, 1H), 7.19 (d, 1H, J=8.6 Hz), 6.20 (s, 1H), 5.32(s, 2H), 3.77 (s, 1H), 3.53 (s, 3H).

c){Imino-[4-(4′-methoxymethoxy-[1,1′;3′,1′]terphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

A 2-dram vial with a septa-containing screwcap was charged with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (50 mg, 0.1 mmol)),4-methoxymethoxy-biphenyl-3-yl-boronic acid (from the previous step 103mg, 0.4 mmol), aqueous Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), ethanol (0.8 mL)and toluene (1.6 mL). A stirbar was added, the vial was capped, thesolution was sparged with argon for 10 min, and Pd(PPh₃)₄ (29.4 mg,0.025 mmol) was added. The biphasic solution was vigorously stirredunder inert atmosphere at 80° C. for 16 h, then was cooled to rt. EtOAc(20 mL) and water (10 mL) were added and the layers were separated. Theorganic layer was washed with saturated NaHCO₃ (2×10 mL), brine (10 mL)and was dried over sodium sulfate. Removal of the solvents in vacuofollowed by preparative TLC (25% EtOAc in hexanes) of the residueyielded the title compound (15 mg, 24%) as a light-yellow glass. ¹H-NMR(CDCl₃): δ 8.27 (t, 1H, J=1.9), 7.99 (ddd, 1H, J=1.2, 1.6, 7.9 Hz), 7.96(s, 1H), 7.84 (dt, 1H, J=1.4, 7.9 Hz), 7.57 (m, 5H), 7.45 (m, 2H), 7.36(m, 1H), 7.30 (m, 1H), 5.18 (s, 2H), 3.41 (s, 3H), 2.59 (s, 3H), 1.52(s, 9H). ESI-MS (m/z): Calcd. for C₃₁H₃₂N₂O₆S₃: 624.8; found: 624.9.

d)4-(4′-Hydroxy-[1,1′;3′,1′]terphenyl-3′-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The{imino-[4-(4′-methoxymethoxy-[1,1′;3′,1′]terphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester ((Example 1: step c) 15 mg, 0.024 mmol) wasdissolved in DCM (5 mL), water (3 drops) was added, followed bytrifluoroacetic acid (5 mL). The solution was stirred for 2 h at rt andthe solvents were removed in vacuo. The residue was purified via HPLC(C₁₈-column, 10–70% CH₃CN over 30 min) which yielded the title compoundas a white solid (11 mg, 73%). ¹H-NMR (CD₃OD): δ 8.34 (t, 1H, J=1.6 Hz),8.32 (s, 1H), 7.98 (m, 2H), 7.66 (t, 1H, J=7.9 Hz), 7.58 (m, 2H), 7.53(d, 1H, J=2.1 Hz), 7.50 (dd, 1H, J=2.3, 8.4 Hz), 7.41 (m, 2H), 7.29 (m,1H), 7.02 (d, 1H, J=8.4 Hz), 2.71 (s, 3H). ESI-MS (m/z): Calcd. forC₂₄H₂₀N₂O₃S₃: 481.6 (M+H); found: 481.3.

Example 24-(2′-Methoxymethoxy-[1,1′;3′,1′]terphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 2-Methoxymethoxy-biphenyl

The procedure as in Example 1: step a was followed using2-hydroxybiphenyl (1.70 g, 10 mmol), p-toluenesulfonic acid (190 mg, 1.1mmol), DCM (5 mL), and dimethoxypropane (5 mL). Analogous aqueous workupyielded the title compound (225 mg, 11%) which was used without furtherpurification. ¹H-NMR (CDCl₃): δ 7.58 (m, 2H), 7.44 (m, 2H), 7.36 (m,2H), 7.32 (m, 1H), 7.25 (dd, 1H, J=1.2, 8.1 Hz), 7.12 (dt, 1H, J=1.2,7.4 Hz), 5.14 (s, 2H), 3.42 (s, 3H).

b) 4-Methoxymethoxy-biphenyl-3-yl-boronic acid

The procedure used in Example 1: step b was followed using2-methoxymethoxy-biphenyl ((Example 2: step a) 225 mg, 1.05 mmol),butyllithium (2.5M, 1.44 mL, 3.6 mmol), and trimethylborate (1.23 mL,10.8 mmol). Analogous aqueous workup and SiO₂ flash chromatographyyielded the title compound (123 mg, 45%) as a light brown solid. Thetitle compound exists as a mixture of boronic acids and anhydrides inCDCl₃; therefore the reported NMR signals represent pairs or groups ofrelated signals. ¹H-NMR (CDCl₃): δ 7.53 (m, 1H), 7.23 (m, 2H), 7.12 (m,3H), 7.05 (m, 1H), 6.94 (m, 1H), 4.28 (s, 2H), 3.51 (s, 1H), 2.96 (s,3H).

c){Imino-[4-(2′-Methoxymethoxy-[1,1′;3′,1′]terphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (50 mg, 0.1 mmol)),2-methoxymethoxy-biphenyl-3-yl-boronic acid ((Example 2: step b) 103 mg,0.4 mmol), Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), Pd(PPh₃)₄ (29.4 mg, 0.025mmol), ethanol (0.8 mL), and toluene (1.6 mL). Analogous aqueous workupand purification of the crude material by preparative TLC (25% EtOAc inhexanes) yielded the title compound (18 mg, 29%) as a light-yellowglass. ¹H-NMR (CDCl₃): δ 8.24 (t, 1H, J=1.7 Hz), 8.06 (s, 1H), 7.95(ddd, 1H, J=1.2, 1.9, 7.9 Hz), 7.86 (dt, 1H, J=1.4, 7.7 Hz), 7.60 (t,1H, J=7.9 Hz), 7.56 (m, 2H), 7.2–7.45 (m, 6H), 4.22 (s, 2H), 2.60 (s,3H), 2.47 (s, 3H), 1.48 (s, 9H). ESI-MS (m/z): Calcd. for C₃₁H₃₂N₂O₆S₃:624.8; found: 624.9.

d)4-(2′-Methoxymethoxy-[1,1′;3′,1′]terphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure used in Example 1: step d was followed using{imino-[4-(2′-methoxymethoxy-[1,1′;3′,1′]terphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester ((Example 2: step c) 18 mg, 0.029 mmol). Analogouspurification by HPLC yielded the title compound as a white solid (17 mg,94%). ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 8.27 (t, 1H, J=1.7 Hz), 7.99 (ddd,1H, J=1.2, 1.9, 7.9 Hz), 7.92 (ddd, 1H, J=1.2, 1.6, 7.9 Hz), 7.66 (dt,1H, J=0.5, 7.9 Hz), 7.52 (m, 2H), 7.45 (m, 2H), 7.36 (m, 2H), 7.26 (ddd,2H, J=1.7, 3.5, 7.2 Hz), 7.07 (t, 1H, J=7.9 Hz), 2.71 (s, 3H). ESI-MS(m/z): Calcd. for C₂₄H₂₀N₂O₃S₃ (M+H): 481.6; found: 481.2.

Example 33′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-3-carboxylicacid isopropyl ester trifluoroacetate

a) 3-Bromo-2-methyl-benzoic acid isopropyl ester

Thionyl chloride (6 mL) was addend over 1 min to a 0° C. suspension of3-bromo-2-methyl benzoic acid (2.15 g, 10 mmol) in DCM (10 mL). After 30min of stirring, THF (5 mL) was added to induce dissolution. The nowhomogeneous solution was stirred for 24 h at rt and the volatilecomponent were removed in vacuo. A portion of the crude acid chloridewas dissolved in dry isopropyl alcohol (10 mL) and pyridine (2 mL) wasadded. After stirring for 4 h at rt, the volatile components wereremoved in vacuo. The residue was partitioned between EtOAc (70 mL) andHCl (1M, 30 mL) and the layers were separated. The organic layer waswashed with HCl (1M, 10 mL), NaHCO₃ (3×20 mL), water (30 mL), brine (30mL), and was dried over sodium sulfate. Removal of solvent in vacuoyielded the title compound as a light-yellow oil which was used withoutfurther purification. ¹H-NMR (CDCl₃): δ 7.69 (d, 2H, J=7.7 Hz), 7.11 (t,1H, J=7.9 Hz), 5.26 (heptet, 1H, J=6.3 Hz), 2.63 (s, 3H), 1.39 (d, 6H,J=6.3 Hz).

b) 2-Methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoicacid isopropyl ester

A 2-dram vial with a septa-containing screwcap was charged with astirbar, 3-bromo-2-methyl-benzoic acid isopropyl ester ((Example 3: stepa) 257 mg, 1 mmol), PdCl₂(PPh₃)₂ (42 mg, 0.06 mmol), dioxane (4 mL), andtriethylamine (420 μL, 3 mmol). Upon dissolution,4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (220 μL, 1.5 mmol) was addedand the solution was vigorously stirred for 16 h at 100° C. Aftercooling to rt, EtOAc (30 mL) and water (10 mL) were added (gasevolution!) and the layers were separated. The organic layer was washedwith NaHCO₃ (2×10 mL), brine (10 mL), and was dried over sodium sulfate.Removal of the solvents in vacuo followed by SiO₂ flash chromatographyof the residue yielded the title compound (130 mg, 43%) as alight-yellow glass. ¹H-NMR (CDCl₃): δ 7.86 (dd, 1H, J=1.4, 7.4 Hz), 7.80(dd, 1H, J=1.6, 7.7 Hz), 7.23 (t, 1H, J=7.7 Hz), 5.26 (heptet, 1H, J=6.3Hz), 2.75 (s, 3H), 1.37 (m, 18H).

c)3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-3-carboxylicacid isopropyl ester

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (50 mg, 0.1 mmol)),2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acidisopropyl ester ((Example 3: step b) 92 mg, 0.3 mmol), Na₂CO₃ (2M, 0.4mL, 0.8 mmol), Pd(PPh₃)₄ (29.4 mg, 0.025 mmol), ethanol (0.4 mL) andtoluene (0.8 mL). Analogous aqueous workup and purification of the crudematerial by preparative TLC (25% EtOAc in hexanes) yielded the titlecompound (29 mg, 49%) as a colorless glass. ¹H-NMR (CDCl₃): δ 7.98 (dt,1H, J=1.6, 7.6 Hz), 7.93 (m, 2H), 7.79 (t, 1H, J=1.7 Hz), 7.58 (t, 1H,J=7.6 Hz), 7.53 (dt, 1H, J=1.6, 7.6 Hz), 7.36 (s, 1H), 7.30 (d, 1H,J=4.5 Hz), 5.27 (heptet, 1H, J=6.2 Hz), 2.58 (s, 3H), 2.35 (s, 3H), 1.51(s, 9H), 1.39 (d, 1H, J=6.2 Hz). ESI-MS (m/z): Calcd. for C₂₈H₃₂N₂O₆S₃:588.8; found: 588.9.

d)3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-3-carboxylicacid isopropyl ester trifluoroacetate

The procedure used in Example 1: step d was followed using3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-3-carboxylicacid isopropyl ester ((Example 3: step c) 29 mg, 0.049 mmol). Analogouspurification by HPLC yielded the title compound (25 mg, 83%) as a whitesolid. ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 8.05 (dt, 1H, J=1.7, 7.7 Hz),7.95 (t, 1H, J=1.7 Hz), 7.78 (m, 1H), 7.70 (t, 1H, J=7.7 Hz), 7.66 (dt,1H, J=1.4, 7.7 Hz), 7.36 (s, 1H), 7.35 (d, 1H, J=1.2 Hz), 5.22 (heptet,1H, J=6.3 Hz), 2.71 (s, 3H), 2.31 (s, 3H), 1.38 (d, 1H, J=6.3. Hz).ESI-MS (m/z): Calcd. for C₂₃H₂₄N₂O₄S₃: 489.7 (M+H); found: 489.2.

Example 43′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-carboxylicacid trifluoroacetate

a) 2-Iodo-3-methyl-benzoic acid tert-butyl ester

A 100-mL RB flask was charged with 2-iodo-3-methylbenzoic acid (1.1 g,4.2 mmol), a stirbar, Et₂O (15 mL) and DCM (35 mL) and was cooled to−78° C. under an argon atmosphere. Trifluoromethanesulfonic acid (250μL) was added over 30 sec and isobutylene was bubbled into the solution(until the solution became cloudy) using a 8″/20 gauge steel needle. Thereaction was stirred for 6 h between −78 and −20° C. Solid NaHCO₃ (250mg) was added and the solution was allowed to warm to rt with stirring.After 20 min, the solution was poured into an extraction funnelcontaining DCM (50 mL) and Na₂CO₃ (2M, 20 mL). The layers were separatedand the organic layer was washed with Na₂CO₃ (2M, 2×10 mL), water (20mL), brine (30 mL) and dried over sodium sulfate. Removal of the solventin vacuo yielded the title compound (1.05 g, 78%) which was used withoutfurther purification. ¹H-NMR (CDCl₃): δ 7.25 (m, 3H), 2.50 (s, 3H), 1.62(m, 9H).

b) 4-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoicacid tert-butyl ester

The procedure used in Example 3: step b was followed using2-iodo-3-methyl-benzoic acid tert-butyl ester ((Example 4: step a) 960mg, 3 mmol), PdCl₂(PPh₃)₂ (126 mg, 0.18 mmol), triethylamine (1.25 mL, 9mmol), and 4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (660 μL, 4.5 mmol)in dioxane (12 mL) at a reaction temperature of 80° C. Analogous aqueousworkup and purification by SiO₂ flash chromatography yielded the titlecompound (618 mg, 64%). ¹H-NMR (CDCl₃): δ 7.67 (m, 1H), 7.25 (m, 2H),2.43 (s, 3H), 1.57 (m, 9H), 1.44 (m, 12H).

c)3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-carboxylicacid tert-butyl ester

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (50 mg, 0.1 mmol)),4-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acidtert-butyl ester ((Example 4: step b) 127 mg, 0.4 mmol), Na₂CO₃ (2M, 0.8mL, 1.6 mmol), Pd(PPh₃)₄ (29.4 mg, 0.025 mmol), ethanol (0.8 mL) andtoluene (1.6 mL). Analogous aqueous workup and purification of the crudematerial by preparative TLC (25% EtOAc in hexanes) yielded the titlecompound (35 mg, 58%) as a light-yellow glass. ¹H-NMR (CDCl₃): δ 8.01(ddd, 1H, J=1.2, 1.9, 7.9 Hz), 7.92 (s, 1H), 7.83 (t, 1H, J=1.7 Hz),7.65 (m, 1H), 7.56 (t, 1H, J=7.8 Hz), 7.43 (dt, 1H, J=1.4, 7.7 Hz), 7.36(m, 2H), 2.58 (s, 3H), 2.00 (s, 3H), 1.51 (s, 9H). ESI-MS (m/z): Calcd.for C₂₉H₃₄N₂O₆S₃: 602.8; found: 602.9.

d)3′(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-carboxylicacid trifluoroacetate

The procedure used in Example 1: step d was followed using3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-carboxylicacid tert-butyl ester ((Example 4, step c) 29 mg, 0.048 mmol). Analogouspurification by HPLC yielded the title compound (23 mg, 70%) as a whitesolid. ¹H-NMR (CD₃OD): δ 8.28 (s, 1H), 7.99 (ddd, 1H, J=1.2, 1.9, 7.9Hz), 7.83 (m, 1H, J=0.5, 1.9 Hz), 7.76 (ddd, 1H, J=0.5, 1.4, 7.7 Hz),7.63 (dt, 1H, J=0.5, 7.7 Hz), 7.50 (ddd, 1H, J=1.2, 1.6, 4.9 Hz), 7.49(ddd, 1H, J=0.7, 1.4, 7.7 Hz), 7.40 (t, 1H, J=7.7 Hz), 2.72 (s, 3H),2.02 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₁₈N₂O₄S₃ (M+H): 447.6; found:447.1.

Example 54-(6′-Hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

a) (2-Iodo-3-methyl-phenyl)-methanol

Thionyl chloride (6 mL) was added over 1 min to a 0° C. solution of2-iodo-3-methyl benzoic acid (3.0 g, 11.4 mmol) in DCM (10 mL). Thesolution was stirred for 24 h at rt and the volatile components wereremoved in vacuo. A portion of the crude acid chloride (955 mg) wasdissolved in THF (15 mL) and NaBH₄ (380 mg, 10 mmol) was added. Afterstirring for 90 min, multiple spots were evident by TLC analysis. Thereaction mixture was cooled to −78° C. and solid LiAlH₄ (300 mg, 7.91mmol) was added. The reaction was stirred for 30 min, after which TLCanalysis showed one major spot. The reaction was quenched by addition ofEtOAc (10 mL) and was slowly poured into a vigorously stirred solutionof HCl (1M, 30 mL). EtOAc (70 mL) was added, the layers were separated,and the organic layer was washed with NaHCO₃ (3×15 mL), water (15 mL),brine (40 mL), and was dried over sodium sulfate. Removal of the solventin vacuo yielded the title compound (752 mg, 89%) as a thick oil whichwas used without further purification. ¹H-NMR (CDCl₃): δ 7.27 (m, 2H),7.20 (m, 2H), 4.74 (m, 2H), 2.50 (s, 3H), 2.0 (br s, 1H).

b) 7-Methyl-3H-benzo[c][1,2]oxaborol-1-ol

Butyllithium (2.5 M, 2.91 mL, 7.3 mmol) was added dropwise to a −78° C.solution of aryl halide ((Example 5: step a) 723 mg, 2.91 mmol) in Et₂O(12 mL). The solution was stirred at −78° C. for 2 h and trimethylborate(3.3 mL, 29.1 mmol) was added in one portion. The solution was warmed tort over 15 min and stirred for 1 h at rt (appearance of gelatin-likeppt). EtOAc (80 mL) and HCl (0.1 N, 30 mL) were added and the biphasicsolution was stirred for 15 min. The layers were separated and theorganic layer was washed with HCl (0.1N, 2×10 mL), water (10 mL), brine(30 mL), and was dried over sodium sulfate. Concentration of thesolution in vacuo yielded an oily solid which further solidified upontrituration with hexanes. The crude title compound (contaminated withbutylboronate products) was used without further purification, existingas a mixture of the cyclic half-ester and the free boronic acid. ¹H-NMR(CDCl₃): δ 7.1–7.4 (m, 3H), 5.23 (m, 2H), 2.57 (s, 3H).

c){[4-(6′-Hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (50 mg, 0.1 mmol)),7-methyl-3H-benzo[c][1,2]oxaborol-1-ol ((Example 5: step b) 59 mg, 0.4mmol), Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), Pd(PPh₃)₄ (29.4 mg, 0.025 mmol),ethanol (0.8 mL) and toluene (1.6 mL). Analogous aqueous workup andpurification of the crude material by preparative TLC (40% EtOAc inhexanes) yielded the title compound (21 mg, 40%) as a light-yellowglass. ¹H-NMR (CDCl₃): δ 7.96 (m, 2H), 7.86 (m, 1H), 7.54 (m, 1H), 7.43(m, 1H), 7.18–7.38 (m, 3H), 4.53 (d, 1H, J=13.3 Hz), 4.45 (d, 1H, J=13.3Hz), 2.54 (s, 3H), 1.96 (s, 3H), 1.49 (s, 9H). ESI-MS (m/z): Calcd. forC₂₅H₂₈N₂O₅S₃: 532.7; found: 532.9.

d)4-(6′-Hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

The procedure used in Example 1: step d was followed using{[4-(6′-hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 5, step c) 21 mg, 0.039 mmol). Analogouspurification by C₁₈-HPLC yielded the title compound (19 mg, 86%) as awhite solid. ¹H-NMR (CD₃OD): δ 8.33 (s, 1H), 8.04 (ddd, 1H, J=1.2, 1.9,7.9 Hz), 7.88 (m, 1H), 7.71 (dt, 1H, J=0.5, 7.7 Hz), 7.57 (ddd, 1H,J=1.2, 1.6, 7.7 Hz), 7.42 (m, 1H), 7.34 (t, 1H, J=7.7 Hz), 7.26 (m, 1H),4.20 (s, 2H), 2.72 (s, 3H), 1.99 (s, 3H). ESI-MS (m/z): Calcd. forC₂₀H₂₀N₂O₃S₃ (M+H): 433.6; found: 433.1.

Example 64-(3′-formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 3-Bromo-N-methoxy-2,N-dimethyl-benzamide

Thionyl chloride (6 mL) was added over 1 min to a 0° C. solution of2-iodo-3-methyl benzoic acid (3.0 g, 11.4 mmol) in DCM (10 mL). Thesolution was stirred for 24 h at rt and the volatile components wereremoved in vacuo. A portion of the crude acid chloride (1.56 g, 6.7mmol) was dissolved in dry DCM (15 mL). N,O-dimethylhydroxylamine (814mg, 8.35 mmol) was added followed by triethylamine (2.80 mL, 20.1 mmol).After stirring for 18 h at rt the solvents were removed in vacuo. Afterpartitioning the residue between EtOAc (60 mL) and aqueous HCl (1N, 20mL), the organic layer was further extracted with HCl (1N, 10 mL), NaOH(1N, 3×10 mL), water (10 mL), brine (20 mL), and was dried over sodiumsulfate. Removal of the solvent in vacuo yielded the title compound(1.58 g, 92%) which was used in subsequent reactions without furtherpurification. ¹H-NMR (CDCl₃): δ 7.57 (dd, 1H, J=1.2, 7.9 Hz), 7.21 (d,1H, J=7.4 Hz), 7.08 (t, 1H, J=7.7 Hz), 3.39 (br s, 3H), 3.35 (br s, 3H),2.36 (s, 3H).

b) 3-Bromo-2-methyl-benzaldehyde

Lithium aluminum hydride (201 mg, 5.31 mmol) was added in one portion toa −78° C. solution of 3-bromo-N-methoxy-2,N-dimethyl-benzamide ((Example6: step b) 1.1 g, 4.24 mmol) in THF (25 mL). After stirring for 1 h at−78° C., the hydride reagent was quenched with EtOAc (10 mL), and thesolution was slowly poured into a vigorously stirred mixture of citricacid (10%, 30 mL) and EtOAc (50 mL). After separating the layers, theorganic layer was washed with NaHCO₃ (3×20 mL), water (20 mL), and brine(30 mL). The solution was dried (sodium sulfate) and the solvent wasremoved in vacuo, giving the title compound (813 mg, 96%) as a colorlessoil which was used without further purification. ¹H-NMR (CDCl₃): δ 10.28(s, 1H), 7.80 (m, 2H), 7.25 (m, 1H), 2.78 (s, 3H).

c) 1-Bromo-3-dimethoxymethyl-2-methyl-benzene

The 3-bromo-2-methyl-benzaldehyde ((Example 6: step c) 813 mg, 4.08mmol) was dissolved in dry MeOH (50 mL) and trimethyl orthoformate (8mL). Toluenesulfonic acid (100 mg) was added and the solution wasstirred for 6 h at rt. Solid NaHCO₃ (200 mg) was added, the solution wasstirred for 30 min, and the volatile components were removed in vacuo.The residue was dissolved in dry EtOAc (10 mL), the solution wasfiltered (45 micron filter), and the solvent was removed in vacuo. ¹HNMR analysis of the crude material (918 mg, 92%) revealed approximatelya 90% conversion of the starting material to the title compound, whichwas used without further purification. ¹H-NMR (CDCl₃): δ 7.47 (dd, 1H,J=1.2, 8.1 Hz), 7.44 (dd, 1H, J=0.9, 7.9 Hz), 6.99 (t, 1H, J=7.9 Hz),5.37 (s, 1H), 3.25 (s, 6H), 2.37 (s, 3H).

d) 2-Formyl-1-methyl-phenylboronic acid

The 1-bromo-3-dimethoxymethyl-2-methyl-benzene ((Example 6: step c) 500mg, 2 mmol), butyllithium (2.5 M, 1 mL, 2.5 mmol), and trimethylborate(2.3 mL, 20 mmol) were reacted as in Example 5: step b. After aqueousworkup, the residue was dissolved in acetone (18 mL) and HCl (1N, 2 mL).After standing for 18 h at rt, the volatile components were removed invacuo and the residue was purified by SiO₂ flash chromatography (25–40%EtOAc in hexanes) to give the title compound (126 mg, 38%). The titlecompound exists as a mixture of boronic acids and anhydrides in CDCl₃,therefore the reported NMR signals represent pairs or groups of relatedsignals. ¹H-NMR (CDCl₃): δ 10.44 (s, 1H), 8.38 (dd, 1H, J=1.4, 7.4 Hz),7.49 (t, 1H, J=7.5 Hz), 3.12 (s, 3H).

e)[4-(3′-Formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl)-carbamicacid tert-butyl ester

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27) 50 mg, 0.1 mmol), Pd(PPh₃)₄ (29.4mg, 0.025 mmol), 2-formyl-1-methyl-phenylboronic acid ((Example 6: stepd) 65 mg, 0.4 mmol), Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), ethanol (0.8 mL) andtoluene (1.6 mL). Analogous aqueous workup and purification of the crudematerial by preparative TLC (25% EtOAc in hexanes) yielded the titlecompound (30 mg, 56%) as a light-yellow glass. ¹H-NMR (CDCl₃): δ 10.36(s, 1H), 8.02 (s, 1H), 7.99 (ddd, 1H, J=1.4, 1.9, 7.7 Hz), 7.93 (t, 1H,J=1.6 Hz), 7.87 (dd, 1H, J=3.0, 6.3 Hz), 7.60 (dt, 1H, J=0.5, 7.7 Hz),7.54 (dt, 1H, J=1.5, 7.7 Hz), 7.43 (m, 2H), 2.57 (s, 3H), 2.49 (s, 3H),1.51 (s, 9H). ESI-MS (m/z): Calcd. for C₂₅H₂₆N₂O₅S₃: 530.7; found:530.9.

f)4-(3′-Formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure used in Example 1: step d was followed using{[4-(3′-formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 6: step e) 30 mg, 0.056 mmol). Analogouspurification by HPLC yielded the title compound (22 mg, 73%) as a whitesolid. The aldehyde is hydrated according to proton NMR analysis. ¹H-NMR(CD₃OD): δ 8.36 (s, 1H), 8.07 (ddd, 1H, J=1.4, 1.9, 7.7 Hz), 7.98 (t,1H, J=1.5 Hz), 7.72 (dt, 1H, J=0.5, 7.7 Hz), 7.67 (dt, 1H, J=1.5, 7.9Hz), 7.63 (dd, 1H, J=1.4, 7.7 Hz), 7.33 (t, 1H, J=7.7 Hz), 7.22 (dd, 1H,J=1.4, 7.4 Hz), 5.56 (s, 1H), 2.76 (s, 3H), 2.22 (s, 3H). ESI-MS (m/z):Calcd. for C₂₀H₁₈N₂O₃S₃: 431.6 (M+H); found: 431.3, 448.2 (M+H₂O).

Example 74-(5′-Hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 3-Hydroxymethyl-2-methyl-phenylboronic acid

Butyllithium (2.5 M, 4 mL, 10 mmol), 3-iodo-4-methyl-benzyl alcohol (1g, 4 mmol), and trimethylborate (6 mL, 53 mmol) were reacted as inExample 5: step b. Aqueous workup and purification by SiO₂ flashchromatography (40–50% EtOAc in hexanes) yielded the title compound (180mg, 27%). The title compound exists as a mixture of boronic acids andanhydrides in CDCl₃, therefore the reported NMR signals represent pairsor groups of related signals. ¹H-NMR (CDCl₃): δ 7.06–7.30 (m, 3H), 4.56(s, 3H), 4.16 (br s, 1H), 2.32 (s, 3H).

b){[4-(5′-Hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (100 mg, 0.2 mmol)), Pd(PPh₃)₄ (59 mg,0.05 mmol), 3-hydroxymethyl-2-methyl-phenylboronic acid ((Example 7:step a) 105 mg, 0.63 mmol), Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), ethanol (0.8mL) and toluene (1.6 mL). Analogous aqueous workup and purification ofthe crude material by SiO₂ flash chromatography (25–50% EtOAc inhexanes) yielded the title compound (72 mg, 67%) as a light-yellowglass. ¹H-NMR (CDCl₃): δ 8.00 (s, 1H), 7.96 (dt, 1H, J=2.1, 4.4 Hz),7.93 (m, 1H), 7.54 (m, 2H), 7.27 (m, 2H), 7.18 (d, 1H, J=1.4 Hz), 4.68(s, 2H), 2.54 (s, 3H), 2.20 (s, 3H), 1.51 (s, 9H).

c)4-(5′-Hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure used in Example 1: step d was followed using{[4-(3′-formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 7: step b) 15 mg, 0.028 mmol). Analogouspurification by HPLC yielded the title compound (12 mg, 80%) as a whitesolid. ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 8.02 (m, 1H), 7.99 (m, 1H), 7.68(m, 2H), 7.29 (d, 2H, J=1.8 Hz), 7.21 (br s, 1H), 4.61 (s, 2H), 2.72 (s,3H), 2.22 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₂₀N₂O₃S₃ (M+H): 433.6;found: 433.1.

Example 84-(5′-Formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(5′-formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

The{[4-(5′-hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 7: step b) 30 mg, 0.056 mmol) wasdissolved in a mixture of DMSO (1 mL) and DCM (1 mL) and cooled to 0° C.Triethylamine (12 μL, 0.084 mmol) and sulfur trioxide-pyridine complex(11 mg, 0.068 mmol) were added and the solution was stirred for 1 h at0° C. Partial conversion was evident by TLC. Additional triethylamine(20 μL, 0.14 μL) and sulfur trioxide-pyridine complex (18 mg, 0.11 mmol)were added and the solution was stirred for 3 h at rt. Isopropanol (250μL) was added, the reaction was stirred for 15 min, and EtOAc (40 mL)was added. The EtOAc solution was extracted with citric acid (2×10 mL),NaHCO₃ (2×10 mL), water (5×10 mL), and brine (20 mL), and was dried oversodium sulfate. Removal of the solvent in vacuo yielded the titlecompound (26 mg, 87%) which was used without further purification.1H-NMR (CD₃OD): δ 10.00 (s, 1H), 7.99 (m, 3H), 7.81 (dd, 1H, J=1.6 7.7Hz), 7.72 (d, 1H, J=7.7 Hz), 7.59 (m, 2H), 7.46 (d, 1H, J=7.7 Hz), 2.58(s, 3H), 2.30 (s, 3H), 1.51 (s, 9H).

b)4-(5′-Formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure used in Example 1: step d was followed using{[4-(5′-formyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 8: step b) 15 mg). Analogouspurification by HPLC yielded the title compound (12 mg, 80%) as a whitesolid. The aldehyde is apparently 80% hydrated according to proton NMRanalysis. 1H-NMR (CD₃OD): δ 8.33 (s, 1H), 8.03 (m, 1H), 7.98 (m, 1H),7.68 (m, 2H), 7.35 (m, 2H), 7.26 (d, 1H, J=1.6 Hz), 5.39 (s, 1H),2.73(s, 3H), 2.24 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₁₈N₂O₃S₃ (M+H):431.6; found: 431.2.

Example 94-[3-(4-Methyl-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)(Imino-{4-[3-(4-methyl-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

Butyllithium (2.5 M, 1.88 mL, 4.5 mmol) was added dropwise to a −78° C.solution of 3-bromo-4-methylpyridine (645 mg, 3.75 mmol) in Et₂O (15mL). The solution was stirred at −78° C. for 1 h and trimethylborate (5mL, 44 mmol) was added in one portion. The solution was warmed to rtover 15 min and stirred for 2 h at rt. The volatile components wereremoved in vacuo and the solid residue was dried under high vacuum for 2h. A portion of the crude solid (81 mg, 0.4 mmol) was reacted with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (50 mg, 0.1 mmol)), Pd(PPh₃)₄ (29 mg,0.025 mmol), Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), ethanol (0.8 mL) and toluene(1.6 mL) according to the procedure used in Example 1: step c. Analogousaqueous workup and purification of the crude material by preparative TLC(50% EtOAc in hexanes) yielded the title compound (36 mg, 71%) as alight-yellow glass. ¹H-NMR (CDCl₃): δ 8.50 (d 1H, J=5.1 Hz), 8.42 (s,1H), 8.07 (s, 1H), 7.99 (m, 2H), 7.45–7.70 (m, 5H), 7.24 (d, 1H, J=5.1Hz), 2.59 (s, 3H), 2.27 (s, 3H), 1.52 (s, 9H). ESI-MS (m/z): Calcd. forC₂₃H₂₅N₃O₄S₃: 503.7; found: 503.8.

b)4-[3-(4-Methyl-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

The procedure used in Example 1: step d was followed using(imino-{4-[3-(4-methyl-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester ((Example 9: step a) 36 mg, 0.071 mmol). Analogouspurification by C₁₈-HPLC (10–40% CH₃CN over 30 min) yielded the titlecompound (22 mg, 49%) as a white solid. ¹H-NMR (CD₃OD): δ 8.74 (br s,2H), 8.37 (s, 1H), 8.19 (m, 2H), 8.01 (d, 1H, J=5.6 Hz), 7.85 (m, 2H),2.74 (s, 3H), 2.55 (s, 3H). ESI-MS (m/z): Calcd. for C₁₈H₁₇N₃O₂S₃ (M+H):404.5; found: 404.1.

Example 104-[3-(2-Chloro-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine;bis-trifluoroacetate

a)({4-[3-(2-Chloro-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

Butyllithium (2.5 M, 1.0 mL, 2.5 mmol) was added dropwise to a −78° C.solution of 3-bromo-2-chloropyridine (384 mg, 2.0 mmol) in Et₂O (10 mL).The solution was stirred at −78° C. for 1 h and trimethylborate (2.3 mL,20 mmol) was added in one portion. The solution was warmed to rt over 15min and stirred for 2 h at rt. The volatile components were removed andthe solid material was dried under high vacuum for 2 h. A portion of thecrude solid (105 mg, 0.63 mmol) was reacted with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (50 mg, 0.1 mmol)), Pd(PPh₃)₄ (29 mg,0.025 mmol), Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), ethanol (0.8 mL) and toluene(1.6 mL) according to the procedure used in Example 1: step c. Analogousaqueous workup and purification of the crude material by preparative TLC(50% EtOAc in hexanes) yielded the title compound (31 mg, 58%) as alight-yellow glass.

b)4-[3-(2-Chloro-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine;bis-trifluoroacetate

The procedure used in Example 1: step d was followed using({4-[3-(2-chloro-pyridin-3-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester ((Example 10: step b) 31 mg, 0.059 mmol).Analogous purification by C₁₈-HPLC (10–40% CH₃CN over 30 min) yieldedthe title compound (29 mg, 74%) as a white solid. ¹H-NMR (CD₃OD): δ 8.45(dd, 1H, J=1.9, 4.9 Hz), 8.36 (s, 1H), 8.16 (t, 1H, J=1.5 Hz), 8.12(ddd, 1H, J=1.2, 1.9, 7.7 Hz), 7.90 (dd, 1H, J=1.9, 7.7 Hz), 7.83 (dt,1H, J=1.5, 7.7 Hz), 7.75 (dt, 1H, J=0.5, 7.7 Hz), 7.53 (dd, 1H, J=4.9,7.7 Hz), 2.73 (s, 3H). ESI-MS (m/z): Calcd. for C₁₇H₁₄ClN₃O₂S₃ (M+H):424.0; found: 424.1.

Example 114-[3-(3-Methyl-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

A 2-dram vial with a septa-containing screwcap was charged with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 27 (100 mg, 0.2 mmol)) and Pd(PPh₃)₄ (59mg, 0.025 mmol). Tetrahydrofuran was added followed by3-methyl-2-pyridylzinc bromide (Aldrich Chemical Company) (0.5 M in THF,800 μL, 0.4 mmol). The reaction was heated to 80° C. for 1 h and wasworked up as in Example 1: step c. Flash chromatography (SiO₂) of thecrude material (25–50% EtOAc in hexanes) yielded a light-yellow glass(74 mg, 73%) which was treated with trifluoroacetic acid and purified byC₁₈-HPLC (10–40% CH₃CN over 30 min) as in Example 1: step d, giving thetitle compound (46 mg, 61%) as a white solid. ¹H-NMR (CD₃OD): δ 8.59(dd, 1H, J=0.9, 5.1 Hz), 8.34 (s, 1H), 8.22 (m, 2H), 8.16 (ddd, 1H,J=0.7, 1.4, 7.9 Hz), 7.92 (ddd, 1H, J=0.5, 1.1, 7.7 Hz), 7.82 (dt, 1H,J=0.7, 7.7 Hz), 7.68 (dd, 1H, J=5.4, 7.9 Hz), 2.73 (s, 3H), 2.39 (s,3H). ESI-MS (m/z): Calcd. for C₁₈H₁₇N₃O₂S₃ (M+H): 404.5; found: 404.1.

Example 124-(3-Allyloxy-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

a) 1,3-Dibromo-5-tert-butoxy-benzene

To a vigorously stirred solution of 1,3-dibromophenylboronic acid (4.5g, 16.1 mmol) in MeOH (50 mL) and THF (50 mL) was alternately added(dropwise) aqueous hydrogen peroxide (30%, 10 mL) and NaOH (1M, 20 mL)(dropwise), maintaining pH˜10. The solution became cloudy and wasstirred for 30 min (pH maintained at ˜10 using 10 N NaOH). EtOAc (200mL) and sat'd NaHCO₃ (50 mL) were added and the layers were separated.The organic layer was extracted with NaHCO₃ (50 mL), water (20 mL),brine (50 mL), and was dried over sodium sulfate. The solvent wasremoved in vacuo and the residue was dissolved in DCM (80 mL). Aftercooling to −78° C., isobutylene was added (˜20 mL) followed bytrifluoromethanesulfonic acid (300 μL). The cloudy solution was stirredfor 15 min at −78° C. and for 1 h at −20 to −10° C. Additional amountsof isobutylene (˜10 mL) and trifluoromethanesulfonic acid (200 μL) wereadded and the solution was stirred for 1 h. Solid K₂CO₃ (1 g) wascarefully added, the solution was stirred for 10 min at rt, and NaOH(1N, 30 mL) was added. The layers were separated and the organic layerwas further extracted with NaOH (1N, 5×10 mL), water (10 mL), and brine(30 mL). After drying and removal of the solvent in vacuo, the residuewas purified by SiO₂ flash chromatography (2–5% EtOAc in hexanes) toyield the title compound (3.80 g, 77%). ¹H-NMR (CDCl₃): δ 7.38 (t, 1H,J=1.6 Hz), 7.09 (d, 2H, J=1.6 Hz), 1.36 (s, 9H).

b)4-(3-Bromo-5-tert-butoxy-benzenesulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester

Butyllithium (2.5 M, 3.25 mL, 8.13 mmol) was added dropwise to a −78° C.solution of 1,3-dibromo-5-tert-butoxy-benzene ((Example 12: step a) 2.4g, 7.71 mmol) in Et₂O (80 mL). The solution was stirred at −78° C. for 2h and sulfur (310 mg, 9.69 mmol) was added in one portion. The solutionwas warmed to rt over 30 min and stirred for 2 h at rt. EtOAc (50 mL)and citric acid (5%, 30 mL) were added and the layers were separated.The organic layer was washed with NaHCO₃ (2×30 mL), water (10 mL) andbrine (30 mL), and was dried over sodium sulfate. The solvent wasremoved in vacuo and the residue was redissolved in THF (40 mL).Triphenylphosphine (2.03 g, 7.74 mmol),4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 2.13 g, 8.0 mmol), water (1 mL), and DMAP-resin (7.0 g, 10 mmol)were added and the mixture was stirred for 18 h at rt. The solution wasfiltered, the solids were washed with DCM, and the solvent was removedin vacuo. The residue was partially purified by SiO₂ flashchromatography (25% EtOAc in hexanes) to yield a mixture of the titlecompound and 4-bromo-5-nitro-thiophene-2-carboxylic acid methyl esterstarting material. The crude material was redissolved in DCM (60 mL),mCPBA (77%, 6.04 g, 27.1 mmol) was added, and the solution was stirredfor 5 h at 40° C. DCM (50 mL) and aqueous sodium thiosulfate were added(exothermic), and the layers were separated. The organic layer wasextracted with Na₂CO₃ (2M, 6×30 mL), brine (50 mL), and was dried oversodium sulfate. Concentration of the solvent in vacuo followed by SiO₂flash chromatography (25–75% DCM in hexanes) yielded the title compoundas a colorless glass (2.85 g, 77%). ¹H-NMR (CDCl₃): δ 8.28 (d, 1H, J=0.5Hz), 7.71 (t, 1H, J=1.6 Hz), 7.68 (m, 1H), 7.39 (m, 1H), 4.00 (s, 3H),1.42 (s, 9H).

c)4-(3-Bromo-5-tert-butoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

Sodium thiomethoxide (1M in EtOH, 4.4 mL, 4.4 mmol) was added dropwiseto a −78° C. solution of4-(3-bromo-5-tert-butoxy-benzenesulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester (1.91 g, 4.0 mmol) in THF (40 mL). The solution wasstirred for 30 min at −78° C. and glacial acetic acid (1 mL) was added.The solution was diluted with EtOAc (60 mL), extracted with NaHCO₃ (2×30mL), water (2×20 mL), brine (30 mL), and was dried over sodium sulfate.Concentration of the solution in vacuo followed by SiO₂ flashchromatography of the residue yielded the title compound (1.48 g, 76%).¹H-NMR (CDCl₃): δ 8.01 (d, 1H, J=0.5 Hz), 7.74 (m, 1H), 7.66 (m, 1H),7.37 (m, 1H), 3.99 (s, 3H), 2.48 (s, 3H), 1.41 (s, 9H).

d)4-(3-Bromo-5-hydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

Trifluoroacetic acid (5 mL) was added to a solution of4-(3-bromo-5-tert-butoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 12: step c) 240 mg, 0.5 mmol) in DCM (5 mL).The solution was stirred at rt for 2 h and the solvents were removed invacuo, yielding 214 mg of an oil (quantitative) which was used withoutfurther purification.

e)4-(3-Allyloxy-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

Cesium carbonate (33 mg, 0.1 mmol) and allylbromide (30 μL, 0.35 mmol)were added to a solution of4-(3-bromo-5-hydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 12: step d) 30 mg, 0.71 mmol) dissolved indry DMF (3 mL). After stirring for 16 h at rt, the solution was pouredinto a mixture of water (20 mL) and EtOAc (30 mL). The layers wereseparated and the organic layer was extracted with water (5×5 mL), brine(20 mL), and was dried over sodium sulfate. The solvent was removed invacuo to yield the title compound, which was used without furtherpurification.

f)4-(3-Allyloxy-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

A 1M stock solution of dimethylaluminum amide was freshly prepared bycareful addition of trimethylaluminum (2M in toluene, 10 mL) to asuspension of NH₄Cl (1.08 g, 11 mmol) in toluene (10 mL).4-(3-Allyloxy-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (33 mg, 0.07 mmol) was treated with thedimethylaluminum amide solution (2 mL, 20 mmol) and was heated to 100°C. for 2 h, during which a precipitate formed. The solution was pouredinto a vigorously stirred mixture of SiO₂ (20 g) in CHCl₃ (70 mL). Theflask was rinsed with methanol (10 mL) and the SiO₂ mixture was stirredfor 10 min. The solution was filtered through a fritted column and theSiO₂ was eluted with 15% MeOH in DCM (150 mL). Concentration of theeluent and purification of the residue by preparative TLC (10% MeOH inDCM) yielded the title compound (15 mg, 44%) as a white solid. ¹H-NMR(CD₃OD): δ 8.27 (s, 1H), 7.69 (t, 1H, J=1.6 Hz), 7.52 (dd, 1H, J=1.6,2.3 Hz), 7.44 (dd, 1H, J=1.6, 2.3 Hz), 6.03 (m, 1H), 5.41 (ddd, 1H,J=1.6, 3.3, 17.2 Hz), 5.29 (ddd, 1H, J=1.4, 2.8, 10.5 Hz), 4.64 (dt, 2H,J=1.6, 5.4 Hz), 2.74 (s, 3H). ESI-MS (m/z): Calcd. for C₁₅H₁₅BrN₂O₃S₃:447.4; found: 447.1.

Example 134-(3-Bromo-5-methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

Following the procedure for Example 12: step e,4-(3-bromo-5-hydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester ((Example 12: step d) 30 mg, 0.71 mmol) was alkylatedusing cesium carbonate (33 mg, 0.1 mmol) and methyl iodide (44 μL, 0.71mmol). After analogous workup, the residue was subjected to amidinationconditions as Example 12: step f. Analogous purification proceduresyielded the title compound (17 mg, 53%) as a white solid. ¹H-NMR(CD₃OD): δ 8.27 (s, 1H), 7.69 (t, 1H, J=1.6 Hz), 7.52 (dd, 1H, J=1.6,2.3 Hz), 7.37 (dd, 1H, J=1.6, 2.3 Hz), 3.87 (s, 3H), 2.72 (s, 3H).ESI-MS (m/z): Calcd. for C₁₃H₁₃BrN₂O₃S₃: 421.4; found: 421.1.

Example 144-(5-Hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

a)4-(5-tert-Butoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester

The procedure used in Example 1: step d was followed usingbenzeneboronic acid (42 mg, 0.35 mmol),4-(3-bromo-5-tert-butoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 12: step c) (83 mg, 0.17 mmol)), Na₂CO₃ (2M,1.4 mL, 2.8 mmol), Pd(PPh₃)₄ (48 mg, 0.04 mmol), toluene (5.6 mL), andethanol (2.8 mL). Analogous aqueous workup and SiO₂ flash chromatography(20% EtOAc in hexanes) yielded the title compound (55 mg, 65%). ¹H-NMR(CDCl₃): δ 8.03 (s, 1H), 7.91 (t, 1H, J=1.6 Hz), 7.63 (t, 1H, J=2.0 Hz),7.57 (m, 2H), 7.47 (m, 2H), 7.41 (m, 2H), 4.33 (q, 2H, J=7.2 Hz), 2.60(s, 3H), 1.42 (s, 9H), 1.36 (t, 3H, J=7.2 Hz).

b)4-(5-Hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester

4-(5-tert-butoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester (55 mg, 0.11 mmol) was dissolved in 1:1 TFA/DCM (10 mL)and stirring for 1 h. Removal of the solvent in vacuo yielded the titlecompound (48 mg, 98%), which was used without further purification.

c)4-(5-Hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

4-(5-Hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester ((Example 14: step b) 12 mg, 0.028 mmol) was treatedwith dimethylaluminum amide reagent (2 mL, 2 mmol) as in Example 12:step f. Analogous quench, workup, and purification procedures yieldedthe title compound (10 mg, 89%) as a white solid. ¹H-NMR (CD₃OD): δ 8.30(s, 1H), 7.69 (t, 1H, J=1.6 Hz), 7.59 (m, 2H), 7.47 (m, 2H), 7.40 (m,2H), 7.32 (m, 1H), 2.74 (s, 3H). ESI-MS (m/z): Calcd. forC₁₃H₁₃BrN₂O₃S₃: 421.36; found: 421.1.

Example 154-(5-Methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

Following the procedure in Example 12: step e,4-(5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester ((Example 14: step b) 12 mg, 0.028 mmol) was alkylatedusing cesium carbonate (13.5 mg, 0.041 mmol) and iodomethane (9 μL,0.138 mmol) in DMF (1.2 mL). After analogous workup, the residue wastreated with dimethylaluminum amide reagent (2 mL) following theprocedure in Example 12: step f. The title compound was isolated as awhite solid (10 mg, 86%) after preparative TLC purification (15% MeOH inDCM). ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 7.82 (t, 1H, J=1.6 Hz), 7.65 (m,1H), 7.63 (m, 1H), 7.53 (dd, 1H, J=1.6, 2.3 Hz), 7.46–7.50 (m, 3H), 7.41(m, 1H), 3.93 (s, 3H), 2.74 (s, 3H). ESI-MS (m/z): Calcd. forC₁₃H₁₃BrN₂O₃S₃: 421.4; found: 421.1.

Example 164-(5-Allyloxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

Following the procedure in Example 12: step e,4-(5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester ((Example 14: step b) 12 mg, 0.028 mmol) was alkylatedusing cesium carbonate (13.5 mg, 0.041 mmol) and allyl bromide (12 μL,0.138 mmol) in DMF (1.2 mL). After analogous workup, the residue wastreated with dimethylaluminum amide reagent (2 mL) following theprocedure in Example 12: step f. The title compound was isolated as awhite solid (10 mg, 81%) after preparative TLC purification (15% MeOH inDCM). ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 7.82 (t, 1H, J=1.6 Hz), 7.63 (m,2H), (dd, 1H, J=1.6, 2.3 Hz), 7.48 (m, 3H), 7.42 (m, 1H), 6.08 (m, 1H),5.45 (ddd, 1H, J=1.6, 3.3, 17.2 Hz), 5.31 (ddd, 1H, J=1.4, 2.8, 10.5Hz), 4.64 (dt, 2H, J=1.6, 5.1 Hz), 2.75 (s, 3H).

Example 174-(5-Benzyloxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

Following the procedure in Example 12: step e,4-(5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester ((Example 14: step b) 12 mg, 0.028 mmol) was alkylatedusing cesium carbonate (13.5 mg, 0.041 mmol) and benzyl bromide (17 μL,0.138 mmol) in DMF (2 mL). After analogous workup, the residue wastreated with dimethylaluminum amide reagent (2 mL) following theprocedure in Example 12: step f. The title compound was isolated as awhite solid (9 mg, 66%) after preparative TLC purification (15% MeOH inDCM). ¹H-NMR (CD₃OD): δ 8.26 (s, 1H), 7.82 (t, 1H, J=1.6 Hz), 7.62 (m,2H), 7.54 (m, 2H), 7.30–7.50 (m, 8H), 5.26 (s, 2H), 2.70 (s, 3H). ESI-MS(m/z): Calcd. for C₁₃H₁₃BrN₂O₃S₃: 421.4; found: 421.1.

Example 184-(2′-Chloro-5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(3-Bromo-5-hydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

Following the procedure and workup in Example 14: step f, the4-(3-bromo-5-tert-butoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 12: step c) 1.48 g, 3.1 mmol) was convertedto the amidine (40 mL of dimethylaluminum amide reagent) withconcomitant removal of the tert-butyl ether. A portion of the crudeamidine (800 mg) was dissolved in DMF and di-tert-butyl dicarbonate (436mg, 2 mmol), diisopropylethylamine (350 μL, 2 mmol), and DMAP (50 mg)were added. After stirring for 16 h, the solution was poured into EtOAc(60 mL) and citric acid (20 mL). The layers were separated and theorganic layer was further extracted with citric acid (10 mL), NaHCO₃(2×20 mL), water (5×10 mL), and brine (30 mL). After drying over sodiumsulfate and removal of solvent in vacuo, the residue was dissolved inMeOH and solid K₂CO₃ was added. The mixture was stirred overnight, thesolution was filtered, and the solvent was removed in vacuo.Purification of the residue by SiO₂ flash chromatography yielded thetitle compound (80 mg, 0.158 mmol).

b){[4-(2′-Chloro-5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl]-carbamicacid tert-butyl ester

Following the procedure outlined in Example 1: step c,{[4-(3-bromo-5-hydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (80 mg, 0.158 mmol) was reacted with2-chlorophenylboronic acid (98.6 mg, 0.631 mmol), Na₂CO₃ (134 mg, 1.26mmol), and Pd(PPh₃)₄ (45.5 mg, 0.039 mmol). Aqueous workup followed bySiO₂ flash chromatography yielded the title compound (20 mg, 24%).

c)4-(2′-Chloro-5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure used in Example 1: step d was followed using{[4-(2′-chloro-5-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (10 mg, 0.0185 mmol). Analogous purification byC₁₈-HPLC yielded the title compound (4 mg, 50%) as a white solid. ¹H-NMR(CD₃OD): δ 8.28 (s, 1H), 7.51 (m, 2H), 7.44 (dd, 1H, J=1.6, 2.3 Hz),7.40 (m, 2H), 7.38 (m, 3H), 7.13 (dd, 1H, J=1.6, 2.3 Hz), 2.73 (s, 3H).ESI-MS (m/z): Calcd. for C₁₃H₁₃BrN₂O₃S₃: 421.4; found: 421.1.

Example 194-(2′-Chloro-5-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(2′-Chloro-5-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

Iodomethane (3 μL, 0.045 mmol) and tetrabutylammonium fluoride (1M inTHF, 14 μL, 0.014 mmol) was added to a solution of{[4-(2′-chloro-5-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 19: step b) 5 mg, 0.009 mmol) in THF.After stirring for 2 hours, the solution was diluted with EtOAc (20 mL).The organic layer was washed with water (2×4 mL) and brine (5 mL), andwas dried over MgSO₄. Removal of the solvent in vacuo followed bypurification of the residue (preparative TLC; 30% EtOAc in hexanes)afforded the title compound (3.1 mg, 62%). ¹H-NMR (CDCl₃): δ 7.84 (s,1H), 7.64 (t, 1H, J=1.6 Hz), 7.53 (dd, 1H, J=1.6, 2.6 Hz), 7.47 (m, 1H),7.33 (m, 3H), 7.21 (dd, 1H, J=1.6, 2.6 Hz), 3.89 (s, 3H), 2.60 (s, 3H),1.52 (s, 9H). ESI-MS (m/z): Calcd. for C₁₃H₁₃BrN₂O₃S₃: 421.4; found:421.1.

b)4-(2′-Chloro-5-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure used in Example 1: step d was followed using{[4-(2′-chloro-5-methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (3.1 mg, 0.008 mmol). Analogous purification byC₁₈-HPLC yielded the title compound (1.8 mg, 50%) as a white solid.¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 7.64 (t, 1H, J=1.6 Hz), 7.59 (dd, 1H,J=1.4, 2.6 Hz), 7.55 (m, 1H), 7.42 (m, 3H), 7.13 (dd, 1H, J=1.4, 2.6Hz), 3.93 (s, 3H), 2.75 (s, 3H). ESI-MS (m/z): Calcd. forC₁₃H₁₃BrN₂O₃S₃: 421.4; found: 421.1.

Example 205-Bromo-4-(3′-formyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

a) 4-(3-Bromo-phenylsulfanyl)-5-nitro-thiophene-2-carboxylic acid methylester

4-Bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 1 g, 3.75 mmol) and Et₃N (523 μL, 3.75 mmol) were dissolved withTHF (10 mL) into a round bottom flask with stir bar. To this3-bromothiophenol (467 μL, 4.51 mmol) was added with stirring. Thereaction became turbid therefore additional THF (12 mL) was added. Thereaction was stirred at rt for 12 hours. The reaction mixture wasconcentrated in vacuo and then dissolved into EtOAc. The organic layerwas washed several times with saturated NaHCO₃ and brine. The combinedorganic layers were dried over sodium sulfate. Removal of the solventsin vacuo yielded the title compound (1.40 g, quantitative yield), whichwas used without further purification. ¹H-NMR (CDCl₃): δ 7.79 (t, 1H,J=1.8 Hz), 7.67–7.70 (m, 1H), 7.54–7.85 (m, 1H), 7.37–7.41 (t, 1H, J=7.9Hz), 6.87 (s, 1H), 3.88 (s, 1H).

b) 4-(3-Bromo-benzenesulfonyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester

4-(3-Bromo-phenylsulfanyl)-5-nitro-thiophene-2-carboxylic acid methylester (1.40 g, 4 mmol) and m-CPBA (6.1 g, 20 mmol) were dissolved intoDCM (25 mL) with heating at 40° C. for 2 hours. The reaction mixture wasquenched by the addition of saturated sodium thiosulfate followed byaqueous workup with brine and saturated NaHCO₃. The combined organiclayers were dried over sodium sulfate. Removal of the solvents in vacuoyielded the title compound (1.60 g, quantitative yield) which was usedwithout further purification. ¹H-NMR (CDCl₃): δ 8.31 (s, 1H), 8.12–8.14(t, 1H, J=1.9 Hz), 8.02–8.05 (m, 1H), 7.78–7.82 (m, 1H), 7.44–7.50 (t,1H, J=7.9 Hz), 4.01 (s, 3H).

c) 5-Amino-4-(3-bromo-benzenesulfonyl)-thiophene-2-carboxylic acidmethyl ester

4-(3-Bromo-benzenesulfonyl)-5-nitro-thiophene-2-carboxylic acid methylester (407 mg, 1.0 mmol, Example 20: step b) was dissolved into EtOH (6mL). To this was added ammonium chloride (535 mg, 10 mmol) dissolvedinto water (3 mL). This mixture was heated to 50° C. with stirring andthen iron (277 mg, 5 mmol) was added. The reaction was then heated to80° C. with stirring for 12 hours. The reaction mixture was thenfiltered through Celite® and washed with 10% DCM/MeOH. Removal of thesolvents in vacuo yielded the title compound (598 mg, quantitativeyield) which was used without further purification. ¹H-NMR (CDCl₃): δ8.05 (s, 1H), 7.84–7.86 (m, 1H), 7.70–7.75 (m, 1H), 7.56 (s, 1H), 7.40(m, 1H), 6.02 (br s, 2H), 3.85 (s, 3H). ESI-MS (m/z): Calcd. forC₁₂H₁₀BrNO₄S₂: 375.9 (M+H); found: 376.1.

d) 5-Amino-4-(3′-formyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester

The procedure as in Example 1: step c was followed using5-amino-4-(3-bromo-benzenesulfonyl)-thiophene-2-carboxylic acid methylester (754.2 mg, 2 mmol, Example 20: step e), 3-formyl phenyl boronicacid (599.7 mg, 4 mmol), Pd(PPh₃)₄ (462.2 mg, 0.4 mmol), aqueous Na₂CO₃(2M, 8 mL, 16 mmol), ethanol (8 mL) and toluene (16 mL). Purification byflash column chromatography (Biotage Flash™ System—40 M SiO₂ column)(25% EtOAc in hexanes) of the residue yielded the title compound (317mg, 40%) as a brown solid. ¹H-NMR (CDCl₃): δ 10.10 (s, 1H), 8.10–8.17(m, 2H), 7.92–7.95 (m, 2H), 7.82–7.89 (t, 2H, J=8.1 Hz), 7.58–7.70 (m,3H), 6.05 (br s, 2H), 3.80 (s, 3H).

e) 5-Bromo-43-(3′-formyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylicacid methyl ester

A dry 3-neck flask fitted with addition funnel, condenser and septa capwas purged with argon. To this flask t-butylnitrite (121 μL, 1.58 mmol)and copper(II) bromide (36.8 mg, 1.58 mmol) were dissolved withacetonitrile (2 mL) and heated to 60° C. A solution of5-amino-4-(3′-formyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (317.2 mg, 0.79 mmol, Example 20: step d) in acetonitrile(2 mL) was added dropwise with continued stirring and heat for 1.5hours. The reaction mixture was dissolved into EtOAc and washed withbrine. The organic layer was dried over sodium sulfate. Removal of thesolvents in vacuo followed by flash column chromatography (BiotageFlash™ System—40 M SiO₂ column) (25% EtOAc in hexanes) of the residueyielded the title compound (128 mg, 34%) as a brown solid. ¹H-NMR(CDCl₃): δ 10.10 (s, 1H), 8.26–8.28 (m, 1H), 8.08–8.16 (m, 2H) 8.01–8.06(m, 1H), 7.86–7.89 (m, 3H), 7.64–7.70 (t, 2H, J=8.1 Hz), 3.90 (s, 3H).

f) 5-Bromo-4-(3′-formyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

A 1M solution of dimethylaluminum amide was prepared by combining NH₄Cl(426 mg, 8 mmol), AlMe₃ (2M solution in toluene, 4 mL, 8 mmol) andtoluene (4 mL). This solution was then heated to 80° C. for 15 minutesand then allowed to cool to rt. The 1M solution of dimethyl aluminumamide was then added to a dry flask containing5-bromo-4-(3′-formyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (128 mg, 0.28 mmol) and the reaction was heated 90° C. for2 hours. The reaction was quenched by adding silica (1 g) to thesolution with stirring followed by filtration and elution with 10% MeOHin DCM. Concentration of the filtrate in vacuo followed by purificationby C₁₈-HPLC (10–80% CH₃CN over 25 min) yielded the title compound (49mg, 38%) as an off-white solid. ¹H-NMR (CD₃OD and CD₃Cl): δ: 10.10 (s,1H), 8.35 (s, 1H), 8.31–8.33 (m, 1H), 8.17–8.18 (t, 1H, J=1.39 Hz),8.04–8.10 (m, 2H), 7.96–7.99 (m, 2H), 7.75–7.77 (m, 2H). ESI-MS (m/z):Calcd. for C₁₈H₁₃BrN₂O₃S₂: 448.9 (M+H); found: 449.2.

Example 215-Amino-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

5-Amino-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester was prepared following the procedure as in Example 1: stepc using 5-amino-4-(3-bromo-benzenesulfonyl)-thiophene-2-carboxylic acidmethyl ester (598.9 mg, 1.6 mmol) (Example 20: steps a–c),o-tolyl-phenyl boronic acid (435.6 mg, 3.2 mmol), Pd(PPh₃)₄ (366.6 mg,0.32 mmol), aqueous Na₂CO₃ (2M, 6.4 mL, 12.8 mmol), ethanol (6.4 mL) andtoluene (12.8 mL). Purification by flash column chromatography (BiotageFlash™ System—40 M SiO₂ column) (25% EtOAc in hexanes) of the residueyielded the adduct (137 mg, 23%) as a light brown solid. ESI-MS (m/z):Calcd. for C₁₉H₁₇NO₄S₂: 387.02; found: 388.3.5-Amino-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (61 mg, 16 mmol) was then converted to the amidine andpurified as described in Example 20: step f to isolate the titlecompound (6 mg, 10%) as a light brown solid. ¹H-NMR (CD₃OD): δ:7.96–7.99 (m, 1H), 7.95 (s, 1H), 7.93–7.94 (m, 1H), 7.63–7.69(m, 3H),7.18–7.32 (m, 3H), 2.22 (s, 3H). ESI-MS (m/z): Calcd. for C₁₈H₁₇N₃O₂S₂:372.0 (M+H); found: 372.2.

Example 225-Chloro-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

a) 5-Chloro-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylicacid methyl ester

The procedure as in Example 20: step e was followed using t-butylnitrite(104 μL, 88 mmol) and copper(I) chloride (118.5 mg, 0.88 mmol),acetonitrile (2 mL) and5-amino-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (170.2 mg, 0.43 mmol, Example 21) in acetonitrile (2 mL).Purification by flash column chromatography (Biotage Flash™ System—12 MSiO₂ column) (25% EtOAc in hexanes) of the residue yielded the titlecompound (128 mg, 34%) as a brown solid. ¹H-NMR (CDCl₃): δ 8.26 (1H, s),7.92–7.98 (3H, m), 7.56–7.60 (2H, m) 7.28–7.32 (3H, m), 3.90 (3H, s),2.24 (3H, s).

b) 5-Chloro-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

5-Chloro-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (36 mg, 0.09 mmol) was then converted to the amidine andpurified as described in Example 20: step f to isolate the titlecompound (7.1 mg, 20%) as a white solid. ¹H-NMR (CD₃OD): δ: 8.35 (s,1H), 8.03–8.06 (m, 1H), 7.95–7.97 (m, 1H), 7.71–7.74 (m, 2H), 7.30–7.33(m, 2H), 7.25–7.30 (m, 1H), 7.19–7.21 (d, 1H, J=6.74 Hz), 2.24 (s, 3H).ESI-MS (m/z): Calcd. for C₁₈H₁₅ClN₂O₂S₂: 391.0 (M+H); found: 391.2.

Example 23 4-(2′-Methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acid methylester (4.0 mg, 0.01 mmol) was isolated as a byproduct from Example 22:step a. The molecule was then converted to the amidine and purified asdescribed in Example 20: step f to isolate the title compound (0.9 mg,25%). ¹H-NMR (CD₃OD): δ: 8.80 (s, 1H), 8.25–8.26 (d, 1H, J=1.6 Hz),8.02–8.05 (m, 1H), 7.95–7.96 (m, 2H), 7.68–7.71 (m, 2H), 7.17–7.21 (m,1H), 2.24 (s, 3H). ESI-MS (m/z): Calcd. for C₁₈H₁₆N₂O₂S₂: 357.0 (M+H);found: 357.3.

Example 245-Bromo-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

a) 5-Chloro-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylicacid methyl ester

The procedure as in Example 20: step e was followed using t-butylnitrite(10 μL, 0.05 mmol) and copper(II) bromide (11 mg, 0.05 mmol) and5-amino-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (9.1 mg, 0.03 mmol, Example 21) in acetonitrile (1 mL).Purification by flash column chromatography (Biotage Flash™ System—12 MSiO₂ column) (25% EtOAc in hexanes) of the residue yielded the titlecompound (5.1 mg, 42%) as an off-white solid. ¹H-NMR (CDCl₃): δ 8.08 (s,1H), 7.92–7.98 (m, 2H), 7.59–7.61 (m, 2H) 7.29–7.30 (m, 3H), 7.19–7.21(m, 1H), 3.90 (s, 3H), 2.24 (s, 3H).

b) 5-Bromo-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

5-Bromo-4-(2′-methyl-biphenyl-3-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (5.1 mg, 0.01 mmol, Example 24: step a) was then convertedto the amidine and purified as described in Example 20: step f toisolate the title compound (1.1 mg, 21%). ¹H-NMR (CD₃OD): δ: 8.33 (s,1H), 8.04–8.07 (m, 1H), 7.98–7.99 (m, 1H) 7.71–7.73 (m, 2H), 7.30–7.32(m, 3H), 7.25–7.30 (m, 1H), 7.19–7.21 (m, 1H), 2.24 (s, 3H). ESI-MS(m/z): Calcd. for C₁₈H₁₃BrN₂O₂S₂: 434.0 found: 437.1.

Example 254-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 2-Bromo-3-methyl-phenylamine

The procedure as in Example 20: step c was followed using2-bromo-1-methyl-3-nitro-benzene (1 g, 4.6 mmol dissolved in 12 mL EtOH,Aldrich Chemical Company), ammonium chloride (2.5 g, 46 mmol dissolvedin 6 mL H₂O) and iron (1.3 g, 23 mmol). The title compound was obtained(1.0 g, quantitative yield) which was used without further purification.¹H-NMR (CDCl₃): δ 6.95–7.00 (t, 1H, J=7.6 Hz), 6.60–6.65 (dd, 2H, J=8.1,4.4 Hz), 4.10 (br s, 2H), 2.35 (s, 3H).

b) 3-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine

The procedure described in Example 3: step b was followed using2-bromo-3-methyl-phenylamine (185 mg, 1.0 mmol, Example 25: step a),PdCl₂(PPh₃)₂ (70.2 mg, 0.1 mmol), dioxane (3 mL), and Et₃N (729 μL, 6mmol), 4,4,5,5,-tetramethyl-[1,3,2]-dioxaborolane (453 μL, 3 mmol).Purification by preparative SiO₂ TLC (25% EtOAc in hexanes) of theresidue yielded the title compound (94 mg, 40%) as a yellow solid.ESI-MS (m/z): Calcd. for C₁₃H₂₀BNO₂: 234.1 (M+H) found: 234.1.

c){[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

The procedure described in Example 1: step c was followed using3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(95 mg. 0.41 mmol, Example 25: step b),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100.7 mg, 0.21 mmol, Example 27: step c),Pd(PPh₃)₄ (47 mg, 0.04 mmol), aqueous Na₂CO₃ (2M, 0.8 mL, 1.6 mmol),ethanol (0.8 mL) and toluene (1.6 mL). Purification by preparative SiO₂TLC (33% EtOAc in hexanes) of the residue yielded the title compound (30mg, 28%) as an off-white solid. ESI-MS (m/z): Calcd. For C₂₄H₂₇N₃O₄S₃:517.2; found: 517.8.

d)4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (30 mg, 0.058 mmol, Example 25: step c) wasdeprotected and purified as in Example 1: step d, yielding the titlecompound as an off-white solid (28.1 mg, 94%). ¹H-NMR (CD₃OD): δ 8.36(s, 1H), 8.08–8.12 (m, 1H), 7.96 (t, 1H, J=1.6 Hz), 7.76–7.80 (t, 1H,J=7.6 Hz), 7.60–7.64 (dd, 1H, J=1.6, 7.6 Hz), 7.22–7.25 (t, 1H, J=7.9Hz), 6.98–7.03 (m, 2H), 2.73 (s, 3H), 1.97 (s, 3H). ESI-MS (m/z): Calcd.for C₁₈H₁₉N₃O₂S₃: 418.1 (M+1); found: 418.1.

Example 264-(3′-Formyl-4′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 4-Bromo-2-dimethoxymethyl-phenol

To a solution of 5-bromo-2-hydroxy-benzaldehyde (1 g, 4.9 mmol, AldrichChemical Company) in MeOH (25 mL) at 0° C., sodium borohydride (226 mg,5.9 mmol) was added slowly with stirring. After the addition, thereaction was allowed to warm to rt and stir for an additional hour.Reaction mixture was dissolved into EtOAc and washed with brine (20mL×2). The organic layer was dried over sodium sulfate. Removal of thesolvents in vacuo gave the title compound (1.2 g, quantitative) a yellowoil which was used with out further purification. ¹H-NMR (CD₃OD): δ 7.35(m, 2H), 6.75–6.77 (d, 1H, J=7.2 Hz), 5.55 (s, 1H), 3.33 (s, 6H).

b){[4-(3′-Dimethoxymethyl-4′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

2-Dimethoxymethyl-4-hydroxyl phenylboronic acid (212 mg, 1.0 mmol) wasprepared using the procedure described in Example 1: step b usingbutyllithium (2.5M, 2.8 mL, 7 mmol), trimethylborate (0.812 mL, 5.6mmol), 4-bromo-2-dimethoxymethyl-phenol (685 mg, 2.8 mmol, Example 26:step a) in THF (5 mL) and was used in the next step withoutpurification. The procedure described in Example 1: step c was followedusing{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100 mg, 0.21 mmol, Example 27: step c), Pd(PPh₃)₄(47 mg, 0.04 mmol), aqueous Na₂CO₃ (2M, 0.8 mL, 1.6 mmol), ethanol (0.8mL), toluene (1.6 mL) and 2-dimethoxymethyl-4-hydroxy-phenylboronic acid(212 mg, 1.0 mmol). Purification by preparative SiO₂ TLC (33% EtOAc inhexanes) of the residue yielded the title compound (37 mg, 28%) as awhite solid. ESI-MS (m/z): Calcd. for C₂₆H₃₀N₂O₇S₃: 579.1 (M+1); found:579.9.

c)4-(3′-Formyl-4′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{[4-(3′-Dimethoxymethyl-4′-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (37 mg) (Example 26: step b) was deprotected andpurified as in Example 1: step d, yielding the title compound as anoff-white solid (5 mg, 14%). ¹H-NMR (CD₃OD): δ 10.34 (s, 1H), 8.46 (m,1H), 8.25–8.27 (m, 1H), 7.89–7.94 (m, 3H), 7.72–7.75 (m, 1H), 7.13–7.16(m, 1H), 2.49 (s, 3H). ESI-MS (m/z): Calcd. for C₁₉H₁₆N₂O₄S₃: 433.0(M+1); found: 433.2.

Example 27{[4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

a) 4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

4-(3-Bromo-benzenesulfonyl)-5-nitro-thiophene-2-carboxylic acid methylester (5.9 g, 0.015 mol, Example 20: step b) was dissolved into 40 mLTHF and cooled to −78° C. To this was added sodium thiomethoxide (1M, 15mL, 0.015 mmol, in EtOH) dropwise for an hour. The reaction was quenchedwith acetic acid (878 μL, 0.015 mol) and the reaction mixture wasconcentrated in vacuo. The residue was then dissolved into EtOAc andwashed with saturated NaHCO₃ and brine solutions. The organic layer wasdried over sodium sulfate. Removal of the solvents in vacuo followed byflash column chromatography SiO₂ (25% EtOAc in hexanes) of the residueyielded the title compound (3.0 g, 50%) as a yellow solid. ¹H-NMR(CDCl₃): δ 8.14 (t, 1H, J=1.8 Hz), 8.02 (s 1H), 7.94–7.96 (m, 1H),7.72–7.74 (m, 1H), 7.38–7.42 (t, 1H, J=7.9 Hz), 7.26 (s 1H), 3.88 (s1H), 2.62 (s 1H).

b)4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylic acidmethyl ester (1.9 g, 0.004 mol) was converted to the amidine andpurified as described in Example 20: step f to isolate the titlecompound (1.9 g, quantitative yield). ¹H-NMR (CD₃OD): δ: 8.31 (s, 1H),8.16 (t, 1H, J=1.8 Hz), 8.01–8.04 (m, 1H), 7.86–7.90 (m, 1H), 7.52–7.57(t, 1H, J=7.9 Hz), 2.74 (s, 3H).

c){[4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine(1.9 g, 0.0048 mol, Example 27: step b) was dissolved into DMF (35 mL)with sonication. To this was added DIEA (1.67 mL, 0.0096 mol) anddi-tert-butyl-dicarbonate (1.27 g, 0.0058 mol) and reaction stirred atrt for 16 hours. The reaction mixture was dissolved into EtOAc andwashed with 20% citric acid and then brine. The organic layer was driedover Na₂SO₄ and concentrated in vacuo. The remaining residue wastriturated with hexane to isolate the title compound (1.84 g, 76%).¹H-NMR (CDCl₃): δ: 8.15 (s, 1H), 8.13–8.14 (t, 1H, J=1.6 Hz), 7.95–7.99(m, 1H), 7.79–7.84 (m, 1H), 7.72 (s, 1H), 7.48–7.52 (t, 1H, J=7.9 Hz),7.19–7.21 (m, 1H), 2.66 (s, 3H), 1.51 (s, 9H). ESI-MS (m/z): Calcd. forC₁₇H₁₉BrN₂O₄S₃: 492.4 (M+1); found: 492.6.

Example 285-Methylsulfanyl-4-[3′-(2,2,2-trifluoro-1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-thiophene-2-carboxamidinetrifluoroacetate

a) 1-(3-Bromo-phenyl)-2,2,2-trifluoro-ethanone

In a dry round bottom flask, 3-bromo-benzoic acid methyl ester (2 g, 9.3mmol, Aldrich Chemical Company) and trimethyl(trifluoromethyl)silane(1.72 mL, 11.6 mmol, Aldrich Chemical Company) were dissolved in drytoluene (50 mL). Upon cooling the solution to −78° C., TBAF (232 μL,0.23 mmol) was added and the reaction was allowed to warm up slowly tort overnight. After stirring for 20 hr, 2N HCl (50 mL) and EtOAc (100mL) were added, the layers were separated, and the aqueous layer wasextracted with another portion of EtOAc. The combined organic fractionswere dried (MgSO₄), concentrated in vacuo, and resulting crude oil waspurified using SiO₂ flash chromatography (elution: 5–20% EtOAc inhexanes) to give 1.5 g (65%) the title compound as a light yellow oil.¹H-NMR (CDCl₃; 400 MHz) δ 8.18 (br s, 1H), 7.98–8.00 (m, 1H), 7.82–7.85(m, 1H), 7.42–7.46 (m, 1H). ¹⁹F-NMR (CDCl₃; 400 MHz) δ −72.06 (s).

b)2,2,2-Trifluoro-1-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethanol

To an oven-dried round bottom flask fitted with a stir bar and a rubberseptum was added 1-(3-bromo-phenyl)-2,2,2-trifluoro-ethanone (560 mg,2.2 mmol, as prepared in Example 28, step a),4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (0.96 mL, 6.6 mmol, AldrichChemical Company), (PPh₃)₂PdCl₂ (93 mg, 0.132 mmol, Strem Chemicals,Inc., Newburyport, Mass.), and Et₃N (1.8 mL, 13.2 mmol). The reactionmixture was evacuated, purged with argon, and then suspended in dioxane(16 mL). After stirring for 18 hr at 95° C., the reaction was allowed tocool and then filtered through Celite.® The filtrate was concentrated invacuo and the residue was purified by chromatography (SiO₂, flashelution: 5% EtOAc in hexanes) to give 350 mg (53%) of an oil that wasused without further purification.

c)(Imino-{5-methylsulfanyl-4-[3′-(2,2,2-trifluoro-1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

Following the same procedure in Example 1, step c, reaction of2,2,2-trifluoro-1-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethanol(123 mg, 416 mmol, as prepared in Example 28, step b),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100 mg, 0.2 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosphine)palladium(0) (59 mg, 0.05 mmol, StremChemicals Inc, Newburyport, Mass.), Na₂CO₃ (800 μL, 2M aqueous), andtoluene/EtOH mixture (2:1, 2.4 mL) afforded 100 mg (85%) afterpurification (SiO₂, flash elution: 30% EtOAc in hexanes) of the titlecompound as a white foam. ¹H-NMR (CDCl₃; 400 MHz) δ 8.20 (t, 1H, J=1.7Hz), 7.94–7.99 (m, 2H), 7.77–7.81 (m, 1H), 7.67 (br s, 1H), 7.57 (m,1H), 7.27–7.34 (m, 1H), 7.15–7.21 (m, 2H), 5.11 (q, 1H, J=6.8 Hz), 2.51(s, 3H), 1.49 (s, 9H). ¹⁹F-NMR (CDCl₃; 400 MHz) δ −78.51 (d, J=6.9 Hz).ESI-MS (m/z): Calcd. for C₂₅H₂₅F₃N₂O₅S₃: 586.7; found: 586.7.

d)5-Methylsulfanyl-4-[3′-(2,2,2-trifluoro-1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-thiophene-2-carboxamidinetrifluoroacetate

(Imino-{5-methylsulfanyl-4-[3′-(2,2,2-trifluoro-1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (25 mg, 0.043 mmol, as prepared in Example 28,step c) was treated with trifluoroacetic acid (50% in DCM) for 1 hr atrt. The reaction mixture was concentrated in vacuo and the residueobtained was purified using C₁₈-HPLC (10–80% CH₃CN in H₂O (0.1% TFA)over 25 min) to give 18 mg (86%) of the title compound as a white solid.¹H-NMR (CD₃OD; 400 MHz) δ 8.33 (s, 1H), 8.30 (t, 1H, J=1.7), 7.97–8.05(m, 2H), 7.91 (br s, 1H), 7.68–7.74 (m, 2H), 7.53–7.56 (m, 2H), 5.15 (q,1H, J=7.0 Hz), 2.74 (s, 3H). ¹⁹F-NMR (CD₃OD; 400 MHz) δ −80.09 (d, J=6.9Hz). ESI-MS (m/z): Calcd. for C₂₀H₁₇F₃N₂O₃S₃: 487.6 (M+H); found: 487.3.

Example 295-Methylsulfanyl-4-[3′-(2,2,2-trifluoro-acetyl)-biphenyl-3-sulfonyl]-thiophene-2-carboxamidinetrifluoroacetate

a)(Imino-{5-methylsulfanyl-4-[3′-(2,2,2-trifluoro-acetyl)-biphenyl-3-sulfonyl]-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

In a reaction vial,(imino-{5-methylsulfanyl-4-[3′-(2,2,2-trifluoro-1-hydroxy-ethyl)-biphenyl-3-sulfonyl]-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (30 mg, 0.051 mmol, as prepared in Example 28,step c) and 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (31mg, 0.072 mmol, Lancaster Synthesis, Windham, N.H.) were dissolved inDCM (2 mL). To that solution, wet DCM (1 mL, 4 μL H₂O) was added slowlyvia a syringe. After 1 hr of stirring at rt, the reaction was evaporatedand the residue was partitioned between Et₂O (30 mL) and 10%Na₂S₂O₃-saturated NaHCO₃ (1:1, 15 mL). The aqueous layer was washed withan additional portion of Et₂O. The combined organic washes were driedwith MgSO₄ and concentrated in vacuo to give 30 mg (quantitative yield)of the title compound that was used without purification. ¹H-NMR (CDCl₃;400 MHz) δ 8.28 (br s, 1H), 8.26 (t, 1H, J=1.7 Hz), 8.08–8.13 (m, 1H),7.99–8.04 (m, 1H), 7.96 (s, 1H), 7.91–7.95 (m, 1H), 7.82–7.86 (m, 1H),7.62–7.71 (m, 2H), 2.59 (s, 3H), 1.51 (s, 9H). ¹⁹F-NMR (CDCl₃; 400 MHz)δ −84.93 (s). ESI-MS (m/z) Calcd. for C₂₅H₂₃F₃N₂O₅S₃: 487.6 (M+H);found: 487.2.

b)5-Methylsulfanyl-4-[3′-(2,2,2-trifluoro-acetyl)-biphenyl-3-sulfonyl]-thiophene-2-carboxamidinetrifluoroacetate

(Imino-{5-methylsulfanyl-4-[3′-(2,2,2-trifluoro-acetyl)-biphenyl-3-sulfonyl]-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (30 mg, 0.051 mmol, as prepared in Example 29,step a) was treated with trifluoroacetic acid (50% in DCM) for 1 hr atrt. The reaction mixture was concentrated in vacuo and the residueobtained was purified using C₁₈-HPLC (20–60% CH₃CN in H₂O (0.1% TFA)over 25 min) to give 20 mg (80%) of the title compound as a white solid.¹H-NMR (CD₃OD; 400 MHz) δ 8.35 (s, 1H), 8.33 (t, 1H, J=1.7 Hz),7.98–8.07 (m, 2H), 7.90–7.93 (m, 1H), 7.68–7.78 (m, 3H), 7.60 (t, 1H,J=7.8 Hz), 2.77 (s, 3H). ¹⁹F-NMR (CDCl₃; 400 MHz) δ −84.99 (s). ESI-MS(m/z): Calcd. for C₂₀H₁₅F₃N₂O₃S₃: 485.5 (M+H); found: 485.3, 503.3(M+H₂O), 517.3 (M+CH₃OH).

Example 304-[3-(6-Methyl-3H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a) 5-Chloro-6-methyl-benzoimidazole-1-carboxylic acid tert-butyl esterand 5-Chloro-6-methyl-benzoimidazole-3-carboxylic acid tert-butyl ester

4-Chloro-5-methyl-benzene-1,2-diamine (560 mg, 3.6 mmol, MaybridgeChemical Co. Ltd., Cornwall, UK) was dissolved in formic acid (10 mL)and the solution was refluxed at 100° C. for 18 hr. The reaction wasallowed to cool and then evaporated to dryness in vacuo to give5-chloro-6-methyl-1H-benzoimidazole as a tan solid (quantitative yield)that was used without further purification. The solid obtained above(410 mg, 2.4 mmol), di-tert-butyl dicarbonate (1.6 g, 7.4 mmol), andDMAP (29 mg, 0.24 mmol) were dissolved in CH₃CN (20 mL). To the mixture,DIEA (1.3 mL, 7.4 mmol) was added and the reaction was stirred for 18 hrat rt. The solvents were evaporated in vacuo and the residue partitionedbetween EtOAc (100 mL) and saturated aqueous NaHCO₃ (75 mL). The aqueouslayer was separated and washed with EtOAc (100 mL). The combined organiclayers were dried with MgSO₄ and concentrated in vacuo. The cruderesidue was purified using flash SiO₂ chromatography (20% EtOAc inhexanes) to give 620 mg (97%) of the title compound as a 1:1 mixture ofregioisomers that were used without separation. ¹H-NMR (CDCl₃; 400 MHz,1:1 mixture of isomers) δ 8.35 and 8.36 (s, 1H), 7.89 and 7.99 (s, 1H),7.62 and 7.75 (s, 1H), 2.48 and 2.50 (s, 3H), 1.698 and 1.700 (s, 9H).ESI-MS (m/z): Calcd. for C₁₃H₁₅ClN₂O₂: 266.7; found: 266.9, 167.2(M−Boc).

b)5-Methyl-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoimidazole-1-carboxylicacid tert-butyl ester and5-Methyl-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoimidazole-1-carboxylicacid tert-butyl ester

To a dry reaction vial fitted with a stir bar and a Teflon®-lined screwcap, a mixture of 5-chloro-6-methyl-benzoimidazole-1-carboxylic acidtert-butyl ester and 5-chloro-6-methyl-benzoimidazole-3-carboxylic acidtert-butyl ester (150 mg, 0.56 mmol, as prepared in Example 30, step a),4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl] (284 mg,1.12 mmol, Aldrich Chemical Company),(2′-dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine (17.7 mg, 0.045mmol, Strem Chemicals Inc, Newburyport, Mass.), Pd(OAc)₂ (6.7 mg, 0.03mmol. Strem Chemicals Inc, Newburyport, Mass.), and K₃PO₄ (238 mg, 1.12,mmol) were added. The vial was capped, purged with argon, and thensuspended in toluene (3 mL). After stirring for 18 hr at 95° C., thereaction was allowed to cool and then filtered through Celite.® Thefiltrate was concentrated in vacuo and the residue was purified usingpreparative thin layer chromatography (1:3 EtOAc/hexanes, 2000μ SiO₂plate) to afford 100 mg (50%) of the title compound (1:1 mixture ofregioisomers) as a yellow oil. ESI-MS (m/z): Calcd. for C₁₉H₂₇BN₂O₄:358.2; found: 303.2 (M−^(t)Bu), 259.3 (M−Boc).

c)4-[3-(6-Methyl-3H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

Following the same procedure in Example 1, step c,5-methyl-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoimidazole-1-carboxylicacid tert-butyl ester and5-methyl-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoimidazole-1-carboxylicacid tert-butyl ester (90 mg, 0.25 mmol, as prepared in Example 30, stepb),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (62 mg, 0.126 mmol, as prepared in Example 27,step c), tetrakis(triphenylphosphine)palladium(0) (37 mg, 0.032 mmol,Strem Chemicals, Inc., Newburyport, Mass.), Na₂CO₃ (400 μL, 2M aqueous),and toluene/EtOH mixture (2:1, 1.2 mL) were reacted to give 170 mg of atan foam. This crude material was separated using preparative thin layerchromatography (1:2 EtOAc/hexanes, 2000μ SiO₂ plate). From several bandsthat were isolated and analyzed by ESI-MS, two bands exhibited anobserved mass consistent with the di-Boc (7 mg) and mono-Boc (47 mg)products, respectively. Both of these compounds were combined and thentreated with trifluoroacetic acid (50% in DCM) for 1 hr at rt. Thereaction mixture was concentrated in vacuo and the residue obtained waspurified using C₁₈-HPLC (15–35% CH₃CN in H₂O (0.1% TFA) over 25 min) togive 8 mg (15%) of the title compound as a white solid. ¹H-NMR (CD₃OD):δ 9.34 (s, 1H), 8.34 (s, 1H), 8.04–8.10 (m, 2H), 7.79 (br s, 1H),7.74–7.75 (m, 2H), 7.67 (br s, 1H), 2.72 (s, 3H), 2.37 (s, 3H). ESI-MS(m/z): Calcd. for C₂₀H₁₈N₄O₂S₃: 443.6 M+H); found: 443.1, 222.3 (M⁺⁺).

Example 31N-Hydroxy-4-[3-(6-methyl-3H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)N-Hydroxy-4-[3-(6-methyl-3H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[3-(6-Methyl-3H-benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate (5 mg, 7.5 μmmol, as prepared in Example 30, stepc), hydroxylamine hydrochloride (50 mg, 720 μmol), and Et₃N (139 μL, 1mmol)) were suspended in EtOH (3 mL). The reaction mixture was refluxedfor 2 hr at which time thin layer chromatography showed completedisappearance of the starting material. The reaction mixture wasconcentrated in vacuo and the residue was purified using C₁₈-HPLC(10–50% CH₃CN in H₂O (0.1% TFA) over 20 min) to give 4.9 mg(quantitative yield) of the title compound as a hygroscopic white solid.¹H-NMR (CD₃OD): δ 9.38 (s, 1H), 8.08–8.12 (m, 2H), 8.05–8.07 (m, 1H),7.82 (br s, 1H), 7.73–7.77 (m, 2H), 7.70 (br s, 1H), 2.70 (s, 3H), 2.38(s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₁₈N₄O₃S₃: 459.6 (M+M); found:459.2.

Example 324-[2′-(1-Hydroxy-ethyl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){Imino-[5-methylsulfanyl-4-(2′-vinyl-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

Following the procedure outlined for Examples 41–107, reaction of2-vinyl-phenylboronic acid (30 mg, 0.20 mmol, Aldrich Chemical Company),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (50 mg, 0.1 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosphine)palladium(0) (29 mg, 0.025 mmol, StremChemicals, Inc., Newburyport, Mass.), Na₂CO₃ (400 μL, 2M aqueous), andtoluene/EtOH mixture (2:1, 1.2 mL) afforded 25 mg (50%) afterpurification (1:3 EtOAc/hexanes, 2000μ SiO₂ plate) of the title compoundas a white foam.

b)4-[2′-(1-Hydroxy-ethyl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{Imino-[5-methylsulfanyl-4-(2′-vinyl-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (25 mg, 0.05 mmol) was treated withtrifluoroacetic acid (50% in DCM) for 1 hr at rt. The reaction mixturewas concentrated in vacuo and then basified with 1 M NaOH to pH 8 andallowed to stand for 10 min. The solution was then re-acidified with TFAand purified using C₁₈-HPLC (10–80% CH₃CN in H₂O (0.1% TFA) over 30 min)to give 7 mg (33%) of the title compound as a white solid (R_(t): 12.3min). ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 8.01–8.05 (m, 1H), 7.98–8.00 (m,1H), 7.64–7.71 (m, 3H), 7.44–7.49 (m, 1H), 7.32–7.36 (m, 1H), 7.16–7.18(m, 1H), 4.75 (q, 1H, J=6.5 Hz), 2.72 (s, 3H), 1.28 (d, 3H, J=6.5 Hz).ESI-MS (m/z): Calcd. for C₂₀H₂₀N₂O₃S₃: 433.6 (M+H); found: 433.1.

Example 334-[4′-(1-Hydroxy-ethyl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidineTrifluoroacetate

a){Imino-[5-methylsulfanyl-4-(4′-vinyl-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

Following the procedure outlined in Example 1, step c, reaction of4-vinyl-phenyl-boronic acid (181 mg, 1.22 mmol),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (300 mg, 0.61 mmol, as prepared in Example 27,step c), tetrakis(triphenylphosphine)palladium(0) (141 mg, 0.122 mmol,Strem Chemicals, Inc., Newburyport, Mass.), Na₂CO₃ (2.4 mL, 2M aqueous),and toluene/EtOH mixture (2:1, 7.2 mL) afforded 138 mg (45%) of thetitle compound as a white glassy solid after SiO₂ flash chromatography(1:3 EtOAc/hexanes). ¹H-NMR (CDCl₃): δ 8.21 (t, 1H, 1.7 Hz), 8.00 (brs,1H), 7.92–7.95 (m, 1H), 7.79–7.81 (m, 1H), 7.48–7.58 (m, 5H), 6.75 (dd,1H, J=17.7, 10.9 Hz), 5.82 (d, 1H, J=17.5), 5.31 (d, 1H, J=10.9 Hz),2.54 (s, 3H), 1.50 (s, 9H).

b)4-[4′-(1-Hydroxy-ethyl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidineTrifluoroacetate

{Imino-[5-methylsulfanyl-4-(4′-vinyl-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (14 mg, 0.027 mmol, as prepared in Example 33,step a) was treated with trifluoroacetic acid (50% in DCM) for 1 hr atrt. The reaction mixture was concentrated in vacuo and then brought topH 8 with 1 M NaOH and allowed to stand for 10 min. The solution wasthen re-acidified with TFA and purified using C₁₈-HPLC (10–80% CH₃CN inH₂O (0.1% TFA) over 30 min) to give 9 mg (81%) of the title compound asa white solid (R_(t): 11.8 min). ¹H-NMR (CD₃OD): δ 8.33 (s, 1H), 8.25(t, 1H, 1.7 Hz), 7.95–8.01 (m, 2H), 7.61–7.71 (m, 3H), 7.49–7.53 (m,2H), 4.89 (q, 1H, J=6.5 Hz), 2.73 (s, 3H), 1.47 (d, 3H, J=6.5 Hz).ESI-MS (m/z): Calcd. for C₂₀H₂₀N₂O₃S₃: 433.6 (M+H); found: 433.2.

Example 344-(2′-Hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(2′-Methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoracetate

Following the procedure outlined in Example 1, step c, reaction of2-methoxy-phenyl-boronic acid (181 mg, 1.22 mmol),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100 mg, 0.2 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosphine)palladium(0) (141 mg, 0.122 mmol, StremChemicals, Inc., Newburyport, Mass.), Na₂CO₃ (800 μL, 2M aqueous), andtoluene/EtOH mixture (2:1, 2.4 mL) afforded 100 mg (96%) of a whiteglassy solid after SiO₂ flash chromatography (1:3 EtOAc/hexanes). Thismaterial was treated with trifluoroacetic acid. (50% in DCM) for 1 hr atrt and the crude product was purified using C₁₈-HPLC to give 65 mg (80%)of the title compound as a white solid. ¹H-NMR (CD₃OD): δ 8.29 (s, 1H),8.12 (brs, 1H), 8.02 (brd, 1H, J=7.9 Hz), 7.86–7.90 (m, 1H), 7.54 (t,1H, J=8.0 Hz), 6.88–7.36 (m, 4H), 3.30 (s, 3H), 2.73 (s, 3H). ESI-MS(m/z): Calcd. for C₁₉H₁₈N₂O₃S₃: 419.5 (M+H); found: 419.3.

b)4-(2′-Hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(2′-Methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (46 mg, 0.086 mmol, as prepared in Example 34, step a)was treated with BBr₃ (1 M in DCM) for 18 hr at rt. The reaction wasquenched with MeOH at 0° C. and then concentrated in vacuo to a solid.Purification of this solid using C₁₈-HPLC (10–80% CH₃CN in H₂O (0.1%TFA) over 25 min) afforded 34 mg (77%) of the title compound as a whitesolid. ¹H-NMR (CD₃OD): δ 8.30 (s, 1H), 8.27 (t, 1H, J=1.9 Hz), 7.89–7.96(m, 2H), 7.61 (t, 1H, J=7.9 Hz), 7.26–7.30 (m, 1H), 7.19–7.24 (m, 1H),6.90–6.95 (m, 2H), 2.70 (s, 3H). ESI-MS (m/z): Calcd. for C₁₈H₁₆N₂O₃S₃:405.5 (M+H); found: 405.2.

Example 354-(3′-Hydroxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(3′-Methoxy-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (1.4 mg, 3.3 μmol, as prepared in Example 44) wastreated with BBr₃ (1 M in DCM) for 18 hr at rt. The reaction wasquenched with MeOH at 0° C. and then concentrated in vacuo to a solid.Purification of this solid using C₁₈-HPLC (10–80% CH₃CN in H₂O (0.1%TFA) over 25 min) afforded 1.0 mg (77%) of the title compound as a whitesolid. ¹H-NMR (CD₃OD): δ 8.33 (s, 1H), 8.23 (t, 1H, J=1.6 Hz), 7.98–8.01(m, 1H), 7.92–7.95 (m, 1H), 7.68 (t, 1H, J=7.8 Hz), 7.31 (t, 1H, J=7.8Hz), 7.05–7.12 (m, 2H), 6.84–6.87 (m, 1H), 2.74 (s, 3H). ESI-MS (m/z):Calcd. for C₁₈H₁₆N₂O₃S₃: 405.5 (M+H); found: 405.2.

Example 365-Bromo-4-(2-methoxy-benzenesulfonyl)-thiophene-2-carboxamidinetriflouroacetate

The procedure as in Example 20: step a was followed using4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 200 mg, 0.75 mmol) and 2-methoxy-benzenethiol (109 μL, 1.25mmol, Aldrich Chemical Company) to isolate4-(2-methoxy-phenylsulfanyl)-5-nitro-thiophene-2-carboxylic acid methylester. 4-(2-Methoxy-phenylsulfanyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester (200 mg, 0.61 mmol) was then treated with TiCl₃ (20% aq.HCl solution, 5 mL, 6.1 mmol) in THF (6 mL). The reaction was stirredfor 20 minutes at rt. The reaction mixture was concentrated in vacuo andthen dissolved into EtOAc. The organic layer was washed several timeswith saturated NaHCO₃. The combined organic layers were dried oversodium sulfate. Removal of the solvents in vacuo yielded5-amino-4-(2-methoxy-phenylsulfanyl)-thiophene-2-carboxylic acid methylester. The procedure as in Example 20: step e was followed using5-amino-4-(2-methoxy-phenylsulfanyl)-thiophene-2-carboxylic acid methylester (160 mg, 0.54 mmol), t-butylnitrite (96 μL, 0.81 mmol), andcopper(II) bromide (112.6 mg, 0.65 mmol) resulting in5-bromo-4-(2-methoxy-phenylsulfanyl)-thiophene-2-carboxylic acid methylester. The procedure as in Example 20: step b was followed using5-bromo-4-(2-methoxy-phenylsulfanyl)-thiophene-2-carboxylic acid methylester (18 mg, 0.05 mmol) and m-CPBA (32 mg, 0.25 mmol) resulting in5-bromo-4-(2-methoxy-benzenesulfonyl)-thiophene-2-carboxylic acid methylester. The procedure as in Example 20: step f was followed using5-bromo-4-(2-methoxy-benzenesulfonyl)-thiophene-2-carboxylic acid methylester (45 mg, 11 mmol) and dimethyl aluminum amide (1M, 0.57 mL, 0.55mmol) resulting in the title compound5-bromo-4-(2-methoxy-benzenesulfonyl)-thiophene-2-carboxamidine (4 mg,13%). ¹H-NMR (CD₃OD): δ: 8.30 (s, 1H), 8.12–8.14 (d of d, J=6.1, 1.8 Hz,1H), 7.70–7.74 (m, 1H), 7.16–7.24 (m, 2H), 3.79 (s, 3H).

Example 375-Methylsulfanyl-4-(naphthalene-2-sulfonyl)-thiophene-2-carboxamidinetriflouroacetate

To a suspension of NaH (30 mg, 1.24 mmol) in DMF was slowly addeddropwise naphthalene-2-thiol (199 mg, 1.24 mmol, Aldrich ChemicalCompany) in DMF at rt. This clear solution was then added dropwise to asolution of 4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester((Example 114, step c) 300 mg, 1.27 mmol) in DMF at rt. Aqueous workupresulted in isolation of4-(naphthalen-2-ylsulfanyl)-5-nitro-thiophene-2-carboxylic acid methylester. The procedure as in Example 20: step b was followed using4-(naphthalen-2-ylsulfanyl)-5-nitro-thiophene-2-carboxylic acid methylester (194 mg, 0.56 mmol) and m-CPBA (354.4 mg, 1.2 mmol) resulting in4-(naphthalene-2-sulfonyl)-5-nitro-thiophene-2-carboxylic acid methylester. The procedure as in Example 27: step a was followed using4-(naphthalene-2-sulfonyl)-5-nitro-thiophene-2-carboxylic acid methylester (32 mg, 0.085 mmol) sodium thiomethoxide (7.55 mg, 0.94 mmol)resulting in5-methylsulfanyl-4-(naphthalene-2-sulfonyl)-thiophene-2-carboxylic acidmethyl ester. The procedure as in Example 20: step f was followed using5-methylsulfanyl-4-(naphthalene-2-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (29 mg, 0.77 mmol) and dimethyl aluminum amide (0.39 mL,0.39 mmol) resulting in the title compound5-methylsulfanyl-4-(naphthalene-2-sulfonyl)-thiophene-2-carboxamidinetriflouroacetate (19 mg, 70%). ¹H-NMR (CD₃OD): δ: 8.67 (m, 1H), 8.37 (s,1H), 8.05–8.15 (m, 2H), 7.95–8.01 (d, J=7.21 Hz, 1H), 7.90–7.95 (d of d,J=6.7, 2.0 Hz), 7.65–7.75 (m, 2H), 2.70 (s, 3H).

Example 384-(7-Bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 4-Chlorosulfonyl-5-methylsulfanyl-thiophene-2-carboxylic acid methylester

To a −5° C. solution of 4-amino-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (Illig et al. U.S. Pat. No. 6,291,514, 24 g, 0.12 mol)in methylene chloride:methanol (2:1, 40 mL), CuCl₂.H₂O (6.04 g, 0.035mol), and concentrated HCl (19.7 mL, 0.24 mol) was added. Excess SO₂ wascondensed into the reaction mixture. To this mixture, was added t-butylnitrite (27.6 mL, 0.24 mol) dropwise at −5° C. and then stirred at sametemperature for 2 hours. The reaction mixture was allowed to warm up toroom temperature, and the solvents were removed in vacuo. The residuewas diluted in methylene chloride (500 mL), washed with water (100 mL)and brine (50 mL), and dried over Na₂SO₄. The solvent was removed invacuo and the residue was purified by flash chromatography in 30–50%ethyl acetate in hexanes to afford4-chlorosulfonyl-5-methylsulfanyl-thiophene-2-carboxylic acid methylester as a solid (12 g, 35%).

b) Sodium salt of 5-methylsulfanyl-4-sulfino-thiophene-2-carboxylic acidmethyl ester

To a solution of Na₂SO₃ (7.51 g, 0.06 mol) and NaHCO₃ (5.22 g, 0.06 mol)in water (27 mL) at 75° C. was added4-chlorosulfonyl-5-methylsulfanyl-thiophene-2-carboxylic acid methylester ((Example 38, step a) 12 g, 0.05 mol) portion-wise over 3 hoursand then stirred for an additional hour. Water was removed in vacuo, andthe residue was dissolved in hot water (10 mL). This solution was cooledin a refrigerator for 1 week at which time the product precipitated out.This solid was filtered, washed with cold water and dried to give 12 g(87%) of the sodium salt of5-methylsulfanyl-4-sulfino-thiophene-2-carboxylic acid methyl ester.¹H-NMR (DMSO-d₆): δ 7.64 (s, 1H), 3.78 (s, 3H), 2.57 (s, 3H).

c)4-(7-Bromo-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a solution of 4,6-dibromo-spiro[benzoimidazole-2,1′-cyclohexane] (200mg, 0.58 mmol, prepared according to Hazelton et al.,Tetrahedron:51:5597 (1995)) in ethanol (15 mL) was added an aqueoussolution of the sodium salt of5-methylsulfanylsulfino-thiophene-2-carboxylic acid methyl ester((Example 38, step b) 175 mg, 0.64 mmol, 15 mL H₂O) and acetic acid (40μL, 0.70 mmol). This mixture was stirred for 2.5 hours at roomtemperature and poured into an ice-water slurry. The resulting aqueoussolution was extracted with methylene chloride (100 mL, 3×). The organiclayer was separated, washed with brine (25 mL), and dried over MgSO₄.The solvents were removed in vacuo to afford4-(7-bromo-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester as a brown solid (200 mg, 67%). ¹H-NMR (CDCl₃): δ 8.08(m, 1H), 8.04 (s, 1H), 7.60 (m, 1H), 3.91 (s, 3H), 2.66 (s, 3H),2.00–1.24 (m, 10H).

d)4-(3,4-Diamino-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a solution of4-(7-bromo-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 38, step c) 200 mg, 0.39 mmol) in 1:1ethanol:water (30 mL) was added sodium dithionite (159 mg, 0.78 mmol)and heated to 80° C. for 45 minutes. The solution was cooled to roomtemperature and poured into an ice-water slurry. This aqueous mixturewas extracted with methylene chloride (50 mL, 3×). The organic layer wasseparated, washed with brine (25 mL), and dried over MgSO₄. The solventswere removed in vacuo to afford 170 mg of4-(3,4-diamino-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester as a brown oil. This was used in the next step withoutfurther purification.

e)4-(7-Bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

4-(3,4-Diamino-5-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 38, step d) 170 mg, 0.39 mmol) was dissolvedin formic acid (2.5 mL) and heated to 100° C. for 2 hours. The resultingsolution was cooled to room temperature, poured over ice-water slurry,and basified to pH 8 with NaHCO₃. This aqueous solution was extractedwith ethyl acetate (75 mL, 3×). The organic layer was separated andwashed with water, brine, and dried over MgSO₄. Solvents were removed invacuo to afford 100 mg (57%) of4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester as a brown oil. ESI-MS (m/z): Calcd. forC₁₄H₁₁BrN₂O₄S₃: 447 (M+H); found: 447.1 and 449.1.

f)4-(7-Bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

1M stock solution of dimethylaluminum amide reagent was made by theaddition of AlMe₃ solution (2M in toluene, 5 mL, 10 mmol) to asuspension of NH₄Cl (0.54 g, 10 mmol) in toluene (5 mL) under inertconditions, and then heated to 80° C. for 5 minutes. This solution (2.5mL, 2.5 mmol) was added to4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 38, step e) 15 mg, 0.034 mmol) and thenheated to 100° C. for 2 hrs. The resulting solution was cooled to roomtemperature and added to a slurry of silica gel in methylene chloride(15 g silica gel in methylene chloride 120 mL), and stirred for 30minutes. The slurry was filtered and the silica was washed withmethanol. The filtrate and methanol fractions were combined andevaporated under vacuum. The residue was purified by HPLC (C₁₈-column,10–70% CH₃CN over 30 min) to afford 3.0 mg (21%) of4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate as a white solid. ¹H-NMR (CD₃OD): δ 8.51 (s, 1H), 8.36(d, 1H, J=1.6), 8.33 (s, 1H), 8.05 (d, 1H, J=1.6), 2.72 (s, 3H). ESI-MS(m/z): Calcd. for C₁₃H₁₁BrN₄O₂S₃: 430.92 (M+H); found 431.2 and 433.1.

Examples 39–404-(7-Bromo-3-methyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(7-Bromo-1-methyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(7-Bromo-3-methyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-(7-Bromo-1-methyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a solution of4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (as prepared in Example 38, step e) (100 mg, 0.22mmol) in dimethylformamide (2 mL) was added MeI (13.9 μL, 0.22 mmol) andK₂CO₃ (61.8 mg, 0.45 mmol), then stirred overnight at room temperature.The solvents were removed in vacuo and the residue was diluted withethyl acetate (100 mL). The ethyl acetate layer was washed with water(15 mL) and brine (25 mL), and dried over MgSO₄. The solvent was removedin vacuo to afford 20 mg (19%) of4-(7-bromo-3-methyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-(7-bromo-1-methyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester as a mixture. This mixture was used directly in thefollowing step.

b)4-(7-Bromo-3-methyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(7-Bromo-1-methyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

1M stock solution of dimethylaluminum amide reagent was made by theaddition of AlMe₃ solution (2M in toluene, 5 mL, 10 mmol) to asuspension of NH₄Cl (0.54 g, 10 mmol) in toluene (5 mL) under inertconditions, and then heated to 80° C. for 5 minutes. To the mixture fromabove ((Examples 39–40, step a) 20 mg, 0.043 mmol) was addeddimethylaluminum amide reagent (2.5 mL, 2.5 mmol), and then heated to100° C. for 2 hrs. This solution was cooled to room temperature, addedto 15 g silica gel and methylene chloride (120 mL) slurry, and stirredfor 30 minutes. The slurry was filtered and washed with methanol. Thesolvents were removed in vacuo, and the crude material was purified byHPLC (C₁₈-column, 10–70% CH₃CN over 30 min) to afford4-(7-bromo-3-methyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate, 39 (4.5 mg) and4-(7-bromo-1-methyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate, 40 (2.5 mg).

Example 39: ¹H-NMR (CD₃OD): δ 8.48 (s, 1H), 8.34 (s, 1H), 8.33 d, 1H,J=1.6), 8.06 (d, 1H, J=1.6), 4.01 (s, 3H), 2.72 (s, 3H). ESI-MS (m/z):Calcd. for C₁₄H₁₃BrN₄O₂S₃: 445 (M+H); found 445.1 and 447.1.

Example 40: ¹H-NMR (CD₃OD): δ 8.39 (s, 1H), 8.34 (d, 1H, J=1.4), 8.33(s, 1H), 8.07 (d, 1H, J=1.2), 4.21 (s, 3H), 2.72 (s, 3H). ESI-MS (m/z):Calcd. for C₁₄H₁₃BrN₄O₂S₃: 445 (M+H); found 445.1 and 447.1.

Examples 41–107

The compounds in examples 41 to 107 (see table 1) were synthesized in aparallel fashion as follows: To dry 2-dram vials, each fitted with astir bar and a Teflon®-lined screw cap was added{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.1 mmol, as prepared in Example 27, step c), theappropriate boronic acid (0.2 mmol), andtetrakis(triphenylphosine)palladium(0) (0.025 mmol). Each vial was twicetreated with an argon purge/evacuation cycle and then charged with amixture of toluene/EtOH (2:1, 1.2 mL) and 2 M Na₂CO₃ (0.4 mL) via asyringe. The vials were placed in an oil bath at 80° C. and stirredovernight. To the cooled reaction mixtures was added EtOAc (4 mL), theorganic layer was filtered (1-g silica SPE column), and the filtrate wasevaporated in vacuo. The resulting residue was purified usingpreparative TLC (SiO₂) to afford the Boc-protected amidine product.After treatment of this material with trifluoroacetic acid (50% in DCM)for 1 hr at rt, the solvents were removed in vacuo and the residue waspurified using C₁₈-HPLC (typical HPLC method: 10% to 80% CH₃CN in H₂O(0.1% TFA) over 25 min) to afford the desired compound. Example 94 wasprepared in an identical fashion except for removal of the Bocprotecting group which was achieved by treatment with 4 N HCl in dioxanefor 1 hr at rt. This was found to minimize side reactions involving thevinylic group (see Example 32).

Ex. Calcd. No. Reagent Compound Formula (M + H) Found 41 2,4-dimethoxyphenyl 4-(2′,4′-Dimethoxy-biphenyl-3- C₂₀H₂₀N₂O₄S₃ 449.5 449.2 boronicacid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 42 4-methoxyphenyl boronic 4-(4′-Methoxy-biphenyl-3- C₁₉H₁₈N₂O₃S₃ 419.5 419.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 43 3,4-dimethoxyphenyl 4-(3′,4′-Dimethoxy-biphenyl-3- C₂₀H₂₀N₂O₄S₃ 449.5 449.3 boronicacid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 44 3-methoxyphenyl boronic 4-(3′-Methoxy-biphenyl-3- C₁₉H₁₈N₂O₃S₃ 419.5 419.3 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 45 2-methoxyphenyl boronic 4-(2′-Methoxy-biphenyl-3- C₁₉H₁₈N₂O₃S₃ 419.5 419.3 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 46 3,5-dichlorophenyl 4-(3′,5′-Dichloro-biphenyl-3- C₁₈H₁₄Cl₂N₂O₂S₃ 457.4 457.2 boronicacid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 472,5-dichloro phenyl 4-(2′,5′-Dichloro-biphenyl-3- C₁₈H₁₄Cl₂N₂O₂S₃ 457.4457.2 boronic acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine48 3,5-di(triflouoromethyl) 4-(3′,5′-Bis-trifluoromethyl- C₂₀H₁₄F₆N₂O₂S₃525.5 525.2 phenyl boronic acid biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2- carboxamidine 49 2-Benzofuran boronic acid4-(3-Benzofuran-2-yl- C₂₀H₁₆N₂O₃S₃ 429.5 429.3 benzenesulfonyl)-5-methylsulfanyl-thiophene-2- carboxamidine 50 2-Benzothiophene boronic4-(3-Benzo[b]thiophen-2-yl- C₂₀H₁₆N₂O₂S₄ 445.6 445.2 acidbenzenesulfonyl)-5- methylsulfanyl-thiophene-2- carboxamidine 514-methyl-3-nitro- 4-(4′-Methyl-3′-nitro-biphenyl- C₁₉H₁₇N₃O₄S₃ 448.5448.3 phenylboronic acid 3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine 52 4-methyl-phenylboronic4-(4′-Methyl-biphenyl-3- C₁₉H₁₈N₂O₂S₃ 403.5 403.3 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 534-Chloro-phenylboronic 4-(4′-Chloro-biphenyl-3- C₁₈H₁₅ClN₂O₂S₃ 423.98423.3 acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 544-Trifluoromethyl- 5-Methylsulfanyl-4-(4′- C₁₉H₁₅F₃N₂O₂S₃ 457.5 457.2phenylbornic acid trifluoromethyl-biphenyl-3- sulfonyl)-thiophene-2-carboxamidine 55 4-trifluoromethoxy- 5-Methylsulfanyl-4-(4′-C₁₉H₁₅F₃N₂O₃S₃ 473.5 473.2 phenylbornic acidtrifluoromethoxy-biphenyl-3- sulfonyl)-thiophene-2- carboxamidine 564-phenoxy-phenyl-boronic 5-Methylsulfanyl-4-(4′-phenoxy- C₂₄H₂₀N₂O₃S₃481.6 481.3 acid biphenyl-3-sulfonyl)-thiophene- 2-carboxamidine 574-methanesulfonyl {Imino-[4-(4′-methanesulfonyl- C₂₄H₂₆N₂O₆S₄ 467.6467.3 phenylboronic acid biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]- methyl}-carbamic acid tert-butyl ester 58Benzo[1,3]dioxole-5- 4-(3-Benzo[1,3]dioxol-5-yl- C₁₉H₁₆N₂O₄S₃ 433.5433.3 boronic acid benzenesulfonyl)-5- methylsulfanyl-thiophene-2-carboxamidine 59 Quinoline-7-boronic acid5-Methylsulfanyl-4-(3-quinolin- C₂₁H₁₇N₃O₂S₃ 440.5 440.17-yl-benzenesulfonyl)- thiophene-2-carboxamidine 60 3-tolylphenylboronic acid 4-(3′-methyl-biphenyl-3- C₁₉H₁₈N₂O₂S₃ 403.5 403.2sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 61 3-formylphenylboronic 4-(3′-Formyl-biphenyl-3- C₁₉H₁₆N₂O₃S₃ 417.5 417.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 62 3-aminophenylboronic 4-(3′-Amino-biphenyl-3- C₁₈H₁₇N₃O₂S₃ 404.5 404.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 633-trifluoromethyl phenyl 5-Methylsulfanyl-4-(3′- C₁₉H₁₅F₃N₂O₂S₃ 457.5457.2 boronic acid trifluoromethyl-biphenyl-3- sulfonyl)-thiophene-2-carboxamidine 64 3-hydroxymethyl phenyl 4-(3′-Hydroxymethyl-biphenyl-C₁₉H₁₈N₂O₃S₃ 419.5 419.2 boronic acid 3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine 65 Biphenyl-3-boronic acid 5-Methylsulfanyl-4-C₂₄H₂₀N₂O₂S₃ 465.6 465.3 ([1,1′;3′,1″]terphenyl-3-sulfonyl)-thiophene-2- carboxamidine 66 4-dibenzofuran boronic4-(3-Dibenzofuran-4-yl- C₂₄H₁₈N₂O₃S₃ 479.6 479.3 acidbenzenesulfonyl)-5- methylsulfanyl-thiophene-2- carboxamidine 672-trifluoromethyl phenyl 5-Methylsulfanyl-4-(2′- C₁₉H₁₅F₃N₂O₂S₃ 457.5457.2 boronic acid trifluoromethyl-biphenyl-3- sulfonyl)-thiophene-2-carboxamidine 68 2-hydroxymethyl phenyl 4-(2′-Hydroxymethyl-biphenyl-C₁₉H₁₈N₂O₃S₃ 419.5 419.1 boronic acid 3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine 69 2-chloro phenylboronic4-(2′-Chloro-biphenyl-3- C₁₈H₁₅ClN₂O₂S₃ 423.9 423.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 70 3-pyridineboronic acid 5-Methylsulfanyl-4-(3-pyridin- C₁₇H₁₅N₃O₂S₃ 390.5 390.13-yl-benzenesulfonyl)- thiophene-2-carboxamidine 71 Pyrimidine-5-boronicacid 5-Methylsulfanyl-4-(3- C₁₆H₁₄N₄O₂S₃ 391.5 391.2 pyrimidin-5-yl-benzenesulfonyl)-thiophene-2- carboxamidine 72 Furan 3-boronic acid4-(3-Furan-3-yl- C₁₆H₁₄N₂O₃S₃ 379.5 379.2 benzenesulfonyl)-5-methylsulfanyl-thiophene-2- carboxamidine 73 3-quinolone boronic acid5-Methylsulfanyl-4-(3-quinolin- C₂₁H₁₇N₃O₂S₃ 440.5 440.23-yl-benzenesulfonyl)- thiophene-2-carboxamidine 74 4-methoxycarbonyl3′-(5-Carbamimidoyl-2- C₂₀H₁₈N₂O₄S₃ 447.5 447.2 phenyl boronic acidmethylsulfanyl-thiophene-3- sulfonyl)-biphenyl-4-carboxylic acid methylester 75 3,5-dimethyl phenyl 4-(3′,5′-Dimethyl-biphenyl-3- C₂₀H₂₀N₂O₂S₃417.5 417.3 boronic acid sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine 76 2-Furan-2-yl-4,4,5,5- 4-(3-Furan-2-yl-C₁₆H₁₄N₂O₃S₃ 379.5 379.2 tetramethyl- benzenesulfonyl)-5-[1,3,2]dioxaborolane methylsulfanyl-thiophene-2- carboxamidine 773-thiophene boronic acid 5-Methylsulfanyl-4-(3-thiophen- C₁₆H₁₄N₂O₂S₄395.5 395.2 3-yl-benzenesulfonyl)- thiophene-2-carboxamidine 78 3-nitrophenyl boronic 5-Methylsulfanyl-4-(3′-nitro- C₁₈H₁₅N₃O₄S₃ 434.5 434.2acid biphenyl-3-sulfonyl)-thiophene- 2-carboxamidine 79 4-hydroxy phenylboronic 4-(4′-Hydroxy-biphenyl-3- C₁₈H₁₆N₂O₃S₃ 405.5 405.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 80 4-formyl phenylboronic 4-(4′-Formyl-biphenyl-3- C₁₉H₁₆N₂O₃S₃ 417.5 417.3 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 81 4-flouro phenylboronic 4-(4′-Fluoro-biphenyl-3- C₁₈H₁₅FN₂O₂S₃ 407.5 407.3 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 82(2-Fluoro-biphenyl-4-yl)- 4-(2′-Fluoro- C₂₄H₁₉FN₂O₂S₃ 483.6 483.0dimethyl-boronic acid [1,1′;4′,1″]terphenyl-3″-sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 834-hydroxymethyl-phenyl- 4-(4′-hydroxymethyl-biphenyl- C₁₉H₁₈N₂O₃S₃ 419.6419.3 boronic acid 3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine 84 4-cyano-phenyl-boronic4-(4′-cyano-biphenyl-3- C₁₉H₁₅N₃O₂S₃ 414.5 414.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 854-acetyl-phenyl-boronic 4-(4′-acetyl-biphenyl-3- C₂₀H₁₈N₂O₃S₃ 431.6431.2 acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 864-dimethylamino-phenyl- 4-(4′-dimethylamino-biphenyl-3- C₂₀H₂₁N₃O₂S₃432.6 432.2 boronic acid sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine 87 2-vinyl-phenyl-boronic5-methylsulfanyl-4-(2′-vinyl- C₂₀H₁₈N₂O₂S₃ 415.6 415.2 acidbiphenyl-3-sulfonyl)-thiophene- 2-carboxamidine 884-ethoxy-phenyl-boronic 4-(4′-ethoxy-biphenyl-3- C₂₀H₂₀N₂O₃S₃ 433.6433.2 acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 893,5-dimethyl-isoxazole-4- 4-[3-(3,5-dimethyl-isoxazol-4- C₁₇H₁₇N₃O₃S₃408.5 408.2 boronic acid yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2- carboxamidine 90 2-methyl-phenyl-boronic4-(2′-methyl-biphenyl-3- C₁₉H₁₈N₂O₂S₃ 403.6 403.3 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 911-naphthyl-boronic acid 5-methylsulfanyl-4-(3- C₂₂H₁₈N₂O₂S₃ 439.6 439.3naphthalen-1-yl- benzenesulfonyl)-thiophene-2- carboxamidine 925-chloro-thiophene-2- 4-[3-(5-Chloro-thiophen-2-yl)- C₁₆H₁₃ClN₂O₂S₄430.0 429.2, boronic acid benzenesulfonyl]-5- 431.1.methylsulfanyl-thiophene-2- carboxamidine 93 2-formyl-phenyl-boronic4-(2′-formyl-biphenyl-3- C₁₉H₁₆N₂O₃S₃ 417.5 417.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 944-vinyl-phenyl-boronic 5-methylsulfanyl-4-(4′-vinyl- C₂₀H₁₈N₂O₂S₃ 415.6415.2 acid biphenyl-3-sulfonyl)-thiophene- 2-carboxamidine 953-ethoxy-phenyl-boronic 4-(3′-ethoxy-biphenyl-3- C₂₀H₂₀N₂O₃S₃ 433.6433.3 acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 962,6-dimethyl-phenyl- 4-(2′,6′-dimethyl-biphenyl-3- C₂₀H₂₀N₂O₂S₃ 417.6417.2 boronic acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine97 3-methyl-phenyl-boronic 4-(3′-methyl-biphenyl-3- C₁₉H₁₈N₂O₂S₃ 403.6403.2 acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 983-isopropyl-phenyl- 4-(3′-isopropyl-biphenyl-3- C₂₁H₂₂N₂O₂S₃ 431.6 431.3boronic acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 992,3-dimethyl-phenyl- 4-(2′,3′-dimethyl-biphenyl-3- C₂₀H₂₀N₂O₂S₃ 417.6417.2 boronic acid sulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine100 2,3-dichloro-phenyl- 4-(2′,3′-dichloro-biphenyl-3- C₁₈H₁₄Cl₂N₂O₂S₃458.4 457.2, boronic acid sulfonyl)-5-methylsulfanyl- 459.2,thiophene-2-carboxamidine 461.2. 101 3-acetyl-phenyl-boronic4-(3′-acetyl-biphenyl-3- C₂₀H₁₈N₂O₃S₃ 431.6 431.2 acidsulfonyl)-5-methylsulfanyl- thiophene-2-carboxamidine 1023-ethoxycarbonyl-phenyl- 3′-(5-carbamimidoyl-2- C₂₁H₂₀N₂O₄S₃ 461.6 461.2boronic acid methylsulfanyl-thiophene-3- sulfonyl)-biphenyl-3-carboxylicacid ethyl ester 103 3-N,N-dimethyl- 3′-(5-carbamimidoyl-2- C₂₁H₂₁N₃O₃S₃460.6 460.3 acetamido-phenyl-boronic methylsulfanyl-thiophene-3- acidsulfonyl)-biphenyl-3-carboxylic acid dimethylamide 1043-carbamoyl-phenyl- 3′-(5-carbamimidoyl-2- C₁₉H₁₇N₃O₃S₃ 432.6 432.3boronic acid methylsulfanyl-thiophene-3- sulfonyl)-biphenyl-3-carboxylicacid amide 105 3-acetamido-phenyl- N-[3′-(5-carbamimidoyl-2-C₁₉H₁₇N₃O₃S₃ 432.6 432.3 boronic acid methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-yl]- acetamide 106 5-(4,4,5,5-Tetramethyl-4-[3-(1H-benzoimidazol-5-yl)- C₁₉H₁₆N₄O₂S₃ 429.6 429.3[1,3,2]dioxaborolan-2-yl)- benzenesulfonyl]-5- benzoimidazole-1-methylsulfanyl-thiophene-2- carboxylic acid tert-butyl carboxamidineester 107 2-tert- 4-(2′-amino-biphenyl-3- C₁₈H₁₇N₃O₂S₃ 404.5 404.2butoxycarbonylamino- sulfonyl)-5-methylsulfanyl- phenyl-boronic acidthiophene-2-carboxamidine

Examples 108–1105-Methylsulfanyl-4-(3-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate,5-Methylsulfanyl-4-(2-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidineand5-Methylsulfanyl-4-(7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidine

a)4-(7-Bromo-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

4-(7-Bromo-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 38, step c) 300 mg, 0.58 mmol) inethanol:water solution (1:1, 60 mL) was treated with sodium dithionite(203 mg, 1.16 mmol) as in Example 38, step d. A brown precipitate formedupon addition of sodium dithionite. This precipitate was filtered anddried under vacuum to give 163.6 mg of4-(7-bromo-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester as a brown solid. This solid was used in the next stepwithout further purification.

b)5-Methylsulfanyl-4-(7-o-tolyl-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-thiophene-2-carboxylicacid methyl ester and5-Methylsulfanyl-4-(7-o-tolyl-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-thiophene-2-carboxylicacid ethyl ester

To a dried flask was added4-(7-bromo-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (129 mg, 0.249 mmol) from above step a, o-tolylboronic acid (136 mg, 0.779 mmol), aqueous Na₂CO₃ (2M, 1 mL, 43 mmol),ethanol (1 mL), and toluene (2 mL). The flask was sparged with argon,and Pd(PPh₃)₄ (72 mg, 0.062 mmol) was added. The reaction mixture wasstirred and heated at 80° for 18 hrs, and then cooled to roomtemperature. The solvents were removed in vacuo. The residue wasdissolved in ethyl acetate (150 mL), washed with water (20 mL) and brine(20 mL), and then dried over MgSO₄. Ethyl acetate was removed in vacuoand the residue was purified via preparative TLC (20–30% ethylacetates/hexanes) to afford a mixture of5-methylsulfanyl-4-(7-o-tolyl-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-thiophene-2-carboxylicacid methyl ester and5-methylsulfanyl-4-(7-o-tolyl-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-thiophene-2-carboxylicacid ethyl ester as a brown oil (130 mg). ESI-MS (m/z): Calcd. forC₂₆H₂₈N₂O₄S₃ and C₂₇H₃₀N₂O₄S₃: 529.12 (M+H); found 529.3 and 543.3.

c)5-Methylsulfanyl-4-(7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxylicacid methyl and ethyl esters

A mixture of5-methylsulfanyl-4-(7-o-tolyl-1,3-dihydro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-thiophene-2-carboxylicacid methyl and ethyl esters (130 mg) from above step b was treated withformic acid as in Example 38: step e followed by analogous work up toafford a crude mixture of5-methylsulfanyl-4-(7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxylicacid methyl and ethyl esters as a brown oil (100 mg). This mixture wasused in the following step without further purification. MS (m/z):Calcd. for C₂₁H₁₈N₂O₄S₃: 459.04 (M+1); found 459.2 and 473.2.

d)5-Methylsulfanyl-4-(3-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate,5-Methylsulfanyl-4-(2-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate and5-Methylsulfanyl-4-(7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

A mixture of5-methylsulfanyl-4-(7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxylicacid methyl and ethyl esters (100 mg, 0.22 mmol) from above step c wastreated with methyl iodide (13.6 μL, 0.22 mmol) and K₂CO₃ (60.2 mg, 0.44mmol) in dimethylformamide (2 mL) as in Example 39: step a, followed byanalogous work up to afford 40 mg of a crude mixture. This mixture wastreated with the dimethylaluminum amide reagent (5 mL, 5 mmol) as inExample 39: step b. After 1 hour, additional dimethylaluminum amidereagent (5 mL, 5 mmol) was added. After 1.5 hours, the reaction wasquenched as in Example 39: step b followed by HPLC (C18-column, 10–70%CH₃CN over 30 min) purification to afford5-methylsulfanyl-4-(3-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate (108),5-methylsulfanyl-4-(2-methyl-7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate (109) and5-methylsulfanyl-4-(7-o-tolyl-3H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate (110). 108: ¹H-NMR (CD₃OD): δ 8.63 (s, 1H), 8.41 (m,1H), 8.36 (m, 1H), 7.82 (m, 1H), 7.38–7.26 (m, 4H), 4.08 (s, 3H), 2.72(s, 3H), 2.09 (s, 3H). 109: ¹H-NMR (CD₃OD): δ 8.41 (m, 1H), 8.35 (s,1H), 7.73 (m, 1H), 7.46–7.28 (m, 4H), 3.32 (s, 3H), 2.70 (s, 3H), 2.02(s, 3H). 110: ¹H-NMR (CD₃OD) C: δ 8.56 (s, 1H), 8.41 (m, 1H), 8.36 (m,1H), 7.78 (m, 1H), 7.44–7.27 (m, 4H), 2.71 (s, 3H), 2.10 (s, 3H).

Example 1114-(2-Methyl-furan-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

a) 4-(2-Methyl-furan-3-ylsulfanyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester

4-Bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 532 mg, 2 mmol), 2-methyl-furan-3-thiol (600 mg, 5.26 mmol), andDMAP-polystyrene resin (2 g, 2.86 mmol) were stirred in THF (10 mL) for12 h at rt. The resin was filtered and washed with several portions ofDCM (100 mL total volume). The filtrate was concentrated in vacuo andthe yellow residue (480 mg, 80%) was used without further purification.¹H-NMR (CDCl₃): δ 7.46 (d, 1H, J=1.9 Hz), 7.05 (s, 1H), 6.43 (d, 1H,J=1.9 Hz), 3.90 (s, 3H), 2.38 (s, 3H).

b) 4-(2-Methyl-furan-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

m-Chloroperbenzoic acid (276 mg, 4 mmol) and4-(2-methyl-furan-3-ylsulfanyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester (117 mg, 0.39 mmol) were dissolved in DCM (15 mL) andstirred for 6 h at 40° C. DCM (50 mL) and aqueous sodium thiosulfatewere added (exothermic), and the layers were separated. The organiclayer was extracted with Na₂CO₃ (2M, 6×30 mL), brine (50 mL), and wasdried over sodium sulfate. Concentration of the solvent in vacuofollowed by SiO₂ flash chromatography (25–75% DCM in hexanes) yieldedthe sulfone compound (85 mg, 66%) which was redissolved THF (5 mL). Theprocedure in Example 12: step c was followed, using 275 μL (0.275 mmol)of sodium thiomethoxide. Analogous aqueous workup and purification bySiO₂ flash chromatography yielded the title compound (72 mg, 85%) as acolorless solid.

c)4-(2-Methyl-furan-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

Following the procedure used in Example 12: step f,4-(2-methyl-furan-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (26 mg, 0.078 mmol) was converted to the amidine using3 mL of dimethylaluminum amide reagent. The title compound was isolatedas a white solid (16 mg, 58%) after preparative TLC purification (15%MeOH in DCM). ¹H-NMR (CD₃OD): δ 8.26 (s, 1H), 7.49 (d, 1H, J=2.1 Hz),6.69 (d, 1H, J=2.1 Hz), 2.74 (s, 3H), 2.63 (s, 3H). ESI-MS (m/z): Calcd.for C₁₁H₁₂N₂O₃S₃ (M+H): 317.4; found: 317.2.

Example 1125-Methylsulfanyl-4-(4-phenyl-thiazole-2-sulfonyl)-thiophene-2-carboxamidinehydrochloride

a) 5-Nitro-4-(4-phenyl-thiazole-2-sulfonyl)-thiophene-2-carboxylic acidmethyl ester

The procedure in Example 111: step a was followed, using4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 532 mg, 2 mmol), 4-phenyl-thiazole-2-thiol (483 mg, 2.5 mmol),and DMAP-polystyrene resin (2 g, 2.86 mmol) in THF (10 mL). Analogousworkup yielded the crude sulfide which was treated withm-chloroperoxybenzoic acid (1.38 g, 8 mmol) in DCM (30 mL) as in Example111: step b. Analogous workup and purification by SiO₂ flashchromatography (25–50% EtOAc in hexanes) yielded the title compound (245mg, 30%) as a white solid. ¹H-NMR (CDCl₃): δ 8.25 (s, 1H), 7.80 (m, 2H),7.75 (s, 1H), 7.34–7.44 (m, 3H), 7.05 (s, 1H), 6.43 (d, 1H, J=1.9 Hz),3.98 (s, 3H).

b)5-Methylsulfanyl-4-(4-phenyl-thiazole-2-sulfonyl)-thiophene-2-carboxamidinehydrochloride

Following the procedure in Example 12: step c,5-nitro-4-(4-phenyl-thiazole-2-sulfonyl)-thiophene-2-carboxylic acidmethyl ester (110 mg, 0.27 mmol) was reacted with sodium thiomethoxide(1M in EtOH, 325 μL, 0.325 mmol) in THF (5 mL). Analogous aqueous workupand purification by SiO₂ flash chromatography yielded the thiomethylatedintermediate (82 mg, 75%) as a white solid. A portion of the solid (52mg, 0.126 mmol) was treated with dimethylaluminum amide reagent (5 mL)as in Example 12: step f. Analogous workup and purification bypreparative TLC (15% MeOH in DCM) resulted in the title compound (21 mg,38%) as a white solid. ¹H-NMR (CD₃OD): δ 8.38 (s, 1H), 8.31 (s, 1H),7.90 (m, 2H), 7.36–7.46 (m, 3H), 2.76 (s, 3H). ESI-MS (m/z): Calcd. forC₁₅H₁₃N₃O₂S₄ (M+H): 396.6; found: 396.1.

Example 1134-(6-Ethoxy-benzothiazole-2-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

a) 4-(6-Ethoxy-benzothiazole-2-sulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester

The procedure in Example 111: step a was followed, using4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 266 mg, 1 mmol), 6-ethoxy-benzothiazole-2-thiol (264 mg, 1.25mmol), and DMAP-polystyrene resin (0.75 g, 1.05 mmol) in THF (6 mL).Analogous workup yielded the crude sulfide, which was treated withm-chloroperoxybenzoic acid (692 mg, 4 mmol) in DCM (30 mL) as in Example111: step b. Analogous workup and purification by SiO₂ flashchromatography (25–50% EtOAc in hexanes) yielded the title compound (250mg, 580%) as a colorless glass. ¹H-NMR (CDCl₃): δ 8.40 (s, 1H), 7.94 (d,1H, J=9.1 Hz), 7.38 (d, 1H, J=2.6 Hz), 7.17 (dd, 1H, J=2.6, 9.1 Hz),4.13 (q, 2H, J=7.0 Hz), 4.00 (s, 3H), 1.47 (t, 3H, J=7.0 Hz). ESI-MS(m/z): Calcd. for C₁₅H₁₂N₂O₇S₃ (M+H): 429.5; found: 429.1.

b)4-(6-Ethoxy-benzothiazole-2-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride

Following the procedure in Example 12: step c,4-(6-ethoxy-benzothiazole-2-sulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester (65 mg, 0.15 mmol) was reacted with sodiumthiomethoxide (1M in EtOH, 175 μL 0.175 μmol) in THF (5 mL). Analogousaqueous workup and purification by SiO₂ flash chromatography yielded thethiomethyl intermediate (53 mg, 82%) as a colorless glass. A portion ofthe material (41 mg, 0.10 mmol) was treated with dimethylaluminum amidereagent (3 mL) as in Example 12: step f. Analogous workup andpurification by preparative TLC (15% MeOH in DCM) yielded the titlecompound (18 mg, 42%) as a white solid. ¹H-NMR (CD₃OD): δ 8.37 (s, 1H),7.96 (d, 1H, J=9.1 Hz), 7.62 (d, 1H, J=2.6 Hz), 7.22 (dd, 1H, J=2.6, 9.1Hz), 4.14 (q, 2H, J=7.0 Hz), 2.74 (s, 3H), 1.44 (t, 3H, J=7.0 Hz).ESI-MS (m/z): Calcd. for C₁₅H₁₅N₃O₃S₄ (M+H): 414.6; found: 414.1.

Example 1144-(3-Methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinehydrochloride HCl

a) 4-Bromothiophene-2-carboxylic acid

To a flask equipped with a mechanical stirrer was added 25 g (130 mmol)4-bromothiophene-2-carbaldehyde (Aldrich Chemical Company), acetonitrile(200 mL), and 4.5 g (37.5 mmol) of sodium dihydrogen phosphate dissolvedin 35 mL of water. After cooling this mixture on an ice-salt bath, 15 mL(169 mmol) of 35% hydrogen peroxide and 15.3 g (169 mmol) of sodiumchlorite were added, and the mixture was stirred for 1 h. The reactionmixture was then stirred at room temperature for 3 h. The solvent wasremoved in vacuo, and the solid was suspended in a mixture of water (175mL) and 1 N hydrochloric acid (4 mL) and stirred for 10 min at rt. Thesolid was collected on a Büchner funnel and washed with water (2×150 mL)to afford 26 g (97%) of 4-bromothiophene-2-carboxylic acid, which wasused in the next step without further purification.

b) 4-Bromothiophene-2-carboxylic acid Methyl Ester

To a dry flask under N₂ with a stirbar was added 6 g (29.1 mmol) of4-bromothiophene-2-carboxylic acid (as prepared in the previous step)and dry methanol (100 mL). The solution was cooled in an ice-salt bathfor 15 min and 2.55 mL (34.9 mmol) of thionyl chloride was added over 15min, keeping the temperature <−5° C. The reaction mixture was stirred onthe ice-salt bath for an additional 15 min, then for 1 h at rt, andfinally refluxed for 8 h under N₂. The resulting solution was cooled andconcentrated to 6.7 g of pale amber oil. This oil was passed through 150g of silica with ˜600 mL CH₂Cl₂ (discarded the first 120 mL whichcontained minor impurities and no ester). The solvent was removed invacuo to afford 6.11 g (95% yield) of the title compound as a colorlesssolid, which was used in the next step without further purification.

c) 4-Bromo-5-nitrothiophene-2-carboxylic acid Methyl Ester

The nitrating mixture (HNO₃ d=1.42, 2 mL; concentrated H₂SO₄, 6 mL) wasslowly added with stirring, at −5° to −10° C., to4-Bromothiophene-2-carboxylic acid methyl ester (3 g, 13.57 mmol)dissolved in concentrated H₂SO₄ (10 mL). After being kept at −5 to −10°C. for 30 min. the mixture was poured over crushed ice. The solidprecipitate was separated by filtration and washed with water and driedover P₂O₅ to give 3.7 g of 4-bromo-5-nitrothiophene-2-carboxylic acidmethyl ester as a tan solid, which was used in the next step withoutfurther purification.

d) 4-(3-Methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a cooled (ice bath) solution of 4-bromo-5-nitrothiophene-2-carboxylicacid methyl ester (0.5 g, 1.88 mmol) from above step c, indimethylformamide (DMF) was added 3-methoxybenzenethiol (0.29 g, 2.1mmol) and Cs₂CO₃ (0.67 g, 2.1 mmol). The resulting mixture was heated at50° C. for 3 h. DMF was removed under vacuum and the residue waspartitioned between EtOAc and 10% HCl. The EtOAc layer was washed withbrine, dried over Na₂SO₄ and concentrated in vacuo to give an oil. Thisoil was purified by silica gel column chromatography (EtOAc:hexane) togive 0.56 g (91%) of4-(3-Methoxy-phenylsulfanyl)-5-nitro-thiophene-2-carboxylic acid methylester. This ester was dissolved in CH₂Cl₂ (6 mL) and treated withm-chloroperoxybenzoic acid (MCPBA, 1.1 g) and heated at reflux for 6 h.The resulting mixture was diluted with CH₂Cl₂ (10 mL) and washed withsat. sodium thiosulfate, 1N NaOH and brine. The organic layer was driedover Na₂SO₄ and concentrated in vacuo. The residue was purified bysilica gel column chromatography (EtOAc:hexane) to give an oil. This oilwas dissolved in DMF (5 mL) and cooled in an ice bath. To this solutionsodium thiomethoxide (126 mg, Aldrich Chemical Company) was added andthe mixture was stirred for 5 h. The reaction was quenched with 10% HCland the solvents were removed in vacuo. The residue was dissolved inEtOAc, washed with brine and dried over Na₂SO₄. The solvent was removedin vacuo and the residue was purified by preparative thin-layerchromatography to give 171 mg of4-(3-methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester, which was directly used in the next step.

e)4-(3-Methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

4-(3-methoxy-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester from above step d (171 mg, 0.48 mmol) was treated withdimethylaluminum amide reagent (2 mL) as in Example 12: step f.Analogous workup and purification by preparative TLC (15% MeOH in DCM)gave the title compound (50 mg, 30%) as a white solid. ¹H-NMR (DMSO-d₆):δ 9.24 (broad s, 4H), 8.43 (s, 1H), 7.64–751 (m, 2H), 7.44 (s, 1H), 7.31(d, 1H, J=9.3 Hz), 3.83 (s, 3H), 2.70 (s, 3H). ESI-MS (m/z): Calcd. forC₁₃H₁₄N₂O₃S₃ (M+H): 343.0; found: 343.2.

Example 1154-(6-Methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 6-Methyl-biphenyl-3-ylamine

To a dried flask was added 3-bromo-4-methyl-phenylamine (1 g, 5.37mmol), phenyl boronic acid (2.62 g, 21.5 mmol), aqueous Na₂CO₃ (2M, 21.5mL, 43 mmol), ethanol (21.5 mL), and toluene (43 mL). The flask wassparged with Ar, and Pd(PPh₃)₄ (1.55 g, 1.34 mmol) was added. Thereaction mixture was stirred and heated at 80° for 18 hrs, then cooledto room temperature. The solvent was removed in vacuo and the residuewas dissolved in ethyl acetate. The organic layer was washed with waterand brine, then dried over MgSO₄. The solvent was removed in vacuo andthe residue was purified via column chromatography (SiO₂, 5% DCM/hexane)to afford a yellow oil (463 mg, 47%). This was directly used in the nextstep.

b) 6-Methyl-biphenyl-3-thiol

To a cooled solution of 6-methyl-biphenyl-3-ylamine (463 mg, 2.53 mmol)from above step a, in hydrochloride solution (0.42 mL conc. HCl in 0.5mL H₂O, 5 mmol) was added dropwise a solution of NaNO₂ (Aldrich, 0.18 gin 0.3 mL H₂O, 2.6 mmol) at −2° C. The resulting diazonium ion solutionwas stirred for 20 min and added to a solution of KS₂COEt in H₂O (0.61 gin 0.8 mL of H₂O, 3.81 mmol) with stirring. The resultant mixture washeated to 80° C. for a few minutes, then cooled to room temperature andextracted with diethyl ether. Ether was removed in vacuo and the residuewas treated with a potassium hydroxide solution (0.5 g in 1.5 mL inethanol, 8.91 mmol, 3.56 eq) and heated at reflux for 8 h. The reactionmixture was cooled to room temperature, diluted with H₂O, and acidifiedwith HCl to pH₃. This solution was extracted with Et₂O and the organiclayer was washed with H₂O and brine, then dried over MgSO₄. The solventwas removed in vacuo to afford a yellow oil (510 mg, 100%). This wasdirectly used in the next step.

c) 4-(6-Methyl-biphenyl-3-ylsulfanyl)-5-nitro-thiophene-2-carboxylicacid methyl ester

To a solution of triphenylphosphine (0.67 g, 2.55 mmol),4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 1 g, 3.76 mmol) and 4-(dimethyl)aminopyridine resin (1 eq) inTHF was added 6-methyl-biphenyl-3-thiol from above step b. This mixturewas stirred for 3 hrs. The reaction mixture was filtered and thesolvents were removed in vacuo. The residue was purified via columnchromatography (SiO₂, 15% ethyl acetate/hexane) to afford a yellow glass(600 mg, 61%), which was used in the following step.

d) 4-(6-Methyl-biphenyl-3-sulfonyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester

To a solution of4-(6-methyl-biphenyl-3-ylsulfanyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester (0.6 g, 1.56 mmol, 1 eq) from above step c, in DCM wasadded 3-chloroperoxybenzoic acid (1.04 g, 3.42 mmol, 2.2 eq). Thereaction mixture was heated to reflux for 2 hrs, then cooled to roomtemperature. The reaction mixture was quenched with saturated Na₂S₂O₃solution, then washed with saturated Na₂CO₃ solution, water, brine, andwas dried over MgSO₄. The solvent was removed in vacuo to afford ayellow solid (170 mg, 26%), which was taken on to the next step.

e)4-(6-Methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a solution of4-(6-methyl-biphenyl-3-sulfonyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester (170 mg, 0.41 mmol) from above step d, in anhydrous THF at−78° C. was added dropwise a 1M solution of NaSMe in ethanol (0.4 mL,0.41 mmol). The reaction mixture was stirred for 2 hrs. at −78° C.,quenched with acetic acid (23 μl, 0.41 mmol), and warmed to roomtemperature. The reaction mixture was diluted with ethyl acetate, washedwith saturated NaHCO₃ solution (2×), water, and brine. The organic layerwas dried over MgSO₄ and removed in vacuo. The residue was purified viacolumn chromatography (SiO₂, 15% DCM/hexane) to afford a yellow glass(130 mg, 76%).

f)4-(6-Methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

In a dried flask was suspended NH₄Cl (Aldrich, 1.08 g, 20 mmol) inanhydrous toluene (10 mL) under argon. To this suspension was added 2Msolution of AlMe₃ in toluene (10 mL, 20 mmol). This mixture was heatedto 100° C. for a few minutes. This dimethylaluminum amide reagent (5 mL,5 mmol) was added to4-(6-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (130 mg, 0.31 mmol) from above step e, under Ar. Thisreaction mixture was heated to reflux for 1.5 h then cooled to roomtemperature. The reaction mixture was quenched by pouring it into aslurry of silica gel in CHCl₃. The slurry was stirred for 30 minutes,and then filtered with 10% MeOH/DCM and MeOH. The solvents were removedin vacuo and the residue was dissolved in 10% MeOH/DCM, and filteredthrough a syringe filter. The solvent was removed in vacuo and theresidue was purified via preparatory HPLC to afford a beige solid (5 mg,4%). ¹H-NMR (DMSO-d₆): δ 9.39 (bs, 1H), 8.96 (bs, 2H), 8.41 (s, 1H),7.88 (dd, 1H), 7.74 (m, 1H), 7.61 (m, 1H), 7.52–7.35 (m, 5H). Calcd. forC₁₉H₁₈N₂O₂S₃: 402.05; found: 403.2.

Example 1165-Methylsulfanyl-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxamidinehydrochloride salt

a) 3-Phenoxy-benzenethiol

To a cooled solution of 3-phenoxyanilne (2 g, 0.01 mol) in hydrochloridesolution (1.69 mL conc. HCl in 2 mL H₂O, 0.02 mol) was added dropwise asolution of NaNO₂ (Aldrich, 0.8 g in 2 mL H₂O, 0.01 mol) at 0–2° C. Theresulting diazonium ion solution was stirred for 20 min and then addedto a solution of KS₂COEt in H₂O (2.6 g in 4 mL of H₂O, 0.02 mol) withstirring. This mixture was heated to 80° C. for a 20 minutes, thencooled to room temperature, and extracted with diethyl ether. The etherlayer was washed with water, brine and dried over Na₂SO₄. Ether wasremoved in vacuo and the residue was taken in ethanol and treated with asodium hydroxide solution (12 N, 0.04 mol, 3.56 eq) and heated at refluxfor 8 h. The reaction mixture was cooled to room temperature, dilutedwith H₂O, and acidified with H₂SO₄ to pH˜3. This solution was extractedwith Et₂O and the organic layer was washed with H₂O and brine, and thendried over MgSO₄. The solvent was removed in vacuo to afford a yellowoil which was purified by silica gel column chromatography to give amixture of 3-Phenoxy-benzenethiol and the corresponding disulfide (1.2g). This was directly used in the next step.

b) 5-Nitro-4-(3-phenoxy-phenylsulfanyl)-thiophene-2-carboxylic acidmethyl ester

The mixture from above step a (171 mg, 0.48 mmol) was treated withtriphenylphosphine (1.98 g, 7.52 mmol),4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 0.5 g, 1.88 mmol) and 4-(dimethyl)aminopyridine resin (1 eq) inTHF (25 mL). This mixture was stirred for 18 h. The reaction mixture wasfiltered and the solvents were removed in vacuo. The residue waspurified via silica gel column chromatography to afford a yellow glass(420 mg), which was used in the following step.

c) 5-Nitro-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxylic acidmethyl ester

To a solution of5-nitro-4-(3-phenoxy-phenylsulfanyl)-thiophene-2-carboxylic acid methylester (420 mg, 1.1 mmol) from above step b, in DCM was added3-chloroperoxybenzoic acid (1.31 g, 4.34 mmol, 4 eq). The reactionmixture was heated to reflux for 18 h, then cooled to room temperature.The reaction mixture was quenched with saturated Na₂S₂O₃ solution, thenwashed with 1N NaOH solution, brine, and dried over MgSO₄. The solventwas removed in vacuo and the residue was taken on to the next step.

d) 5-Methylsulfanyl-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxylicacid methyl ester

To a solution of5-Nitro-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxylic acid methylester from above step c, in anhydrous THF at −78° C. was added dropwisea 1M solution of NaSMe in ethanol (1.06 mL, 1.08 mmol). The reactionmixture was stirred for 5 h at −78° C., quenched with acetic acid (61μL, 1.08 mmol), and warmed to room temperature. The reaction mixture wasdiluted with ethyl acetate, washed with 10% HCl, saturated NaHCO₃solution (2×), water, and brine. The organic layer was dried over Na₂SO₄and removed in vacuo. The residue was purified via silica gel columnchromatography to afford 250 mg (55%) of5-methylsulfanyl-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxylicacid methyl ester.

e)5-Methylsulfanyl-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxamidinehydrochloride salt

5-Methylsulfanyl-4-(3-phenoxy-benzenesulfonyl)-thiophene-2-carboxylicacid methyl ester from above step d (200 mg, 0.48 mmol) was treated withdimethylaluminum amide reagent (2 mL) as in Example 12: step f.Analogous workup and purification by preparative TLC (10% MeOH in DCM)gave the title compound (120 mg, 62%) as a white solid: ¹H-NMR(DMSO-d₆): δ 9.46 (bs, 2H), 9.20 (bs, 2H), 8.43 (s, 1H), 7.71–7.63 (m,2H), 7.49–7.43 (m, 3H), 7.35 (d, 1H, J=7.9 Hz), 7.24 (t, 1H, J=7.2 and7.4 Hz), 7.1 (d, 2H, J=7.7 Hz), 2.68 (s, 3H). Calcd. for C₁₈H₁₆N₂O₃S₃:405.03 (M+H); found: 405.2.

Example 1174-(Biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a dry 2-dram vial, fitted with a stir bar and a Teflon®-lined screwcap was added{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100 mg, 0.2 mmol, as prepared in Example 27, stepc), phenylboronic acid (0.3 mmol), andtetrakis(triphenylphosine)palladium(0) (0.025 mmol). Each vial was twicetreated with an argon purge/evacuation cycle and then charged with amixture of toluene/EtOH (2:1, 2.4 mL) and 2 M Na₂CO₃ (0.8 mL) via asyringe. The vials were placed in an oil bath at 80° C. and stirredovernight. To the cooled reaction mixtures was added EtOAc (4 mL), theorganic layer was filtered (1-g silica SPE column), and the filtrate wasevaporated in vacuo. The resulting residue was purified usingpreparative TLC (SiO₂) to afford the Boc-protected amidine product.After treatment of this material with trifluoroacetic acid (50% in DCM)for 1 hr at rt, the solvents were removed in vacuo and the residue waspurified using C₁₈-HPLC (20% to 100% CH₃CN in H₂O (0.1% TFA) over 15min) to afford 10 mg (13%)4-(biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate: ¹H-NMR (DMSO-d₆): δ 8.32 (s, 1H), 8.25 (m, 2H),8.02–7.95 (m, 2H), 7.72–7.63 (m, 3H), 7.52–7.47 (m, 2H), 7.44–7.39 (m,1H), 2.72 (s, 3H). Calcd. for C₁₈H₁₆N₂O₂S₃: 389.04 (M+H); found: 389.2.

Example 1184-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

a) 5-Bromo-6-chloro-pyridine-3-sulphenic acid

5-Bromo-6-chloro-pyridine-3-sulfonyl chloride (2.5 g, 8.6 mmol), sodiumsulfite (2.0 g, 16.1 mmol), and sodium bicarbonate (1.4 g, 16.9 mmol)were dissolved into water (8 mL) and EtOH (3 mL). The reaction mixturewas allowed to stir at RT for 12 hours. TLC analysis showed loss of SMand formation of a very polar new spot. Reaction mixture wasconcentrated in vacuo resulting in a white solid and was used withoutfurther purification. ESI-MS (m/z): Calcd. for C₅H₃BrClNO₂S: 255.8(M+H); found: 256.0. ¹H-NMR (CD₃OD): δ 8.55 (m, 1H), 8.29 (m, 1H).

b)4-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester

4-Bromo-5-nitro-thiophene-2-carboxylic acid methyl ester (5.0 g, 19.9mmol) was dissolved into DMF (20 mL) and cooled to 0° C. To this wasadded a solution of 5-bromo-6-chloro-pyridine-3-sulphenic acid (Example118, step a) (1.8 g, 6.6 mmol) in DMF (20 mL) dropwise for 2 hours. Thereaction was then warmed to RT and allowed to continue to stir for anadditional 2 hours. The reaction was concentrated in vacuo and purifiedby SiO₂ flash column chromatography (Biotage—40 M, 25% EtOAc inhexanes). The product was isolated as a white solid (2.5 g, 48%). ESI-MS(m/z): Calcd. for C₁₁H₆BrClN₂O₆S₂: 440.8 (M+H); found: 441.0.

c)4-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure as in Example 27, a was followed using4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester (3.5 g, 8.10 mmol, Example 118, step b) and sodiumthiomethoxide (560 mg, 8.10 mmol as 1M solution in EtOH). The reactionwas allowed to stir for 2.5 hours and was quenched with acetic acid. Theresulting mixture was dissolved into EtOAc, and aqueous work up withbrine and saturated NaHCO₃ resulted in isolation of a mixture. Thismixture was purified by SiO₂ flash column chromatography (Biotage—40 M,100% hexanes to 25% EtOAc in hexanes). The product was isolated as ayellow solid (750 mg, 21%). ESI-MS (m/z): Calcd. for C₁₂H₁₀BrClNO₄S₃:441.8 (M+H); found: 442.1. ¹H-NMR (CD₃OD+CDCl₃): δ 8.93 (m, 1H), 8.50(m, 1H), 8.06 (s, 1H), 3.91 (m, 3H), 2.67 (m, 3H).

d)4-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

The procedure as in Example 20, f was followed using4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (14 mg, 0.03 mmol, Example 118, step c)dimethylaluminium amide (1M, 5 mL). The reaction was stirred for 3 hoursat 90° C. and TLC analysis indicated that the reaction was complete. Thereaction was quenched with SiO₂ and filtered. The resulting filtrate wasconcentrated in vacuo followed by purification by C₁₈-HPLC (10–70% CH₃CNover 30 minutes). The title compound was isolated as a white solid (6.4mg, 46%). ESI-MS (m/z): Calcd. for C₁₁H₉BrClN₃O₂S₃: 425.9 (M+H); found:426.1. ¹H-NMR (CD₃OD): δ 8.96 (s, 1H), 8.65 (s, 1H), 8.33 (s, 1H), 2.76(s, 3H).

Example 1194-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

a)4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide

An ammonia bomb was used to prepare the title compound. Ammonia gas (5mL) was condensed into the Teflon® core of a metal bomb with a stir barand4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (321 mg, 0.73 mmol, Example 118, step c). The Teflon®core was kept at −78° C. during the addition of reagents. Following theaddition of reagents, the bomb was assembled and then sealed tight byhand and then tightened by wrench action. The sealed bomb was checkedfor leaks by use of pH paper. The bomb was then added to an oil bath andheated to 80° C. overnight with a shield in place. The following day thebomb was allowed to cool to rt and then was cooled further to −78° C. inan dry ice/acetone bath. The cooled vessel was then opened and remainingammonia was allowed to evaporate. The resulting red solid obtained wasused without further purification (306 mg, 95%). ESI-MS (m/z): Calcd.for C₁₁H₁₀BrN₃O₃S₃: 407.9 (M+H); found: 408.1. ¹H-NMR (CD₃OD): δ 8.56(m, 1H), 8.18 (m, 1H), 8.07 (s, 1H), 2.72 (s, 3H).

b)4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

The procedure as in Example 20, f was followed using4-(6-amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide (14 mg, 0.03 mmol, Example 119, step a) dimethylalumninuimamide (1M, 5 mL). The reaction was stirred for 3 hours at 90° C. and TLCanalysis indicated that the reaction was complete. The reaction wasquenched with SiO₂ and filtered. The resulting filtrate was concentratedin vacuo followed by purification by C₁₈-HPLC (10–70% CH₃CN over 30minutes). The title compound was isolated as a white solid (4.9 mg,39%). ESI-MS (m/z): Calcd. for C₁₁H₁₁BrN₄O₂S₃: 406.9 (M+H); found:407.1. ¹H-NMR (CD₃OD): δ 8.54 (m, 1H), 8.26 (m, 1H), 8.15 (m, 1H), 2.74(s, 3H).

Example 1204-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

a)4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

A flask with4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (25 mg, 0.06 mmol, Example 118, step c) and zinc dust(4 mg, 0.06 mmol) was dissolved with 1 mL acetic acid and heated to 50°C. for 4 hours. TLC analysis indicated the formation of a new spot. Thereaction mixture was concentrated in vacuo and purified by elutionthrough Celite® using 10% MeOH in DCM. The crude product was carried onwithout further purification. ESI-MS (m/z): Calcd. for C₁₂H₁₀BrNO₄S₃:407.9 (M+H); found: 408.1.

b)4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

The procedure as in Example 20, f was followed using4-(5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (5 mg, 0.01 mmol, Example 120, step a)dimethylaluminuim amide (1M, 5 mL). The reaction was stirred for 3 hoursat 90° C. and TLC analysis indicated that the reaction was complete. Thereaction was quenched with SiO₂ and filtered. The resulting filtrate wasconcentrated in vacuo followed by purification by C₁₈-HPLC (10–70% CH₃CNover 30 minutes). The title compound was isolated as a white solid (4.6mg, 92%). ESI-MS (m/z): Calcd. for C₁₁H₁₀BrN₃O₂S₃: 391.9 (M+H); found:392.1. ¹H-NMR (CD₃OD): δ 9.14 (m, 1H), 8.97 (m, 1H), 8.55 (m, 1H), 8.34(s, 1H), 2.76 (m, 3H).

Example 1214-(6-Amino-5-o-tolyl-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

a)4-(6-Amino-5-o-tolyl-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide

The procedure as in Example 1: step c was followed using4-(6-amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide (25 mg, 0.06 mmol, Example 120: step a), o-tolyl phenylboronic acid (33 mg, 0.25 mmol), Pd(PPh₃)₄ (14 mg, 0.01 mmol), aqueousNa₂CO₃ (2M, 0.4 mL), ethanol (0.4 mL) and toluene (0.8 mL). Purificationby preparative SiO₂ chromatography (25% EtOAc in hexanes) of the residueyielded the title compound (7.4 mg, 32%) as a brown solid. ESI-MS (m/z):Calcd. for C₁₈H₁₇N₃O₃S₃: 420.0 (M+H); found: 420.2.

b)4-(6-Amino-5-o-tolyl-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

The procedure as in Example 20, f was followed using4-(6-amino-5-o-tolyl-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide (7.4 mg, 0.02 mmol, Example 121, step a) dimethylaluminuimamide (1M, 5 mL). The reaction was stirred for 3 hours at 90° C. and TLCanalysis indicated that the reaction was complete. The reaction wasquenched with SiO₂ and filtered. The resulting filtrate was concentratedin vacuo followed by purification by C₁₈-HPLC (10–70% CH₃CN over 30minutes). The title compound was isolated as a white solid (2.6 mg,35%). ESI-MS (m/z): Calcd. for C₁₈H₁₈N₄O₂S₃: 419.0 (M+H); found: 419.1.¹H-NMR (CD₃OD): δ 8.6 (m, 1H), 8.28 (s, 1H), 7.74 (m, 1H), 7.36 (m, 3H),7.16 (m, 1H), 2.74 (m, 3H), 2.13 (m, 3H).

Example 1224-(6′-Methyl-2′-morpholin-4-yl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){Imino-[4-(6′-methyl-2′-morpholin-4-yl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (20 mg, 0.04 mmol, Example 25: step c). K₂CO₃ (8mg, 0.06 mmol), 2,6-lutidine (8 mg, 0.08 mmol) and 2-bromoethyl ether(18 mg, 0.08 mmol) were dissolved in acetonitrile (1 mL) and heated to80° C. with stirring under argon. After 6 hours, Et₃N (8 μL, 0.06 mmol)was added and the reaction continued stirring for 20 hours. Purificationof the residue by preparative SiO₂ TLC (50% EtOAc in hexanes) yieldedthe title compound (7.5 mg, 32%) as a yellow solid. ESI-MS (m/z): Calcd.for C₂₈H₃₃N₃O₅S₃: 588.2 (M+1); found: 588.0.

b)4-(6′-Methyl-2′-morpholin-4-yl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{Imino-[4-(6′-methyl-2′-morpholin-4-yl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (7.5 mg, 0.013 mmol, Example 122: step a) wasdeprotected and purified as in Example 1: step d, yielding the titlecompound as a clear glass (2.2 mg, 35%). ¹H-NMR (CD₃OD): δ 8.34 (s, 1H),8.02–8.05 (m, 1H), 7.94–7.92 (t, 1H, J=1.6 Hz), 7.66–7.70 (t, 1H, J=7.2Hz), 7.61–7.64 (m, 1H, J=7.9 Hz), 7.23–7.28 (t, 1H, J=7.67 Hz),6.98–7.05 (m, 2H), 3.13–3.27 (m, 4H), 2.71 (s, 3H), 2.63–2.67 (m, 4H),2.05 (s, 3H). ESI-MS (m/z): Calcd. for C₂₃H₂₅N₃O₃S₃: 488.1 (M+1); found:488.3.

Example 1234-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 6-Bromo-5-chloro-pyridine-3-sodium sulphonate

Sodium sulfite (794 mg, 6.3 mmol) and sodium bicarbonate (554 mg, 6.6mmol) were dissolved into water (4 mL) with heat (70° C.).6-Bromo-5-chloro-pyridine-3-sulfonyl chloride (1000 mg, 3.4 mmol) wasadded slowly as a solid over one hour. The reaction was heated at 70° C.for two additional hours followed by standing at RT overnight. Thesolvents were removed in vacuo resulting in the title compound that wasused without further purification or characterization.

b)4-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester

4-Bromo-5-nitro-thiophene-2-carboxylic acid methyl ester (2.6 g, 10.2mmol, Example 27: step c) was dissolved into DMF (15 mL) and6-Bromo-5-chloro-pyridine-3-sodium sulphonate (946 mg, 3.4 mmol, Example123: step a) was partially dissolved into DMF (15 mL). The solution of4-Bromo-5-nitro-thiophene-2-carboxylic acid methyl ester was cooled to−20° C. and to this was added the solution of6-Bromo-5-chloro-pyridine-3-sodium sulphonate, dropwise over one hour.The reaction mixture was maintained at −20° C. with stirring for 3hours. The solvents were removed in vacuo followed by purification byflash column chromatography (Biotage Flash System—40 M SiO₂ column) (30%EtOAc in hexanes) that yielded the title compound (430 mg, 29%) as awhite solid. ESI-MS (m/z): Calcd. for C₁₁H₆BrClN₂O₂S₂: 440.9 (M+1);found: 441.1.

c)4-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure described in Example 27: step a was followed using4-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-nitro-thiophene-2-carboxylicacid methyl ester (63 mg, 0.14 mmol, Example 123: step b) and sodiumthiomethoxide (0.5 M in EtOH, 0.18 mmol, 360 μL). The reaction wasquenched with acetic acid (10 uL, 0.18 mol) followed by concentration invacuo. The residue was then dissolved into EtOAc and washed withsaturated NaHCO₃ and brine solutions. The organic layers were dried(Na₂SO₄) and removal of the solvents in vacuo was followed bypurification by preparative SiO₂ TLC (30% EtOAc in hexanes) that yieldedthe title compound (14.2 mg, 23%) as a yellow solid. ESI-MS (m/z):Calcd. for C₁₂H₉BrClNO₄S₃: 441.9 (M+1) found: 442.0.

d)4-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (Example 123: step c) was then converted to theamidine and purified as described in Example 20: step f to isolate thetitle compound (6.4 mg, 50%). ¹H-NMR (CD₃OD): δ: 8.97 (s, 1H), 8.66 (s,1H), 8.33 (s, 1H), 2.76 (s, 3H). ESI-MS (m/z): Calcd. forC₁₁H₉BrClN₃O₂S₃: 425.9 (M+1) found: 426.1.

Example 1244-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

Ammonia gas was condensed with a cold finger into the Teflon core of astainless steel bomb. Approximately 5 mL of liquid ammonia was collectedand maintained at −78° C. To this was added4-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (15 mg, 0.034 mmol, Example 123: step c). The reactionvessel was capped, sealed and heated to 80° C. overnight protected byshield. The reaction bomb was cooled to RT then to −78° C. beforeopening. The remaining ammonia mixture was allowed to evaporate todryness in hood resulting in title compound and4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide (14 mg, 98%). ESI-MS (m/z): Calcd. for C₁₂H₁₁BrN₂O₄S₃: 422.9(M+1) found: 423.0.

b)4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The mixture of4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide (Example 124: step a) was then converted to the amidine andpurified as described in Example 20: step f to isolate the titlecompound (4.9 mg, 36%). ¹H-NMR (CD₃OD): δ: 8.55 (s, 1H), 8.27 (s, 1H),8.14 (s, 1H), 2.74 (s, 3H). ESI-MS (m/z): Calcd. for C₁₁H₁₁BrClN₄O₂S₃:406.9 (M+1) found: 407.1.

Example 1254-(6-Amino-5-o-tolyl-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(6-Amino-5-o-tolyl-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure as in Example 1: step c was followed using4-(6-Amino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (25 mg, 0.06 mmol, Example 124: step a), 2-methylphenyl boronic acid (33 mg, 0.25 mmol), Pd(PPh₃)₄ (14 mg, 0.01 mmol),aqueous Na₂CO₃ (2M, 400 μL, 0.5 mmol), ethanol (400 μL) and toluene (800μL). The reaction was heated to 80° C. for 12 hours. The residue wasdissolved into EtOAc and washed with brine. The organic layers weredried (MgSO₄) and removal of the solvents in vacuo was followed bypreparative SiO₂ TLC purification (20% MeOH in DCM) that yielded thetitle compound (7.4 mg, 29%) as a white solid. ESI-MS (m/z): Calcd. forC₁₉H₁₈N₂O₄S₃: 420.0 (M+1) found: 420.2.

b)4-(6-Amino-5-o-tolyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(6-Amino-5-o-tolyl-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (Example 125: step a) was then converted to theamidine and purified as described in Example 20: step f to isolate thetitle compound (2.6 mg, 35%). ¹H-NMR (CD₃OD): δ: 8.60 (s, 1H), 8.28 (s,1H), 8.14 (s, 1H), 7.74–7.73 (d, 1H, J=2.74 Hz) 7.36 (s, 1H), 7.32–7.28(m, 1H), 7.16–7.14 (d, 1H, J=8.14 Hz), 2.74 (s, 3H), 2.13 (s, 3H).ESI-MS (m/z): Calcd. for C₁₈H₁₈N₄O₂S₃: 419.0 (M+1) found: 419.1.

Example 1264-(5-Bromo-6-phenoxy-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(5-Bromo-6-phenoxy-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

4-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (110 mg, 0.24 mmol, Example 123, step c), cesiumcarbonate (156 mg, 0.48 mmol), phenol (180 mg, 1.92 mmol), copper(II)trifluoromethanesulfonate benzene complex (4 mg, 0.006 mmol) and EtOAc(1.0 mg, 0.02 mmol) were all dissolved into toluene (10 mL) and heatedto 110° C. for 12 hours. The reaction mixture was dissolved into EtOAcand washed with brine. The organic layers were dried (MgSO₄) and removalof the solvents in vacuo was followed by purification by flash columnSiO₂ (30% EtOAc in hexanes) that yielded the title compound. ESI-MS(m/z): Calcd. for C₁₈H₁₄BrNO₅S₃: 599.9 (M+1) found: 500.1.

b)4-(5-Bromo-6-phenoxy-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(5-Bromo-6-phenoxy-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (Example 126: step a) was then converted to theamidine and purified as described in Example 20: step f to isolate thetitle compound (1.0 mg). ¹H-NMR (CD₃OD): δ: 8.66–8.65 (m, 1H), 8.59–8.58(m, 1H), 8.33 (s, 1H), 7.48–7.44 (m, 2H), 7.33–7.29 (m, 1H), 7.18–7.15(m, 2H), 2.76 (s, 3H). ESI-MS (m/z): Calcd. for C₁₇H₁₄BrN₃O₃S₃: 483.9(M+1) found: 484.1.

Example 1274-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) Di-5-bromo-3-pyridyl disulfide

2,4-dibromopyridine (2000 mg, 8.4 mmol) was dissolved into ether (10 mL)at RT. The reaction mixture was cooled to −78° C. and n-butyllithium(2.5M, 3.4 mL, 8.4 mmol) was added dropwise. The reaction was stirred at−78° C. for an hour followed by quenching with sulfur (269 mg, 8.4mmol). The reaction was allowed to warm to RT over 2 hours. Removal ofthe solvents in vacuo was followed by purification by flash column SiO₂(30% EtOAc in hexanes). The product was used without furthercharacterization or purification.

b) 4-(5-Bromo-pyridin-3-ylsulfanyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester

Di-5-bromo-3-pyridyl disulfide (600 mg, 1.6 mmol, Example 127: step a),Et₃N (223 μL, 1.6 mmol), triphenylphosphine (419 mg, 1.6 mmol) and4-Bromo-5-nitro-thiophene-2-carboxylic acid methyl ester (427 mg, 1.6mmol, Example 114: step c) were dissolved into THF (5 mL) and stirred atRT for 3 days. Removal of the solvents in vacuo was followed by flashcolumn SiO₂ purification (25% EtOAc in hexanes) to isolate the titlecompound (200 mg, 33%). ESI-MS (m/z): Calcd. for C₁₁H₇BrN₂O₄S₂: 374.9(M+1) found: 377.1.

c) 4-(5-Bromo-pyridine-3-sulfonyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester

4-(5-Bromo-pyridin-3-ylsulfanyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester (126 mg, 0.33 mmol, Example 127: step b) and m-CPBA (438mg, 1.67 mmol, 77%) were dissolved into DCM (10 mL) and heated to 38° C.with stirring for 2 hours. The reaction was quenched with Na₂S₂O₃,dissolved into DCM and washed with NaHCO₃. The organic layers were dried(MgSO₄) and the solvents were removed in vacuo followed by flash columnSiO₂ purification (25% EtOAc in hexanes) to isolate the title compound(151 mg, 99%) as a yellow solid. ESI-MS (m/z): Calcd. for C₁₁H₇BrN₂O₆S₂:406.9 (M+1) found: 407.1

d)4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure described in Example 27: step a was followed using4-(5-Bromo-pyridine-3-sulfonyl)-5-nitro-thiophene-2-carboxylic acidmethyl ester (151 mg, 0.37 mmol, Example 127: step c) and sodiumthiomethoxide (1.0 M in EtOH, 26.3 mg, 0.37 mmol). The reaction wasquenched with acetic acid (21 uL, 0.37 mol) and the solvents wereremoved in vacuo. The residue was then dissolved into EtOAc and washedwith saturated NaHCO₃ and brine solutions. The organic layer was driedNa₂SO₄) and removal of the solvents in vacuo was followed bypurification by flash column chromatography SiO₂ (30% EtOAc in hexanes)to yield the title compound. ESI-MS (m/z): Calcd. for C₁₂H₁₀BrNO₄S₃:407.9 (M+1) found: 408.1.

e)4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (Example 127: step d) was then converted to theamidine and purified as described in Example 20: step f to isolate thetitle compound (2.7 mg). ¹H-NMR (CD₃OD): δ: 9.15 (m, 1H), 9.00 (m, 1H),8.58 (m, 1H), 8.35 (s, 1H), 2.77 (s, 3H). ESI-MS (m/z): Calcd. forC₁₁H₁₀BrN₃O₂S₃: 391.9 (M+1) found: 392.2.

Example 1285-Methylsulfanyl-4-(5-o-tolyl-pyridine-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine(300 mg, 0.77 mmol, Example 127: step e) was dissolved into DMF (10 mL).To this was added DIEA (267 μL mg, 1.53 mmol) and (Boc)₂O (201.6, 0.92mmol). The reaction was stirred at RT for 12 hours. The solvents wereremoved in vacuo and the residue was dissolved into DCM and washed with20% citric acid and brine. The organic layers were dried (MgSO₄) and thesolvents were removed in vacuo followed by purification by flash columnchromatography SiO₂ (50% EtOAc in hexanes) that resulted in the titlecompound. ESI-MS (m/z): Calcd. for C₁₆H₁₈BrN₃O₄S₃: 491.9 (M+1) found:491.1.

b){Imino-[5-methylsulfanyl-4-(5-o-tolyl-pyridine-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

The procedure described in Example 1: step c was followed using{[4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (50 mg, 0.08 mmol), 2-methyl phenyl boronic acid(23 mg, 0.17 mmol), Pd(PPh₃)₄ (19 mg, 0.02 mmol), aqueous Na₂CO₃ (2M,800 μL, 0.4 mmol), ethanol (800 μL) and toluene (1600 μL). The reactionwas heated to 80° C. for 12 hours. The residue was dissolved into EtOAcand washed with brine. The organic layers were dried (MgSO₄) and removalof the solvents in vacuo resulted in a crude mixture of the product thatwas used without further purification or characterization.

c)5-Methylsulfanyl-4-(5-o-tolyl-pyridine-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

{Imino-[5-methylsulfanyl-4-(5-o-tolyl-pyridine-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (127 mg, Example 128: step b) was deprotected andpurified as in Example 1: step d, yielding the title compound as anoff-white solid (8 mg, 8%). ¹H-NMR (CD₃OD): δ 9.15 (s, 1H), 8.84 (s,1H), 8.37 (m, 2H), 8.36 (m, 4H), 2.75 (s, 3H), 2.56 (s, 3H). ESI-MS(m/z): Calcd. for C₁₈H₁₇N₃O₂S₃: 404.1 (M+1); found: 404.1

Example 1294-(2′-Formylamino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (58 mg, 0.11 mmol, Example 25: step c) wasdissolved into formic acid (3 mL, 96%) and heated to 100° C. for 24hours. The solvents were removed in vacuo resulting in the desiredproduct with removal of the tert-butyl protection group. The resultingcompound was purified as in Example 1: step d, yielding the titlecompound as an off-white solid (11 mg, 22%). ESI-MS (m/z): Calcd. forC₂₀H₁₉N₃O₃S₃: 446.1 (M+1); found: 446.1.

Example 130[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylamino]-aceticacid

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (75 mg, 0.15 mmol, Example 25: step c), tert-butylbromoacetate (43 μL, 0.29 mmol), potassium carbonate (29 mg, 0.21 mmol)and 2,6-lutidine (33 μL, 0.29 mmol) were dissolved into toluene (2 mL).The reaction was stirred and heated to 80° C. for 12 hours. Et₃N (41 μL,0.3 mmol) was added to reaction and heated to 80° C. for another 12hours. The reaction mixture was dissolved into EtOAc and washed withbrine. The organic layers were dried (MgSO₄), the solvents were removedin vacuo followed purified by preparative SiO₂ TLC purification (20%MeOH in DCM) resulting in{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylamino}-aceticacid tert-butyl ester. ESI-MS (m/z): Calcd. for C₃₀H₃₇N₃O₆S₃: 632.2(M+1) found: 631.9.{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylamino}-aceticacid tert-butyl ester was deprotected and purified as Example 1: step d,yielding the title compound as brown solid (1.7 mg). ¹H-NMR (CD₃OD): δ8.35 (s, 1H), 8.08–8.06 (d, 1H, J=8.83 Hz), 7.77 (t, 1H, J=7.44 Hz,J=7.67 Hz), 7.63–7.61 (d, 1H, J=7.67 Hz), 7.16 (t, 1H, J=7.91 Hz, J=7.91Hz), 7.05–6.68 (d, 2H, J=7.67 Hz), 6.52–6.50 (d, 1H, J=8.14 Hz), 3.81(s, 1H), 2.72 (s, 3H), 2.17 (s, 3H). ESI-MS (m/z): Calcd. forC₂₁H₂₁N₃O₄S₃: 476.1 (M+1); found: 476.1.

Example 131{2-[5-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-pyridin-3-yl]-3-methyl-benzyloxy}-aceticacid

a) 2-Iodo-3-methyl-benzoyl chloride

2-iodo-3-methyl benzoic acid (1310 mg, 5 mmol) and thionyl chloride (730μL, 10 mmol) were dissolved into THF (10 mL) and stirred at RT for 4days. The solvents were removed in vacuo and the resulting residue wasdissolved into EtOAc, washed with brine. The combined organic layerswere dried (MgSO₄) and the solvents were removed in vacuo resulting inan oil that was used without further purification or characterization.

b) (2-Iodo-3-methyl-phenyl)-methanol

2-Iodo-3-methyl-benzoyl chloride (1360 mg, 4.86 mmol, Example 131: a)was dissolved into THF (2 mL) and cooled to −78° C. To this was slowlyadded a slurry of lithium aluminum hydride (184.3 mg, 4.86 mmol) thatwas carefully weighed into a dry flask and cooled to 78° C., before THF(2 mL) was added. The reaction was warmed to RT slowly and stirred foran hour. The reaction was quenched by cooling back to −78° C. and adding200 μL water, 200 μL 15% NaOH, 600 μL water and then poured over celiteand filtered with THF. The title compound was obtained as a yellowsolid. ¹H-NMR (CDCl₃): δ 7.21–7.19 (m, 2H), 7.14–7.11 (m, 1H,), 4.61 (s,2H), 2.43 (s, 3H).

c) (2-Iodo-3-methyl-benzyloxy)-acetic acid tert-butyl ester

(2-Iodo-3-methyl-phenyl)-methanol (1608 mg, 6.8 mmol, Example 131: stepb) was dissolved into DMF (10 mL). The solution was cooled to 0° C. Tothis was added sodium hydride in one portion and the reaction continuedto stir at 0° C. for 30 minutes. To the cooled solution was addedt-butylbromoacetate (1.3 mL, 8.9 mmol) and then the reaction was warmedto RT and then heated to 50° C. for 4 hours. The solvents were removedin vacuo and the resulting residue was dissolved into EtOAc and washedwith brine. The combined organic layers were dried (MgSO₄) and thesolvent was removed in vacuo resulting in the title compound (1.29 g,53%) that was used with out further purification. ¹H-NMR (CDCl₃): δ7.28–7.13 (m, 3H), 4.63 (s, 2H), 4.07 (s, 2H), 2.44 (s, 3H), 1.47 (s,9H).

d)[3-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester

(2-Iodo-3-methyl-benzyloxy)-acetic acid tert-butyl ester (360 mg, 1.46mmol, Example 131: step c),trans-Dichlorobis(triphenylphosphine)palladium(II) (102 mg, 0.15 mmol)and Et₃N (1.2 mL, 8.76 mmol) were dissolved into dioxane (10 mL). Tothis was slowly added 4,4,4,5,5,5-tetramethyldioxaborolane (423 μL, 2.91mmol) and reaction was heated to 80° C. for 2 hours. Catalytic amountsof 4,4,4,5,5,5-tetramethyldioxaborolane anddichlorobis(triphenylphosphine)palladium(II) were added and the reactioncontinued heating at 50° C. overnight. The solvents were removed invacuo and the residue was dissolved into EtOAc followed by washing withbrine. The combined organic layers were dried (MgSO₄) and the solventswere removed in vacuo. The crude reaction mixture was purified by flashcolumn chromatography (30% EtOAc/hexanes) yielding the title compound(335 mg, 63%) as a brown oil. ¹H-NMR (CDCl₃): δ 7.23–7.06 (m, 3H), 4.72(s, 2H), 4.09 (s, 2H), 2.42 (s, 3H), 1.45 (m, 12H), 1.38 (s, 9H).

e)(2-{5-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-pyridin-3-yl)-3-methyl-benzyloxy)-aceticacid tert-butyl ester

The procedure as in Example 1: step c was followed using[3-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester (252.2 mg, 0.62 mmol, Example 131: step d),{[4-(5-Bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (75.9 mg, 0.15 mmol, Example 128: step a),Pd(PPh₃)₄ (35 mg, 0.03 mmol), aqueous Na₂CO₃ (2M, 1 mL), ethanol (1 mL)and toluene (2 mL). The reaction was heated to 80° C. for 24 hours. Thereaction mixture was dissolved into EtOAc and washed with brine. Theorganic layers were dried (MgSO₄) and removal of the solvents in vacuowas followed by purification by flash column chromatography (SiO₂) (30%EtOAc in hexanes) of the residue yielded the title compound (460 mg) asa brown oil. ESI-MS (m/z): Calcd. for C₃₀H₃₇N₃O₇S₃: 648.2 (M+1) found:647.9.

f){2-[5-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-pyridin-3-yl]-3-methyl-benzyloxy}-aceticacid

(2-{5-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-pyridin-3-yl}-3-methyl-benzyloxy)-aceticacid tert-butyl ester (127 mg) (Example 11: step e) was deprotected andpurified as in Example 1: step d, yielding the title compound as anoff-white solid. ¹H-NMR (CD₃OD): δ 9.05 (s, 1H), 8.65 (s, 1H), 8.26 (m,1H), 8.19 (s, 1H), 7.28–7.24 (m, 3H), 4.12 (s, 2H), 3.67 (s, 2H ), 2.63(s, 3H), 1.92 (s, 3H). ESI-MS (m/z): Calcd. for C₂₁H₂₁N₃O₅S₃: 492.1(M+1); found: 492.1.

Example 132N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-malonamicacid

a)N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-malonamicacid methyl ester

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (22 mg, 0.04 mmol, Example 25: step c) wasdissolved into THF (1 mL) and to this was added chlorocarbonyl-aceticacid methyl ester (9 μL, 0.085 mmol). The reaction was heated to 50° C.for 5 hours and then allowed to stir at RT for 48 hours. The reactionmixture was dissolved into EtOAc and washed with brine. The organiclayers were dried (MgSO₄) and removal of the solvents in vacuo wasfollowed by purification by preparative TLC (SiO₂) (30% EtOAc inhexanes) that yielded the title compound. ESI-MS (m/z): Calcd. forC₂₈H₃₁N₃O₇S₃: 618.1 (M+1) found: 617.9.

b)N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-malonamicacid

N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-malonamicacid methyl ester (20 mg, 0.03 mmol, Example 132: step a) and NaOH (1M,90 μL, 0.09 mmol) were dissolved into MeOH (1.5 mL). The reaction wasstirred for 2 hours. LiOH (1.0 mg, 0.05 mmol) was added and the reactionwas stirred at RT overnight. The solvents were removed in vacuo and usedwith out further purification in the next step. ESI-MS (m/z): Calcd. forC₂₇H₂₉N₃O₇S₃: 604.1 (M+1); found: 504.0 (loss of boc).

c)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-malonamicacid

N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-malonamicacid (Example 132: step b) was deprotected and purified as in Example 1:step d, yielding the title compound as a glassy solid. ¹H-NMR (CD₃OD): δ8.28 (s, 1H), 8.07–8.05 (m, 1H), 7.85 (s, 1H), 7.72–7.68 (t, 1H, J=7.67Hz, J=7.90 Hz), 7.57–7.55 (m, 1H), 7.43–7.26 (m, 3H), 2.74 (s, 3H), 2.07(s, 3H), 2.05 (s, 2H). ESI-MS (m/z): Calcd. for C₂₂H₂₁N₃O₅S₃: 504.1(M+1); found: 503.9.

Example 133N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-succinamicacid trifluoroacetate

a)N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-succinamicacid ethyl ester

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (38.5 mg, 0.07 mmol, Example 25: step c) and3-chlorocaxbonyl-propionic acid ethyl ester (13 μL, 0.09 mmol) weredissolved into THF (1 mL) and heated to 50° C. for one hour. Thereaction was dissolved into EtOAc and washed with brine. The combinedorganic layers were dried, (MgSO₄) and the solvents were removed invacuo. Purification by preparative TLC (30% EtOAc/hexanes) yielded thetitle compound. ESI-MS (m/z): Calcd. for C₃₀H₃₅N₃O₇S₃: 646.2 (M+1);found: 645.8.

b)N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-succinamicacid

N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-succinamicacid ethyl ester (Example 133: step a) and LiOH were dissolved into MeOHand stirred at RT for 2 hours. The solvents were removed in vacuoyielding the title compound that was used with out further purificationor characterization.

c)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-malonamicacid trifluoroacetate

N-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-succinamicacid (Example 133: step c) was deprotected and purified as in Example 1:step d, yielding the title compound as a white solid. ¹H-NMR (CD₃OD): δ8.31 (s, 1H), 8.07–8.05 (m, 1H), 7.85 (s, 1H), 7.72–7.68 (t, 1H, J=7.67Hz, J=7.90 Hz), 7.56–7.53 (m, 1H), 7.37–7.35 (t, 1H, J=7.67 Hz, J=7.67Hz), 7.29–7.21 (m, 1H), 3.36 (s, 4H), 2.74 (s, 3H), 2.09 (s, 3H). ESI-MS(m/z): Calcd. for C₂₃H₂₃N₃O₅S₃: 518.1 (M+1); found: 518.1.

Example 1344-(4′-Amino-2′-chloro-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(2′-Chloro-6′-methyl-4′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

2-Bromo-1-chloro-3-methyl-5-nitro-benzene (45 mg, 0.219 mmol),{[4-(3-Boranyl-dihydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (50 mg, 0.11 mmol, Example 140: step a) andPd(PPh₃)₄ (25 mg, 0.02 mmol) were combined in aqueous Na₂CO₃ (2M, 500μL), ethanol (500 μL) and toluene (1 mL). The reaction was heated to 80°C. overnight. The resulting residue was dissolved into EtOAc and washedwith brine. The organic layers were dried (MgSO₄) and the solvent wasremoved in vacuo followed by preparative TLC purification (30%EtOAc/hexanes) that yielded the title compound (20 mg, 29%). ESI-MS(m/z): Calcd. for C₂₄H₂₄CIN₃O₆S₃: 582.1 (M+1); found: 582.1.

b){[4-(4′-Amino-2′-chloro-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

{[4-(2′-Chloro-6′-methyl-4′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (20 mg, 0.034 mmol, Example 134: step a) wasdissolved into EtOH (2 mL). To this was added ammonium chloride (18 mg,0.34 mmol) dissolved into water (4 mL). The reaction was heated to 50°C. and iron (9.6 mg, 0.34 mmol) was added. The reaction was then heatedto 80° C. for 12 hours followed by filtration through celite withmethanol and EtOAc. The solvents were removed in vacuo resulting indesired product that was used with out further purification orcharacterization.

c)4-(4′-Amino-2′-chloro-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{[4-(4′-Amino-2′-chloro-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 134: step b) was deprotected and purifiedas in Example 1: step d, yielding the title compound as a dark yellowsolid. ¹H-NMR (CD₃OD): δ 8.33 (s, 1H), 8.03–8.00 (m, 1H), 7.85–7.84 (m,1H), 7.70–7.66 (t, 1H, J=7.67 Hz, J=7.67 Hz), 7.54–7.52 (m, 1H), 6.94(s, 1H), 6.84 (m, 1H), 2.70 (s, 3H), 1.99 (s, 3H). ESI-MS (m/z): Calcd.for C₁₉H₁₈N₃O₂S₃: 452.0 (M+1); found: 452.1.

Example 135N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-chloro-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidetrifluoroacetate

a) 4-Bromo-3-methyl-5-nitro-phenylamine

(4-Bromo-3-methyl-5-nitro-phenyl)-carbamic acid tert-butyl ester (1000mg, 2.9 mmol) was dissolved into DCM (10 mL). To this was added TFA (10mL) and the reaction was stirred at RT for 1 hour. The pH was adjustedto 8 with 1 N NaOH and the solvents were removed in vacuo. The reactionmixture was dissolved into EtOAc and the layers were separated. Theorganic layers were dried (MgSO₄) and the solvents were removed in vacuoresulting in title compound (756 mg, quantitative) as a brown oil.¹H-NMR (CDCl₃): δ 8.44 (s, 1H), 8.02 (s, 1H), 7.61 (s, 1H), 3.05 (s,3H).

b) 2-Bromo-5-chloro-1-methyl-3-nitro-benzene

A 3-neck flask fitted with septa, addition funnel and condenser wascharged with t-butylnitrite (966μ, 8.12 mmol) and copper(II) chloride(1090 mg, 8.12 mmol) in acetonitrile (10 mL).4-Bromo-3-methyl-5-nitro-phenylamine (756 mg, 4.06 mmol, Example 135:step a) was dissolved in acetonitrile (6 mL) and added slowly throughthe addition funnel while heating to 60° C. The reaction was quenchedwith EtOAc and washed with water. The organic layers were dried (MgSO₄)and the solvents were removed in vacuo resulting in the title compoundas a brown solid (721 mg, 72%). ¹H-NMR (CDCl₃): δ 7.54 (d, 1H, J=2.33),7.44 (d, 1H, J=2.56 Hz), 2.55 (s, 3H).

c) 2-Bromo-5-chloro-3-methyl-phenylamine

2-Bromo-5-chloro-1-methyl-3-nitro-benzene (721 mg, 3.5 mmol, Example135: step b) was dissolved into EtOH (6 mL). To this was added ammoniumchloride (1.9 g, 35 mmol) dissolved into water (10 mL). The reaction washeated to 50° C., iron (9.6 mg, 0.34 mmol) was added and the reactionwas then heated to 80° C. for 12 hours. The reaction mixture wasfiltered through celite, washed with methanol and EtOAc and the solventswere removed in vacuo. The residue was dissolved into EtOAc and washedwith brine to remove salts. The organic layers were dried (MgSO₄) andthe solvents were removed in vacuo resulting in the title compound (595mg, 78%) as a brown solid. ¹H-NMR (CDCl₃): δ 6.63–6.61 (m, 2H), 2.33 (s,3H).

d)5-Chloro-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine

2-Bromo-5-chloro-3-methyl-phenylamine (595 mg, 2.7 mmol, Example 135:step c), Pd(OAc)₂ (30.3 mg, 0.14 mmol),2-(dicyclohexylphosphino)biphenyl (189.2 mg, 0.54 mmol) and Et₃N (1.5mL, 10.8 mmol) were dissolved into dioxane (10 mL). To this was added4,4,5,5-Tetramethyl-[1,3,2]dioxaborolane (1.2 mL, 8.1 mmol) slowly. Thereaction was heated to 80° C. overnight. The solvents were removed invacuo and the resulting residue was dissolved into EtOAc and washed withbrine. The combined organic layers were dried (MgSO₄) and removal of thesolvents in vacuo resulted in a mixture of the title compound and3-Methyl-2,5-bis-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylaminewere obtained and used with out further purification.

e){[4-(2′-Amino-4′-chloro-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

The procedure as in Example 1: step c was followed5-Chloro-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(663 mg, 2.5 mmol, Example 135, step d),{[4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (1.2 g, 2.5 mmol, Example 27: step c), Pd(PPh₃)₄(577 mg, 0.5 mmol), aqueous Na₂CO₃ (2M, 10 mL), ethanol (10 mL) andtoluene (20 mL). The reaction was heated to 80° C. for 24 hours. Thereaction mixture was dissolved into EtOAc and washed with brine. Theorganic layers were dried (MgSO₄) and removal of the solvents in vacuowas followed by purification by flash column chromatography (SiO₂) (30%EtOAc in hexanes) that yielded the title compound as a brown oil. ESI-MS(m/z): Calcd. for C₂₄H₂₆ClN₃O₄S₃: 552.1 (M+1) found: 551.7.

f)({4-[4′-Chloro-2′-(4-methanesulfonyl-butyrylamino)-6′-methyl-phenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl}-carbamicacid tert-butyl ester

{[4-(2′-Amino-4′-chloro-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (120 mg, 0.22 mmol, Example 135, e) and Et₃N (0.91mL, 0.65 mmol) were dissolved into DCM (4 mL). To this was added(4-Methanesulfonyl-butyryl chloride (0.144 M, 3.1 mL, 0.44 mmol, Example209: a) and the reaction was stirred at RT overnight. The solvents wereremoved in vacuo followed by purification by flash column chromatography(20% EtOAc/hexanes) that yielded the title compound as an orange solid(124 mg, 81%). ESI-MS (m/z): Calcd. for C₂₉H₃₄ClN₃O₇S₄: 700.1 (M+1)found: 700.1.

g)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-chloro-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidetrifluoroacetate

({4-[4′-Chloro-2′-(4-methanesulfonyl-butyrylamino)-6′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (124 mg, 0.18 mmol, Example 135: step f) wasdeprotected and purified as in Example 1: step d, yielding the titlecompound as a clear glass (70 mg, 65%). ¹H-NMR (CD₃OD): δ 8.32 (s, 1H),8.08–8.06 (d, 1H, J=10.00 Hz), 7.87 (m, 1H), 7.71 (t, 1H, J=7.91 Hz,J=8.61 Hz), 7.56–7.54 (d, 1H, J=9.07), 7.33 (m, 2H), 2.92 (s, 3H), 2.85(t, 2H, J=7.91 Hz, J=7.67 Hz), 2.73 (s, 3H), 2.21 (t, 2H, J=5.35 Hz,J=7.91 Hz), 2.07 (s, 3H), 1.82–1.73 (m, 2H). ESI-MS (m/z): Calcd. forC₂₄H₂₆ClN₃O₅S₄: 600.1 (M+1); found: 600.1.

Example 1364-[4′-(N′-Hexyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)({4-[4′-(3-Hexyl-thioureido)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine(26 mg, 0.05 mmol, Example 220: step b) was dissolved into EtOH. To thiswas added hexylisothiocyanate (30 μL) and the reaction was heated for 4hour at 80° C. The solvent was removed in vacuo and the reaction waspurified by preparative TLC resulting in the title compound that wasused without further purification or characterization.

b)({4-[4′-(N′-Hexyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

({4-[4′-(3-Hexyl-thioureido)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (33 mg, 0.14 mmol. Example 136: step a) wasdissolved into ammonia in methanol (2.0 M, 4 mL). To this was addedmercury(II) oxide (33.9 mg, 0.16 mmol) and the reaction stirred at RTfor 2 hours. Additional mercury(II) oxide (154 mg, 0.08 mmol) was addedand the reaction was heated to 40° C. overnight. The reaction wasfiltered with 0.2 μM disk and washed with EtOAc followed by removal ofsolvents in vacuo that yielded the title compound which was used withoutfurther purification (30 mg). ESI-MS (m/z): Calcd. for C₃₁H₄₁N₅O₄S₃:644.2 (M+1); found: 644.1.

c)4-[4′-(N′-Hexyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

({4-[4′-(N′-Hexyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (30 mg, Example 136: step b) was deprotected andpurified as in Example 1: step d, yielding the title compound as ayellow glass (11.5 mg, 43%). ¹H-NMR (CD₃OD): δ 8.34 (s, 1H), 8.03–8.00(m, 2H), 7.73–7.67 (m, 2H), 7.33–7.31 (m, 1H), 7.24–7.18 (m, 2H), 3.63(m, 2H), 2.72 (s, 3H), 2.27 (s, 3H), 1.69–1.62 (m, 2H), 1.44–1.33 (m,6H). ESI-MS (m/z): Calcd. for C₂₆H₃₃N₅O₂S₃: 544.2 (M+1); found: 544.1.

Example 1375-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-pentanoicacid trifluoroacetate

a)5-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-pentanoicacid methyl ester

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100 mg, 0.19 mmol, Example 25: step c) wasdissolved into THF (3 mL). To this was added 5-Chlorocarbonyl-pentanoicacid methyl ester (41.5 mg, 0.23 mmol) and the reaction was stirred atRT for 2 hours. The reaction was dissolved into EtOAc and washed withbrine. The combined organic layers were dried (MgSO₄) followed byremoval of solvents in vacuo resulted in the title compound that wasused without further purification. ESI-MS (m/z): Calcd. forC₃₁H₃₇N₃O₇S₃: 660.2 (M+1); found: 660.8.

b)5-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-pentanoicacid

5-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-pentanoicacid methyl ester (125 mg, 0.19 mmol, Example 137: step a) and LiOH(12.5 mg, 0.54 mmol) were dissolved into MeOH (3 mL) and heated to 60°C. for 12 hours. The reaction was dissolved into EtOAc and washed with20% citric acid. The aqueous layers were acidified with acetic acid (pH3) and extracted with EtOAc. The organic layers were combined and dried(MgSO₄) followed by removal of solvents in vacuo. The resulting materialwas purified by preparative RP-HPLC (0–100% water/acetonitrile—bothsolvents were free of TFA, 45 minutes, λ=245 nm). ¹H-NMR (CDCl₃): δ7.95–7.93 (d, 1H, J=9.3 Hz), 7.81–7.78 (d, 1H, J=7.91 Hz), 7.63–7.59 (m,1H), 7.55–7.53 (t, 1H, J=8.35, Hz, J=7.59 Hz), 7.38–7.36 (d, 1H, J=9.35Hz), 7.25–7.21 (m, 1H), 7.07–7.05 (d, 1H, J=7.07 Hz), 6.78 (s, 1H), 3.55(s, 2H), 2.51 (s, 3H), 2.15–2.12 (m, 2H), 1.96–1.95 (m, 2H), 1.93 (s,3H).

c)5-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-pentanoicacid trifluoroacetate

5-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-pentanoicacid (Example 137: step b) was deprotected and purified as in Example 1:step d, yielding the title compound as a white glass. ¹H-NMR (CD₃OD): δ8.29 (s, 1H), 8.06–8.04 (m, 1H), 7.89 (s, 1H), 7.68 (t, 1H, J=7.67 Hz,J=8.84 Hz), 7.54–7.52 (d, 1H, J=7.91 Hz), 7.38–7.29 (m, 2H), 7.18–7.16(d, 1H, J=7.67 Hz), 2.75 (s, 3H), 2.11–2.09 (m, 2H), 2.08 (s, 3H),2.03–1.91 (m, 2H), 1.27–1.08 (m, 4H). ESI-MS (m/z): Calcd. forC₂₅H₂₇N₃O₅S₃: 546.1 (M+1); found: 546.1.

Example 1384-[3-(3-Methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 4-Bromo-3-methyl-pyridin-1-ol

Acetyl bromide (5 mL) was cooled to 0° C. To this was added4-Nitro-3-methyl-pyridin-1-ol (1000 mg, 6.48 mmol) portionwise whilemaintaining temperature. After the addition was complete, the reactionwas heated to 50° C. and stirred for 2 hours. The reaction was thencooled to 0° C., quenched with ice and neutralized with solid Na₂CO₃(pH=8). The neutral aqueous reaction mixture was extracted into DCM. Theorganic layer was dried (MgSO₄), the solvents were removed in vacuoresulting in the title compound as a yellow solid (1.05 mg, 86%). ESI-MS(m/z): Calcd. for C₆H₆BrNO: 188.0 (M+1); found: 188.0.

b) 4-Bromo-3-methyl-pyridine

4-Bromo-3-methyl-pyridin-1-ol (1050 mg, 5.6 mmol, Example 138: step a)was dissolved into DCM (10 mL) and cooled to −20° C. To this was slowlyadded PCl₃ and the reaction was stirred at −20° C. for 15 minutes. Thereaction was then warmed to RT for 15 minutes. The reaction was thenquenched with water (5 mL) after cooling back to −20° C. The reactionwas then warmed to RT and quenched with NaOH (246 mg, 1.1 mmol) in water(5 mL). The reaction mixture was separated and the organic layers werewashed with brine. The water layer was adjusted with 10N NaOH to pH=10.The aqueous layer was then extracted with DCM and EtOAc, all organiclayers were combined and dried with (MgSO₄) and the solvents wereremoved in vacuo. ¹H-NMR (CDCl₃): δ 8.26 (s, 1H), 8.08–8.06 (d, 1H,J=5.14 Hz), 7.30–7.29 (d, 1H, J=5.35 Hz), 2.21 (s, 3H).

c)(Imino-{4-[3-(3-methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

4-Bromo-3-methyl-pyridine (100 mg, 0.219 mmol, Example 138: step b),{[4-(3-Boranyl-dihydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (266 mg, 0.58 mmol, Example 140: step a) andPd(PPh₃)₄ (134 mg, 0.12 mmol) were combined in aqueous Na₂CO₃ (2M, 2mL), ethanol (2 mL) and toluene (4 mL) and heated to 80° C. overnight.The reaction mixture was dissolved into EtOAc and washed with brine. Theorganic layers were dried (MgSO₄) and the solvent was removed in vacuo.Purification by flash column chromatography (10% DCM/MeOH) afforded thetitle compound (120 mg, 410%). ESI-MS (m/z): Calcd. for C₂₃H₂₅N₃O₄S₃:504.1 (M+1); found: 503.7.

d)4-[3-(3-Methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

(Imino-{4-[3-(3-methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (Example 138: step c) was deprotected and purifiedas in Example 1: step d, yielding the title compound as a white glass.¹H-NMR (CD₃OD): δ 8.85 (s, 1H), 8.78–8.76 (d, 1H, J=5.78 Hz), 8.38 (s,1H), 8.24–8.21 (m, 2H), 7.92–7.84 (m, 3H), 2.75 (s, 3H), 2.47 (s, 3H).ESI-MS (m/z): Calcd. for C₁₈H₁₇N₃O₂S₃: 404.1 (M+1); found: 404.1.

Example 1394-[3-(3-Amino-5-methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) (5-Methyl-pyridin-3-yl)-carbamic acid tert-butyl ester

5-Methyl-nicotinic acid (2 g, 14.6 mmol) was dissolved into t-Butanol(59 mL). To this was added N,N-Diisopropylethylamine (7.6 mL, 43.8 mmol)and diphenylphosphoryl azide (3.8 mL, 17.5 mmol). The reaction washeated to 80° C. overnight in a flask fitted with septa and argon gasline. The solvents were evaporated in vacuo and the resulting residuewas dissolved into EtOAc, washed with saturated NaHCO₃ and water. Thecombined organic layers were dried (MgSO₄) and the solvents were removedin vacuo. The residue was purified by flash column chromatography (SiO₂)(50% EtOAc in hexanes) that yielded the title compound as a white solid(2.03 g, 67%). ¹H-NMR (CDCl₃): δ 8.22 (m, 1H), 8.14 (m, 1H), 7.88 (br s,1H), 6.58 (br s, 1H), 2.34 (s, 3H), 1.55 (s, 9H).

b) (4-Iodo-5-methyl-pyridin-3-yl)-carbamic acid tert-butyl ester

(5-Methyl-pyridin-3-yl)-carbamic acid tert-butyl ester (255 mg, 1.2mmol, Example 139: step a) and trimethylethylenediamine (905 μL, 6.0mmol) were dissolved into THF (4 mL) and cooled to −78° C. To this wasadded n-Butyllithium (2.5M, 2.4 mL, 6.0 mmol). The reaction was stirredat −78° C. for 30 minutes and then warmed to RT for 30 minutes. Iodine(1.5 g, 6.0 mmol) was dissolved into THF (4 mL) and added to thereaction mixture at −78° C. slowly. The reaction was warmed to RT for 1hour and the solvents were removed in vacuo. The residue was dissolvedinto EtOAc and washed with brine and water. The combined organic layerswere dried (MgSO₄) and solvents were removed in vacuo followed bypurification by flash column chromatography (SiO₂) (50% EtOAc inhexanes) that yielded the title compound as a yellow solid (55 mg, 14%).¹H-NMR (CDCl₃): δ 8.91 (s, 1H), 8.07 (s, 1H), 6.81 (br s, 1H), 2.44 (s,3H), 1.56 (s, 9H). ESI-MS (m/z): Calcd. for C₁₁H₁₅IN₂O₂: 335.0 (M+1);found: 334.9.

c)({4-[3-(3-Amino-5-methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

(4-Iodo-5-methyl-pyridin-3-yl)-carbamic acid tert-butyl ester (106 mg,0.32 mmol, Example 139: step b),{[4-(3-Boranyl-dihydroxy-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (145 mg, 0.32 mmol, Example 140: step a) andPd(PPh₃)₄ (74 mg, 0.06 mmol) were combined in aqueous Na₂CO₃ (2M, 1.2mL), ethanol (1.2 mL) and toluene (2.4 mL) and was heated to 80° C.overnight. The reaction mixture was dissolved into EtOAc and washed withbrine. The organic layers were dried MgSO₄) and solvents were removed invacuo. Purification by flash column chromatography (40% EtOAc/hexanes)afforded the title compound. ESI-MS (m/z): Calcd. for C₂₈H₃₄N₄O₆S₃:619.2 (M+1); found: 618.8.

d)4-[3-(3-Amino-5-methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

({4-[3-(3-Amino-5-methyl-pyridin-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (Example 139: step c) was deprotected and purifiedas in Example 1: step d, yielding the title compound as a white solid.¹H-NMR (CD₃OD): δ 8.37 (s, 1H), 8.18–8.16 (d, 1H, J=8.84 Hz), 8.06–8.05(m, 2H), 7.99 (s, 1H), 7.87 (t, 1H, J=7.67 Hz, J=7.44 Hz), 7.71–7.68 (d,1H, J=7.67 Hz), 2.73 (s, 3H), 2.09 (s, 3H). ESI-MS (m/z): Calcd. forC₁₈H₁₈N₄O₂S₃: 419.1 (M+1); found: 419.1

Example 1404-[3-(2,5-Dimethyl-1H-imidazol-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(3-Dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester.

A solution of 2M i-PrMgCl in THF (1.1 mL, 2.2 mmol) was added dropwiseat 0° C. to{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.5 g, 1.0 mmol) (Example 27c) in 5.0 mL THF. Thesolution was stirred for 20 mins at 0° C., then cooled to −78° C. and asolution of 2.5 M n-BuLi in hexanes (0.6 mL, 1.5 mmol) was added. Themixture was stirred for 5 mins then trimethylborate (0.35 mL, 3.3 mmol)was added at −78° C. and the mixture allowed to attain RT. The reactionwas quenched with sat. NH₄Cl (10 mL) and extracted with EtOAc (3×20 mL),dried over Na₂SO₄ and evaporated. The crude solid was purified byelution from a 5 g SPE with 10% MeOH/DCM to give 0.45 g (95%) of thetitle compound as a yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 8.28 (m,1H), 8.05 (m, 1H), 7.95 (m, 1H), 7.60 (m, 2H), 2.66 (s, 3H), 1.51 (s,9H). Mass spectrum (ESI, m/z) calcd. for C₁₇H₂₁BN₂O₆S₃ 456.1, found456.7 (M+H).

General Procedure for Suzuki Coupling:

To a flask charged with 0.50 g (1.1 mmol) of{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester, 0.22 g (1 mmol) of5-iodo-2,4-dimethyl-1H-imidazole and 0.006 g of Pd(PPh₃)₄ (5 mol %) isadded 8 ml of toluene, 4 mL of EtOH, and 4 mL of 2 M Na₂CO₃. The mixtureis backfilled with argon and then heated at 80° C. for 4 hrs. Themixture is diluted with water (10 mL) and the product extracted withEtOAc (3×10 mL), dried (Na₂SO₄), filtered and evaporated. The crudeproduct is purified by flash chromatography to give the title compoundas a BOC-protected amidine. The BOC-protected amidine is stirred at 25°C. for 1 hr in 2 mL of 50% TFA/DCM, and then the solvents are evaporatedand the crude product purified by RP-HPLC, eluting with a lineargradient of 10% CH₃CN to 50% CH₃CN in 0.1% TFA/H₂O over 30 mins to give0.39 g (75%) of the title compound as a yellow solid: ¹H NMR (400 MHz,CD₃OD) δ 8.37 (s, 1H), 8.25 (m, 1H), 8.14 (m, 2H), 7.88 (m, 1H), 7.63(s, 1H), 2.74 (s, 3H), 2.68 (s, 3H), 2.49 (s, 3H). Mass spectrum (ESI,m/z) calcd. for C₁₇H₁₈N₄O₂S₃ 406.1, found 407.1 (M+H).

Example 1414-[3-(3-Methyl-3H-imidazol4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Prepared according to the general procedure in Example 140. ¹H NMR (400MHz, CD₃OD) δ 9.08 (s, 1H), 8.38 (s, 1H), 8.29 (m, 1H), 8.24 (m, 1H),7.96 (m, 1H), 7.85 (m, 1H), 7.81 (s, 1H), 3.92 (s, 3H), 2.75 (s, 3H).Mass spectrum (ESI, m/z) calcd. for C₁₆H₁₆N₄O₂S₃ 392.1, found 393.1(M+H).

Example 1424-[3-(1-Methyl-1H-imidazol-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Prepared according to the general procedure in Example 140. ¹H NMR (400MHz, CD₃OD) δ 8.37 (s, 1H), 8.25 (m, 1H), 8.14 (m, 1H), 7.91 (m, 1H),7.81 (m, 1H), 2.74 (s, 3H), 2.68 (s, 3H), 2.49 (s, 3H). Mass spectrum(ESI, m/z) calcd. for C₁₆H₁₆N₄O₂S₃ 392.1, found 393.1 (M+H).

Example 1434-[3-(1-Methyl-1H-benzoimidazol-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(3-Formyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

A solution of 2 M i-PrMgCl in THF (1.1 mL, 2.2 mmol) was added dropwiseat 0° C. to{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.5 g, 1.0 mmol) (Example 27c) in 5.0 mL THF. Thesolution was stirred for 20 mins at 0° C., then cooled to −78° C. and asolution of 2.5 M n-BuLi in hexanes (0.6 mL, 1.5 mmol) was added. Themixture was stirred for 5 mins then N,N-dimethylformamide (0.30 mL, 3.8mmol) was added at −78° C. and the mixture allowed to attain RT. Thereaction was quenched with sat. NH₄Cl (10 mL) and extracted with EtOAc(3×20 mL), dried over Na₂SO₄ and evaporated. The crude solid waspurified by elution from a 20 g SPE with 50% EtOAc/hex to give 0.33 g(75%) of the title compound as a yellow solid: ¹H NMR (400 MHz, CDCl₃) δ10.06 (s, 1H), 8.48 (s, 1H), 8.26 (m, 1H), 8.10 (m, 1H), 8.06 (s, 1H),7.71 (s, 1H), 2.50 (s, 3H), 1.51 (s, 9H). Mass spectrum (ESI, m/z)calcd. for C₁₈H₂₀N₂O₅S₃ 440.1, found 440.8 (M+H).

The above aldehyde (0.026 g, 0.06 mmol) andN-methyl-1,2-phenylenediamine (0.014 g, 0.12 mmol) in 0.2 mL of ethanolwas heated at 80° C. for 12 hours. The solvent was evaporated and theresidue taken up in 1 mL of 50% TFA/DCM and stirred for 30 mins at 25°C. The solvent was evaporated and the crude product purified by RP-HPLC,eluting with a linear gradient of 10% CH₃CN in 0.1% TFA/H₂O to 50% CH₃CNover 30 mins, to give 0.028 g (87%) of the title compound as red solid:¹H NMR (400 MHz, CD₃OD) δ 8.62 (m, 1H), 8.45 (m, 1H), 8.41 (s, 1H), 8.28(m, 1H), 8.03 (m, 1H), 8.00 (m, 1H), 7.90 (m, 1H), 7.75 (m, 2H), 4.13(s, 3H), 2.76 (s, 3H). Mass spectrum (ESI, m/z) calcd. for C₂₀H₁₈N₄O₂S₃442.1, found 443.1 (M+H).

Example 1444-[3-(1H-Benzoimidazol-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

This compound was prepared according to Example 143 using1,2-phenylenediamine. ¹H NMR (400 MHz, CD₃OD) δ 8.85 (m, 1H), 8.44 (m,1H), 8.42 (s, 1H), 8.33 (m, 1H), 7.95 (m, 1H), 7.82 (m, 2H), 7.56 (m,2H), 2.74 (s, 3H). Mass spectrum (ESI, m/z) calcd. for C₁₉H₁₆N₄O₂S₃428.0, found 429.1 (M+H).

Example 1454-[3-(1-Ethyl-1H-benzoimidazol-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A mixture containing({4-[3-(1H-benzoimidazol-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (prepared in Example 144) (25 mg, 0.05 mmol),K₂CO₃ (13 mg, 0.10 mmol), and iodoethane (12 mg, 0.08 mmol) in 0.5 mLacetone was heated to 60° C. for 2 hrs. The mixture was filtered thenconcentrated, and the residue dissolved in 0.5 ml of 50% TFA/DCM andstirred at 25° C. for 30 mins. The solvent was evaporated and the crudeproduct purified by RP-HPLC, eluting with a linear gradient of 10% CH₃CNin 0.1% TFA/H₂O to 50% CH₃CN over 30 mins, to give 26 mg (93%) of thetitle compound as yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 8.58 (m, 1H),8.44 (m, 1H), 8.41 (s, 1H), 8.20 (m, 1H), 8.02 (m, 2H), 7.90 (m, 1H),7.71 (m, 2H), 4.55 (q, 2H), 2.75 (s, 3H), 1.59 (t, 3H). Mass spectrum(ESI, m/z) calcd. for C₂₁H₂₀N₄O₂S₃ 456.1, found 457.1 (M+H).

Example 1463-{2-[3-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-phenyl]-benzoimidazol-1-yl}-propane-1-sulfonicacid trifluoroacetate

This compound was prepared in a similar manner to Example 145 using1,3-propane sultone in DMF. ¹H NMR (400 MHz, CD₃OD) δ 8.58 (m, 1H), 8.43(m, 1H), 8.36 (s, 1H), 8.25 (m, 1H), 8.10 (m, 1H), 8.00 (m, 1H), 7.88(m, 1H), 7.71 (m, 2H), 4.72 (t, 2H), 2.79 (t, cH), 2.77 (s, 3H), 2.32(m, 2H). Mass spectrum (ESI, m/z) calcd. for C₂₂H₂₂N₄O₅S₄ 550.1, found550.1 (M+H).

Example 1474-[3-(Hydroxy-pyridin-2-yl-methyl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of 2 M i-PrMgCl in THF (0.16 mL, 0.36 mmol) was addeddropwise at 0° C. to{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.08 g, 0.16 mmol) (Example 27c) in 0.75 mL THF.The solution was stirred for 20 mins at 0° C., then cooled to −78° C.and a solution of 2.5 M n-BuLi in hexanes (0.084 mL, 0.21 mmol) wasadded. The mixture was stirred for 5 mins then 2-pyridinecarboxyaldehyde(0.023 mL, 0.24 mmol) was added at −78° C. and the mixture allowed toattain RT. The reaction was quenched with sat. NH₄Cl (5 mL) andextracted with EtOAc (3×10 mL), dried over Na₂SO₄ and evaporated. Thecrude solid was purified by flash chromatography to give the titlecompound as a BOC-protected amidine, which was deprotected in 2 mL of50% TFA/DCM (25° C., 1 hr) to give 0.035 g (40%) of the title compoundas a yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 8.79 (m, 1H), 8.53 (m, 1H),8.33 (s, 1H), 8.24 (m, 1H), 7.97 (m, 3H), 7.86 (m, 1H), 7.67 (m, 1H),6.32 (s, 1H), 2.50 (s, 3H). Mass spectrum (ESI, m/z) calcd. forC₁₈H₁₇N₃O₃S₃ 419.0, found 420.0 (M+H).

Example 1484-[3-(4-Hydroxy-1-methyl-piperidin4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Prepared in a similar manner to Example 147 using 1-methyl-4-piperdone.¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 8.28 (m, 1H), 7.96 (m, 1H), 7.84(m, 1H), 7.66 (m, 1H), 3.48 (m, 4H), 2.96 (s, 3H), 2.73 (s, 3H), 2.38(m, 2H), 1.98 (m, 2H). Mass spectrum (ESI, m/z) calcd. for C₁₈H₂₃N₃O₃S₃425.1, found 426.1 (M+H).

Example 1494-[3-(4-Hydroxy-tetrahydro-pyran-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Prepared in a similar manner to Example 147 usingtetrahydro-4H-pyran-4-one. ¹H NMR (400 MHz, CD₃OD) δ 8.30 (s, 1H), 8.24(m, 1H), 7.92 (m, 1H), 7.83 (m, 1H), 7.60 (m, 1H), 3.88 (m, 4H), 2.71(s, 3H), 2.12 (m, 2H), 1.63 (m, 2H). Mass spectrum (ESI, m/z) calcd. forC₁₇H₂₀N₂O₄S₃ 412.1, found 413.0 (M+H).

Example 1504-[3-(4-Methoxy-tetrahydro-pyran-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a solution of the BOC-protected amidine (46 mg, 0.09 mmol) (preparedin example 149) in 0.2 mL of DMF at 25° C. was added NaH (60% oildispersion, 5.7 mg, 0.14 mmol). The reaction was allowed to stir for 20mins then iodomethane (6 uL, 0.09 mmol) was added and the reactionstirred for additional 12 hrs. The solvent was evaporated and the crudematerial purified by flash chromatography to give the title compound asa BOC protected amidine, which was deprotected in 2 mL of 50% TFA/DCM(25° C., 1 hr) to give the title compound (11.5 mg, 20%) as a yellowsolid: ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 8.14 (m, 1H), 7.92 (m,1H), 7.80 (m, 1H), 7.66 (m, 1H), 3.89 (m, 4H), 3.00 (s, 3H), 2.74 (s,3H), 2.02 (m, 4H). Mass spectrum (ESI, m/z) calcd. for C₁₈H₂₂N₂O₄S₃426.1, found 427.1 (M+H).

Example 1514-(3-Furan-2-yl-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution containing 50 mg (0.10 mmol) of{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (prepared in Example 27c), 54 mg (0.15 mmol) of2-tributylstannylfuran, and 12 mg (10 mol %) of Pd(PPh₃)₄ in 0.5 mL ofTHF was heated at 80° C. under Argon for 10 hrs. The reaction wasquenched with NH₄Ac (5 mL), extracted with EtOAc (3×5 mL), dried overNa₂SO₄ and concentrated under reduced pressure. The crude material wasstirred in 1 mL of 50% TFA/DCM for 1 hr at 25° C. and then concentratedand purified by RP-HPLC to give 19 mg (50%) of the title compound as ayellow solid: ¹H NMR (400 MHz, CD₃OD) δ 8.35 (s, 1H), 8.32 (m, 1H), 8.01(m, 1H), 7.90 (m, 1H), 7.66 (m, 1H), 7.65 (m, 1H), 6.98 (m, 1H), 6.60(m, 1H), 2.75 (s, 3H). Mass spectrum (ESI, m/z) calcd. for C₁₆H₁₄N₂O₃S₃378.0, found 379.1 (M+H).

Example 1523-[3-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-phenyl]-but-2-enoicacid ethyl ester trifluoroacetate

a)Imino-[5-methylsulfanyl-4-(3-tributylstannanyl-benzenesulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

A solution of 2 M i-PrMgCl in THF (1.1 mL, 2.2 mmol) was added dropwiseat 0° C. to{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.5 g, 1.0 mmol) (Example 27c) in 5.0 mL THF. Thesolution was stirred for 20 mins at 0° C., then cooled to −78° C. and asolution of 2.5 M n-BuLi in hexanes (0.6 mL, 1.5 mmol) was added. Themixture was stirred for 5 mins then tributyltin chloride (0.65 g, 2.0mmol) was added at −78° C. and the mixture allowed to attain RT. Thereaction was quenched with sat. NH₄Cl (10 mL) and extracted with EtOAc(3×20 mL), dried over Na₂SO₄ and evaporated. The crude solid waspurified by flash chromatography to give 0.35 g (50%) of the titlecompound as a yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 8.14 (m, 1H), 8.00(s, 1H), 7.87 (m, 1H), 7.71 (m, 1H), 7.46 (m, 1H), 2.59 (s, 3H), 1.53(s, 9H), 1.51 (m, 6H), 1.34 (m, 6H), 1.11 (m, 6H), 0.89 (m, 9H). Massspectrum (ESI, m/z) calcd. for C₂₉H₄₆N₂O₄S₃Sn 702.2, found 702.7 (M+H).

A mixture containing 42 mg (0.06 mmol) of{imino-[5-methylsulfanyl-4-(3-tributylstannanyl-benzenesulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester, 21 mg (0.09 mmol) of ethyl cis-3-iodocrotonate, 3mg (5 mol %) of Pd(PPh₃)₄ and 1 mg (10 mol %) of CuI in 0.3 mL of DMFwas heated under argon at 100° C. for 12 hrs. The DMF was evaporated andthe crude material stirred in 1 mL of 50% TFA/DCM for 1 hr at 25° C. Thesolvents were evaporated and the crude product was purified by RP-HPLCto give 7 mg (23%) of the title compound as a yellow solid: ¹H NMR (400MHz, CD₃OD) δ 8.30 (s, 1H), 8.02 (m, 1H), 7.88 (m, 1H), 7.61 (m, 2H),6.05 (s, 1H), 3.90 (q, 3H), 2.78 (s, 3H), 2.22 (s, 3H), 1.02 (t, 3H).Mass spectrum (ESI, m/z) calcd. for C₁₈H₂₀N₂O₄S₃ 424.1, found 425.1(M+H).

Example 1534-[3-(1H-Imidazol-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A mixture containing 20 mg (0.04 mmol) of{[4-(3-formyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 143a), 10 uL (0.06 mmol) of 40% aqueousglyoxal, and 65 mg (0.84 mmol) of NH₄Ac was heated at 80° C. for 12 hrsin methanol. The solvents were evaporated and the residue stirred in 1mL of 50% TFA/DCM for 1 hr at 25° C. The solvents were again evaporatedand the crude material purified by RP-HPLC to give 4 mg (18%) of thetitle compound as a yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 8.64 (m,1H), 8.39 (s, 1H), 8.24 (m, 2H), 7.88 (m, 1H), 7.63 (s, 1H), 2.73 (s,3H). Mass spectrum (ESI, m/z) calcd. for C₁₅H₁₄N₄O₂S₃ 378.0, found 379.1(M+H).

Example 154N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-2-yl]-acetamidetrifluoroacetate

A solution containing 30 mg (0.06 mmol) of{[4-(2′-amino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (prepared according to the general procedure forSuzuki coupling in Example 140 using 2-aminophenyl boronic acid), 10 mg(0.09 mmol) of 2,6-lutidine, and 7 mg (0.07 mmol) of acetic anhydridewas stirred in 2 mL of DCM at 25° C. for 12 hrs. The crude material waspurified by flash chromatograpy to give the title compound as a BOCprotected amidine which was deprotected by stirring at 25° C. for 1 hrin 1 mL of 50% TFA/DCM. The solvent was evaporated and the crudematerial purified by RP-HPLC to give 20 mg (60%) of the title compoundas a yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 8.31 (s, 1H), 8.18 (m, 1H),8.07 (m, 1H), 7.76 (m, 1H), 7.71 (s, 1H), 7.47 (m, 4H), 2.82 (s, 3H),2.74 (s, 3H). Mass spectrum (ESI, m/z) calcd. for C₂₀H₁₉N₃O₃S₃ 445.1,found 446.1 (M+H).

Example 1554-(2′-Methanesulfonylamino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution containing 30 mg (0.06 mmol) of{[4-(2′-amino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (prepared according to the general procedure forSuzuki coupling in Example 140 using 2-aminophenyl boronic acid), 10 mg(0.09 mmol) of 2,6-lutidine, and 8 mg (0.07 mmol) of methanesulfonylchloride was stirred in 2 mL of DCM at 25° C. for 12 hrs. The crudematerial was purified by flash chromatograpy to give the title compoundas a BOC protected amidine which was deprotected by stirring at 25° C.for 1 hr in 1 mL of 50% TFA/DCM. The solvent was evaporated and thecrude material purified by RP-HPLC to give 25 mg (70%) of the titlecompound as a yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 8.29 (s, 1H), 8.06(m, 1H), 8.03 (m, 1H), 7.73 (m, 2H), 7.42 (m, 4H), 2.73 (s, 3H), 1.96(s, 3H). Mass spectrum (ESI, m/z) calcd. for C₁₉H₁₉N₃O₄S₄ 481.0, found482.1 (M+H).

Example 1564-[5-Bromo-6-(3-imidazol-1-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-[5-Bromo-6-(3-imidazol-1-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a vial containing a stirbar was added4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.050 g, 0.113 mmol), (Example 2: step c),3-imidazol-1-yl-propylamine (0.018 g, 0.146 mmol), diisopropylethylamine(0.073 g, 0.565 mmol), THF [0.50 mL], DMF [0.50 mL]. The reaction vesselwas sealed and the solution was heated to 80° C. for 18 hours. Removalof the solvents in vacuo followed by chromatography (5% MeOH/DCM)yielded the title compound. ¹H-NMR (CDCl₃): δ 8.69 (d, 1H, J=2.1 Hz),8.10 (d, 1H J=2.1 Hz), 8.03 (s, 1H), 8.02 (s, 1H), 7.57 (s, 1H), 7.10(s, 1H), 6.97 (s 1H), 5.70 (t, 1H, J=5.8 Hz), 4.06 (t, 2H, J=6.8 Hz),3.89 (s, 3H), 3.57 (m, 2H), 2.97 (s, 2H), 2.90 (s, 2H), 2.64 (s, 3H),2.17 (m, 2H). ESI-MS (m/z): Calcd. For C₁₈H₁₉BrN₄O₄S₃: 532.5 (M+H);found 530.9, 532.9.

b)4-[5-Bromo-6-(3-imidazol-1-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Trimethyl aluminum [2M in toluene], (1.12 mL, 2.26 mmol) was addedslowly to a flask containing a stirbar and ammonium chloride (0.120 g,2.26 mmol). This solution was placed in a 90° C. oil bath for 5 minutesunder argon. Solution was allowed to cool to room temperature. Thissolution was then added to4-[5-Bromo-6-(3-imidazol-1-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (100 mg, 0.22 mmol) which was dissolved in toluene [2mL]. Reaction was heated at 80° C. for two hours. Reaction was added toa slurry of silica gel in DCM. The slurry was filtered using 15%MeOH/DCM. Removal of the solvents in vacuo followed by reverse-phaseHPLC of the residue [acetonitrile/water (0.01% TFA)] yielded the titlecompound. ¹H-NMR (MeOH): δ 8.96 (s, 1H), 8.62 (d, 1H, J=2.0 Hz), 8.26(s, 1H), 8.12 (d, 1H, J=2.3 Hz), 7.68 (t, 1H, J=1.7 Hz), 7.56 (t, 1H,J=1.6 Hz), 4.32 (t, 2H, J=7.2 Hz), 3.60 (t, 2H, J=6.7 Hz), 2.72 (s, 3H),2.24 (m, 2H). ESI-MS (m/z): Calcd. For C₁₇H₁₉BrN₆O₂S₃: 515.47 (M+H);found 515.1, 517.0.

Example 1574-[5-Bromo-6-(2-methyl-2-morpholin-4-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-[5-Bromo-6-(2-methyl-2-morpholin-4-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The reaction was conducted following the procedure for Example 156: stepa, using4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.050 g, 0.113 mmol), (Example 2: step c),2-methyl-2-morpholin-4-yl-propylamine (0.023 g, 0.146 mmol),diisopropylethylamine (0.073 g, 0.565 mmol), THF [0.5 mL], DMF [0.5 mL].Chromatography of the residue (25%–50% EtOAc/Hx) yielded the titlecompound. ¹H-NMR (CDCl₃): δ 8.70 (d, 1H, J=2.1 Hz), 8.08 (d, 1H, J=2.1Hz), 8.02 (s, 1H), 6.82 (t, 1H, J=4.1), 3.90 (s, 3H), 3.76 (t, 4H,J=4.1), 3.37 (d, 2H, J=4.1), 2.64 (s, 3H), 2.57 (t, 4H, J=4.5), 1.59 (s,3H), 1.13 (s, 6H). ESI-MS (m/z): Calcd. For C₂₀H₂₆BrN₃O₅S₃: 565.54(M+H); found 564.0, 565.9.

b)4-[5-Bromo-6-(2-methyl-2-morpholin-4-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.194 mL, 0.389 mmol),ammonium chloride (0.021 g, 0.389 mmol),4-[5-bromo-6-(2-methyl-2-morpholin-4-yl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.022 g, 0.039 mmol), toluene [1 mL]. Reverse-phaseHPLC yielded title compound. ESI-MS (m/z): Calcd. for C₁₉H₂₆BrN₅O₃S₃:549.54 (M+H); found 547.9, 549.9.

Example 1584-{5-Bromo-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-{5-Bromo-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The reaction was conducted following the procedure for Example 156: stepa, using4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.050 g, 0.113 mmol), (Example 2: step c),3-aminomethyl-6-trifluoromethyl pyridine (0.026 g, 0.146 mmol),diisopropylethylamine (0.073 g, 0.565 mmol), THF [0.5 mL], DMF [0.5 mL].Chromatography of the residue (25%–50% EtOAc/Hx) yielded the titlecompound. ESI-MS (m/z): Calcd. For C₁₉H₁₅BrN₃O₄S₃: 583.44 (M+H); found582.0, 583.9.

b.)4-{5-Bromo-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.463 mL, 0.927 mmol),ammonium chloride (0.049 g, 0.927 mmol),4-{5-bromo-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.054 g, 0.093 mmol), toluene [1 mL]. Reverse-phaseHPLC yielded title compound. ESI-MS (m/z): Calcd. For C₁₈H₁₅BrF₃N₅O₂S₃:567.44 (M+H); found 566.0, 567.9.

Example 1594-{5-Bromo-6-[2-(3H-imidazol-4-yl)-ethylamino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-{5-Bromo-6-[2-(3H-imidazol-4-yl)-ethylamino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The reaction was conducted following the procedure for Example 156: stepa, using.4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.050 g, 0.113 mmol), (Example 2: step c),2-(3H-imidazol-4-yl)-ethylamine (0.027 g, 0.146 mmol),diisopropylethylamine (0.073 g, 0.565 mmol), THF [0.5 mL], DMF [0.5 mL].Chromatography of the residue (0%–6% MeOH/DCM) yielded the titlecompound. ESI-MS (m/z): Calcd. for C₁₇H₁₇BrN₄O₄S₃: 518.44 (M+H); found517.0, 519.

b)4-{5-Bromo-6-[2-(3H-imidazol-4-yl)-ethylamino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.773 mL, 1.546 mmol),ammonium chloride (0.082 g, 1.546 mmol),4-{5-bromo-6-[2-(3H-imidazol-4-yl)-ethylamino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.080 g, 0.155 mmol), toluene [2 mL]. HPLC yieldedtitle compound. ESI-MS (m/z): Calcd. for C₁₇H₁₇BrN₄O₄S₃: 501.45 (M+H);found 502.2, 504.2.

Example 1604-[5-Bromo-6-(4-sulfamoyl-benzylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-[5-Bromo-6-(4-sulfamoyl-benzylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The reaction was conducted following the procedure for Example 156: stepa, using.4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.050 g, 0.113 mmol), (Example 2: step c),4-aminomethyl-benzenesulfonamide (0.033 g, 0.146 mmol),diisopropylethylamine (0.073 g, 0.565 mmol), THF [0.5 mL], DMF [0.5 mL].Chromatography of the residue (0%–5% MeOH/DCM) yielded the titlecompound. ESI-MS (m/z): Calcd. for C₁₉H₁₈BrN₃O₆S₄: 592.53 (M+H); found592.0, 593.9.

b)4-[5-Bromo-6-(4-sulfamoyl-benzylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.773 mL, 1.546 mmol),ammonium chloride (0.082 g, 1.546 mmol),4-{5-bromo-6-[2-(3H-imidazol-4-yl)-ethylamino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.080 g, 0.155 mmol), toluene [2 mL]. Reverse-phaseHPLC yielded the title compound. ESI-MS (m/z): Calcd. forC₁₇H₁₇BrN₄O₄S₃: 501.45 (M+H); found 502.2, 504.2.

Example 1614-(6-Benzylamino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(6-Benzylamino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a vial containing a stirbar was added4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.020 g, 0.045 mmol), (Example 2: step c),benzylamine (0.005 g, 0.407 mmol), MeOH [2.0 mL]. Reaction vessel wassealed and heated to 50° C. for 72 hours. Removal of the solvents invacuo followed by chromatography of the residue (10%–20% EtOAc/Hx)yielded the title compound. ESI-MS (m/z): Calcd. for C₁₉H₁₇BrN₂O₄S₃:514.45 (M+H); found 513.2, 515.1.

b)4-(6-Benzylamino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.120 mL, 0.253 mmol),ammonium chloride (0.014 g, 0.253 mmol),4-(6-Benzylamino-5-bromo-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.013 g, 0.0253 mmol), toluene [2 mL]. Reverse-phaseHPLC yielded title compound. ESI-MS (m/z): Calcd. for C₁₉H₁₈BrN₃O₂S₃:497.47 (M+H); found 497.3, 499.1.

Example 1624-(5-Bromo-6-isobutylamino-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(5-Bromo-6-isopropylamino-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a vial containing a stirbar was added4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.100 g, 0.226 mmol), (Example 2: step c),isopropylamine (0.012 g, 0.204 mmol), THF [2.0 mL]. Reaction vessel wassealed and heated to 70° C. for 72 hours. Removal of the solvents invacuo followed by chromatography (0%–15% EtOAc/Hx) yielded the titlecompound. ESI-MS (m/z): Calcd. for C₁₅H₁₇BrN₂O₄S₃: 466.41 (M+H); found466.9.

b)4-(5-Bromo-6-isobutylamino-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.620 mL, 1.247 mmol),ammonium chloride (0.067 g, 1.247 mmol),4-(5-bromo-6-isopropylamino-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.058 g, 0.125 mmol), toluene [2 mL]. Reverse-phaseHPLC yielded title compound. ESI-MS (m/z): Calcd. for C₁₄H₁₇BrN₄O₂S₃:450.41 (M+H); found 449.1, 451.0.

Example 1634-{5-Bromo-6-[(pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-{5-Bromo-6-[(pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The reaction was conducted following the procedure for Example 162: stepa, using4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.100 g, 0.226 mmol), (Example 2: step c),3-aminomethyl pyridine (0.046 g, 0.430 mmol), THF [4.0 mL].Chromatography of the residue (25%–50% EtOAc/Hx) yielded the titlecompound. ESI-MS (m/z): Calcd. for C₁₈H₁₆BrN₃O₄S₃: 515.44 (M+H); found514.1, 516.0.

b)4-{5-Bromo-6-[(pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.710 mL, 1.439 mmol),ammonium chloride (0.077 g, 1.439 mmol)4-{5-Bromo-6-[(pyridin-3-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.074 g, 0.1439 mmol), toluene [2 mL]. Reverse-phaseHPLC yielded title compound. ESI-MS (m/z): Calcd. for C₁₇H₁₆BrN₅O₂S₃:499.44 (M+H); found 499.1, 501.0.

Example 1644-{5-Bromo-6-[(pyridin-4-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

Trimethyl aluminum [2M in toluene], (0.850 mL, 1.694 mmol) was addedslowly to a flask containing ammonium chloride (0.091 g, 1.694 mmol) anda stir bar. This solution was placed in a 90° C. oil bath for 5 minutesunder argon. Solution was then allowed to cool to room temperature. Thissolution was then added4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.075 g, 0.1694 mmol), (Example 2: step c), which wasdissolved in toluene [1 mL]. Reaction was heated at 80° C. for twohours. Reaction was added to a slurry of silica gel in DCM. The slurrywas filtered using 15% MeOH/DCM. Used crude material in next step.ESI-MS (m/z): Calcd. for C₁₁H₉BrClN₃O₂S₃: 427.76 (M+H); found 426.0,428.0.

b){[4-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

To a flask containing a stir bar was added4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-ethylsulfanyl-thiophene-2-carboxamidine(0.96 g, 2.25 mmol), di-tert-butyl dicarbonate (0.74 g, 3.39 mmol),diisopropylamine (1.16 g, 9.03 mmol), DMF (60.0 mL). Solution wasstirred at room temperature for 18 hours. Removal of the solvents invacuo followed by chromatography (10%–15% EtOAc/Hx). Compound containedresidual di-tert-butyl dicarbonate. Compound was dissolved in hexane,heated to 40° C. for 1 hour. Solution was filtered to yield titlecompound. ESI-MS (m/z): Calcd. for C₁₁H₉BrClN₃O₂S₃: 527.76 (M+H); found426.0, 428.0.

c)[(4-{5-Bromo-6-[(pyridin-4-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester

To a vessel containing a stir bar was added{[4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.035 g, 0.066 mmol), 4-aminomethylpyridine(0.015 g, 0.133 mmol), THF [3 mL]. The reaction vessel was sealed andheated to 70° C. for 18 hours, cooled to room temperature andconcentrated in vacuo. The crude residue was dissolved in a solution ofchloroform/trifluoroacetic acid (1/1) [2 mL] and was allowed to stir atroom temperature for 2 hours. The reaction was concentrated in vacuofollowed by reverse-phase HPLC [acetonitrile/water (0.01% TFA)] to givethe title compound. ESI-MS (m/z): Calcd. for C₁₇H₁₆BrN₅O₂S₃: 499.44(M+H); found 498.0, 500.0.

Example 1654-{5-Bromo-6-[(pyridin-2-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-{5-Bromo-6-[(pyridin-2-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 164: stepc, using{[4-(5-bromo-6-chloropyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.035 g, 0.066 mmol), (example 164: step b),2-aminomethylpyridine (0.014 g, 0.133 mmol), THF [3 mL], followed bychloroform/TFA (1:1) to yield the title compound. ESI-MS (m/z): Calcd.for C₁₇H₁₆BrN₅O₂S₃: 499.44 (M+H); found 499.1, 501.0.

Example 1664-{6-[(4-Amino-pyrimidin-5-ylmethyl)-amino]-5-bromo-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 164: stepc, using{[4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.035 g, 0.067 mmol),4-amino-5-aminomethyl-2-methylpyrimidine (0.018 g, 0.135 mmol), THF [2mL], followed by DCM/TFA (1:1) and reverse-phase HPLC to yield the titlecompound. ESI-MS (m/z): Calcd. for C₁₈H₁₉BrN₆O₂S₃: 528.48 (M+H); found528.0, 529.9.

Example 1674-[5-Bromo-6-(3-hydroxy-2,2-dimethyl-propylamino)-pyridine-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 164: stepc, using{[4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.035 g, 0.066 mmol),3-amino-2,2-dimethylpropanol (0.013 g, 0.133 mmol), THF [2 mL], followedby DCM/TFA (1:1) and reverse-phase HPLC to yield the title compound.ESI-MS (m/z): Calcd. for C₁₇H₂₂BrN₃O₃S₃: 493.48 (M+H); found 493.1,495.0.

Example 1684-{5-Bromo-6-[(3-methyl-thiophen-2-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a vessel containing a stir bar was added{[4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.035 g, 0.066 mmol),3-methylthiophene-2-methylamine (0.016 g, 0.133 mmol), THF [2 mL]. Thereaction vessel was sealed and heated to 70° C. for 18 hours, cooled toroom temperature and concentrated in vacuo. Chromatography of crudematerial (10%–25% EtOAC/Hx) yielded the intermediate which was dissolvedin a solution of chloroform/trifluoroacetic acid (1/1) [2 mL] and wasallowed to stir at room temperature for 2 hours. The reaction wasconcentrated in vacuo followed by reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to give the title compound. ESI-MS (m/z): Calcd. forC₁₈H₁₈BrN₃O₂S₄: 517.52 (M+H); found 516.9, 518.9.

Example 1694-{5-Bromo-6-[(tetrahydro-furan-2-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-{5-Bromo-6-[(tetrahydro-furan-2-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The reaction was conducted following the procedure for Example 156: stepa, using.4-(5-bromo-6-chloro-pyridine-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.050 g, 0.113 mmol), (Example 2: step c),c-(tetrahydro-furan-2-yl)-methylamine (0.015 g, 0.146 mmol),diisopropylethylamine (0.073 g, 0.565 mmol), THF [0.5 mL], DMF [0.5 mL].Chromatography of the residue (10%–35% EtOAc/Hx) yielded the titlecompound. ESI-MS (m/z): Calcd. for C₁₇H₁₉BrN₂O₅S₄: 508.45 (N+H); found507.1, 509.0

b)4-{5-Bromo-6-[(tetrahydro-furan-2-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 156: stepb, using trimethyl aluminum [2M in toluene], (0.443 mL, 0.867 mmol),ammonium chloride (0.046 g, 0.867 mmol),4-{5-bromo-6-[(tetrahydro-furan-2-ylmethyl)-amino]-pyridine-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.044 g, 0.087 mmol), toluene [1 mL]. Reverse-phaseHPLC yielded title compound. ESI-MS (m/z): Calcd. For C₁₆H₁₉BrN₄O₃S₃:492.45 (M+H); found 491.1, 493.0.

Example 1704-{4′-[N′-(4-Methanesulfonyl-butyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 2-methyl-1-(4-methanesulfonyl-butyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea

The reaction was conducted following the procedure for Example 171: stepb, using 4-methanesulfonyl-butylamine (0.058 g, 0.378 mmol),2-methyl-1-(3-methanesulfonyl-propyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea (0.100 g, 0.344 mmol), Triphenylphosphine (0.098 g,0.378 mmol), THF[6 mL]. To this was added Diisopropyl azodicarboxylate(0.076 g, 0.378 mmol). Chromatography of the residue (50% EtOAc/Hx)yielded the title compound.

b) [Imino-(4-{4′-[N′-(4-methanesulfonyl-butyl)-N′,N″-(carbamic acidtert-butylester)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester

The reaction was conducted following the procedure for Example 171: stepc, using{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.025 g, 0.480 mmol), (Example 120: step b),2-methyl-1-(4-methanesulfonyl-butyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea (0.101 g, 0.240 mmol), MeOH [2 mL), acetic acid(0.029 g, 0.480 mmol). Chromatography (10%–20% EtOAc/Hx). The compoundwas dissolved in trifluoroacetic acid/dichloromethane (1:1). [4 mL].Solvent was removed in vacuo followed by reverse-phase HPLC to yield thetitle compound. ESI-MS (m/z): Calcd. for C₂₅H₃₁N₅O₄S₄: 594.81 (M+H);found 594.1.

Example 1714-{4′-[N′-(3-Methanesulfonyl-propyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 3-Methanesulfonyl-propan-1-ol

3-bromo-propan-1-ol was dissolved in EtOH [2 mL], methane sulfinic acidwas dissolved in H₂O [2 mL]. The two solutions were added together andheated to 50° C. for 18 hours. Reaction was cooled to room temperatureand the compound was extracted with EtOAc, dried using sodium sulfate,and the solvent was removed in vacuo. Chromatography of the residue(1%–7% MeOH/DCM) yielded the title compound. ¹H-NMR (CDCl₃): δ 3.69 (m,2H), 3.14 (m, 2H), 2.91 (s, 3H), 2.02 (m, 2H).

b) 2-methyl-1-(3-methanesulfonyl-propyl)-1,3-bis(carbamicacid-tert-butyl ester)-isothiourea

Under argon, 3-methanesulfonyl-propan-1-ol (0.059 g, 0.362 mmol),2-methyl-1-(3-methanesulfonyl-propyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea (0.123 g, 0.329 mmol), Triphenylphosphine (0.112 g,0.362 mmol), THF [8 mL] was charged to a flask containing a stirbar. Tothis was added diisopropyl azodicarboxylate (0.095 g, 0.362 mmol).Reaction stirred at room temperature for 18 hours. Solvent was removedin vacuo followed by chromatography (0%–25% EtOAc/Hx) to yield titlecompound (0.089 g). ¹H-NMR (CDCl₃): δ 3.75 (t, 2H, J=6.7 Hz), 3.14 (m,2H), 2.94 (s, 3H), 2.42 (s, 3H), 2.20 (m, 2H), 1.52 (s, 9H), 1.50 (s,9H).

c) [Imino-(4-{4′-[N′-(3-methanesulfonyl-propyl)-N′,N″-(carbamic acidtert-butylester)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester

2-methyl-1-(3-methanesulfonyl-propyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea (0.089 g, 0.217 mmol),{[4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.022 g, 0.043 mmol), (Example 120: step b), MeOH[2 mL] was added to a flask containing a stirbar. To this was addedacetic acid (0.026 g, 0.434 mmol) and the solution was heated to 40° C.for 18 hours. Reaction was cooled to room temperature, solvent wasremoved in vacuo, and residue was chromatographed (10%–20% EtOAc/DCM)giving the title compound (0.026 g, 68%). ESI-MS (m/z): Calcd. forC₃₉H₅₃N₅O₁₀S₄: 881.13 (M+H); found 879.8, 880.8.

d)4-{4′-[N′-(3-Methanesulfonyl-propyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

[Imino-(4-{4′-[N′-(3-methanesulfonyl-propyl)-N′,N″-(carbamic acidtert-butylester)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester (0.026 g, 0.029 mmol) was dissolved in 1:1solution of trifluoroacetic acid:dichloromethane [1.5 mL:1.5 mL].Solution was allowed to stir at room temperature for 2 hours. Thereaction was concentrated in vacuo followed by reverse-phase HPLC[acetonitrile/water (0.01% TFA)] to give the title compound (0.017 g).ESI-MS (m/z): Calcd. for C₂₄H₂₉N₅O₄S₄: 580.78 (4+H); found 580.1.

Example 1724-{4′-[N′-(6-Methanesulfonyl-hexyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 6-Methanesulfonyl-hexan-1-ol

The reaction was conducted following the procedure for Example 171: stepa, using 6-bromo-hexan-1-ol (0.300 g, 1.660 mmol), methane sulfinicacid, (0.844 g, 8.280 mmol), EtOH [2 mL], H₂O, [2 mL]. Chromatography ofthe residue (1%–5% MeOH/DCM) yielded the title compound (0.141 g 48%).¹H-NMR (CDCl₃): δ 3.67 (t, 2H, J=6.2 Hz), 3.03 (t, 2H, J=8.0 Hz), 2.92(s, 3H), 1.89 (m, 2H), 1.60 (m, 2H), 1.46 (m, 4H).

b) 2-methyl-1-(6-methanesulfonyl-hexyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea

The reaction was conducted following the procedure for Example 171: stepb, using 6-methanesulfonyl-hexan-1-ol (0.141 g, 0.782 mmol),2-methyl-1-(3-methanesulfonyl-propyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea (0.206 g, 0.711 mmol), Triphenylphosphine (0.205 g,0.782 mmol), THF [5 mL]. To this was added Diisopropyl azodicarboxylate(0.158 g, 0.782 mmol). Chromatography of the residue (0%–100% EtOAc/Hx)yielded the title compound (0.213 g, 66%) ESI-MS (m/z): Calcd. forC₁₉H₃₆N₂O₆S₂: 453.63 (M+H); found 253.1.

c) [Imino-(4-{4′-[N′-(6-methanesulfonyl-hexyl)-N′,N″-(carbamic acidtert-butylester)guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester

The reaction was conducted following the procedure for Example 171: stepc, using 2-methyl-1-(6-methanesulfonyl-hexyl)-1,3-bis(carbamicacid-tert-butyl ester)-isothiourea (0.213 g, 0.471 mmol),{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.081 g, 0.157 mmol), (Example 120: step b), MeOH[4 mL], acetic acid (0.094 g, 1.570 mmol). Chromatography (0%–20%EtOAc/Hx) yielded the title compound. (0.086 g 60%) ESI-MS (m/z): Calcd.for C₄₂H₅₉N₅O₁₀S₄: 923.21 (M+H); found 921.8.

d)4-{4′-[N′-(6-Methanesulfonyl-hexyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The reaction was conducted following the procedure for Example 171: stepd, using imino-(4-{4′-[N′-(6-methanesulfonyl-hexyl)-N′,N″-(carbamic acidtert-butylester)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester (0.086 g, 0.093 mmol), trifluoroacetic acid [2mL], DCM [2 mL]. Reverse-phase HPLC yielded the title compound (0.021 g,38%). ESI-MS (m/z): Calcd. for C₂₇H₃₅N₅O₄S₄: 622.86 (M+H); found 622.2.

Example 1734-{4′-[N′-(5-Methanesulfonyl-pentyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 1-Chloro-5-methanesulfonyl-pentane

The reaction was conducted following the procedure for Example 171: stepa, using 1-bromo-5-chloro-pentane (0.400 g, 2.150 mmol), methanesulfinic acid, (1.090 g, 10.75 mmol), EtOH [3 mL], H₂O, [3 mL].Chromatography of the residue (0%–25% MeOH/DCM) yielded the titlecompound (0.213 g 53%). ¹H-NMR (CDCl₃): δ 3.55 (t, 2H, J=6.3 Hz), 3.03(t, 2H, J=8.0 Hz), 2.91 (s, 3H), 1.85 (m, 4H), 1.63 (m, 2H)

b) 2-methyl-1-(5-methanesulfonyl-pentyl)-1,3-bis(carbamicacid-tert-butyl ester)-isothiourea

1-chloro-5-methanesulfonyl-pentane (0.021 g, 1.153 mmol), sodium iodide(0.086 g, 5.765 mmol), acetone [5 mL] were heated to 50° C. for 1 hour.Reaction was cooled to room temperature, extracted EtOAc, andconcentrated in vacuo. This solid was then taken up in DMF [1 mL] andadded to a solution of sodium hydride (0.020 g, 0.865 mmo;) and2-methyl-1-(3-methanesulfonyl-propyl)-1,3-bis(carbamic acid-tert-butylester)-isothiourea (0.016 g, 0.576 mmol) in DMF [3 mL] at 0° C. To thiswas added sodium iodide (0.864 g, 5.765 mmol) and the reaction washeated at 50° C. for 18 hours. The reaction was cooled to roomtemperature and filtered to give the title compound (0.124 g, 49%).ESI-MS (m/z): Calcd. for C₁₈H₃₄N₂O₆S₄: 439.60 (M+H); found 239.2.

c) [Imino-(4-{4′-[N′-(6-methanesulfonyl-hexyl)-N′,N″-(carbamic acidtert-butylester)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester

The reaction was conducted following the procedure for Example 171: stepc, using 2-methyl-1-(5-methanesulfonyl-pentyl)-1,3-bis(carbamicacid-tert-butyl ester)-isothiourea (0.124 g, 0.283 mmol),{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.048 g, 0.094 mmol), (Example 120: step b), MeOH[4 mL], acetic acid (0.057 g, 0.942 mmol). Chromatography (5%–40%EtOAc/Hx) yielded the title compound (0.049 g 18%). ESI-MS (m/z): Calcd.for C₄₁H₅₇N₅O₁₀S₄: 909.18 (M+H); found 907.8, 908.9.

d)4-{4′-[N′-(5-Methanesulfonyl-pentyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

[Imino-(4-{4′-[N′-(6-methanesulfonyl-hexyl)-N′,N″-(carbamic acidtert-butylester)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester (0.049 g, 0.054 mmol) was dissolved in 1:1solution of trifluoroacetic acid:dichloromethane [3 mL:3 mL]. Solutionwas allowed to stir at room temperature for 2 hours. The reaction wasconcentrated in vacuo followed by reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to give the title compound (0.030 g, 92%). ESI-MS (m/z):Calcd. for C₂₆H₃₃N₅O₄S₄: 608.84 (M+H); found 608.2.

Example 174(5-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-pentyl)-phosphonicacid trifloroacetate

a) [5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-pentyl]-phosphonic aciddiethyl ester

Added bromophthalamide (0.400 g, 1.351 mmol) and trimethylphosphite(0.900 mL, 5.250 mmol) together in flask containing stirbar. Heatreaction to 80° C. for 18 hours. Reaction was cooled to room temperaturefollowed by chromatography (50%–100% EtOAc/Hx) to yield the titlecompound (0.300 g, 62%). ESI-MS (m/z): Calcd. for C₂₁H₂₄NO₅P: 354.35(M+H); found 354.1.

b) (5-Amino-pentyl)-phosphonic acid diethyl ester

[5-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pentyl]-phosphonic acid diethylester (0.300 g, 0.849 mmol) was dissolved in THF [2 mL], IPA [4 mL].Hydrazine (0.081 g, 2.540 mmol) was added to this solution and stirredat room temperature for 18 hours. The white precipitate was filtered andwashed with dichloromethane. Removal of the solvent in vacuo yielded thetitle compound (0.136 g, 72%) ¹H-NMR (CDCl₃): δ 4.07 (m, 4H), 2.68 (t,2H, J=6.74 Hz), 1.72 (m, 2H), 1.60 (m, 2H), 1.43 (m, 4H), 1.31 (m, 6H).

c)[5-(3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-pentyl]-phosphonicacid

{[4-(6′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.100 g, 0.204 mmol), (Example 25: step c),4-nitrophenyl chloroformate (0.041 g, 0.204 mmol), pyridine (0.018 g,0.224 mmol), DCM [3 mL] were added to a flask containing a stirbar. Thissolution was stirred at room temperature for 2.5 hours. To this solutionwas added (5-Amino-pentyl)-phosphonic acid diethyl ester (0.136 g, 0.611mmol) and Triethylamine (0.062 g, 0.611 mmol). Solution was stirred atroom temperature for 18 hours. Reaction was concentrated in vacuofollowed by chromatography (50%–100% EtOAc/Hx) to yield title compound(0.138 g, 88%). ESI-MS (m/z): Calcd. for C₃₄H₄₇N₄O₈PS₃: 767.93 (M+H);found 667.1.

d)(5-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-pentyl)-phosphonicacid

[5-(3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-pentyl]-phosphonicacid (0.058 g, 0.076 mmol), trimethylsilyl iodide (0.162 g, 0.756 mmol)and DCM [5 mL] were added to a flask and heated to 40° C. for 10minutes. The reaction was removed from the heat bath and allowed to stirat room temperature for 1 hour. H₂O [56 μL] was added to this solutionand stirred for 1 hour. The reaction was concentrated in vacuo. MeOH [2mL] and 20 wt. % HCl (aq.) [84 μL] were added to the concentrate andallowed to stir at room temperature for 18 hours. Reaction wasconcentrated in vacuo followed by reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to yield the title compound. ESI-MS (m/z): Calcd. forC₂₅H₃₁N₄O₆PS₃: 611.71 (M+H); found 611.0.

Example 175N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidehydrochloride

a)(Imino-{4-[6′-(4-methanesulfonyl-butyrylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

{[4-(6′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.500 g, 2.020 mmol), (Example 25: step c),triethylamine (0.153 g, 3.030 mmol), and DCM [30 mL] were added to aflask containing a stirbar. 4-Methanesulfonyl-butyryl chloride (0.013 g,0.611 mmol) was added slowly while monitoring reaction. Reaction wasconcentrated in vacuo followed by chromatography (50%–80% EtOAc/Hx).Material was dissolved in a solution of trifluoroaceticacid/dichloromethane (1:1), [4 mL]. This solution stirred at roomtemperature for 2 hours. Reaction was concentrated in vacuo followed byreverse-phase HPLC [acetonitrile/water (0.01% TFA)] to yield titlecompound (0.138 g, 88%). ESI-MS (m/z): Calcd. for C₂₄H₂₇N₃O₅S₄: 566.75;found 566.1.

Example 176{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylamino]-methyl}-phosphonicacid

a)({3′-[5-tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-ylamino}-methyl)-phosphonicacid diethyl ester

To a mixture of{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (30 mg, 58.0 μmol), as prepared according to theprocedure of step b of Example 120, cesium carbonate (19 mg, 58 μmol),and N,N-dimethylacetamide (0.4 mL) was added a solution oftrifluoro-methanesulfonic acid diethoxy-phosphorylmethyl ester (18 mg,58 μmol) (Xu, Y. et al, J. Org. Chem. 61, 7697 (1996); Phimon, D. et al,Tetrahedron Lett. 27, 1477 (1986)), and heated at 50° C. for 48 h.Additional trifluoro-methanesulfonic acid diethoxy-phosphorylmethylester (18 mg, 58 μmol) was added. The mixture was heated at 50° C. foradditional 24 h. Solvent was evaporated. The resulting mixture waspartitioned between DCM and H₂O. Aqueous layer was separated andextracted with DCM. All the DCM layers were combined, washed with H₂Oand brine, dried over Na₂SO₄, concentrated, and flash chromatographed onsilica gel column, eluting with EtOAc/DCM (20 and 30%) to give the titlecompound (38 mg, 98% yield) as an orange oil. ¹H NMR (CDCl₃): δ 8.23 (s,1H), 7.92–7.88 (m, 2H), 7.53–7.46 (m, 2H), 6.98 (d, 1H, J=8.0 Hz),6.56–6.53 (m, 2H), 4.23–4.15 (m, 4H), 3.56 (d, 2H, J=12.5 Hz), 2.43 (s,3H), 2.16 (s, 3H), 1.52 (s, 9H), 1.35 (t, 6H, J=7.0 Hz). ESI-MS (m/z):Cald. For C₂₉H₃₉N₃O₇PS₃: 668.2 (M+H); found: 667.8.

b){[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylamino]-methyl}-phosphonicacid

To a solution of({3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-ylamino}-methyl)phosphonicacid diethyl ester (38 mg, 0.057 mmol) in DCM (1.2 mL) at 0° C. wasadded iodotrimethylsilane (25 μL) over 3 minutes period. After 1 h at 0°C., H₂O was added. The mixture was stirred for 30 minutes, and thenconcentrated to give a brown solid. The solid was dissolved in MeOH(1.32 mL), 20% HCl was added, and stirred at ambient temperature for 3h. The mixture was concentrated to give a brown solid. To this solid wasadded TFA/DCM (1:1, 3 mL) and stirred at ambient temperature for 40minutes. The reaction mixture was then concentrated and purified by HPLC(C₁₈ column, 10–70% CH₃CN over 30 minutes) to give the title compound(11 mg, 38% yield) as a white solid.

ESI-MS (m/z): Cald. For C₂₀H₂₃N₃O₅PS₃: 512.1 (M+H); found: 512.1.

Example 1775-Methylsulfanyl-4-(2′-methyl-4′-trifluoromethanesulfonylamino-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

a){Imino-[5-methylsulfanyl-4-(2′-methyl-4′-trifluoromethanesulfonylamino-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

To a solution of{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (34 mg, 66 μmol), as prepared according to theprocedure of step b of Example 120, and DIEA (28 μL, 0.16 mmol) in DCM(1.0 mL) in an ice-H₂O bath was added trifluoromethanesulfonic anhydride(12 μL, 72 μmol) with stirring. After the ice bath expired, the mixturewas continued to stir at ambient temperature for 16 h, and then pouredinto saturated NaHCO₃, and extracted with EtOAc (2×). The extracts werecombined, washed with H₂O and brine, dried over Na₂SO₄, concentrated,and flash chromatographed on silica gel column, eluting withEtOAc/hexane (20 to 40%) to give the title compound (9 mg, 21% yield) asan oil.

ESI-MS (m/z): Cald. For C₂₅H₂₇F₃N₃O₆S₄: 650.1 (M+H); found: 649.6.

b)5-Methylsulfanyl-4-(2′-methyl-4′-trifluoromethanesulfonylamino-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

A mixture of{imino-[5-methylsulfanyl-4-(2′-methyl-4′-trifluoromethanesulfonylamino-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (9 mg, 14 μmol) in TFA/DCM (1:1, 3 mL) was stirredat ambient temperature for 40 min. The mixture was concentrated, andflashed chromatographed on silica gel column, eluting with MeOH/DCM (5to 8%) to give the title compound (5 mg, 54% yield) as a pale yellowsolid. ¹H NMR (CDCl₃): δ 8.32 (s, 1H), 8.04–8.01 (m, 1H), 7.96–7.95 (m,1H), 7.68–7.66 (m, 2H), 7.17 (m, 3H), 2.72 (s, 3H), 2.21 (s, 3H), ESI-MS(m/z): Cald. For C₂₀H₁₉F₃N₃O₄S₄: 550.0 (M+H); found: 550.0.

Example 1783-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylmethoxy]-propionicacid

a)3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylmethoxy}-propionicacid ethyl ester

To a suspension of NaH (2.7 mg, 68 μmol, 60% oil dispersion) in DMF (0.1mL) was added a solution of{[4-(2′-hydroxymethyl-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (30 mg, 56.4 μmol) in DMF (0.1 mL), as preparedaccording to the procedure of step b of Example 213. The mixture wasstirred at ambient temperature for 30 min, and then placed in anice-water bath. After 20 min, a solution of ethyl 3-bromopropionate (8.6μL, 67.0 μmol) in DMF (0.05 mL) was added once. Ice-water bath wasremoved, and the mixture was stirred for 16 h. H₂O was added, and themixture was extracted with EtOAc (3×). The extracts were combined,washed with H₂O, dried over Na₂SO₄, concentrated, and flashchromatographed on silica gel, eluting with EtOAc/DCM (15%) followed byEtOAc/hexane (40%) to give the title compound (9 mg, 25%) yield) as anoil.

¹H NMR (CDCl₃): δ 7.99 (d, 1H, J=7.7 Hz), 7.88 (s, 1H), 7.68 (s, 1H),7.60–7.56 (m, 1H), 7.44 (d, 1H, J=7.6 Hz), 7.38 (d, 1H, J=7.4 Hz),7.34–7.30 (m, 1H), 7.23 (d, 1H, J=7.3 Hz), 4.27–4.09 (m, 4H), 3.78 (bs,2H), 2.67 (t, 2H, J=5.9 Hz), 2.57 (s, 3H), 2.02 (s, 3H), 1.47 (s, 9H),1.28 (t, 3H, J=7.1 Hz).

ESI-MS (m/z): Cald. For C₃₀H₃₇N₂O₇S₃: 633.2 (M+H); found: 632.9.

b)3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylmethoxy}-propionicacid

To a solution of3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylmethoxy}-propionicacid ethyl ester (7.0 mg, 11 μmol) in THF (0.5 mL) and MeOH (0.25 mL)was added a solution of lithium hydroxide monohydrate (0.56 mg, 13 μmol)in H₂O (50 mL). The mixture was microwaved at 80° C. for 150 seconds,acidified with 0.25 N HCl to ˜pH 3, extracted with EtOAc/DCM (1:1, 3×).The extracts were combined, washed with H₂O, dried over Na₂SO₄,concentrated, and flash chromatographed on silica gel column, elutingwith MeOH/DCM (2 to 4%) to give the title compound (5.1 mg, 76% yield)as a white solid.

¹H NMR (CDCl₃): δ 8.03–8.00 (m, 1H), 7.88–7.87 (m, 1H), 7.70 (bs, 1H),7.57 (t, 1H, J=7.7 Hz), 7.43–7.40 (m, 1H), 7.36–7.28 (m, 2H), 7.23 (d,1H, J=6.9 Hz), 4.28–4.15 (m, 2H), 3.65–3.75 (m, 2H), 2.65 (t, 2H, J=6.0Hz), 2.58 (s, 3H), 2.01 (s, 3H).

ESI-MS (m/z): Cald. For C₂₈H₃₃N₂O₇S₃: 605.1 (M+H); found: 604.8.

c)3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylmethoxy]-propionicacid

A mixture of3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylmethoxy}-propionicacid (5.1 mg, 8.4 μmol) in TFA/DCM (1:1, 1.5 mL) was stirred at ambienttemperature for 1 h. The mixture was concentrated and flashchromatographed on silica gel, eluting with MeOH/DCM (5 to 12%) to givethe title compound (3.0 mg, 69% yield) as a white solid.

¹H NMR (CD₃OD): δ 8.18 (s, 1H), 8.03–8.00 (m, 1H), 7.88 (t, 1H, J=1.6Hz), 7.68 (t, 1H, J=7.8 Hz), 7.54–7.52 (m, 1H), 7.41 (d, 1H, J=7.6 Hz),7.33 (t, 1H, J=7.6 Hz), 7.24 (d, 1H, J=7.4 Hz), 4.23–4.16 (m, 2H), 3.64(t, 2H, J=6.1 Hz), 2.69 (s, 3H), 2.54 (t, 2H, J=6.0 Hz), 1.99 (s, 3H).

ESI-MS (m/z): Cald. for C₂₃H₂₄N₂O₅S₃: 505.1 (M+H); found: 505.1.

Example 1795-Methylsulfanyl-4-(6′-methyl-2′-{3-[4-(2H-tetrazol-5-yl)-butyl]-ureido}-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

a) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-pentanenitrile

To a solution of 5-bromovaleronitrile (5.12 g, 30.0 mmol) in DMF (40 mL)was added potassium phthalimide (6.00 g, 32.4 mmol). The abovesuspension was heated at 60° C. for 16 h, concentrated, and partitionedbetween H₂O and DCM. The DCM layer was separated, washed with H₂O (3×)and brine, dried over Na₂SO₄, and concentrated to give the titlecompound (6.84 g, quantitative yield) as a white solid.

¹H NMR (CDCl₃): δ 7.87–7.80 (m, 2H), 7.76–7.70 (m, 2H), 3.73 (t, 2H,J=6.1 Hz), 2.43 (t, 2H, J=7.1 Hz), 1.89–1.82 (m, 2H), 1.74–1.67 (m, 2H).

ESI-MS (m/z): Cald. For C₁₃H₁₃N₂O₂: 229.1 (M+); found: 229.1.

b) 2-[4-(2H-Tetrazol-5-yl)-butyl]-isoindole-1,3-dione

To a solution of 5-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pentanenitrile(6.84 g, 30 mmol) and azidotrimethylsilane (14 mL, 108 mmol) in toluene(40 mL) was added dibutyltin oxide (2.1 g, 6.0 mmol). The mixture washeated at 100° C. for 48 h, concentrated, and flash chromatographed onsilica gel column, eluting with EtOAc/DCM (30 and 60%) followed bymethanol/DCM (2.5 and 5%) to give the title compound (6.72 g, 83% yield)as a white solid.

¹H NMR (DMSO-d₆): δ 7.86–7.80 (m, 4H), 3.59 (t, 2H, J=6.8 Hz), 2.90 (t,2H, J=7.1 Hz), 1.74–1.58 (m, 4H).

ESI-MS (m/z): Cald. For C₁₃H₁₄N₅O₂: 272.1 (M+H); found: 272.0.

c) 2-[4-(2-Trityl-2H-etrazol-5-yl)-butyl]-isoindole-1,3-dione

To a solution of 2-[4-(2H-tetrazol-5-yl)-butyl]-isoindole-1,3-dione(4.07 g, 15.0 mmol) and diisopropylethylamine (7.8 mL, 45.0 mmol) in DCM(60 mL) was added trityl chloride (5.86 g, 21.0 mmol). The solution wasstirred at ambient temperature for 14 h, and concentrated. The resultingresidue was partitioned between EtOAc/DCM (3:1) and H₂O. Organic layerwas separated, washed with H₂O and brine, dried over Na₂SO₄,concentrated, and flash chromatographed on silica gel, eluting withDCM/hexane (40, 80, and 100%) followed by EtOAc/DCM (1 and 2%) to givethe title compound (5.08 g, 66% yield) as a pale yellow solid.

¹H NMR (CDCl₃): δ 7.87–7.82 (m, 2H), 7.74–7.70 (m, 2H), 7.36–7.31 (m,9H), 7.12–7.09 (m, 6H), 3.71 (t, 2H, J=7.1 Hz), 2.99 (t, 2H, J=7.2 Hz),1.89–1.71 (m, 4H).

d) 4-(2-Trityl-2H-tetrazol-5-yl)-butylamine

To a solution of2-[4-(2-trityl-2H-tetrazol-5-yl)-butyl]-isoindole-1,3-dione (175 mg,0.313 mmol) in 2-propanol/THF (2:1, 3.0 mL) was added hydrazine (30 mL,0.939 mmol). The solution was stirred at ambient temperature for 16 h.White solid was filtered off and washed with DCM (5×). The filtrate andthe washings were combined, concentrated, dissolved in DCM, washed withH₂O (2×) and brine, dried over Na₂SO₄, and concentrated to give thetitle compound (131 mg, 97% yield) as a pale yellow oil.

¹H NMR (CDCl₃): δ 7.36–7.28 (m, 9H), 7.12–7.09 (m, 6H), 2.93 (t, 2H,J=7.6 Hz), 2.69 (t, 2H, J=7.0 Hz), 1.84–1.77 (m, 2H), 1.52–1.45 (m, 2H).

e){Imino-[5-methylsulfanyl-4-(6′-methyl-2′-{3-[4-(2-trityl-2H-tetrazol-5-yl)-butyl]-ureido}-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

To a solution of{[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (60 mg, 0.116 mmol), as prepared according to theprocedure of step c of Example 25, and pyridine (10 mg, 0.128 mmol) inDCM (1.1 mL) was added 4-nitrophenyl chloroformate (23 mg, 0.116 mmol),and stirred at ambient temperature for 4 h. To the above mixture wasadded a solution of 4-(2-trityl-2H-tetrazol-5-yl)-butylamine (65 mg,0.151 mmol) in DCM (0.65 mL), and stirred for 48 h. The mixture wasconcentrated and purified on a preparative TLC plate (1000 μm),developing with EtOAc/DCM (5 and 20%) to give the title compound (15 mg,14% yield) as a yellow solid.

¹H NMR (CDCl₃): δ 7.95 (d, 1H, J=7.93 Hz), 7.88 (t, 1H, J=1.6 Hz), 7.74(s, 1H), 7.56 (t, 1H, J=7.7 Hz), 7.44–7.42 (m, 1H), 7.35–7.28 (m, 13H),7.23–7.19 (m, 1H), 7.11–7.08 (m, 7H), 4.94 (t, 1H, J=5.5 Hz), 3.26–3.16(m, 2H), 2.91 (t, 2H, J=7.3 Hz), 2.62 (s, 3H), 2.10 (s, 3H), 1.80–1.72(m, 2H), 1.56–1.44 (m, 1H).

ESI-MS (m/z): Cald. For C₄₉H₅₁N₈O₅S₃: 927.3 (M+H); found: 926.8.

f)5-Methylsulfanyl-4-(6′-methyl-2′-{3-[4-(2H-tetrazol-5-yl)-butyl]-ureido}-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

A solution of{imino-[5-methylsulfanyl-4-(6′-methyl-2′-{3-[4-(2-trityl-2H-tetrazol-5-yl)-butyl]-ureido}-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (15 mg, 16 μmol) in TFA/DCM (1:1, 2.0 mL) wasstirred at ambient temperature for 1 h. The mixture was concentrated,and flash chromatographed on silica gel column, eluting with MeOH/DCM (3to 7.5% containing 0.1% TFA) to give the title compound (5 mg, 45%yield) as a white solid.

¹H NMR (CDCl₃): δ 8.29 (s, 1H), 8.02–8.00 (m, 1H), 7.88 (t, 1H, J=1.7Hz), 7.67 (t, 1H, J=7.7 Hz), 7.56–7.53 (m, 1H), 7.42 (d, 1H, J=7.8 Hz),7.28 (t, 1H, J=7.7 Hz), 7.12 (d, 1H, J=7.5 Hz), 3.05 (t, 2H, J=6.4 Hz),2.92 (t, 2H, J=7.5 Hz), 2.70 (s, 3H), 2.92 (s, 3H), 1.73–1.65 (m, 2H),1.44–136 (m, 2H)

ESI-MS (m/z): Cald. For C₂₅H₂₉N₈O₅S₃: 585.1 (M+H); found: 585.0.

Example 1805-Methylsulfanyl-4-(6′-methyl-2′-{3-[5-(2H-tetrazol-5-yl)-pentyl]-ureido}-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

The title compound was prepared from 6-bromohexanenitrile according tothe procedures in Example 179.

¹H NMR (CD₃OD): δ 8.30 (s, 1H), 8.05–8.02 (m, 1H), 7.89 (t, 1H, J=1.6Hz), 7.69 (t, 1H, J=7.8 Hz), 7.56–7.54 (m, 1H), 7.42 (d, 1H, J=7.8 Hz),7.28 (t, 1H, J=7.8 Hz), 7.11 (d, 1H, J=7.5 Hz), 3.00 (t, 2H, J=6.5 Hz),2.93 (t, 2H, J=7.5 Hz), 2.70 (s, 3H), 1.99 (s, 3H), 1.78–1.71 (m, 2H),1.42–1.34 (m, 2H), 1.30–1.25 (m, 2H).

ESI-MS (m/z): Cald. For C₂₆H₃₁N₈O₃S₃: 599.2 (M+H); found: 599.0.

Example 1815-Methylsulfanyl-4-(6′-methyl-2′-{3-[2-(2H-tetrazol-5-yl)-ethyl]-ureido}-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

a){Imino-[5-methylsulfanyl-4-(6′-methyl-2′-{3-[2-(2H-tetrazol-5-yl)-ethyl]-ureido}-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

A mixture of[(4-{2′-[3-(2-cyano-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester (31 mg, 51 μmol), as prepared from{[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester and 3-aminopropionitrile according to theprocedure of step e of Example 179, azidotrimethylsilane (40 μL, 0.30mmol), dibutyltin oxide (3.5 mg, 10 μmol), and toluene (1.5 mL) washeated at 70° C. for 16 h and 80° C. for 4 h. The mixture wasconcentrated and purified by flash chromatography on silica gel, elutingwith EtOAc/DCM (50, 100%) followed by MeOH/DCM (5, 10%) to give thetitle compound (14 mg, 42% yield) as a colorless oil.

¹H NMR (CDCl₃): δ 8.00 (s, 1H), 7.75–7.71 (m, 2H), 7.34–7.29 (m, 3H),7.21 (t, 1H, J=7.8 Hz), 7.10–1.01 (m, 2H), 6.58 (bs, 1H), 6.00 (bs, 1H),3.60 (bs, 2H), 3.04 (bs, 2H), 2.52 (s, 3H), 1.93 (s, 3H), 1.49 (s, 9H).

ESI-MS (m/z): Cald. For C₂₈H₃₃N₈O₅S₃: 657.2 (M+H); found: 656.8.

b)5-Methylsulfanyl-4-(6′-methyl-2′-{3-[2-(2H-tetrazol-5-yl)-ethyl]-ureido}-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

A solution of{imino-[5-methylsulfanyl-4-(6′-methyl-2′-{3-[2-(2H-tetrazol-5-yl)-ethyl]-ureido}-biphenyl-3-sulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (10 mg, 15.3 μmol) in TFA/DCM (2.0 mL, 1:1) wasstirred at ambient temperature for 1.5 h. The reaction mixture wasconcentrated to dryness, and flash chromatographed on silica gel column,eluting with 10% MeOH/DCM containing 0.1% TFA to give the title compound(4.7 mg, 46% yield) as a white solid.

¹H NMR (CD₃OD): δ 8.29 (s, 1H), 8.03–8.01 (m, 1H), 7.86 (t, 1H, J=1.6Hz), 7.68 (t, 1H, J=7.8 Hz), 7.52–7.50 (m, 1H), 7.42 (d, 1H, J=7.9 Hz),7.28 (t, 1H, J=7.7 Hz), 7.12 (d, 1H, J=7.5 Hz), 3.48–3.41 (m, 2H), 3.00(t, 2H, J=6.7 Hz), 2.70 (s, 3H), 1.99 (s, 3H).

ESI-MS (m/z): Cald. For C₂₃H₂₅N₈O₃S₃: 557.1 (M+H); found: 557.0.

Example 1825-Methylsulfanyl-4-(2′-methyl-4′-{3-[4-(2H-tetrazol-5-yl)-butyl]-ureido}-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

According to the procedures of Example 179, the title compound wassynthesized from{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester, which was prepared using the procedure of step bof Example 120.

¹H NMR (CD₃OD): δ 8.32 (s, 1H), 8.00–7.95 (m, 2H), 7.66–7.65 (m, 2H),7.31–7.27 (m, 2H), 7.10 (d, 1H, J=8.3 Hz), 3.26 (t, 2H, J=6.8 Hz), 3.00(t, 2H, J=7.5 Hz), 2.72 (s, 3H), 2.20 (s, 3H), 1.90–1.82 (m, 2H),1.64–1.57 (m, 2H)

ESI-MS (m/z): Cald. For C₂₅H₂₉N₈O₅S₃: 585.1 (M+H); found: 585.0.

Example 1834-[4′-(N′-Acetyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 1-Acetyl-1,3-bis-tert-butoxycarbonylimino-2-methyl-isothiourea

To a solution of 1,3-bis-tert-butoxycarbonylimino-2-methyl-isothiourea(2.33 g, 8.0 mmol) in dichloromethane (DCM) (8.0 mL) was addeddiisopropylethylamine (DIEA) (2.79 mL, 16.0 mmol) and acetyl chloride(0.60 mL, 8.4 mmol) and stirred at ambient temperature for 2 hours.Additional DIEA (2.79 mL, 16.0 mmol) and acetyl chloride (0.60 mL, 8.4mmol) were added. After 1 hour the mixture was concentrated to dryness,partitioned between dichloromethane and saturated NaHCO₃. Organic layerwas separated, washed with H₂O and brine, dried over Na₂SO₄,concentrated, and flash chromatographed on silica gel column, elutingwith DCM/hexane (40%, 100%) to give the title compound (2.60 g, 97%yield) as a yellow oil.

¹H NMR (CDCl₃): δ 2.48 (s, 3H), 2.46 (s, 3H), 1.52 (s, 9H), 1.47 (s,9H).

b)4-[4′-(N′-Acetyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a solution of{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (60 mg, 0.116 mmol), as synthesized from{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester using the procedure of step b of Example 120, and1-acetyl-1,3-bis-tert-butoxycarbonylimino-2-methyl-isothiourea (193 mg,0.58 mmol) in methanol (4.0 mL) was added acetic acid (66 μL, 1.16 mmol)and heated at 40° C. for 16 h. Triethylamine (0.25 mL) was added. Themixture was concentrated to dryness followed by flash chromatography onsilica gel column, eluting with ethylacetate/DCM (5, 10 15%) to deliverthe guanidinated product (60 mg) as a yellow solid. This solid wastreated with trifluoroacetic acid/DCM (6 mL, 1:1) at ambient temperaturefor 1 h, and concentrated to dryness. The resulting residue was purifiedvia HPLC (C₁₈-column, 20–65% CH₃CN over 25 min) to give the titlecompound (33 mg, 49% yield) as a white solid.

¹H NMR (CD₃OD): δ 8.32 (s, 1H), 8.02–7.98 (m, 1H), 7.96 (s, 1H),7.67–7.66 (m, 2H), 7.50–7.48 (m, 2H), 7.15 (d, 1H, J=8.0 Hz), 2.72 (s,3H), 2.22 (s, 3H), 2.14 (s, 3H).

Example 1844-{4′-Guanidino-2′-[3-(4-methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)[(4-{4′-Amino-2′-[3-(4-methlanesulfonyl-butyl)-ureido-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester

To a solution of a){3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-[3-(4-methanesulfonyl-butyl)-ureido]-6-methyl-biphenyl-4-yl}-carbamicacid 2-methyl silanyl-ethyl ester (148 mg, 0.173 mmol), as prepared from4-methanesulfonyl-butylamine (step c of Example 202) and[2-amino-3′-(5-carbamoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-4-yl]-carbamicacid 2-trimethylsilanyl-ethyl ester (step c of Example 294) using theprocedure of step e of Example 179, in THF (5.0 mL) was added a solutionof tetrabutylammonium fluoride in THF (0.87 mL, 0.87 mmol, 1.0 M) over 5minutes period. The mixture was then heated at 50° C. for 30 minutes,concentrated, and flash chromatographed on silica gel column, elutingwith EtOAc followed by methanol/DCM (2.5, 5%) to give the title compound(100 mg, 82% yield) as a yellow solid.

¹H NMR (CD₃OD): δ 8.16 (s, 1H), 7.98–7.95 (m, 1H), 7.85 (t, 1H, J=1.6Hz), 7.64 (t, 1H, J=7.8 Hz), 7.50–7.48 (m, 1H), 6.82 (d, 1H, J=2.2 Hz),6.49–6.48 (m, 1H), 3.11–3.02 (m, 4H), 2.94 (s, 3H), 2.65 (s, 3H), 1.90(s, 3H), 1.73–1.67 (m, 2H), 1.51–1.46 (m, 1H).

b)[(4-{4′-(N′,N″-Di-tert-tert-butoxycarbonyl-guanidino)-2′-[3-(4-methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester

To a mixture of[(4-{4′-amino-2′-[3-(4-methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester (100 mg, 0.141 mmol),1,3-bis-tert-butoxycarbonylimino-2-methyl-isothiourea (205 mg, 0.705mmol), and methanol (5.0 mL) was added acetic acid (0.081 mL, 1.41mmol), and heated at 40° C. for 16 h. Triethylamine (0.3 mL) was added.The mixture was concentrated, and flash chromatographed on silica gelcolumn, eluting with EtOAc/DCM (0 to 40%) to afford the title compound(110 mg, 82% yield) as an off-white solid.

¹H NMR (CD₃OD): δ 8.19 (s, 1H), 8.04–802 (m, 1H), 7.87 (t, 1H, J=1.6Hz), 7.70 (t, 1H, J=7.9 Hz), 7.63 (bs, 1H), 7.51–7.54 (m, 1H), 7.35 (bs,1H), 3.11–3.04 (m, 4H), 2.93 (s, 3H), 2.64 (s, 3H), 1.98 (s, 3H),1.76–1.68 (m, 2H), 1.58 (bs, 9H), 1.54–1.46 (m, 20H).

c)4-{4′-Guanidino-2′-[3-(4-methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a flask charged with[(4-{4′-(N′,N″-di-tert-butoxycarbonyl-guanidino)-2′-[3-(4-methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester (110 mg, 0.116 mmol) was added a solution oftrifluoroacetic acid in DCM (3.0 mL, 50%) and stirred at ambienttemperature for 1 h. The mixture was concentrated, and purified by HPLC(C₁₈-column, 5–50% CH₃CN in H₂O over 15 min.) to give the title compound(63 mg, 62% yield) as a white solid.

¹H NMR (CD₃OD): δ 8.34 (s, 1H), 8.08–8.05 (m, 1H), 7.91 (t, 1H, J=1.7Hz), 7.76 (t, 1H, J=7.9 Hz), 7.57–7.52 (m, 2H), 7.00 (d, 1H, J=1.7 Hz),3.13–3.10 (m, 4H), 2.95 (s, 3H), 2.71 (s, 3H), 2.00 (s, 3H), 1.78–1.71(m, 2H), 1.57–1.50 (m, 2H).

ESI-MS (m/z): Cald. For C₂₆H₃₄N₇O₅S₄: 652.1 (M+H); found: 652.1.

Examples 185–1864-[7-Chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[7-Chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) Sodium salt of 5-methylsulfanyl-4-sulfino-thiophene-2-carboxylic acidmethyl ester

4,6-Dichloro-spiro[benzoimidazole-2,1′-cyclohexane]4-(7-Chloro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

A solution of 4,6-dichloro-spiro[benzoimidazole-2,1′-cyclohexane] ((madeaccording to literature preparation: Hazelton, C. J. et al.,Tetrahedron, 51:5597 (1995)) 0.200 g, 0.729 mmol) in absolute ethanol (5mL) was treated with the sodium salt of5-methylsulfanyl-4-sulfino-thiophene-2-carboxylic acid methyl ester((Example 38: step b) 0.200 g, 0.729 mmol) as a solution inwater:ethanol (2:1, 3.3 mL). Acetic acid was added and the reactionstirred at room temperature 21.5 h. The reaction mixture was poured overice water and the ethanol was removed in vacuo. The resulting aqueousmixture was extracted with CH₂Cl₂ (4×25 mL). The combined organic layerswere washed with brine and dried over Na₂SO₄. The solvents were removedin vacuo to afford the product4-(7-chloro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.307 g, 89%) as a brown oil. ¹H NMR (CDCl₃): δ 8.051(d, 1H, J=1.2 Hz), 8.038 (s, 1H), 7.381 (d, 1H, J=1.2 Hz), 3.908 (s,3H), 2.662 (s, 3H), 1.964 (m, 10H).

b)4-(3,4-Diamino-5-chloro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

A solution of4-(7-chloro-spiro[benzoimidazole-2,1′-cyclohex]e-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (from above step a, 0.307 g, 0.652 mmol) inethanol:water (1:1, 6.4 mL) was treated with Na₂S₂O₄ and heated to 80°C. 1.5 h. The mixture was cooled, poured over ice water, and extractedwith CH₂Cl₂ (4×25 mL). The combined organic layers were washed withbrine and dried over Na₂SO₄. The solvents were removed in vacuo toafford the product4-(3,4-diamino-5-chloro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.224 g, 87%) as a brown oil. Formic acid (4.5 mL)was added and the resulting solution was refrigerated for storageovernight due to the instability of the free diamine.

c)4-(7-Chloro-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The refrigerated solution of4-(3,4-diamino-5-chloro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((from above step b) 0.224 g, 0.570 mmol) in formicacid (4.5 mL) from above was allowed to slowly warm to room temperatureand then heated to reflux (110° C.) 3 h. The mixture was cooled to roomtemperature and poured over ice. The pH was adjusted to pH 8 bycarefully adding solid NaHCO₃ portionwise with stirring. The aqueoussolution was extracted with EtOAc (2×150 mL). The combined organiclayers were washed with brine and dried over Na₂SO₄. The solvent wasremoved in vacuo to afford the product4-(7-chloro-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.201 g, 87%) as a brown foamy solid. The crudematerial was used directly in the next reaction.

d)4-[7-Chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

4-[7-Chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

A solution of4-(7-chloro-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((from above step c) 0.201 g, 0.499 mmol) in DMF (4mL) was treated with α-bromo-2,6-difluorotoluene (0.114 g, 0.549 mmol)and solid K₂CO₃ (0.152 g, 1.10 mmol). The reaction was stirred at roomtemperature 17 h, diluted with EtOAc and washed well with water (5×150mL). The organic layer was dried over MgSO₄ and concentrated in vacuo.Silica gel chromatography (2% MeOH with 2 M NH₃ in CH₂Cl₂) afforded theproducts4-[7-chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-[7-chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (0.102 g, 38%). These isomers were not separable bysilica gel chromatography, but they were carried on together into thenext reaction.

e)4-[7-Chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[7-Chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of4-[7-chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-[7-chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((from above step d) 0.101 g, 0.191 mmol) in drytoluene (5 mL) was treated with preformed dimethylaluminum amide andheated to 100° C. 2.5 h. The reaction mixture was cooled to roomtemperature and added portionwise to silica suspended in CH₂Cl₂. Thesuspension was stirred 20 min. then was filtered through a fine porosityfritted funnel. The silica was rinsed with 10% MeOH in CH₂Cl₂ (1000 mL),and the filtrate was concentrated in vacuo. Preparatory HPLC (10–55%acetonitrile in 1% TFA/water over 30 min.) afforded products4-[7-chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.006 g, 6%) and4-[7-chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.007 g, 7%) as white solids.

Example 1854-[7-chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.479 (s, 1H), 8.348 (d, 1H, J=1.6 Hz), 8.341 (s, 1H),7.931 (d, 1H, J=1.6 Hz), 7.460 (m, 1H), 7.049 (t, 2H, J=8.4 Hz), 6.004(s, 2H), 2.736 (s, 3H). C₂₀H₁₅ClF₂N₄O₂S₃: 513.00 (M+1) found: 513.10.

Example 1864-[7-chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 9.001 (s, 1H), 8.384 (d, 1H, J=2.0 Hz), 8.372 (s, 1H),7.984 (d, 1H, J=1.6 Hz), 7.532 (m, 1H), 7.141 (t, 2H, J=8.0 Hz), 5.825(s, 2H), 2.674 (s, 3H).

C₂₀H₁₅ClF₂N₄O₂S₃: 513.00 (M+1) found: 513.10

Example 187–1884-[7-Bromo-3-(2-fluoro-5-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[7-Bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(7-Bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

4-(7-Bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

A solution of4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 38: step

e) 2.19 g, 4.90 mmol) in dry toluene (20 mL) was treated with a solutionof 2 M AlMe₃ (39.0 mL, 78.0 mmol) and NH₄Cl (4.21 g, 78.7 mmol) in drytoluene (39 mL) as described in Example 20: step f. The crude material(2.11 g, 100%) was used directly in the next reaction.b)4-Bromo-6-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-benzoimidazole-1-carboxylicacid tert-butyl ester

A solution of4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine((from above step a) 2.11 g, 4.89 mmol) in dry DMF (30 mL) was treatedwith di-tert-butyl dicarbonate (4.27 g, 19.6 mmol) andN,N-diisopropylethylamine (3.40 mL, 19.5 mmol). The reaction mixture wasstirred at room temperature 2 days, and the solvents were removed invacuo. Silica gel chromatography (30–50% EtOAc in hexanes raised in 5%increments) afforded the product4-bromo-6-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-benzoimidazole-1-carboxylicacid tert-butyl ester (1.30 g, 42%) as a brown oil. ¹H NMR (CDCl₃): δ8.675 (m, 1H), 8.62 (s, 1H), 8.16 (d, 1H, J=1.6 Hz), 7.89 (s, 1H), 2.56(s, 3H), 1.73 (s, 9H), 1.52 (s, 9H).

c){[4-(7-Bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

A solution of4-bromo-6-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-benzoimidazole-1-carboxylicacid tert-butyl ester ((from above step b) 1.00 g, 1.58 mmol) in MeOH(10 mL) was treated with aqueous Na₂CO₃ (0.340 g, 3.17 mmol in 2 mLwater). The reaction mixture was stirred at room temperature 30 min.,and solvents were removed in vacuo. The residue was taken up in EtOAcand washed with water (1×50 mL) and brine (1×50 mL). The organic layerwas dried over MgSO₄ and concentrated in vacuo to afford the product{[4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.755 g, 90%) as a brown solid. ¹H NMR (MeOD): δ8.48 (s, 1H), 8.32 (m, 1H), 8.20 (s, 1H), 8.03 (d, 1H, J=1.6 Hz), 2.63(s, 3H), 1.48 (s, 9H).

d)({4-[7-Bromo-4-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

{4-[7-Bromo-3-(2-fluoro-5-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

A solution of{[4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((from above step c) 0.132 g, 0.248 mmol) in dryDMF (3 mL) was treated with 2-fluoro-5-nitrobenzylbromide (0.087 g,0.373 mmol) and diisopropylamine (0.070 mL, 0.497 mmol) and heated to40° C. 24 h. The solution was diluted with EtOAc and washed well withwater (4×35 mL). The organic layer was dried over MgSO₄ and concentratedin vacuo to afford the products({4-[7-bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester and({4-[7-bromo-3-(2-fluoro-5-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (0.015 g, 9%) as a brown solid. C₂₅H₂₃BrFN₅O₆S₃:684.00 (M+1) found 684.60.

e)4-[7-Bromo-3-(2-fluoro-5-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-[7-Bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of({4-[7-bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester and({4-[7-bromo-3-(2-fluoro-5-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester ((from above step d) 0.015 g, 0.022 mmol) inCH₂Cl₂ (1 mL) was cooled to 0° C. and treated with 25% trifluoroaceticacid in CH₂Cl₂ (1.00 mL). The mixture was allowed to warm to roomtemperature and was stirred 3.2 h. The solvents were removed in vacuo.Preparatory HPLC (10–80% acetonitrile in 1% TFA/water over 30 min.)afforded the products4-[7-bromo-3-(2-fluoro-5-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.002 g, 47%) and4-[7-bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.002 g, 47%) as white solids.

Example 1874-[7-bromo-3-(2-fluoro-5-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.728 (s, 1H), 8.355 (m, 2H), 8.309 (s 1H), 8.286 (d,1H, J=1.6 Hz), 8.060 (d, 1H, J=1.6 Hz), 7.468 (t, 1H, J=9.6 Hz), 5.832(s, 2H), 2.623 (s, 3H). C₂₀H₁₅BrFN₅O₄S₃: 583.95 (M+1) found 585.0.

Example 1884-[7-bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.636 (s, 1H), 8.455 (d, 1H, J=1.6 Hz), 8.337 (s, 1H),8.295 (m, 1H), 8.098 (d, 1H, J=2.0 Hz), 7.610 (dd, 1H, J=6.4 Hz, J=2.8Hz), 7.468 (t, 1H, J=8.8 Hz), 6.054 (s, 2H), 2.722 (s, 3H).C₂₀H₁₅BrFN₅O₄S₃: 583.95 (M+1) found 585.0.

Example 1894-[7-Bromo-3-(2-fluoronitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)({4-[7-Bromo-1-(2-fluoro-4-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl)-imino)methyl)-carbamicacid tert-butyl ester

{4-[7-Bromo-3-(2-fluoro-4-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl)-imino-methyl)-carbamicacid tert-butyl ester

A solution of{[4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 187–188: step c) 0.097 g, 0.183 mmol) inDMF (3 mL) was treated with 2-fluoro-4-nitrobenzylbromide (0.064 g,0.274 mmol) and diisopropylamine (0.051 mL, 0.365 mmol) and heated to40° C. 24 h. The solution was diluted with EtOAc and washed well withwater (4×35 mL). The organic layer was dried over MgSO₄ and concentratedin vacuo to afford the products({4-[7-bromo-1-(2-fluoronitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl)-imino-methyl)-carbamicacid tert-butyl ester and({4-[7-bromo-3-(2-fluoronitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl)-imino-methyl)-carbamicacid tert-butyl ester (0.012 g, 10%) as a brown solid. C₂₅H₂₃BrFN₅O₆S₃:684.00 (M+1) found 684.50.

b)4-[7-Bromo-3-(2-fluoro-4-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of({4-[7-bromo-1-(2-fluoro-4-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl)-imino-methyl)-carbamicacid tert-butyl ester and({4-[7-bromo-3-(2-fluoro-4-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl)-imino-methyl)-carbamicacid tert-butyl ester ((from above step a) 0.005 g, 0.007 mmol) inCH₂Cl₂ (1 mL) was cooled to 0° C. and treated with 25% trifluoroaceticacid in CH₂Cl₂ (1.00 mL). The mixture was allowed to warm to roomtemperature and was stirred 3 h. Solvents were removed in vacuo.Preparatory HPLC (10–80% acetonitrile in 1% TFA/water over 30 min.)afforded the product4-[7-bromo-3-(2-fluoro-4-nitro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.002 g, 47%) as a white solid. ¹H NMR (MeOD): δ 8.714(s, 1H), 8.308 (s, 1H), 8.231 (d, 1H, J=1.6 Hz), 8.106 (m, 2H), 8.047(d, 1H, J=0.8 Hz), 7.556 (t, 1H, J=8.4 Hz), 5.854 (s, 2H), 2.630 (s,3H). C₂₀H₁₅BrFN₅O₄S₃: 583.95 (M+1) found 585.05.

Example 1904-[1-(5-Amino-2-fluoro-benzyl)-7-bromo-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of({4-[7-bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester ((Example 187–188: step d) 0.030 g, 0.044 mmol) inEtOH (3 mL) was treated with NH₄Cl (0.023 g, 0.438 mmol) as an aqueoussolution and heated to 50° C. Iron powder (0.012 g, 0.219 mmol) wasadded and the reaction heated to 80° C. for 4 h. The mixture was cooledand filtered through Celite. The filter cake was rinsed with EtOH, andthe EtOH was removed in vacuo. The remaining aqueous solution wasbasified to pH 10 with saturated aqueous NaHCO₃ and extracted with EtOAc(2×25 mL). The combined organic layers were dried over MgSO₄ andconcentrated in vacuo. The residue was taken up in CH₂Cl₂ (3 mL) andtreated with trifluoroacetic acid (0.75 mL). The mixture was stirred atroom temperature 1.5 h, and solvents were removed in vacuo. PreparatoryHPLC (10–50% acetonitrile in 1% TFA/water over 30 min.) afforded theproduct4-[3-(5-amino-2-fluoro-benzyl)-7-bromo-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.014 g, 49%) as a white solid. ¹H NMR (MeOD): δ 8.714(s, 1H), 8.308 (s, 1H), 8.231 (d, 1H, J=1.6 Hz), 8.106 (m, 2H), 8.047(d, 1H, J=0.8 Hz), 7.556 (t, 1H, J=8.4 Hz), 5.854 (s, 2H), 2.630 (s,3H).

Example 1913-({3-[4-Bromo-6-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-benzoimidazol-1-ylmethyl]-4-fluoro-phenylcarbamoyl}-methylsulfanyl)-propionicacid trifluoroacetate

a)[(4-{7-Bromo-3-[52-bromo-acetylamino)-2-fluoro-benzyl-3H-benzoimidazole-5-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester

A solution of({4-[3-(5-amino-2-fluoro-benzyl)-7-bromo-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophen-2-yl)-imino-methyl)-carbamicacid tert-butyl ester ((Example 190) 0.012 g, 0.018 mmol) in CH₂Cl₂ (3mL) was treated with bromoacetylbromide (0.007 g, 0.037 mmol) andtriethylamine (0.006 mL, 0.046 mmol) and stirred at room temperature 3h. The reaction mixture was diluted with CH₂Cl₂ and washed with water(2×10 mL). The organic layer was dried over MgSO₄ and concentrated invacuo to afford the product[(4-{7-bromo-3-[5-(2-bromo-acetylamino)-2-fluoro-benzyl]-3H-benzoimidazole-5-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester (0.014 g, 92%) as a tan solid. C₂₇H₂₆Br₂FN₅O₅S₃:773.94 (M+1) found 774.10.

b)3-[(3-{4-Bromo-6-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-benzoimidazol-1-ylmethyl}-4-fluoro-phenylcarbamoyl)-methylsulfanyl]-propionicacid methyl ester

A solution of[(4-{7-bromo-3-[5-(2-bromo-acetylamino)-2-fluoro-benzyl]-3H-benzoimidazole-5-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester ((Example 191: step a) 0.014 g, 0.017 mmol) inCH₂Cl₂ (2 mL) was treated with methyl 3-mercaptopropionoate (2.50 μL,0.025 mmol) and stirred at room temperature 30 min. The reaction wasdiluted with CH₂Cl₂ and washed with water (1×10 mL). The organic layerwas dried over MgSO₄ and concentrated in vacuo to afford the product3-[(3-{4-bromo-6-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-benzoimidazol-1-ylmethyl}-4-fluoro-phenylcarbamoyl)-methylsulfanyl]-propionicacid methyl ester (0.011, 85%) as a tan solid. C₃₁H₃₃BrFN₅O₈S₄: 814.04(M+1) found 814.70.

c)3-({3-[4-Bromo-6-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-benzoimidazol-1-ylmethyl]-4-fluoro-phenylcarbamoyl}-methylsulfanyl)-propionicacid trifluoroacetate

A solution of3-[(3-{4-bromo-6-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-benzoimidazol-1-ylmethyl}-4-fluoro-phenylcarbamoyl)-methylsulfanyl]-propionicacid methyl ester ((Example 191: step b) 0.011 g, 0.014 mmol) inMeOH:H₂O (2:1, 3 mL) was treated with LiOH (1.61 mg, 0.070 mmol) and thereaction stirred at room temperature 2 h. The solvents were evaporatedin vacuo and the residue taken up in CH₂Cl₂ (3 mL). Trifluoroacetic acid(0.750 mL) was added and the reaction stirred at room temperature 45min. Solvents were evaporated in vacuo. Preparatory HPLC (10–50%acetonitrile in 1% TFA/water over 30 min.) afforded the product3-({3-[4-bromo-6-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-benzoimidazol-1-ylmethyl]-4-fluoro-phenylcarbamoyl}-methylsulfanyl)-propionicacid trifluoroacetate (0.004 g, 43%) as a white solid. ¹H NMR (MeOD): δ8.691 (s, 1H), 8.140 (s, 1H), 8.068 (s, 1H), 8.018 (s, 1H), 7.647 (m,1H), 7.547 (dd, 1H, J=6.4 Hz, J=2.4 Hz), 7.176 (t, 1H, J=9.6 Hz), 5.692(s, 2H), 3.498 (quint, 1H, J=1.6 Hz), 3.148 (quint, 1H, J=1.6 Hz), 2.875(d, 2H, J=7.2 Hz), 2.651 (d, 2H, J=7.2 Hz), 2.529 (s, 3H).C₂₅H₂₃BrFN₅O₅S₄: 699.97 (M+1) found 700.90.

Example 192[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylmethoxy]-aceticacid trifluoroacetate

a) 2-Bromo-5-methoxy-1,3-dimethyl-benzene

A solution of 4-bromo-3,5-dimethylphenol (1.00 g, 4.97 mmol) in acetone(40 mL) was treated with solid CsCO₃ (1.17 g, 4.97 mmol) and methyliodide (0.310 mL, 4.97 mmol) and heated to 40° C. for 3 h. Additionalmethyl iodide (0.310 mL, 4.97 mmol) was added over the course of thereaction to replace that lost to evaporation. The acetone was removed invacuo. The resulting white solid residue was partitioned between waterand CH₂Cl₂. The layers were separated and the aqueous layer was furtherextracted with CH₂Cl₂ (2×25 mL). The combined organic layers were washedwith water (1×25 mL) and dried over MgSO₄. The solvent was removed invacuo to afford the product 2-bromo-5-methoxy-1,3-dimethyl-benzene (1.01g, 94%) as a colorless oil, which slowly solidified upon standing. ¹HNMR (CDCl₃): δ 6.644 (s, 2H), 3.762 (s, 3H), 2.382 (s, 6H).

b) 2-Bromo-1-bromomethyl-5-methoxy-3-methyl-benzene

A solution of 2-bromo-5-methoxy-1,3-dimethyl-benzene ((Example 192: stepa) 1.01 g, 4.70 mmol) in CCl₄ (50 mL) was treated withN-bromosuccinamide and AIBN (catalytic amount) and heated to 75° C. 3.5h. The reaction was diluted with CH₂Cl₂ and washed with saturatedaqueous NaHCO₃. The organic layer was dried over MgSO₄ and concentratedin vacuo to afford the product2-bromo-1-bromomethyl-5-methoxy-3-methyl-benzene (1.27 g, 92%) as a paleorange solid. ¹H NMR (CDCl₃): δ 6.641 (s, 2H), 4.601 (s, 2H), 3.760 (s,3H), 2.380 (s, 3H).

c) (2-Bromo-5-methoxy-3-methyl-phenyl)-methanol

A solution of 2-bromo-1-bromomethyl-5-methoxy-3-methyl-benzene ((Example192: step b) 10.8 g, 36.7 mmol) in dioxane:water (1:1, 200 mL) wastreated with CaCO₃ and heated to reflux (110° C.) 18 h. The reactionmixture was cooled to room temperature and filtered by gravity to removesolid salts. The dioxane was removed in vacuo. Dilute HCl (10 mL) wasadded, and the mixture was extracted with CH₂Cl₂ (2×150 mL). Thecombined organic layers were dried over MgSO₄. The solvents were removedin vacuo to afford a pale orange oil, which slowly solidified uponstanding. Silica gel chromatography (25% EtOAc in hexanes) yielded theproduct (2-bromo-5-methoxy-3-methyl-phenyl)-methanol (1.03 g, 12%) as ayellow oil. ¹H NMR (CDCl₃): δ 6.905 (d, 1H, J=3.2 Hz), 6.746 (d, 1H,J=3.2 Hz), 4.720 (d, 2H, J=3.6 Hz), 3.798 (s, 3H), 2.390 (s, 3H).

d) (2-Bromo-5-methoxy-3-methyl-benzyloxy)-acetic acid tert-butyl ester

A solution of (2-bromo-5-methoxy-3-methyl-phenyl)-methanol ((Example192: step c) 0.800 g, 3.46 mmol) in DMF (10 mL) was cooled to 0° C. andtreated with NaH (0.100 g of 95% dispersion, 4.15 mmol) and allowed towarm to room temperature 30 min. The mixture was then treated withtert-butyl bromoacetate (0.614 mL, 4.15 mmol) and stirred at roomtemperature 1 h. The reaction was diluted with water and extracted withEtOAc (2×125 mL). The combined organic layers were washed well withwater (3×300 mL), dried over MgSO₄, and concentrated in vacuo to affordthe product (2-bromo-5-methoxy-3-methyl-benzyloxy)-acetic acidtert-butyl ester (1.19 g, 98%) as a yellow oil. ¹H NMR (CDCl₃): δ 6.967(d, 1H, J=2.8 Hz), 6.745 (d, 1H, J=3.2 Hz), 4.683 (s, 2H), 4.086 (s,2H), 3.794 (s, 3H), 2.380 (s, 3H), 1.496 (s, 9H).

e)[5-Methoxy-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester

A solution of (2-bromo-5-methoxy-3-methyl-benzyloxy)-acetic acidtert-butyl ester ((Example 192: step d) 1.19 g, 3.45 mmol) in dioxane(10 mL) was treated with PdCl₂(PPh₃)₂ (0.242 g, 0.345 mmol) andtriethylamine (2.88 mL, 20.7 mmol).4,4,5,5-Tetramethyl-1,3,2-dioxaborolane (1.00 mL, 6.89 mmol) was addedslowly and the mixture heated to 80° C. 15 h. The reaction was dilutedwith EtOAc and washed with brine (2×50 mL). The organic layer was driedover MgSO₄ and concentrated in vacuo. Silica gel chromatography (25%EtOAc in hexanes) afforded the product[5-methoxy-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester (0.793 g, 58%) as a brown oil. The crude materialwas used directly in the next reaction.

f)3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-methoxy-6-methyl-biphenyl-2-ylmethoxy}-aceticacid tert-butyl ester

A solution of[5-methoxy-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester ((Example 192: step e) 0.790 g, 2.01 mmol) intolutene:EtOH (2:1, 15 mL) was treated with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) 0.247 g, 0.503 mmol),aqueous Na₂CO₃ (2 M, 2.01 mL, 4.03 mmol), and Pd(PPh₃)₄ (0.116 g, 0.101mmol). The mixture was heated to 80° C. 16.3 h. The reaction was dilutedwith EtOAc and washed with brine (2×25 mL). The organic layer was driedover MgSO₄ and concentrated in vacuo. Silica gel chromatography (5%–60%EtOAc in hexanes raised in 5% increments) afforded the product3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-methoxy-6-methyl-biphenyl-2-ylmethoxy}-aceticacid tert-butyl ester (0.107 g, 31%) as an off-white solid. ¹H NMR(CDCl₃): δ 8.013 (d, 1H, J=7.6 Hz), 7.961 (s, 1H), 7.934 (t, 1H, J=1.6Hz), 7.570 (t, 1H, J=7.6 Hz), 7.440 (d, 1H, J=2.0 Hz), 6.896 (d, 1H,J=2.4 Hz), 6.832 (d, 1H, J=2.4 Hz), 4.200 (s, 2H), 3.876 (s, 3H), 3.868(s, 2H), 2.630 (s, 3H), 2.036 (s, 3H), 1.585 (s, 9H), 1.540 (s, 9H).C₃₂H₄₀N₂O₈S₃: 677.19 (M+1) found 676.90.

g)[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylmethoxy]-aceticacid trifluoroacetate

A solution of3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-methoxy-6-methyl-biphenyl-2-ylmethoxy}-aceticacid tert-butyl ester ((Example 192: step f) 0.107 g, 0.158 mmol) inCH₂Cl₂ (10 mL) was treated with 50% trifluoroacetic acid in CH₂Cl₂ (10mL) and stirred at room temperature 4 h. Solvents were evaporated invacuo. Preparatory HPLC (5–50% acetonitrile in 1% TFA/water over 30min.) afforded the product[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylmethoxy]-aceticacid trifluoroacetate (0.080 g, 97%) as a white glassy solid. ¹H NMR(MeOD): δ 8.345 (s, 1H), 8.047 (d, 1H, J=8.8 Hz), 7.848 (t, 1H, J=1.6Hz), 7.692 (t, 1H, J=7.6 Hz), 7.554 (d, 1H, J=7.6 Hz), 6.992 (d, 1H,J=2.0 Hz), 6.871 (d, 1H, J=2.0 Hz), 4.202 (d, 2H, J=5.6 Hz), 3.852 (s,3H), 3.818 (d, 2H, J=2.4 Hz), 2.736 (s, 3H), 1.999 (s, 3H).C₂₃H₂₄N₂O₆S₃: 521.08 (M+1) found 521.00.

Example 193

a)[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-hydroxy-6-methyl-biphenyl-2-ylmethoxy]-aceticacid trifluoroacetate

A solution of[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylmethoxy]-aceticacid ((Example 192: step g) 0.077 g, 0.0148 mmol) in dry CH₂Cl₂ (10 mL)was cooled to 0° C. and treated with BBr₃ (0.592 mL, 0.592 mmol)dropwise. The reaction stirred at 0° C. for 30 min. then was allowed towarm to room temperature and stir 27 h. The reaction mixture was cooledto 0° C. and quenched with MeOH. Some HBr evolution was seen. Allsolvents were evaporated in vacuo, and the residue was taken up in EtOAc(100 mL) and washed with water (1×75 mL) and brine (2×50 mL). Theorganic layer was dried over MgSO₄ and concentrated in vacuo.Preparatory HPLC (5–50% acetonitrile in 1% TFA/water over 30 min.)afforded the product[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-hydroxy-6-methyl-biphenyl-2-ylmethoxy]-aceticacid trifloroacetate (0.039, 52%) as a white glassy solid. ¹H NMR(MeOD): δ 8.344 (s, 1H), 8.090 (d, 1H, J=8.0 Hz), 7.877 (t, 1H, J=2.0Hz), 7.721 (t, 1H, J=7.6 Hz), 7.572 (d, 1H, J=7.6 Hz), 6.778 (d, 1H,J=2.8 Hz), 6.735 (d, 1H, J=2.0 Hz), 2.710 (s, 3H), 2.028 (s, 2H), 1.935(s, 3H), 1.254 (t, 2H, J=7.6 Hz).

Example 1944-{2′-[3-(2-Benzenesulfonylamino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)(4-{2′-[3-(2-Amino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester

A solution of[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 25: step c) 0.150 g, 0.290 mmol) in dryCH₂Cl₂ (10 mL) was treated with pyridine (0.026 mL, 0.319 mol) andp-nitrophenyl chloroformate (0.064 g, 0.319 mmol) and stirred 1.7 h. Thereaction mixture was treated with ethylene diamine (0.194 mL, 2.90 mmol)and triethylamine (0.485 mL, 3.48 mmol) and stirred at room temperature16 h. The reaction was diluted with CH₂Cl₂ and washed with water (3×50mL). The combined organic layers were dried over MgSO₄ and concentratedin vacuo to afford the product[(4-{2′-[3-(2-amino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester (0.145 g, 82%) as a tan solid. ¹H NMR (MeOD): δ8.195 (s, 1H), 8.057 (d, 1H, J=8.0 Hz), 7.902 (t, 1H, J=1.6 Hz), 7.718(t, 1H, J=8.0 Hz), 7.554 (d, 1H, J=8.0 Hz), 7.511 (d, 1H, J=8.0 Hz),7.289 (t, 1H, J=7.6 Hz), 7.119 (d, 1H, J=7.2 Hz), 3.099 (m, 2H), 2.676(s, 3H), 2.621 (m, 2H), 2.007 (s, 3H), 1.511 (s, 9H). C₂₇H₃₃N₅O₅S₃:604.16 (M+1) found 603.90.

b)4-{2′-[3-(2-Benzenesulfonylamino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of[(4-{2′-[3-(2-amino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester ((Example 194: step a) 0.060 g, 0.099 mmol) inCH₂Cl₂ (10 mL) was treated with phenylsulfonyl chloride (0.015 mL, 0.119mmol) and triethylamine (0.033 mL, 0.238 mmol) and stirred 16 h. Thereaction mixture was diluted with CH₂Cl₂ and washed with water (2×25mL). The organic layer was dried over MgSO₄ and concentrated in vacuo.The residue was taken up in CH₂Cl₂ (10 mL), treated with trifluoroaceticacid (2 mL), and stirred at room temperature 1.5 h. The solvents wereevaporated in vacuo. Preparatory HPLC (10–80% acetonitrile in 1%TFA/water over 30 min.) afforded the product4-{2′-[3-(2-benzenesulfonylamino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.026 g, 41%) as a white glassy solid. ¹H NMR (MeOD):δ 8.292 (s, 1H), 8.036 (d, 1H, J=8.0 Hz), 7.878 (t, 1H, J=1.6 Hz), 7.820(d, 2H, J=6.8 Hz), 7.534 (t, 1H, J=1.6 Hz), 7.694 (t, 1H, J=8.0 Hz),7.616 (m, 1H), 7.562 (d, 2H, J=7.6 Hz), 7.438 (d, 1H, J=7.6 Hz), 7.276(t, 1H, J=7.6 Hz), 7.212 (d, 1H, J=7.2 Hz), 3.075 (q, 2H, J=4.8 Hz),2.448 (dt, 2H, J=6.0 Hz, J=2.4 Hz), 2.710 (s, 3H), 2.003 (s, 3H).

Example 195

a)4-{2′-[3-(2-Methanesulfonylamino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of[(4-{2′-[3-(2-amino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester ((Example 194: step a) 0.050 g, 0.083 mmol) inCH₂Cl₂ (10 mL) was treated with methylsulfonylchloride (9.50 μL, 0.099mmol) and triethylamine (27.7 μL, 0.199 mmol) and stirred at roomtemperature 7 h. The reaction was diluted with CH₂Cl₂ and washed withwater (1×50 mL). The organic layer was dried over MgSO₄, concentrated invacuo, taken up in CH₂Cl₂ (8 mL), treated with trifluoroacetic acid (0.4mL) and stirred at room temperature 2 h. Solvents were evaporated invacuo. Preparatory HPLC (10–50% acetonitrile in 1% TFA/water over 30min.) afforded the product4-{2′-[3-(2-methanesulfonylamino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.023 g, 48%) as a white glassy solid. ¹H NMR (MeOD):δ 8.305 (s, 1H), 8.052 (d, 1H, J=9.2 Hz), 7.887 (t, 1H, J=1.6 Hz), 7.719(t, 1H, J=7.6 Hz), 7.571 (d, 1H, J=7.2 Hz), 7.450 (d, 1H, J=7.2 Hz),7.284 (t, 1H, J=8.0 Hz), 7.131 (d, 1H, J=7.6 Hz), 3.140 (m, 2H), 3.040(m, 2H), 2.898 (s, 3H), 2.718 (s, 3H), 2.005 (s, 3H). C₂₃H₂₇N₅O₅S₄:582.09 (M+1) found 582.00.

Example 196[3-(2-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-ethyl)-ureido]-aceticacid trifluoroacetate

a){3-[2-(3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-ethyl]-ureido}-aceticacid methyl ester

A solution of[(4-{2′-[3-(2-amino-ethyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester ((Example 194: step a) 0.030 g, 0.050 mmol) inCH₂Cl₂ (10 mL) was treated with ethyl isocyanatoacetate (6.70 μL, 0.060mmol) and stirred at room temperature 35 min. The reaction was dilutedwith CH₂Cl₂ and washed with water (1×15 mL). The organic layer was driedover MgSO₄ and concentrated in vacuo to afford the product{3-[2-(3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-ethyl]-ureido}-aceticacid methyl ester (0.031 g, 86%) as an off-white solid. C₃₂H₄₀N₆O₈S₃:733.21 (M+1) found 732.90.

b){3-[2-(3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-ethyl]-ureido}-aceticacid

A solution of{3-[2-(3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-ethyl]-ureido}-aceticacid methyl ester ((Example 197: step a) 0.031 g, 0.042 mmol) inMeOH:water (2:1, 15 mL) was treated with NaOH (10 N, 0.042 mL, 0.420mmol) and stirred at room temperature 18 h. MeOH was evaporated in vacuoand the remaining aqueous solution was acidified to pH 5 with glacialacetic acid. The solution was extracted with CH₂Cl₂ (3×50 mL). Thecombined organic layers were dried over MgSO₄ and evaporated in vacuo toafford the product{3-[2-(3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-ethyl]-ureido}-aceticacid (0.025 g, 83%) as an off-white solid. The crude material was useddirectly in the next reaction.

c)[3-(2-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-ethyl)-ureido]-aceticacid trifluoroacetate

A suspension of{3-[2-(3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-ethyl]-ureido}-aceticacid ((Example 196: step b) 0.025 g, 0.035 mmol) in CH₂Cl₂ (10 mL) wastreated with trifluoroacetic acid (1.00 mL) and stirred at roomtemperature 1.2 h. Solvents were removed in vacuo. Preparatory HPLC(10–80% acetonitrile in 1% TFA/water over 30 min.) afforded the product[3-(2-{3-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-ethyl)-ureido]-aceticacid trifluoroacetate (0.013 g, 60%) as a white glassy solid. ¹H NMR(CD₃CN): δ 8.099 (s, 1H), 8.048 (d, 1H, J=9.6 Hz), 7.815 (t, 1H, J=1.6Hz), 7.709 (t, 1H, J=8.0 Hz), 7.575 (d, 1H, J=7.6 Hz), 7.498 (d, 1H,J=8.0 Hz), 7.295 (t, 1H, J=7.6 Hz), 7.161 (d, 1H, J=8.0 Hz), 3.756 (s,2H), 2.979 (s br, 4H), 2.681 (s, 3H), 2.079 (s, 3H).

Example 197

a)5-methylsulfanyl-4-[6′-methyl-2′-(N′-methanesulfonylureido)-biphenyl-3-sulfonyl]-thiophene-2-carboxamidine

A solution of[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 25: step c) 0.050 g, 0.097 mmol) inCH₂Cl₂ (5 mL) was treated with pyridine (8.6 μL, 0.106 mmol) andp-nitrophenylchloroformate (0.021 g, 0.106 mmol) and stirred 2 h. Themixture was treated with methane sulfonamide (0.018 g, 0.193 mmol) andtriethylamine (0.108 mL, 0.773 mmol) and stirred 2 h. The reactionmixture was diluted with CH₂Cl₂ and washed with water (2×25 mL). Theorganic layer was dried over MgSO₄ and concentrated in vacuo. Theresidue was taken up in CH₂Cl₂ (5 mL), treated with trifluoroacetic acid(1.00 mL), and stirred 1 h. Solvents were evaporated in vacuo.Preparatory HPLC (10–80% acetonitrile in 1% TFA/water over 30 min.)afforded the title compound (0.015 g, 57%) as a white glassy solid. ¹HNMR (MeOD): δ 8.359 (s, 1H), 8.123 (d, 1H, J=9.6 Hz), 7.993 (t, 1H J=1.6Hz), 7.790 (t, 1H, J=8.4 Hz), 7.625 (d, 1H, J=7.6 Hz), 7.370 (t, 1H,J=8.0 Hz), 7.244 (d, 1H, J=7.2 Hz), 7.170 (d, 1H, J=7.2 Hz), 3.008 (s,3H), 2.722 (s, 3H), 2.003 (s, 3H). C₂₁H₂₂N₄O₅S₄: 539.05 (M+1) found538.90.

Example 1984-[4′-Methoxy-6′-methyl-2′-(2-oxo-imidazolidin-1-yl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 2-Bromo-5-methoxy-3-methyl-benzoic acid

A solution of (2-bromo-5-methoxy-3-methyl-phenyl)-methanol ((Example192: step c) 7.85 g, 34.0 mmol) in acetone (300 mL) was heated to 60° C.and treated over 25 min. with KMnO₄ (12.6 g, 79.8 mmol) as an aqueoussolution (175 mL). The mixture was heated to 60° C. for an additional 35min. A saturated aqueous solution of NaHSO₃ was added until the solutionturned beige in color. Concentrated NH₄OH was added to pH 10 and thesolids were filtered through a medium porosity fritted funnel. Thefiltrate was acidified to pH 4 with concentrated HCl, and the solutionwas extracted with ether (2×200 mL). The combined organic layers weredried over MgSO₄ and concentrated in vacuo to afford the product2-bromo-5-methoxy-3-methyl-benzoic acid (4.15 g, 50%) as a white solid.¹H NMR (MeOD): δ 6.968 (d, 1H, J=2.8 Hz), 6.775 (d, 1H, J=3.2 Hz), 3.776(s, 3H), 2.352 (s, 3H).

b) (2-Bromo-5-methoxy-3-methyl-phenyl)-carbamic acid tert-butyl ester

A solution of 2-bromo-5-methoxy-3-methyl-benzoic acid ((Example 198:step a) 3.39 g, 13.8 mmol) in dry tert-butanol was treated with DPPA(3.58 mL, 16.6 mmol) dropwise and stirred 5 min. The solution wastreated with diisopropylethylamine (2.89 mL, 16.6 mmol) and heated to80° C. 17.5 h. Tert-butanol was removed in vacuo. The residue was takenup in EtOAc and washed with saturated aqueous NaHCO₃ (2×60 mL) and water(1×60 mL). The combined organic layers were dried over MgSO₄ andconcentrated in vacuo. Silica gel chromatography (10% EtOAc in hexanes)afforded the product (2-bromo-5-methoxy-3-methyl-phenyl)-carbamic acidtert-butyl ester (3.05 g, 70%) as a colorless oil. ¹H NMR (CDCl₃): δ7.701 (d, 1H, J=1.6 Hz), 7.146 (s, NH), 6.517 (d, 1H, J=3.2 Hz), 3.797(s, 3H), 2.360 (s, 3H), 1.534 (s, 9H).

c) 2-Bromo-5-methoxy-3-methyl-phenylamine

A solution of (2-bromo-5-methoxy-3-methyl-phenyl)-carbamic acidtert-butyl ester ((Example 198: step b) 3.00 g, 9.49 mmol) in CH₂Cl₂ (50mL) was treated with trifluoroacetic acid (7.00 mL) dropwise. Thesolution was stirred at room temperature 1.3 h. The solvents wereevaporated in vacuo to yield the product2-bromo-5-methoxy-3-methyl-phenylamine (2.04 g, 65%) as a yellow solidtrifluoroacetate salt. The crude mixture was used directly in the nextreaction.

d)5-Methoxy-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine

A solution of 2-bromo-5-methoxy-3-methyl-phenylamine ((Example 198: stepc) 2.04 g, 6.18 mmol) in dry dioxane (100 mL) was treated withtriethylamine (5.26 mL, 37.7 mmol), 2-(dicyclohexylphosphino)biphenyl(0.662 g, 1.89 mmol), and Pd(OAc)₂ (0.106 g, 0.472 mmol).4,4,5,5-Tetramethyl-1,3,2-dioxaborolane (4.09 mL, 28.3 mmol) was addedslowly and the mixture heated to reflux for 1 h. The dioxane wasevaporated in vacuo. The residue was taken up in EtOAc and washed withwater (2×75 mL). The organic layer was filtered by gravity to remove thepalladium residue, dried over MgSO₄ and concentrated in vacuo. Silicagel chromatography (10–25% EtOAc in hexanes raised in 5% increments)afforded the product5-methoxy-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(1.61 g, 98%) as a light brown solid. ¹H NMR (CDCl₃): δ 7.361 (d, 1H,J=7.6 Hz), 7.279 (d, 1H, J=8.0 Hz), 3.815 (s, 3H), 2.46 (s, 3H), 1.356(s, 12H).

e){[4-(2′-Amino-4′-methoxy-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

A solution of{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) 1.50 g, 3.05 mmol) intoluene:EtOH (2:1, 45 mL) was treated with5-methoxy-3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(((Example 198: step d) 1.61 g, 6.11 mmol), aqueous Na₂CO₃ (2 M, 12.2mL, 24.4 mmol) and Pd(PPh₃)₄ (0.706 g, 0.611 mmol). The mixture washeated to 80° C. 4 h. The reaction was cooled to room temperature,diluted with EtOAc, washed with brine (1×75 mL) and water (2×75 mL),dried over MgSO₄ and concentrated in vacuo. Silica gel chromatography(25% then 35% then 50% EtOAc in hexanes) afforded the product{[4-(2′-amino-4′-methoxy-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.680 g, 40%) as a yellow-brown solid. ¹H NMR(MeOD): δ 8.223 (s, 1H), 8.001 (d, 1H, J=7.2 Hz), 7.879 (t, 1H, J=1.6Hz), 7.698 (t, 1H, J=8.0 Hz), 7.549 (d, 1H, J=8.0 Hz), 6.287 (dd, 2H,J=7.2 Hz, J=2.4 Hz), 3.770 (s, 3H), 2.669 (s, 3H), 1.900 (s, 3H), 1.510(s, 9H). C₂₅H₂₉N₃O₅S₃: 548.13 (M+1) found 547.70.

f)4-[4′-Methoxy-6′-methyl-2′-(2-oxo-imidazolidin-1-yl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of{[4-(2′-amino-4′-methoxy-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 198: step e) 0.050 g, 0.091 mmol) in dryCH₂Cl₂ (10 mL) was treated with bromoethylisocyanate (0.010 mL, 0.110mmol) and stirred at room temperature 4 h. Additionalbromoethylisocyanate (0.010 mL, 0.110 mmol) was added and the reactionstirred at room temperature 15 h. The reaction mixture was washed withwater (1×15 mL), dried over MgSO₄, and concentrated in vacuo. Theresidue was taken up in CH₂Cl₂ (10 mL), treated with trifluoroaceticacid (1.00 mL), and stirred at room temperature 1 h. The solvents wereevaporated in vacuo. Preparatory HPLC (10–80% acetonitrile in 1%TFA/water over 30 min.) afforded the product4-[4′-methoxy-6′-methyl-2′-(2-oxo-imidazolidin-1-yl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.010 g, 21%) as a white glassy solid. ¹H NMR (MeOD):δ 8.354 (s, 1H), 8.032 (d, 1H, J=7.6 Hz), 7.946 (s, 1H), 7.733 (t, 1H,J=7.6 Hz), 7.574 (d, 1H, J=8.0 Hz), 7.059 (s, 1H), 6.967 (s, 1H), 3.877(s, 3H), 2.730 (s, 3H), 2.101 (s, 3H), 3.841 (dt, 4H, J=8.8 Hz, J=2.4Hz). C₂₃H₂₄N₄O₄S₃: 517.10 (M+1) found 517.10.

Example 199N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidetrifluoroacetate

A solution of{[4-(2′-amino-4′-methoxy-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 198: step e) 0.050 g, 0.091 mmol) inCH₂Cl₂ (10 mL) was treated with triethylamine (38.0 μL, 0.274 mmol) and4-methanesulfonyl-butyryl chloride (0.025 g, 0.137 mmol) as a solutionin CH₂Cl₂ (3 mL) and stirred at room temperature 3 h. The reactionmixture was washed with saturated aqueous NaHCO₃ (1×15 mL). The organiclayer was dried over MgSO₄ and trifluoroacetic acid (0.5 mL) was added.The solution stirred at room temperature 1 h and solvents were removedin vacuo. Preparatory HPLC (10–50% acetonitrile in 1% TFA/water over 30min.) afforded the productN-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidetrifluoroacetate (0.013 g, 24%) as a white glassy solid. ¹H NMR (MeOD):δ 8.309 (s, 1H), 8.032 (d, 1H, J=8.8 Hz), 7.868 (t, 1H, J=1.6 Hz), 7.684(t, 1H, J=8.0 Hz), 7.543 (d, 1H, J=8.0 Hz), 6.871 (s, 1H), 6.817 (d, 1H,J=2.4 Hz), 3.841 (s, 3H), 2.922 (s, 3H), 2.822 (t, 2H, J=7.6 Hz), 2.742(s, 3H), 2.202 (t, 2H, J=6.8 Hz), 2.063 (s, 3H), 1.765 (m, 2H).C₂₅H₂₉N₃O₆S₄: 596.09 (M+1) found 596.10.

Example 200

a)4-{2′-[3-(2-Methanesulfonyl-ethyl)-ureido]-4′-methoxy-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifloroacetate

A solution of{[4-(2′-amino-4′-methoxy-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 198: step e) 0.070 g, 0.128 mmol) in dryCH₂Cl₂ (3 mL) was treated with 1-isocyanato-2-methanesulfonyl-ethane(0.019 g, 0.128 mmol) as a solution in CH₂Cl₂ (2 mL) and stirred 20 min.The reaction mixture was washed with saturated aqueous NaHCO₃ (1×25 mL).The organic layer was dried over MgSO₄ and concentrated in vacuo. Theresidue was taken up in CH₂Cl₂ (10 mL) and treated with trifluoroaceticacid (2.00 mL), stirring at room temperature 30 min. The solvents wereremoved in vacuo. Preparatory HPLC (10–80% acetonitrile in 1% TFA/waterover 30 min.) afforded the product4-{2′-[3-(2-methanesulfonyl-ethyl)-ureido]-4′-methoxy-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.040 g, 53%) as a white glassy solid. ¹H NMR (MeOD):δ 8.300 (s, 1H), 8.031 (d, 1H, J=8.0 Hz), 7.865 (t, 1H, J=1.6 Hz), 7.688(t, 1H, J=7.6 Hz), 7.568 (d, 1H, J=8.0 Hz), 7.063 (d, 1H, J=1.6 Hz),6.730 (d, 1H, J=1.6 Hz), 3.818 (s, 3H), 3.507 (t, 2H, J=6.4 Hz), 3.171(t, 2H, J=6.0 Hz), 2.928 (s, 3H), 2.725 (s, 3H), 2.315 (s, 3H).C₂₄H₂₈N₄O₆S₄: 597.09 (M+1) found 597.00.

Example 2014-{2′-[3-(4-Methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 2-(4-Methylsulfanyl-butyl)-isoindole-1,3-dione

A solution of 2-(4-bromo-butyl)-isoindole-1,3-dione (1.00 g, 3.54 mmol)in MeOH (60 mL) was treated with sodium thiomethoxide (0.298 g, 4.25mmol) and heated to reflux 18 h. The solvent was evaporated in vacuo andthe residue partitioned between EtOAc and water. The aqueous layer wasfurther extracted with EtOAc (1×75 mL). The organic layers were driedover MgSO₄ and concentrated in vacuo to afford the product2-(4-methylsulfanyl-butyl)-isoindole-1,3-dione (0.803 g, 91%). ¹H NMR(MeOD) 7.844 (m, 4H), 3.704 (t, 2H, J=7.2 Hz), 2.549 (t, 2H, J=7.2 Hz),2.063 (s, 3H), 1.792 (quint, 2H, J=7.2 Hz), 1.731 (quint, 2H, J=7.2 Hz).

b) 2-(4-Methanesulfonyl-butyl)-isoindole-1,3-dione

A solution of 2-(4-methylsulfanyl-butyl)-isoindole-1,3-dione ((Example201: step a) 1.35 g, 5.42 mmol) in CH₂Cl₂ (50 mL) was treated with3-chloroperbenzoic acid (mCPBA, 3.03 g, 13.5 mmol) and stirred at roomtemperature 17 h. The solution was washed with aqueous Na₂S₂O₃ (2×40 mL)and water (1×40 mL). The organic layer was dried over MgSO₄ andconcentrated in vacuo to afford the product2-(4-methanesulfonyl-butyl)-isoindole-1,3-dione (0.866 g, 57%). ¹H NMR(MeOD): δ 7.827 (m, 4H), 3.732 (t, 2H, J=6.4 Hz), 3.193 (t, 2H, J=7.2Hz), 2.939 (s, 3H), 1.843 (m, 4H).

c) 4-Methanesulfonyl-butylamine

A solution of 2-(4-methanesulfonyl-butyl)-isoindole-1,3-dione ((Example201: step b) 0.866 g, 3.08 mmol) in EtOH (30 mL) was treated withhydrazine and stirred at room temperature 18 h. The solid precipitatewas removed by filtration and the filtrate was concentrated in vacuo. Toremove any excess hydrazine, the resulting waxy solid was titrated withtoluene and with THF and placed under high vacuum overnight to affordthe product (0.400 g, 86%) as a waxy, off-white solid. ¹NMR (MeOD): δ3.153 (dd, 2H, J=8.8 Hz, J=0.0 Hz), 2.962 (s, 3H), 2.582 (dd, 2H, J=7.6Hz, J=0.0 Hz), 1.811 (m, 2H) 1.747 (m, 2H).

d)4-{2′-[3-(4-Methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

A solution of[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 25: step c) 0.100 g, 0.193 mmol) inCH₂Cl₂ (10 mL) was treated with pyridine (0.017 mL, 0.213 mmol) andp-nitrophenylchloroformate (0.043 g, 0.213 mmol) and stirred 2 h. Thesolution was treated with 4-methanesulfonylbutylamine (Example 201: stepc, 0.035 g, 0.232 mmol) and triethylamine (0.215 mL, 1.54 mmol) andstirred 2 h. The mixture was diluted with CH₂Cl₂ and washed with water(1×50 mL). The organic layer was dried over MgSO₄ and filtered. Theremaining CH₂Cl₂ solution was treated with trifluoroacetic acid (1.00mL) and stirred 1.5 h. The solvents were evaporated in vacuo.Preparatory HPLC (10–50% acetonitrile in 1% TFA/water over 30 min.)afforded the product4-{2′-[3-(4-methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate (0.022 g, 19%) as a white glassy solid. ¹H NMR (MeOD):δ 8.326 (s, 1H), 8.069 (d, 1H, J=8.0 Hz), 7.917 (t, 1H, J=1.6 Hz), 7.740(t, 1H, J=8.0 Hz), 7.586 (d, 1H, J=7.6 Hz), 7.441 (d, 1H, J=7.2 Hz),7.305 (t, 1H, J=8.0 Hz), 7.151 (d, 1H, J=8.0 Hz), 3.116 (dd, 2H, J=8.8Hz, J=6.4 Hz), 3.069 (t, 2H, J=6.8 Hz), 2.962 (s, 3H), 2.739 (s, 3H),2.025 (s, 3H) 1.732 (quint, 2H, J=7.6 Hz), 1.506 (quint, 2H, J=7.6 Hz).C₂₅H₃₀N₄O₅S₄: 595.11 (M+1) found 595.10.

Examples 202–208

A solution of[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 25: step c) 1.00 g, 1.93 mmol) in dryCH₂Cl₂ (20 mL) was treated with pyridine (0.172 mL, 2.13 mmol) andp-nitrophenylchloroformate (0.428 g, 2.13 mmol). The mixture was stirredat room temperature 2 h. The solution of the resulting carbamate,{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-carbamicacid 4-nitro-phenyl ester, was divided into vials and treated with thefollowing amines (1.1 equivalents) and triethylamine (8.0 equivalents).

Example 202 2-((4-Bromo-phenyl)-ethylamine) Example 203(3-Phenyl-propylamine) Example 204 (Benzylamine) Example 205(2-Amino-3-phenyl-propionic acid) Example 206(6-Amino-2-tert-butoxycarbonylamino-hexanoic acid) Example 207(2-(1H-Indol-3-yl)-ethylamine) Example 208 (3,3-Diphenyl-propylamine)

The reaction mixtures stirred at room temperature 4 h. The solutionswere washed with water and the organic layers dried over MgSO₄ andconcentrated in vacuo. The residues were taken up in CH₂Cl₂ (1 mL) andtreated with trifluoroacetic acid (0.25 mL) for 2 h. Solvents wereevaporated in vacuo. Preparatory HPLC (10–80% acetonitrile in 1%TFA/water over 30 min.) afforded the products shown in Examples 203–208.All were white glassy solids.

Example 2024-(2′-{3-[2-(4-Bromo-phenyl)-ethyl]-ureido}-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.299 (s, 1H), 8.075 (d, 1H, J=8.4 Hz), 7.894 t, 1H,J=1.6 Hz), 7.708 (t, 1H, J=8.0 Hz), 7.529 (d, 1H, J=8.4 Hz), 7.376 (d,2H, J=8.4 Hz), 7.834 (t, 1H, J=8.4 Hz), 7.279 (t, 1H, J=7.6 Hz), 7.134(d, 1H, J=7.6 Hz), 6.957 (d, 2H, J=7.6 Hz), 3.20 (m, 2H), 2.656 (s, 3H),2.555 (m, 2H), 1.995 (s, 3H). C₂₈H₂₇BrN₄O₃S₃: 643.04 (M+1) found 643.00.

Example 2034-{6′-Methyl-2′-[3-(3-phenyl-propyl)-ureido]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.293 (s, 1H), 8.056 (d, 1H, J=8.0 Hz), 7.916 (t, 1H,J=1.6 Hz), 7.715 (t, 1H, J=7.6 Hz), 7.592 (d, 1H, J=7.6 Hz), 7.449 (d,1H, J=7.6 Hz), 7.308 (t, 1H, J=7.6 Hz), 7.255 (d, 2H, J=7.2 Hz), 7.166(t, 2H, J=7.2 Hz), 7.147 (d, 2H, J=8.0 Hz), 3.021 (t, 2H, J=6.4 Hz),2.697 (s, 3H), 2.515 (t, 2H, J=7.6 Hz), 2.026 (s, 3H), 1.638 (quint, 2H,J=7.6 Hz). C₂₉H₃₀N₄O₃S₃: 579.15 (M+1) found 579.10.

Example 2044-[2′-(3-Benzyl-ureido)-6′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.243 (s, 1H), 8.073 (d, 1H, J=9.2 Hz), 7.951 (t, 1H,J=1.6 Hz), 7.685 (t, 1H, J=8.0 Hz), 7.558 (d, 1H, J=7.6 Hz), 7.406 (d,1H, J=8.8 Hz), 7.301 (t, 1H, J=8.0 Hz), 7.232 (m, 4H), 6.977 (d, 2H,J=8.4 Hz), 4.137 (q, 2H, J=16 Hz), 2.649 (s, 3H), 2.029 (s, 3H).C₂₇H₂₆N₄O₃S₃: 55.12 (M+1) found 551.10.

Example 2052-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-3-phenyl-propionicacid trifluoroacetate

¹H NMR (CD₃CN): δ 10.027 (s br, 1H), 8.083 (s, 1H), 7.875 (s, 1H), 7.807(s, 1H), 7.729 (t, 1H, J=7.525 Hz), 7.525 (d, 1H, J=6.8 Hz), 7.429 (m,1H), 7.272 (m, 5H), 7.101 (m, 2H), 5.446 (t, 1H, J=10.4 Hz), 3.077 (m,2H), 2.674 (s, 3H), 2.018 (s, 3H). C₂₉H₂₈N₄O₅S₃: 609.12 (M+1) found609.10.

Example 2062-Amino-6-{3-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-hexanoicacid trifluoroacetate

¹H NMR (CD₃CN): δ 8.135 (s, 1H), 8.037 (d, 1H, J=7.6 Hz), 7.839 (s, 1H),7.702 (t, 1H, J=7.6 Hz), 7.566 (d, 1H, J=8.0 Hz), 7.413 (d, 1H, J=8.0Hz), 7.297 (t, 1H, J=7.6 Hz), 7.186 (d, 1H, J=7.2 Hz), 3.951 (s br, 1H),2.939 (t, 2H, J=1.6 Hz), 2.674 (s, 3H), 2.043 (s, 3H), 1.854 (m, 2H),1.311 (m, 4H). C₂₆H₃₁N₅O₅S₃: 590.15 (M+1) found 590.10.

Example 2074-(2′-{3-[2-(1H-Indol-3-yl)-ethyl]-ureido}-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.270 (s, 1H), 8.069 (d, 1H, J=8.0 Hz), 7.901 (t, 1H,J=1.6 Hz), 7.661 (t, 1H, J=7.2 Hz), 7.467 (t, 2H, J=8.8 Hz), 7.351 (t,2H, J=6.8 Hz), 7.296 (t, 1H, J=7.6 Hz), 7.163 (d, 1H, J=8.0 Hz), 7.103(t, 1H, J=7.2 Hz), 6.991 (t, 1H, J=6.8), 6.855 (s, 1H), 3.428 (m, 2H),2.712 (t, 2H, J=8.8 Hz), 2.575 (s, 3H), 2.028 (s, 3H). C₃₀H₂₉N₅O₃S₃:604.14 (M+1) found 604.10.

Example 2084-{2′-[3-(3,3-Diphenyl-propyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

¹H NMR (MeOD): δ 8.263 (s, 1H), 8.022 (d, 1H, J=8.8 Hz), 7.913 (t, 1H,J=1.6 Hz), 7.679 (t, 1H, J=7.6 Hz), 7.585 (d, 1H, J=7.6 Hz), 7.416 (d,1H, J=7.416 Hz), 7.253 (m, 9H), 7.163 (t, 3H, J=6.8 Hz), 3.878 (t, 1H,J=7.6 Hz), 2.944 (dt, 2H, J=6.8 Hz, J=2.4 Hz), 2.689 (s, 3H), 2.081 (q,2H, J=7.6 Hz), 2.032 (s, 3H). C₃₅H₃₄N₄O₃S₃: 655.18 (M+1) found 655.10.

Example 209N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidetrifluoroacetate

a) 4-Methanesulfonyl-butyryl chloride

4-Methylsulfanyl-butyric acid methyl ester (0.50 g, 3.37 mmol) indichloromethane [5 mL] was added dropwise to a solution of mCPBA (1.57g, 9.10 mmol) in dichloromethane [15 mL] at room temperature and thenrefluxed for 1 hour. The solution was then cooled to room temperatureand solid sodium sulfite was added. The reaction was filtered, washedwith 1N NaOH, brine and dried with magnesium sulfate and evaporated. Thecrude residue was then dissolved in THF/methanol/water [2/1/0.1 mL] andlithium hydroxide (0.18 g, 4.38 mmol) was added. The reaction was heatedto 50° C. for 24 hours. The reaction was cooled to room temperature and1N HCl was added and the product was extracted with ethyl acetate, driedwith magnesium sulfate to give the product (0.12 g, 21%). ¹H-NMR(CDCl₃): δ 3.20 (t, 2H, J=7.6 Hz), 2.98 (s, 3H), 2.52 (t, 2H, J=7.2 Hz),2.09 (m, 2H). The acid was dissolved in dichloromethane [5 mL] andthionyl chloride [5 mL] was added. The reaction was stirred at roomtemperature for 3 hours, evaporated and used directly in the next step.

b)(Imino-{4-[2′-(4-methanesulfonyl-butyrylamino)-6′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

4-Methanesulfonyl-butyryl chloride (0.333 g, 1.81 mmol) [example 209,step a] was added to a solution of{[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.468 g, 0.905 mmol) [example 25, step c] andtriethylamine (1.83 g, 18.1 mmol) in dichloromethane at roomtemperature. The reaction was stirred for 24 hours and then evaporated.Column chromatography (25% EtOAc in hexanes) of the residue yielded thetitle compound (0.520 g, 78%) as a solid. ESI-MS (m/z): Calcd. forC₂₉H₃₅N₃O₇S₄: 665.14; found: 665.8.

c)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidetrifluoroacetate

A solution of dichloromethane/trifluoroacetic acid (1/1) [1 mL] wasadded to(imino-{4-[2′-(4-methanesulfonyl-butyrylamino)-6′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (0.011 g, 0.017 mmol) [example 209, step b] atroom temperature and stirred for 1 hour. The reaction mixture wasevaporated and purified via reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to give the title compound (0.004 g, 36%) as a solid.¹H-NMR (MeOD): δ 8.29 (s, 1H), 8.04 (md, 1H, J=6.4 Hz), 7.87 (t, 1H,J=2.0 Hz), 7.69 (t, 1H, J=7.6 Hz), 7.54 (md, 1H, J=7.6 Hz), 7.34 (t, 1H,J=7.6 Hz), 7.28 (d, 1H, J=7.2 Hz), 7.18 (d, 1H, J=7.2 Hz), 2.91 (s, 3H),2.78 (t, 2H, J=7.6 Hz), 2.72 (s, 3H), 2.18 (t, 2H, J=7.6 Hz), 2.07 (s,3H), 1.74 (m, 2H). ESI-MS (m/z): Calcd. for C₂₄H₂₇N₃O₅S₄: 566.1; found:566.8.

Example 210N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-4-sulfamoyl-butyramidetrifluoroacetate

a)(Imino-{4-[6′-methyl-2′-(4-sulfamoyl-butyrylamino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.013 g, 0.025 mmol) [example 25, step c] wasadded to a solution of 4-sulfamoyl-butyric acid (0.011 g, 0.068 mmol),EDCI (0.013 g, 0.068 mmol) and HOBt (0.009 g, 0.068 mmol) in DMF [0.5mL] at room temperature. The reaction was stirred for 24 hours and thenevaporated. Column chromatography (25% EtOAc in hexanes) of the residueyielded the title compound (0.010 g, 60%) as a solid. ESI-MS (m/z):Calcd. for C₂₈H₃₄N₄O₇S₄: 666.13; found: 666.8.

b)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-4-sulfamoylbutyramidetrifluoroacetate

A solution of dichloromethane/trifluoroacetic acid (1/1) [1 mL] wasadded(imino-{4-[6′-methyl-2′-(4-sulfamoyl-butyrylamino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (0.010 g, 0.015 mmol) [example 210, step a] atroom temperature and stirred for 1 hour. The reaction mixture wasevaporated and purified via reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to give the title compound (0.005 g, 36%) as a solid.¹H-NMR (MeOD): δ 8.30 (s, 1H), 8.04 (md, 1H, J=7.6 Hz), 7.88 (t, 1H,J=1.6 Hz), 7.70 (t, 1H, J=7.6 Hz), 7.54 (md, 1H, J=7.6 Hz), 7.36 (t, 1H,J=7.6 Hz), 7.29 (d, 1H, J=6.8 Hz), 7.19 (d, 1H, J=8.0 Hz), 2.77–2.72 (m,5H), 2.16 (t, 2H, J=7.2 Hz), 2.09 (s, 3H), 1.76 (m, 2H). ESI-MS (m/z):Calcd. for C₂₃H₂₆N₄O₅S₄: 566.08; found: 567.1.

Example 211 11-Amino-undecanoic acid[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-amidebistrifluoroacetate

a)(10{-3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-decyl)-carbamicacid 9H-fluoren-9-ylmethyl ester

Thionyl chloride (0.86 mL, 2.36 mmol) was added to a solution of11-(9H-fluoren-9-ylmethoxycarbonylamino)-undecanoic acid (0.086 g, 0.194mmol) in dichloromethane/DMF [1 mL/1 drop] and stirred at roomtemperature for 3 hours. The reaction mixture was evaporated, dissolvedin dichloromethane [5 mL] was added dropwise to a solution of{[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.050 g, 0.097 mmol) [example 25, step c] andtriethylamine (0.03 mL, 0.19 mmol) in dichloromethane [3 mL] at roomtemperature and stirred for several hours. The crude reaction wasevaporated and column chromatography (25% EtOAc in hexanes) of theresidue yielded the title compound (0.042 g, 47%) as a solid. ESI-MS(m/z): Calcd. for C₅₀H₅₈N₄O₇S₃: 922.35; found: 923.0.

b)({4-[2′-(11-Amino-undecanoylamino)-6′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

A solution of 50% piperidine in DMF [1 mL] was added to(10-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-decyl)-carbamicacid 9H-fluoren-9-ylmethyl ester (0.040 g, 0.043 mmol) [example 211,step a] and stirred for 0.5 hours, followed by evaporation. Columnchromatography (10% MeOH in dichloromethane) of the residue yielded thetitle compound (0.024 g, 77%) as a solid. ESI-MS (m/z): Calcd. forC₃₅H₄₈N₄O₅S₃: 700.28; found: 701.0.

c) 11-Amino-undecanoic acid[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-amidebistrifluoroacetate

A solution of dichloromethane/trifluoroacetic acid (1/1) [1 mL] wasadded to({4-[2′-(11-amino-undecanoylamino)-6′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (0.005 g, 0.007 mmol) [example 211, step b] atroom temperature and stirred for 1 hour. The reaction mixture wasevaporated and purified via reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to give the title compound (0.003 g, 76%) as a solid.¹H-NMR (MeOD): δ 8.28 (s, 1H), 8.02 (d, 1H, J=7.2 Hz), 7.87 (m, 1H),7.66 (t, 1H, J=8.0 Hz), 7.53 (d, 1H, J=8.0 Hz), 7.34 (t, 1H, J=7.6 Hz),7.27 (d, 1H, J=7.6 Hz), 2.91 (t, 2H, J=8.0 Hz), 2.71 (s, 3H), 2.03 (s,3H), 1.96 (q, 2H, J=7.2 Hz), 1.65 (m, 2H), 1.41–1.12 (m, 14H). ESI-MS(m/z): Calcd. for C₃₀H₄₀N₄O₃S₃: 600.23; found: 601.2.

Example 212N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-4-trifluoromethanesulfonylamino-butyramidetrifluoroacetate

a) 4-Trifluoromethanesulfonylamino-butyric acid methyl ester

Trifluoromethanesulfonyl chloride (0.23 mL, 2.16 mmol) was addeddropwise to a solution of 4-amino-butyric acid methyl esterhydrochloride (0.30 g, 1.96 mmol) and triethylamine (0.68 mL, 4.90 mmol)in dichloromethane and stirred at room temperature for 18 hours. 1N HClwas added and the product was extracted with dichloromethane, dried withmagnesium sulfate and evaporated to give the title compound (0.42 g,85%). ¹H-NMR (CDCl₃): δ 4.89 (s, 1H), 3.12 (t, 2H, J=7.2 Hz), 2.94 (s,3H), 2.41 (t, 2H, J=7.2 Hz), 1.84 (m, 2H, J=7.2 Hz).

b) 4-Trifluoromethanesulfonylamino-butyryl chloride

4-Trifluoromethanesulfonylamino-butyric acid methyl ester (0.42 g, 1.77mmol) [example 212, step a] was taken up in methanol [2 mL] and 1N NaOHwas added [2.66 mL] and stirred for 2 hours. 1N HCl was added and theproduct was extracted with ethyl acetate, dried with magnesium sulfateand evaporated. The crude product (0.13 g, 0.57 mmol) was dissolved indichloromethane/DMF [1 mL/1 drop] and thionyl chloride (0.08 mL, 1.14was added. The reaction was stirred at room temperature for 2 hours andthen evaporated and used directly in the next step.

c)(Imino-{5-methylsulfanyl-4-[6′-methyl-2′-(4-trifluoromethanesulfonylaminobutyrylamino)-biphenyl-3-sulfonyl]-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

A solution of 4-trifluoromethanesulfonylamino-butyryl chloride (0.015 g,0.058 mmol) [example 212, step b] in dichloromethane [1 mL] was added toa solution of{[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.025 g, 0.049 mmol) [example 25, step c] indichloromethane [1 mL] at room temperature with vigorous stirring for0.5 hours. The reaction mixture was evaporated and column chromatography(25% EtOAc in hexanes) of the residue yielded the title compound (0.020g, 57%) as a solid. ESI-MS (m/z): Calcd. for C₂₉H₃₃F₃N₄O₇S₄: 734.12;found: 734.7.

d)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-4-trifluoromethanesulfonylamino-butyramidetrifluoroacetate

A solution of dichloromethane/trifluoroacetic acid (1/1) [2 mL] wasadded to(imino-{5-methylsulfanyl-4-[6′-methyl-2′-(4-trifluoromethanesulfonylaminobutyrylamino)-biphenyl-3-sulfonyl]-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (0.020 g, 0.027 mmol) [example 212, step c] atroom temperature and stirred for 1 hour. The reaction mixture wasevaporated and purified via reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to give the title compound (0.009 g, 54%) as a solid.¹H-NMR (MeOD): δ 8.29 (s, 1H), 8.03 (md, 1H, J=8.4 Hz), 7.87 (m, 1H),7.68 (t, 1H, J=7.6 Hz), 7.53 (md, 1H, J=7.6 Hz), 7.34 (t, 1H, J=7.6 Hz),7.28 (d, 1H, J=7.2 Hz), 7.19 (d, 1H, J=7.2 Hz), 2.98 (m, 2H), 2.72 (s,3H), 2.06 (s, 3H), 2.05 (t, 2H, J=7.6 Hz), 1.48 (m, 2H). ESI-MS (m/z):Calcd. for C₂₄H₂₅F₃N₄O₅S₄: 634.07; found: 635.1.

Example 213E/Z-{2-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-vinyl}-phosphonicacid trifluoroacetate

a) (2-Iodo-3-methyl-phenyl)-methanol

Thionyl chloride [5 mL] was added to 2-iodo-3-methyl-benzoic acid (2.00g, 7.63 mmol) at room temperature and heated to 50° C. for 1 hour. Thesolution was then cooled and evaporated. The crude residue was dissolvedin ethyl acetate, washed with brine and dried with magnesium sulfate.The crude product was then dissolved in THF [5 mL] and a 1M solution oflithium aluminum hydride [10.7 mL] was added at room temperature andstirred for 1 hour. Water [0.1 mL] and 15% NaOH [0.1 mL] were addedfollowed by evaporation. Column chromatography (50% EtOAc in hexanes) ofthe residue yielded the title compound (0.50 g, 26%) as a solid. ¹H-NMR(CDCl₃): δ 3.20 (t, 2H, J=7.6 Hz), 2.98 (s, 3H), 2.52 (t, 2H, J=7.2 Hz),2.09 (m, 2H).

b){[4-(2′-Hydroxymethyl-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

n-Butyllithium (2.5M) [4.03 mL] was added to a solution of(2-iodo-3-methyl-phenyl)-methanol (1.00 g, 4.04 mL) [example 213, stepa] in ether [20 mL] at −78° C. and stirred for 0.5 hours. Trimethylborate [1.13 mL, 10.1 mmol) was added and the solution was stirred for 2hours at room temperature, followed by evaporation. The crude residuewas dissolved in ethanol/toluene (1/2) [30 mL] and 2M sodium carbonate[16.2 mL] followed by addition of{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.49 g, 1.01 mmol) [example 27, step c]. Thesolution was bubbled with argon and thentetrakis(triphenylphosphine)palladium(0) (0.18 g, 0.15 mmol) was added.The reaction was refluxed for 3 hours and then cooled to roomtemperature. Ethyl acetate was added and the crude reaction was washedwith brine, dried over magnesium sulfate and evaporated. Columnchromatography (50% EtOAc in hexanes) of the residue yielded the titlecompound (0.40 g, 74%) as a solid. ESI-MS (m/z): Calcd. forC₂₅H₂₈N₂O₅S₃: 532.12; found: 532.7.

c)E/Z-(2-{3′-[5-tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-vinyl)-phosphonicacid diethylester

Manganese dioxide (0.041 g, 0.470 mmol) was added to a solution of({[4-(2′-hydroxymethyl-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.025 g, 0.047 mmol) [example 213, step b] indichloromethane [5 mL] and refluxed for 3 hours. The reaction wasfiltered through Celite and evaporated. The crude residue was dissolvedin anhydrous THF [2 mL] and added to a solution of(diethoxy-phosphorylmethyl)-phosphonic acid diethyl ester (0.011 g,0.061 mmol) and sodium hydride (0.003 g, 0.056 mmol) in THF [2 mL] atroom temperature and stirred for 0.5 hours. A solution of 1N NaOH/MeOH(1/1) [10 mL] was added and the crude product was extracted with ether,dried with magnesium sulfate and evaporated. Column chromatography (50%EtOAc in hexanes) of the residue yielded the title compound (0.019 g,57%) as a solid. ESI-MS (m/z): Calcd. for C₃₀H₃₇N₂O₇PS₃: 664.15; found:664.8.

d)E/Z-{2-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-vinyl}-phosphonicacid trifluoroacetate

Trimethylsilyl iodide (0.058 g, 0.271 mmol) was added dropwise to asolution ofE/Z-(2-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-vinyl)-phosphonicacid diethylester (0.018 g, 0.027 mmol) [example 213, step c] indichloromethane [3 mL] and heated to 45° C. for 3 hours. The reactionwas quenched with water [0.025 mL], stirred for 0.5 hours andevaporated. The crude residue was the dissolved in methanol and 20% HClwas added [0.020 mL], stirred for 1 hour and concentrated. The reactionmixture was purified via reverse-phase HPLC [acetonitrile/water (0.01%TFA)] to give the title compound (0.005 g, 28%) as a solid. ¹H-NMR(MeOD): δ 8.28 (s, 1H), 8.04 (t, 1H, J=7.6 Hz), 7.83 (s, 1H), 7.71 (t,1H, J=7.6 Hz), 7.63 (m, 1H), 7.52 (m, 1H), 7.38 (m, 1H), 7.26 (m, 1H),7.18 (t, 1H, J=7.2 Hz), 6.92 (t, 1H, J=17.6 Hz), 6.34 (t, 1H, J=18.0Hz), 2.74 (s, 3H), 2.02–1.95 (d, 3H). ESI-MS (m/z): Calcd. forC₂₁H₂₁N₂O₅PS₃: 508.04; found: 509.1.

Example 2142-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylmethylsulfanyl]-succinicacid trifluoroacetate

a) Methanesulfonic acid3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylmethylester

Methanesulfonyl chloride (0.027 g, 0.241 mmol) was added to a solutionof{[4-(2′-hydroxymethyl-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.100 g, 0.188 mmol) [example 213, step b] andtriethylamine (0.048 g, 0.470 mmol) in THF [3 mL] at room temperatureand stirred for 18 hours. Column chromatography (25% EtOAc in hexanes)of the residue yielded the title compound (0.017 g, 14%). ESI-MS (m/z):Calcd. for C₂₆H₃₀N₂O₇S₄: 610.09; found: 611.8.

b)2-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylmethylsulfanyl]-succinicacid trifluoroacetate

2-Mercapto-succinic acid (0.004 g, 0.028 mmol) was added to a solutionof methanesulfonic acid3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylmethylester (0.017 g, 0.028 mmol) [example 214, step a] and triethylamine(0.009 g, 0.084 mmol) in dichloromethane [0.5 mL] at 40° C., stirred for2 hours and then evaporated. The crude reaction was dissolved in asolution of dichloromethane/trifluoroacetic acid (1/1) [2 mL] andstirred for 1 hour. The reaction mixture was evaporated and purified viareverse-phase HPLC [acetonitrile/water (0.01% TFA)] to give the titlecompound (0.005 g, 42%) as a solid. ¹H-NMR (MeOD): δ 8.31 (s, 1H), 8.06(t, 1H, J=8.0 Hz), 7.83 (d, 1H, J=16.8 Hz), 7.70 (q, 1H, J=6.8 Hz), 7.57(t, 1H, J=7.2 Hz), 7.29–7.21 (m, 3H), 3.60–3.48 (m, 1H), 3.54 (s, 3H),3.37–3.34 (m, 1H), 2.70 (s, 3H), 2.68–2.57 (m, 1H), 2.31–2.14 (m, 1H),1.97 (s, 3H). ESI-MS (m/z): Calcd. for C₂₄H₂₄N₂O₆S₄: 564.05; found:565.1.

Example 215[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2,6-dimethyl-biphenyl-4-yloxy]-aceticacid trifluoroacetate

a){3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2,6-dimethyl-biphenyl-4-yloxy}-aceticacid tert-butyl ester

Bromo-acetic acid tert-butyl ester (0.013 mL, 0.085 mmol) was addeddropwise to a solution of{[4-(4′-hydroxy-2′,6′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.050 g, 0.077 mmol) [example 124, step b] andpotassium carbonate (0.021 g, 0.154 mmol) in acetone [1 mL] at roomtemperature and stirred for 18 hours. The reaction was evaporated andcolumn chromatography (25% EtOAc in hexanes) of the residue yielded thetitle compound (0.011 g, 28%) as a solid. ESI-MS (m/z): Calcd. forC₃₁H₃₈N₂O₇S₃: 646.18; found: 646.8.

b)[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2,6-dimethyl-biphenyl-4-yloxy]-aceticacid trifluoroacetate

A solution of dichloromethane/trifluoroacetic acid (1/1) [2 mL] wasadded to{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2,6-dimethyl-biphenyl-4-yloxy}-aceticacid tert-butyl ester (0.020 g, 0.030 mmol) [example 215, step a] atroom temperature and stirred for 1 hour. The reaction mixture wasevaporated and purified via reverse-phase HPLC [acetonitrile/water(0.01% TFA)] to give the title compound (0.011 g, 75%) as a solid.¹H-NMR (MeOD): δ 8.36 (s, 1H), 8.01 (md, 1H, J=7.6 Hz), 7.81 (m, 1H),7.72 (m, 1H), 7.51 (d, 1H, J=7.6 Hz), 7.26 (d, 1H, J=8.0 Hz), 6.74 (s,2H), 4.67 (s, 2H), 2.73 (s, 3H), 1.96 (s, 6H). ESI-MS (m/z): Calcd. forC₂₂H₂₂N₂O₅S₃: 490.07; found: 491.2.

Example 2164-{4′-Guanidino-6′-methyl-2′-[3-(2-phenylamino-ethyl)-ureido]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)[(4-{4′-Amino-6′-methyl-2′-[3-(2-phenylaminoethyl)-ureido]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester

4-Nitrophenylchloroformate (0.047 g, 0.232 mmol) was added to a solutionof{2-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-4-yl}-carbamicacid 2-trimethylsilanyl-ethyl ester (0.150 g, 0.222 mmol) [example 294,step f] and pyridine (0.018 g, 0.232 mmol) in dichloromethane [5 mL] andstirred at room temperature for 1 hour. N-1-Phenyl-ethane-1,2-diamine(0.060 g, 0.444 mmol) was added and the reaction was stirred for anadditional hour. The reaction was evaporated and column chromatography(50% EtOAc in hexanes) of the residue yielded the title compound (0.150g, 81%) as a solid. This solid was dissolved in THF [1 mL] andtetrabutylammonium fluoride [0.536 mL] was added. The reaction washeated to 50° C. and stirred for 2 hours. The reaction was evaporatedand column chromatography (50% EtOAc in hexanes) of the residue yieldedthe title compound (0.079 g, 64%) as a solid. ESI-MS (m/z): Calcd. forC₃₃H₃₈N₆O₅S₃: 694.21; found: 694.9.

b)[(4-{4′-(N′,N″-di-tert-butoxycarbonyl-guanidino)-6′-methyl-2′-[3-(2-phenylamino-ethyl)-ureido]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butylester

1,3-Bis-t-butoxycarbonyl-2-methyl-2-thiopseudourea (0.033 g, 0.114 mmol)was added to a solution of[(4-{4′-amino-6′-methyl-2′-[3-(2-phenylamino-ethyl)-ureido]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butyl ester [example 216, step a] in methanol [1 mL] and 1drop of acetic acid. The reaction was stirred at room temperature for 1hour and evaporated. The reaction was evaporated and columnchromatography (25% EtOAc in hexanes) of the residue yielded the titlecompound (0.072 g, 68%) as a solid. ESI-MS (m/z): Calcd. forC₄₄H₅₆N₈O₉S₃: 936.33; found: 936.9.

c)4-{4′-Guanidino-6′-methyl-2′-[3-(2-phenylamino-ethyl)-ureido]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

A solution of dichloromethane/trifluoroacetic acid (1/1) [1 mL] wasadded to[(4-{4′-(N′,N″-di-tert-butoxycarbonyl-guanidino)-6′-methyl-2′-[3-(2-phenylamino-ethyl)-ureido]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophen-2-yl)-imino-methyl]-carbamicacid tert-butylester (0.007 g, 0.007 mmol) [example 216, step b] at roomtemperature and stirred for 1 hour. The reaction mixture was evaporatedand purified via reverse-phase HPLC [acetonitrile/water (0.01% TFA)] togive the title compound as a solid. ¹H-NMR (MeOD): δ 8.35 (s, 1H), 8.05(md, 1H, J=8.0 Hz), 7.95 (m, 1H), 7.73 (t, 1H, J=8.0 Hz), 7.57 (m, 1H),7.39 (m, 2H), 7.14 (m, 3H), 7.05 (m, 1H), 3.37 (m, 4H), 2.71 (s, 3H),2.03 (s, 3H). ESI-MS (m/z): Calcd. for C₂₉H₃₂N₈O₃S₃: 636.18; found:637.1.

Example 2174-(3′-Formylamino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a){[4-(3′-Amino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

Following the same procedure as in Example 1, step c, reaction of3-amino-phenyl boronic acid (27 mg, 0.2 mmol),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (50 mg, 0.1 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosine)palladium(0) (29 mg, 0.025 mmol, StremChemicals Inc, Newburyport, Mass.), Na₂CO₃ (400 μL, 2M), andtoluene/EtOH mixture (2:1, 1.2 mL) afforded 35 mg (70%) afterpurification (SiO₂, flash elution: 30% EtOAc in hexanes) of the titlecompound as a white foam. ESI-MS (m/z): Calcd. for C₂₃H₂₅N₃O₄S₃: 503.6;found: 503.9, 404.1 (M−Boc).

b)4-(3′-Formylamino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{[4-(3′-Amino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (30 mg, 0.06 mmol, as prepared in Example 217,step a) was dissolved in formic acid (5 mL) and the reaction mixture wasrefluxed overnight. The formic acid was removed in vacuo and the residuewas treated with trifluoroacetic acid (50% in DCM) for 1 h at rt. Themixture was concentrated in vacuo and the residue obtained was purifiedusing C₁₈-HPLC (10–80% CH₃CN in H₂O (0.1% TFA) over 25 min) to give thetitle compound as a white solid. ¹H-NMR (CD₃OD; 400 MHz): δ 8.34 (s,1H), 8.33 (s, 1H), 8.29 (t, 1H, J=1.6 Hz), 8.11–8.13 (m, 1H), 7.96–8.03(m, 2H), 7.70 (t, 1H, J=7.7 Hz), 7.42–7.50 (m, 3H), 2.75 (s, 3H). ESI-MS(m/z): Calcd. for C₁₉H₁₇N₃O₃S₃: 432.1 (M+H); found: 432.1.

Example 2183′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-biphenyl-3-carboxylicacid amide trifluoracetate

Following the same procedure as in Example 1: step c, reaction of3-carbamoyl-phenyl boronic acid (33 mg, 0.2 mmol),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (50 mg, 0.1 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosine)palladium(0) (29 mg, 0.025 mmol, StremChemicals Inc, Newburyport, Mass.), Na₂CO₃ (400 μL, 2M), andtoluene/EtOH mixture (2:1, 1.2 mL) afforded 38 mg (72%) afterpurification (SiO₂, flash elution: 30% EtOAc in hexanes) of a white foamwhose mass was consistent with the Boc protected title intermediate.ESI-MS (m/z): Calcd. for C₂₄H₂₅N₃O₅S₃: 531.7; found: 531.9, 432.1(M−Boc). Treatment of this intermediate with trifluoroacetic acid (50%in DCM) for 1 h at rt and purification using C₁₈-HPLC (10–65% CH₃CN inH₂O (0.1% TFA) over 30 min) provided the title compound as a white solid(25 mg, 66%). ¹H-NMR (CD₃OD; 400 MHz): δ 8.34 (s, 1H), 8.33 (t, 1H,J=1.9 Hz), 8.19 (t, 1H, J=1.9 Hz), 8.00–8.05 (m, 2H), 7.85–7.88 (m, 2H),7.73 (t, 1H, J=7.8 Hz), 7.62 (t, 1H, J=7.8 Hz), 2.74 (s, 3H). ESI-MS(m/z): Calcd. for C₁₉H₁₇N₃O₃S₃: 432.2 (M+H); found: 432.2.

Example 2194-(4′-Fluoro-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Following the same procedure as in Example 1, step c, reaction of4-fluoro-2-methyl-phenyl boronic acid (35 mg, 0.2 mmol),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (50 mg, 0.1 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosine)palladium(0) (29 mg, 0.025 mmol, StremChemicals Inc, Newburyport, Mass.), Na₂CO₃ (400 μL, 2M), andtoluene/EtOH mixture (2:1, 1.2 mL) afforded after purification(Preparative TLC, 1:3 EtOAc/hexanes, 2000μ SiO₂ plate) 62 mg of{[4-(4′-fluoro-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester as a tan oil. NMR (CDCl₃; 400 MHz) δ 8.02 (s, 1H),7.91–7.97 (m, 2H), 7.51–7.57 (m, 2H), 7.14 (dd, 1H, J=8.4, 5.8 Hz),6.92–7.00 (m, 2H), 2.57 (s, 3H), 2.20 (s, 3H), 1.51 (s, 9H). Treatmentof this intermediate with trifluoroacetic acid (50% in DCM) for 1 h atrt and purification using C₁₈-HPLC (20–70% CH₃CN in H₂O (0.1% TFA) over30 min) provided the title compound as a white solid (30 mg, 60%).¹H-NMR (CD₃OD; 400 MHz) δ 8.32 (s, 1H), 8.03 (dt, 1H, J=7.0, 1.9 Hz),7.94–7.96 (m, 1H), 7.64–7.70 (m, 2H), 7.22 (dd, 1H, J=8.6, 5.8 Hz),6.98–7.09 (m, 2H), 2.72 (s, 3H), 2.22 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁₇FN₂O₂S₃: 421.2 (M+H); found: 421.2.

Example 2204-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a) 3-Methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine

To an oven-dried round bottom flask fitted with a stir bar was added4-bromo-3-methylaniline (5.7 gm, 31 mmol),4,4,5,5-tetramethyl-1,3,2-dioxaborolane (13.3 mL, 92 mmol, AldrichChemical Company), and PdCl₂(PPh₃)₂ (2.2 gm, 3.1 mmol, Strem ChemicalsInc, Newburyport, Mass.). The flask was sealed with a rubber septum,purged with Argon, and then charged with dry dioxane (100 mL) andtriethylamine (26 mL). The reaction mixture was stirred vigorously at95° C. for 16 h. After cooling to rt, the dioxane was removed in vacuoand the residue was partitioned between EtOAc (200 mL) and water (100mL). The organic layer was washed with saturated NaHCO₃ (2×75 mL), brine(50 mL), and was dried over MgSO₄. Removal of the solvents in vacuofollowed by flash chromatography of the residue yielded the product (3.3gm, 46%) as a tan oil. ¹H-NMR (CDCl₃; 400 MHz): δ 7.61–7.64 (m, 1H),6.48–6.58 (m, 2H), 3.60–3.90, (br s, 2H), 2.49 (s, 3H), 1.34 (s, 12H).ESI-MS (m/z): Calcd. for C₁₃H₂₀BNO₂: 234.1 (M+H); found: 234.2

b){4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

Following the same procedure as in Example 1, step c, reaction of3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine(432 mg, 1.86 mmol, as prepared in Example 220, step a),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (610 mg, 1.24 mmol, as prepared in Example 27,step c), tetrakis(triphenylphosine)palladium(0) (215 mg, 0.186 mmol,Strem Chemicals Inc, Newburyport, Mass.), Na₂CO₃ (5 mL, 2M), andtoluene/EtOH mixture (2:1, 15 mL) afforded 403 mg (63%) afterpurification (SiO₂, flash elution: 30% to 50% EtOAc in hexanes) of thetitle compound as a white foam. ¹H-NMR (CDCl₃, 400 MHz): δ 8.00 (s, 1H),7.87–7.92 (m, 2H), 7.47–7.55 (m, 2H), 6.98 (d, 1H, J=7.9 Hz), 6.55–6.61(m, 2H), 3.65–3.82 (br s, 2H), 2.53 (s, 3H), 2.15 (s, 3H), 1.51 (s, 9H).ESI-MS (m/z): Calcd. for C₂₄H₂₇N₃O₄S₃: 517.7; found: 517.7, 418.1(M−Boc).

c)4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

{4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (32 mg, 0.06 mmol, as prepared in Example 220,step b) was treated with trifluoroacetic (50% in DCM) for 1 h at rt andpurified using C₁₈-HPLC (20–70% CH₃CN in H₂O (0.1% TFA) over 30 min)affording the title compound as a white solid (20 mg, 55%). ¹H-NMR(CD₃OD; 400 MHz) δ 8.35 (s, 1H), 7.99–8.05 (m, 2H), 7.67–7.73 (m, 2H),7.28 (d, 1H, J=8.1 Hz), 7.10–7.17 (m, 2H), 2.74 (s, 3H), 2.27 (s, 3H).ESI-MS (m/z): Calcd. for C₁₉H₁₉N₃O₂S₃: 418.1 N+H); found: 418.1.

Example 2214-[2′-Methyl-4′-(2-morpholin-4-yl-ethylamino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a) (4-Bromo-3-methyl-phenyl)-(2-morpholin-4-yl-ethyl)-amine

4-Bromo-3-methylaniline (0.96 gm, 5.14 mmol),4-(2-chloro-ethyl)-morpholine (1 gm, 5.4 mmol), K₂CO₃ (1.5 gm, 10.8mmol), and NaI (0.81 gm, 5.4 mmol) were suspended in DMSO (10 mL) andthe mixture was stirred vigorously at reflux for 12 h. The mixture wascooled, diluted with EtOAc, and washed with saturated NaHCO₃. Theorganic layer was washed with another portion of NaHCO₃, brine (50 mL),and was dried over MgSO₄. Removal of the solvents in vacuo followed byflash chromatography of the residue (Biotage Flash System—40 M SiO₂column, 10% EtOAc in hexanes to 100% EtOAc) yielded the product (500 mg,31%) as a tan oil. ¹H-NMR (CDCl₃; 400 MHz): δ 7.36 (d, 1H, J=8.6 Hz),6.61 (d, 1H, J=2.8 Hz), 6.43 (dd, 1H, d, 8.6, 2.8 Hz), 4.36 (br s, 1H),3.80 (t, 4H, J=4.6 Hz), 3.20 (t, 2H, J=5.8 Hz), 2.69 (t, 2H, J=6.0 Hz),2.54 (t, 4H, J=4.4 Hz), 2.40 (s, 3H). ESI-MS (m/z): Calcd. forC₁₃H₁₉BrN₂O: 299.2; found: 299.1, 301.1.

b)4-[2′-Methyl-4′-(2-morpholin-4-yl-ethylamino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

Following the same procedure as in Example 220, step a, reaction of(4-bromo-3-methyl-phenyl)-(2-morpholin-4-yl-ethyl)-amine (440 mg, 1.9mmol, as prepared in Example 221, step a),4,4,5,5-tetramethyl-1,3,2-dioxaborolane (13.3 mL, 92 mmol, AldrichChemical Company), PdCl₂(PPh₃)₂ (2.2 gm, 3.1 mmol, Strem Chemicals Inc,Newburyport, Mass.), Et₃N (1.6 mL, 11.4 mmol), and dioxane (5 nm)afforded 520 mg (79%) after purification (SiO₂, flash elution: 30% EtOAcin hexanes) of a tan oil. ESI-MS (m/z): Calcd. for C₁₉H₃₁BN₂O₃: 347.3(M+H); found: 347.2. The above boronate ester (520 mg, 1.5 mmol) wasreacted according to the procedure used in Example 1, step c, with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (368 mg, 0.75 mmol, as prepared in Example 27,step c), tetrakis(triphenylphosine)palladium(0) (217 mg, 0.19 mmol,Strem Chemicals Inc, Newburyport, Mass.), Na₂CO₃ (3 mL, 2M), andtoluene/EtOH mixture (2:1, 9 mL) to afford 400 mg (85%) of(imino-{4-[2′-methyl-4′-(2-morpholin-4-yl-ethylamino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester after purification (SiO₂, flash elution: EtOAc inhexanes). ESI-MS (m/z): Calcd. for C₃₀H₃₈N₄O₅S₃: 630.8; found: 630.9,531.1 (M−Boc). Treatment of this intermediate with trifluoroacetic acidand purification using C₁₈-HPLC (as in Example 220, step c) provided 312mg (78%) of the title compound as a white solid. ¹H-NMR (CD₃OD, 400MHz): δ 8.31 (s, 1H), 7.90–7.95 (m, 2H), 7.60–7.65 (m, 2H), 7.04 (d, 1H,J=8.1 Hz), 6.61–6.66 (m, 2H), 3.95 (br s, 4H), 3.61 (t, 2H, J=6.3 Hz),3.41 (m, 6H), 2.71 (s, 3H), 2.19 (s, 3H). ESI-MS (m/z): Calcd. forC₂₅H₃₀N₄O₃S₃: 531.2 (M+H); found: 531.1, 266.2 (M²⁺).

Example 2223′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-carboxylicacid trifluoroacetate

Following the same procedure as in Example 220, step a, reaction of4-bromo-3-methyl-benzoic acid methyl ester (1.75 gm, 7.6 mmol),4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.3 mL, 23 mmol, AldrichChemical Company), PdCl₂(PPh₃)₂ (530 mg, 0.76 mmol, Strem Chemicals Inc,Newburyport, Mass.), Et₃N (6.3 mL, 46 mmol), and dioxane (30 mL)afforded 1.2 gm of a clear oil (79%) after purification (SiO₂, flashelution: 30% EtOAc in hexanes. The above boronate ester (220 mg, 0.8mmol) was reacted according to the procedure used in Example 1, step c,with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100 mg, 0.8 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosine)palladium(0) (58 mg, 0.05 mmol, StremChemicals Inc, Newburyport, Mass.), Na₂CO₃ (1.6 mL, 2 M), andtoluene/EtOH mixture (2:1, 2.4 mL) to afford3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-carboxylicacid methyl ester after purification (preparative TLC, 1:3EtOAc/hexanes, 2000μ SiO₂ plate). ESI-MS (m/z): Calcd. for C₂₆H₂₈N₂O₆S₃:560.7; found: 461.1 (M−Boc). The above methyl benzoate (45 mg. 0.08mmol) was treated with 1 N NaOH in MeOH (1:1) and stirred at 50° C.overnight. The reaction mixture was neutralized with acetic acid, thesolvents were removed in vacuo, and the residue was subjected to TFAtreatment followed by C₁₈-HPLC purification as described in Example 220,step c to afford the title compound as a white solid. ¹H-NMR (CD₃OD; 400MHz) δ 8.35 (s, 1H), 8.06–8.11 (m, 1H), 8.00–8.03 (m, 2H), 7.95 (m, 1H),7.72–7.76 (m, 2H), 7.35 (d, 1H, J=7.9 Hz), 2.75 (s, 3H), 2.30 (s, 3H).ESI-MS (m/z): Calcd. for C₂₀H₁₈N₂O₄S₃: 447.1 (M+H); found: 447.1.

Example 2232-Amino-N-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-acetamidetrifluoroacetate

To a solution of{4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (80 mg, 0.15 mmol, as prepared in Example 220,step b) in DCM (2.2 mL) was added Boc-gly-N-hydroxysuccinimide ester(126 mg, 0.5 mmol), and triethylamine (69 μL, 0.5 mmol). The reactionmixture was stirred at rt overnight (16 h). The reaction mixture wasthen diluted with EtOAc and extracted with water and saturated NaHCO₃.The separated organic layer was dried with MgSO₄, filtered, andconcentrated in vacuo to give a residue that was purified usingpreparative TLC (1:3 EtOAc/hexanes, 1000μ SiO₂ plate) to provide 100 mg(99%) of a tan glassy solid. ESI-MS (m/z): Calcd. for C₃₁H₃₈N₄O₇S₃:674.8 (M⁺); found: 674.8, 575.0, 519.0, 475.1. Treatment of thisintermediate with trifluoroacetic acid and purification using C₁₈-HPLC(as in Example 220, step c) provided the title compound as a white solidin 78% yield. ¹H-NMR (CD₃OD, 400 MHz): δ 8.34 (s, 1H), 7.99–8.05 (m,2H), 7.67–7.72 (m, 2H), 7.57 (m, 2H), 7.22 (d, 1H, J=8.1 Hz), 3.90 (s,2H), 2.74 (s, 3H), 2.25 (s, 3H). ESI-MS (m/z): Calcd. for C₂₁H₂₂N₄O₃S₃:475.1 (M+H); found: 475.1.

Example 2244-(4′-Hydroxy-2′,6′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 3,5-Dimethyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol

Following the procedure described in Example 220, step a, reaction of4-bromo-3,5-dimethyl-phenol (1.5 gm, 7.6 mmol),4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.3 mL, 23 mmol, AldrichChemical Company), PdCl₂(PPh₃)₂ (530 mg, 0.76 mmol, Strem Chemicals Inc,Newburyport, Mass.), Et₃N (634 μL, 46 mmol), and dioxane (30 mL)afforded 3.4 gm of a tan glassy solid after chromatography (50 gm,silica SPE column) which was used without further purification. ¹H-NMR(CDCl₃; 400 MHz): δ 6.4 (s, 2H), 2.3 (s, 6H), 1.4 (s, 12H).

b){[4-(4′-Hydroxy-2′,6′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

Following the same procedure as in Example 1, step c, reaction of3,5-dimethyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol(355 mg, 0.8 mmol, assuming quantitative yield from Example 224, stepa),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (100 mg, 0.2 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosine)palladium(0) (58 mg, 0.05 mmol, StremChemicals Inc, Newburyport, Mass.), Na₂CO₃ (0.8 mL, 2M), andtoluene/EtOH mixture (2:1, 2.4 mL) afforded 35 mg (13%) afterpurification (PTLC) of the title compound as a tan solid. ESI-MS (m/z):Calcd. for C₂₅H₂₈N₂O₅S₃: 532.7; found: 532.8, 477.0, 433.1 (M−Boc).

c)4-(4′-Hydroxy-2′,6′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{[4-(4′-Hydroxy-2′,6′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (15 mg, 0.03 mmol, as prepared in Example 224,step c) was treated with trifluoroacetic (50% in DCM) for 1 h at rt andpurified using C₁₈-HPLC (10–60% CH₃CN in H₂O (0.1% TFA) over 30 min)affording the title compound as a white solid (8 mg, 53%). ¹H-NMR(CD₃OD; 400 MHz) δ 8.35 (s, 1H), 8.00 (m, 1H), 7.80 (t, 1H, J=1.6 Hz),7.68 (t, 1H, J=7.7 Hz), 7.50 (m, 1H), 6.58 (s, 2H), 0.67–7.73 (m, 2H),7.28 (d, 1H, J=8.1 Hz), 7.10–7.17 (m, 2H), 2.73 (s, 3H), 1.91 (s, 6H).ESI-MS (m/z): Calcd. for C₂₀H₂₀N₂O₃S₃: 433.1 (M+H); found: 433.1.

Example 2253′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-carboxylicacid amide trifluoroacetate

Following the same procedure as in Example 220, step a, reaction of4-bromo-3-methyl-benzamide (200 mg, 0.93 mmol),4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.41 mL, 2.8 mmol, AldrichChemical Company), PdCl₂(PPh₃)₂ (65 mg, 0.093 mmol, Strem Chemicals Inc,Newburyport, Mass.), Et₃N (700 μL, 46 mmol), and dioxane (5 mL) afforded140 mg of a brown oil (58%) after purification (SiO₂, flash elution: 30%EtOAc in hexanes. The above boronate ester (140 mg, 0.54 mmol) wasreacted according to the procedure used in Example 1, step c, with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (88 mg, 0.18 mmol, as prepared in Example 27, stepc), tetrakis(triphenylphosine)palladium(0) (52 mg, 0.05 mmol, StremChemicals Inc, Newburyport, Mass.), Na₂CO₃ (0.7 mL, 2 M), andtoluene/EtOH mixture (2:1, 2.1 mL) to afford{[4-(4′-Carbamoyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester after purification (preparative TLC, 1:3EtOAc/hexanes, 3×1000μ SiO₂ plate). ESI-MS (m/z): Calcd. forC₂₅H₂₇N₃O₅S₃: 545.7; found: 446.1 (M−Boc). The above benzamide (44 mg.0.08 mmol) was subjected to TFA treatment followed by C₁₈-HPLCpurification as described in Example 220, step c to afford 26 mg (59%)of the title compound as a white solid. ¹H-NMR (CD₃OD; 400 MHz) δ 8.33(s, 1H), 8.04–8.08 (m, 1H), 7.99–8.01 (m, 1H), 7.85 (m, 1H), 7.78 (m,1H), 7.70–7.73 (m, 2H), 7.32 (d, 1H, J=7.9 Hz), 2.72 (s, 3H), 2.29 (s,3H). ESI-MS (m/z): Calcd. for C₂₀H₁₉N₃O₃S₃: 446.1 (M+H); found: 446.1.

Example 226{2-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-ethyl}-phosphonicacid trifluoroacetate

Thionyl chloride (1.7 mL, 23.0 mmol) was added dropwise to a suspensionof 3-(diethylphosphono)propanoic acid (0.5 gm, 2.3 mmol, EpsilponChimie, Brest, France) in DCM (2 mL) at 0° C. The reaction mixturebecame clear upon addition of acid chloride. The ice bath was removedand stirring was continued overnight at rt. The solvents were removed invacuo and the resulting solid was stored under high vacuum beforefurther use. The acid chloride prepared above (53 mg, 0.232 mmol) wastransferred to a solution of{4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (40 mg, 0.077 mmol, as prepared in Step 220, stepb) and Et₃N (900 μL, 0.62 mmol) in DCM (2 mL). The mixture was stirredfor 4 h at rt and then another 40 mg of the acid chloride was added.After stirring for ˜12 h, the volatiles were removed and the residue waspartitioned between EtOAc and water. The organic layer was washed withanother portion of water and saturated NaHCO₃, dried over MgSO₄, andfiltered. The crude product was chromatographed (PTLC 1000μ plate) togive 33 mg (61%) of the desired (diethylphosphono)propanamide. ESI-MS(m/z): Calcd. for C₃₁H₄₀N₃O₈PS₃: 709.8 (M⁺); found: 709.8, 610.1(M−Boc).

Using a modification of the procedure reported by Zhang, Z.-Y., et al.,(J. Med. Chem., 1999, 42:3199–3202), the above(diethylphosphono)propanamide (33 mg, 0.046) in DCM (2 mL) was treatedwith iodotrimethylsilane (20 μL, 0.14 mmol) at 0° C. for 1 h. Water wasadded to quench the reaction. After stirring for 20 minutes, 2.0 N HCl(2 mL) and MeOH (2 mL) were added to the reaction mixture. The reactionmixture became clear following the addition. Stirring was continued for3 h at rt, solvents were removed in vacuo, and the resulting residue wastreated with TFA and purified using C₁₈-HPLC as described in Example220, step c to afford 12 mg (50%) of the title compound as a whitesolid. ¹H-NMR (CD₃OD; 400 MHz): δ 7.61–7.69 (m, 3H), 6.95–7.27 (m, 4H),6.55 (d, 1H, J=8.6 Hz), 2.41–2.50 (m, 2H), 2.19 (s, 3H), 1.76 (s, 3H),1.58–1.63 (m, 2H). ESI-MS (m/z): Calcd. for C₂₂H₂₄N₃O₆PS₃: 554.1 (M+H);found: 554.1.

Example 227{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-methoxy}-aceticacid trifluoroacetate

To a solution of{4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (25 mg, 0.048 mmol, as prepared in Step 220, stepb) and Et₃N (33 μL, 0.24 mmol) in DCM (1 mL) was added diglycolicanhydride (17 mg, 0.144 mmol). The reaction was stirred overnight at rt.The solvents were removed in vacuo and the residue was treated with TFA(as in Example 220, step c). Purification using a C₁₈-HPLC provided 17mg (68%) of the title compound as a white solid. ¹H-NMR (CD₃OD, 400MHz): δ 8.32 (s, 1H), 7.96–8.03 (m, 2H), 7.65–7.70 (m, 2H), 7.57–7.62(m, 2H), 7.19 (d, 1H, J=8.6 Hz), 4.31 (s, 2H), 4.24 (s, 2H), 2.72 (s,3H), 2.23 (s, 3H). ESI-MS (m/z): Calcd. for C₂₃H₂₃N₃O₆S₃: 534.1 (M+H);found: 534.1.

Example 2285-Methylsulfanyl-4-(2′-methyl-4′-ureido-biphenyl-3-sulfonyl)-thiophene-2-carboxamidinetrifluoroacetate

According to the procedure by Rivier et al. (J. Med. Chem. 2001, 44,453–467) Trimethylsilyl isocyante (45 μL, 0.29 mmol) was added to asolution of{4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (43 mg, 0.083 mmol, as prepared in Step 220, stepb) in DMF (0.2 mL). The reaction was stirred for 3 days at rt. The DMFwas removed in vacuo and the residue was treated with TFA (as in Example220, step c, except 1% m-cresol was added in the deprotection mixture).The crude reaction mixture was concentrated to an oily residue that wastriturated with Et₂O to remove m-cresol. Purification using C₁₈-HPLCprovided 10 mg (25%) of the title compound as a white solid. ¹H-NMR(CD₃OD, 400 MHz): δ 8.34 (s, 1H), 7.96–8.04 (m, 2H), 7.65–7.70 (m, 2H),7.31–7.38 (m, 2H), 7.13 (d, 1H, J=7.9 Hz), 2.74 (s, 3H), 2.22 (s, 3H).ESI-MS (m/z): Calcd. for C₂₀H₂₀N₄O₃S₃: 461.1 (M+H); found: 461.1.

Example 2292-Amino-4-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-butyricacid bis-trifluoroacetate

Following the same procedure described for Example 223, but substitutingBoc-L-glu(OSu)-OtBu for Boc-gly-N-hydroxysuccinimide ester, provided thetitle compound as a white solid in 75% yield. ¹H-NMR (CD₃OD, 400 MHz): δ8.34 (s, 1H), 7.97–8.03 (m, 2H), 7.66–7.71 (m, 2H), 7.52–7.56 (m, 2H),7.18 (d, 1H, J=8.1 Hz), 4.12 (t, 1H, J=6.5 Hz), 2.73 (s, 3H), 2.71–2.75(m, 2H), 2.24 (s, 3H), 2.24–2.38 (m, 2H). ESI-MS (m/z): Calcd. forC₂₄H₂₆N₄O₅S₃: 547.1 (M+H); found: 547.1.

Example 2306-[5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-hexanoicacid[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-amidetrifluoroacetate

Following the same procedure described for Example 223, but substitutingN-(+)-biotinyl-6-aminocaproic acid N-succinimidyl ester forBoc-gly-N-hydroxysuccinimide ester, provided the title compound as awhite solid in 11% yield. ¹H-NMR (CD₃OD, 400 MHz): δ 8.33 (s, 1H),7.99–8.02, (m, 1H), 7.95–7.97 (m, 1H), 7.66–7.69 (m, 2H), 7.49–7.53 (m,2H), 7.17 (d, 1H, J=8.4 Hz), 4.47 (dd, 1H, J=7.9, 4.2 Hz), 4.27 (dd, 1H,J=7.8, 4.2 Hz), 3.15–3.22 (m, 4H), 2.91 (dd, 1H, J=12.6, 4.9 Hz), 2.73(s, 3H), 2.41 (t, 2H, J=7.6 Hz), 2.23 (s, 3H), 2.19 (t, 2H, J=7.4 Hz),1.35–1.80 (m, 12H). ESI-MS (m/z): Calcd. for C₃₅H₄₄N₆O₅S₄: 757.2 (M+H);found: 757.3

Example 2314-Amino-4-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-butyricacid bis-trifluoroacetate

Following the same procedure described for Example 223, but substitutingBoc-L-glu(OtBu)-OSu for Boc-gly-N-hydroxysuccinimide ester, provided thetitle compound as a white solid in 64% yield. ¹H-NMR (CD₃OD, 400 MHz): δ8.34 (s, 1H), 7.99–8.05 (m, 2H), 7.67–7.73 (m, 2H), 7.56–7.61 (m, 2H),7.23 (d, 1H, J=8.1 Hz), 4.10 (t, 1H, J=6.0 Hz), 2.74 (s, 3H), 2.58 (t,2H, J=7.4 Hz), 2.26 (s, 3H), 2.20–2.35 (m, 2H). ESI-MS (m/z): Calcd. forC₂₄H₂₆N₄O₅S₃: 547.1 (M+H); found: 547.1.

Example 2322-Amino-N-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-4-methanesulfonyl-butyramidebis-trifluoroacetate

In a scintillation vial, Boc-L-methionine sulfone (124 mg, 0.44 mmol,Chem-Impex, International, INC., Wood Dale, Ill.) was dissolved in DMF(2 mL). To the solution was added HBTU (159 mg, 0.42 mmol), HOBT (60 mg,0.44 mmol), and DIEA (400 μL, 2.1 mmol). After 10 min of vigorousstirring (solution turned pale yellow), the mixture was transferred to areaction vial charged with a stir bar and{4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (73 mg, 0.14 mmol, as prepared in Step 220, stepb). The resulting mixture was stirred overnight at rt. Analogous work upas described for Example 223 followed by TFA treatment and RP-HPLCprovided 58 mg (72%) of the title compound as the bis-trifluoroacetatesalt. ¹H-NMR (CD₃OD, 400 MHz): δ 8.33 (s, 1H), 7.97–8.03 (m, 2H),7.66–7.71 (m, 2H), 7.57–7.62 (m, 2H), 7.23 (d, 1H, J=8.1 Hz), 4.24 (t,1H, J=6.4 Hz), 3.25–3.39 (m, 2H), 3.06 (s, 3H), 2.72 (s, 3H), 2.40–2.56(m, 2H), 2.25 (s, 3H). ESI-MS (m/z): Calcd. for C₂₄H₂₈N₄O₅S₄: 581.1(M+H); found: 581.0.

Example 2334-[4′-(4,5-Dihydro-1H-imidazol-2-ylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a) 2-Methytsulfanyl-4,5-dihydro-imidazole-1-carboxylic acid tert-butylester

4,5-Dihydro-2-methylthioimidazole hydroiodide (3 gm, 12 mmol, AldrichChemical Company), di-tert-butyl-dicarbonate (5.4 gm, 24.8 mmol), Et₃N(5 mL, 36 mmol), and DMAP (70 mg, 0.57 mmol) were dissolved in DCM (35mL). The reaction was stirred at rt for 16 h then diluted with more DCMand washed with water and saturated NaHCO₃. The organic layer was dried(MgSO₄), filtered, and evaporated in vacuo to give 1 gm (38%) of thetitle compound as a white crystalline solid. ¹H-NMR (CDCl₃; 400 MHz): δ3.82–3.86 (m, 4H), 2.39 (s, 3H), 1.51 (s, 9H). ESI-MS (m/z): Calcd. forC₉H₁₆N₂O₂S: 217.1 (M+H); found: 216.8, 161.0, 117.2 (M−Boc).

b)4-[4′-(4,5-Dihydro-1H-imidazol-2-ylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

According to a procedure by Mundla et al. (Tetrahedron Lett. 2000, 41,6563–6566),{(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (18 mg, 0.035 mmol, as prepared in Example 220,step b) and 2-methylsulfanyl-4,5-dihydro-imidazole-1-carboxylic acidtert-butyl ester (23 mg, 0.1 mmol, as prepared in Example 233, step a)were dissolved in a MeOH/Acetic acid mixture (10:1, 1 mL). The reactionmixture was stirred overnight at 55° C. and then concentrated todryness. The resulting residue was treated with TFA and purified usingC₁₈-HPLC as described in Example 220, step c to afford 12 mg (70%) ofthe title compound as a white solid. ¹H-NMR (CD₃OD; 400 MHz): δ8.00–8.05 (m, 2H), 7.66–7.73 (m, 2H), 7.19–7.33 (m, 3H), 3.84 (s, 4H),2.72 (s, 3H), 2.27 (s, 3H). ESI-MS (m/z): Calcd. for C₂₂H₂₃N₅O₂S₃: 486.1(M+H); found: 486.1.

Example 2342-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-methylsulfanyl}-acetamidetrifluoroacetate

a)({4-[4′-(2-Bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

{4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (110 mg, 0.21 mmol, as prepared in Example 220,step b), bromoacetyl bromide (19 μL, 0.21 mmol), and Et₃N (33 μL, 0.23mmol) were dissolved in chloroform (2 mL) and the reaction was stirredfor 3 h at rt. As TLC indicated small amount of 20 aniline remaining inthe reaction mixture, 4 μL of bromoacetyl bromide were added and thereaction was stirred for 2 more hours. The volatiles were removed invacuo and the residue was partitioned between EtOAc and 20% citric acid.The organic layer was washed with saturated NaHCO₃, water, and brine,then dried (MgSO₄), and concentrated in vacuo to give 135 mg (100%) ofcrude product as a tan solid. Purification of this material using PTLC(1:1 EtOAc/hexanes, 2×1500μ SiO₂ plate) provided the title compound in89% yield as a pale yellow solid. ¹H-NMR (CDCl₃, 400 MHz): δ 8.24 (s,1H), 8.00 (dt, 1H, J=7.3, 1.8 Hz), 7.96 (br s, 1H), 7.92 (m, 1H),7.55–7.62 (m, 2H), 7.41–7.47 (m, 2H), 7.19 (d, 1H, J=8.1 Hz), 4.09 (s,2H), 2.52 (s, 3H), 2.25 (s, 3H), 1.54 (s, 9H). ESI-MS (m/z): Calcd. forC₂₄H₂₇N₃O₄S₃: 517.7; found: 517.7, 418.1 (M−Boc).

b)2-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-methylsulfanyl}-acetamidetrifluoroacetate

To a solution of({4-[4′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (44 mg, 0.069 mmol, as prepared in Example 234,step a) in MeOH (0.6 mL) was added 2-mercapto acetamide (100 μL of 10%methanolic solution, Maybridge plc) and Et₃N (30 μL, 0.21 mmol). Thereaction mixture was stirred at rt for 0.5 h and then concentrated invacuo. The residue was treated with TFA and purified using C₁₈-HPLC asdescribed in Example 220, step c to afford 32 mg (84%) of the titlecompound as a white solid. ¹H-NMR (CD₃OD; 400 MHz): δ 8.32 (s, 1H),7.99–8.02 (n, 1H), 7.95–7.97 (m, 1H), 7.66–7.68 (m, 2H), 7.51–7.55 (m,2H), 7.17 (d, 1H, J=8.1 Hz), 3.48 (s, 2H), 3.37 (s, 2H), 2.72 (s, 3H),2.23 (s, 3H). ESI-MS (m/z): Calcd. for C₂₄H₂₅N₃O₅S₄: 664.1 (M+H); found:564.1.

Example 2352-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-methylsulfanyl}-succinicacid trifluoroacetate

Following the same procedure as described in Example 234, step b,reaction of({4-[4′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (17 mg, 0.027 mmol, as prepared in Example 234,step a), mercaptosuccinate (6 mg, 0.04 mmol), Et₃N (12 μL, 0.08 mmol),and MeOH (3 mL) provided 12 mg (75%) of the title compound as a whitesolid after RP-HPLC purification. ¹H-NMR (CD₃OD; 400 MHz): δ 8.34 (s,1H), 7.99–8.00–8.05 (m, 1H), 7.97–7.99 (m, 1H), 7.68–7.70 (m, 2H),7.54–7.58 (m, 2H), 7.19 (d, 1H, J=7.9 Hz), 3.85 (dd, 1H, J=9.5, 5.6 Hz),3.56 and 3.69 (AB quartet, 2H, J=15.1 Hz), 2.97 (dd, 1H, J=17.2, 9.8Hz), 2.76 (dd, 1H, J=17.0, 5.6 Hz), 2.74 (s, 3H), 2.25 (s, 3H). ESI-MS(m/z): Calcd. for C₂₅H₂₅N₃O₇S₄: 608.1 (M+H); found: 608.1.

Example 2364-(4′-Guanidino-2′-methyl-6′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a){[4-(4′-Amino-2′-methyl-6′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

Following the procedure used for Example 295, step h, reaction of4-bromo-3-methyl-5-nitro-phenylamine (350 mg, 1.5 mmol, as prepared inExample 135, step a),{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (1.0 gm, 2.27 mmol, as prepared in Example 140,step a), tetrakis(triphenylphosine)palladium(0) (433 mg, 0.375 mmol,Strem Chemicals Inc, Newburyport, Mass.), Na₂CO₃ (6 mL, 2M), andtoluene/EtOH mixture (2:1, 18 mL) at 80° C. for 24 h afforded 250 mg(30%) after purification (SiO₂, flash elution: 5% to 50% EtOAc inhexanes) of the title compound as a yellow solid. ESI-MS (m/z): Calcd.for C₂₄H₂₆N₄O₆S₃: 563.1 (M+H); found: 562.8, 463.1 (M−Boc).

b)({4-[4′-(N,N′-Bis-tert-butoxycarbonyl)-guanidino-2′-methyl-6′-nitro-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

According to a previously published procedure (Bergerson et al., J. Org.Chem. 1987, 52, 1700–1703; WO 99/20608), mercury(II) chloride (190 mg,0.7 mmol) was added in one portion to a stirred mixture of{[4-(4′-amino-2′-methyl-6′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (130 mg, 0.23 mmol, as prepared in Example 236,step a), N,N′-bis(tert-butoxycarbonyl)-S-methylisothiourea (203 mg, 0.7mmol, Aldrich Chemical Company), and Et₃N (173 μL, 1.15 mmol) in DCM (3mL). The mixture was stirred for 24 h at rt and then purified usingflash chromatorgraphy (Biotage Flash System—40 M SiO₂ column, 10% to 30%EtOAc in hexanes) to afford 145 mg (78%) of the title compound as aclear oil. ESI-MS (m/z): Calcd. for C₃₅H₄₄N₆O₁₀S₃: 805.2 (M+H); found:804.7, 704.9, 604.9, 505.1 (M−3×Boc).

c)4-(4′-Guanidino-2′-methyl-6′-nitrobiphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

({4-[4′-(N,N′-Bis-tert-butoxycarbonyl)-guanidino-2′-methyl-6′-nitro-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (10 mg, 12.4 μmol, as prepared in Example 236,step b) was treated with TFA and purified using C₁₈-HPLC as described inExample 220, step c to afford 1.1 mg (17%) of the title compound as awhite solid. ¹H-NMR (CD₃OD; 400 MHz): δ 8.34 (s, 1H), 8.04 (ddd, 1H,J=7.9, 1.9, 1.2 Hz), 7.92–7.94 (m, 1H), 7.72–7.79 (m, 2H), 7.62 (ddd,1H, J=7.7, 1.6, 1.2 Hz), 7.60 (dd, 1H, J=2.1, 0.7 Hz), 2.72 (s, 3H),2.18 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₂₀N₆O₄S₃: 505.1 (M+H); found:505.1.

Example 2374-(6′-Amino-4′-guanidino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a){[4-(2′-(4′-Diamino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

{2-Amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-4-yl}-carbamicacid 2-trimethylsilanyl-ethyl ester (1000 mg, 1.48 mmol, Example 294,step f) was dissolved into THF (25 mL). To this was added TBAF (1M, 1.62mL, 1.62 mmol) and the reaction was warmed to 40° C. with stirring for 3hours. Additional TBAF (1.48 mL, 1.48 mmol) was added and the reactionwas stirred at rt overnight. The solvents were removed in vacuo, theresidue was dissolved into EtOAc and washed with water several times (5washes). The combined organic layers were dried (MgSO₄) and the solventswere removed in vacuo resulting in the title compound as a yellow solid(800 mg, 100%). ¹H-NMR (CDCl₃): δ: 8.03 (s, 1H), 7.95–7.93 (m, 1H),7.89–7.88 (m, 1H), 7.59–7.53 (m, 2H), 6.08 (m, 1H), 5.99 (m, 1H), 2.55(s, 3H), 1.85 (s, 3H), 1.52 (s, 9H).

b)(4-{4′-[N′N″-Bis(tert-butoxycarbonyl)]-}-{[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

{[4-(2′,4′-Diamino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (342 mg, 0.64 mmol, Example 237, step a) wasdissolved into MeOH (4 mL) and acetic acid (200 μL). To this was added1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (203 mg, 0.70mmol) slowly as a suspension in MeOH and the reaction was stirred at rtovernight. The solvents were removed in vacuo followed by flash columnchromatography purification (SiO₂) (40% EtOAc in hexanes) that yieldedthe title compound (235 mg, 47%) as a white solid. ESI-MS (m/z): Calcd.for C₃₅H₄₆N₆O₈S₃: 775.3 (M+1); found: 774.8.

c)4-(6′Amino-4′-guanidino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

4-{4′-[N′,N″-Bis(tert-butoxycarbonyl)]-}-{[4-(2′-amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (10 mg, 12.9 μmol, as prepared in Example 237,step b) was treated with TFA and purified using C₁₈-HPLC as described inExample 220, step c to afford 3 mg (50%) of the title compound as awhite solid. ¹H-NMR (CD₃OD; 400 MHz): δ 8.35 (s, 1H), 8.04 (ddd, 1H,J=7.9, 1.9, 1.1 Hz), 7.92–7.95 (m, 1H), 7.75 (t, 1H, J=7.8 Hz), 7.58(dt, 1H, J=7.6, 1.1 Hz), 6.65–6.63 (m, 2H), 2.71 (s, 3H), 1.94 (s, 3H).ESI-MS (m/z): Calcd. for C₂₀H₂₂N₆O₂S₃: 475.1 (M+H); found: 475.1.

Example 2383-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid methyl ester bis-trifluoroacetate

a)({4-[6′-(2-Hydroxy-acetylamino)-2′-methyl-4′-nitro-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

To a solution of{[4-(6′-amino-2′-methyl-4′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (216 mg, 0.384 mmol, as prepared in Example 295,step h) in DCM (2 mL) was added DIEA (212 μL, 1.15 mmol) andacetoxyacetyl chloride (54 mL, 0.5 mmol). The solution was stirred at rtfor 3 hr. The reaction mixture was diluted with EtOAc and washed withsaturated NaHCO₃, water, and brine. The organic layer was dried overMgSO₄, filtered, and concentrated in vacuo to provide 256 mg of a crudeoil that was used without further purification. ESI-MS (m/z): Calcd. forC₂₈H₃₀N₄O₉S₃: 663.1 (M+H); found: 662.7, 563.0 (M−Boc). To a solution ofthe crude intermediate obtained above in MeOH (2.5 mL) was added 1 NNaOH (2.5 mL) and the mixture was stirred at rt for 45 min at which timeTLC was consistent with complete conversion. The reaction mixture wasneutralized with acetic acid, concentrated in vacuo, and the residuepartitioned between EtOAc and saturated NaHCO₃. The organic layer waswashed with water and brine, dried over MgSO₄, filtered, andconcentrated in vacuo to give 220 mg (92%, crude yield over two steps)of the title compound which was used without further purification.ESI-MS (m/z): Calcd. for C₂₆H₂₈N₄O₈S₃: 621.1 (M+H); found: 620.7, 521.0(M−Boc).

b)({4-[4′-(N,N′-Bis-tert-butoxycarbonyl)-guanidino-6′-(2-hydroxy-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

To a solution of({4-[6′-(2-hydroxy-acetylamino)-2′-methyl-4′-nitro-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (220 mg, 0.354 mmol, as prepared in Example 237,step a) in EtOH (2.2 mL) was added a solution of NH₄Cl (1.1 mL, 3.2 M,3.54 mmol). The mixture was stirred vigorously at 50° C. for 30 min.Iron powder (100 mg, 1.77 mmol) was added and the mixture was heated to80° C. for 3.5 h. The reaction mixture was filtered (0.2μ, Wheatonsyringe filter) and the filtrate was concentrated to a solid that waspartitioned between EtOAc and 1 N Na₂CO₃. The organic layer was washedwith another portion of Na₂CO₃, dried (MgSO₄), filtered, andconcentrated to give the crude desired product. Purification using PTLC(4×1500μ plate, 5% MeOH in DCM) provided 58 mg of the desired aniline.ESI-MS (m/z): Calcd. for C₂₆H₃₀N₄O₆S₃: 591.1 (M+H); found: 591.0, 491.0(M−Boc). To a solution of this aniline (55 mg, 0.09 mmol) in MeOH/AcOH(10:1, 5 mL), N,N′-bis(tert-butoxycarbonyl)-5-methylisothiourea (78 mg,0.27 mmol, Aldrich Chemical Company) was added. The reaction mixture waswarmed to 40° C. and stirred for 3 h. The mixture was concentrated invacuo to a solid that was purified on PTLC (2×1000μ plate, 1:1EtOAc/hexanes) to give 45 mg (60%) of the title compound as a clear oil.¹H-NMR (CDCl₃; 400 MHz): δ 11.60 (s, 1H), 10.27 (s, 1H), 8.20 (m, 2H),8.04 (d, 1H, J=6.7 Hz), 7.90 (br s, 1H), 7.64 (t, 1H, J=7.8 Hz),7.40–7.45 (m, 2H), 4.42 (br s, 1H), 3.84 and 3.99 (AB quartet, 2H,J=15.4 Hz), 2.55 (s, 3H), 1.93 (s, 3H), 1.57 (s, 9H), 1.53 (s, 9H), 1.48(s, 9H). ESI-MS (m/z): Calcd. for C₃₇H₄₈N₆O₁₀S₃: 833.2 (M+H); found:832.8, 732.8, 632.9, 533.1.

c) Methanesulfonic acid{3′-[5-tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-(N,N′-bis-tert-butoxycarbonyl)-guanidino-6-methyl-biphenyl-2-ylcarbamoyl}-methylester

To a solution of({4-[4′-(N,N-bis-tert-butoxycarbonyl)-guanidino-6′-(2-hydroxy-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (40 mg, 48 μmmol, as prepared in Example 238, stepb) and diisopropyl ethylamine (100 μL, 192 μmol) in DCM (1 mL) at 0° C.was added methanesulfonyl chloride (10 μL, 130 μmol). The solution wasstirred at 0° C. for 30 min and then allowed to warm up and stirred atrt for 5 h. The reaction mixture was concentrated in vacuo and theresidue was chromatographed (PTLC, 1:1 EtOAc/hexanes, 1000μ SiO₂ plate)to afford 40 mg (97%) of the desired title compound as a glassy solid.ESI-MS (m/z): Calcd. for C₃₈H₅₀N₆O₁₂S₄: 911.2 (M+H); found: 910.7,810.8, 710.8, 611.1.

d)3-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid methyl ester bis-trifluoroacetate

Methyl 3-mercapto propionate (large molar excess) was added to asolution of (Methanesulfonic acid{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-(N,N′-Bis-tert-butoxycarbonyl)-guanidino-6-methyl-biphenyl-2-ylcarbamoyl}-methylester (7 mg, 7.7 μmol, as prepared in Example 238, step c) and Et₃N (20μL) in DCM (200 μL). The solution was stirred for 1 hr at rt thenconcentrated in vacuo. The resulting residue was treated with TFA andpurified using C₁₈-HPLC as described in Example 220, step c to afford 3mg (45%) of the title compound as a white solid. ¹H-NMR (CD₃OD; 400MHz): δ 8.32 (s, 1H), 8.08 (ddd, 1H, J=8.0, 2.0, 1.2 Hz), 7.92 (t, 1H,J=1.6 Hz), 7.74 (t, 1H, J=8.0 Hz), 7.57 (dt, 1H, J=7.6, 1.6 Hz), 7.45(d, 1H, J=2.3 Hz), 7.20 (dd, 1H, J=2.3, 0.7 Hz), 3.67 (s, 3H), 3.05 and3.10 (AB quartet, 2H, J=15.5 Hz), 2.73 (s, 3H), 2.40–2.44 (m, 2H),2.27–2.33 (m, 2H), 2.08 (s, 3H). ESI-MS (m/z): Calcd. for C₂₆H₃₀N₆O₅S₄:635.1 (M+H); found: 635.1.

Example 2393-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid bis-trifluoroacetate

3-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid methyl ester bis-trifluoroacetate (5.7 mg, 6.3 μmol, as prepared inExample 238, step d), dissolved in MeOH (200 μL), was treated with 1 NNaOH (200 μL) at rt for 2 hr. The reaction was acidified with aceticacid and the crude product was purified using C₁₈-HPLC as described inExample 220, step c to provide 4 mg (75%) of the title compound as awhite solid. ¹H-NMR (CD₃CN; 400 MHz): δ 9.67 (br s, 1H), 9.44 (br s,2H), 8.36 (s, 1H), 8.19 (s, 1H), 8.12 (ddd, 1H, J=8.1, 1.9, 1.1 Hz),7.88 (t, 1H, J=1.6 Hz), 7.75–7.81 (m, 3H), 7.55 (dt, 1H, J=7.7, 1.5 Hz),7.10 (d, 1H, J=1.9 Hz), 6.84 (br s, 4H), 3.01 and 3.08 (AB quartet, 2H,J=16.2 Hz), 2.69 (s, 3H), 2.24–236 (m, 4H), 2.04 (s, 3H). ESI-MS (m/z):Calcd. for C₂₅H₂₈N₆O₅S₄: 621.1 (M+H); found: 621.0.

Example 2406-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-hexanoicacid trifluoroacetate

To a solution of{[4-(6′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (23 mg, 0.044 mmol, as prepared in Example 25,step c) and Et₃N (50 μL, 0.36 mmol) in DCM (2 mL) was added6-isocyanato-hexanoic acid ethyl ester (40 μL, 0.22 mmol) and themixture was stirred for 3 h at rt. The reaction mixture was diluted withEtOAc and then washed with water and saturated NaHCO₃. The organic layerwas dried over MgSO₄, filtered, and concentrated in vacuo. The resultingcrude product was taken up in MeOH (3 mL) and treated with 1 N NaOH (3mL) at rt for 2 h. The reaction was acidified with acetic acid,concentrated in vacuo, and the residue was subjected to TFA treatmentfollowed by C₁₈-HPLC purification as described in Example 220, step c toafford the title compound as a white solid. ¹H-NMR (CD₃OD; 400 MHz) δ8.30 (s, 1H), 8.05 (ddd, 1H, J=7.9, 1.9, 1.2 Hz), 7.89 (t, 1H, J=1.6Hz), 7.71 (t, 1H, J=7.8 Hz), 7.54–758 (m, 1H), 7.43 (d, 1H, J=7.7 Hz),7.28 (t, 1H, J=7.8 Hz), 7.10–7.14 (m, 1H), 2.97 (td, 2H, J=6.8, 2.2 Hz),2.72 (s, 3H), 2.26 (t, 2H, J=7.4 Hz), 2.00 (s, 3H), 1.51–1.59 (m, 2H),1.19–1.36 (m, 4H). ESI-MS (m/z): Calcd. for C₂₆H₃₀N₄O₅S₃: 575.1 (M+H);found: 575.1.

Example 2413-(2-{2-[2-(2-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-propionicacid trifluoroacetate

As described in Example 194, step a,{[4-(6′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (75 mg, 0.145 mmol, as prepared in Example 25,step c), p-nitrophenyl chloroformate (31 mg, 0.152 mmol), pyridine (40μL, 0.435 mmol) in DCM (1 mL) were stirred at rt for 3 h. To the mixturewas added amino-dPEG₄-™-t-butyl ester (93 mg, 0.29 mmol, QuantaBiodesign, Powell, Ohio) and the reaction was stirred for another 16 hat rt. The mixture was concentrated and the residue was subjected to TFAtreatment followed by C₁₈-HPLC purification as described in Example 220,step c to afford 25 mg (24%) of the title compound as a glassy solid.¹H-NMR (CD₃OD; 400 MHz) δ 8.31 (s, 1H), 8.07 (ddd, 1H, J=7.9, 1.9, 1.1Hz), 7.87–7.90 (m, 1H), 7.72 (t, 1H, J=7.8 Hz), 7.55–7.58 (m, 1H), 7.45(d, 1H, J=8.1 Hz), 7.28, (t, 1H, J=7.8 Hz), 7.12 (d, 1H, J=7.3 Hz), 3.68(t, 2H, J=6.3 Hz), 3.50–3.62 (m, 12H), 3.39 (t, 2H, J=5.2 Hz), 3.16 (t,2H, J=5.3 Hz), 2.72 (s, 3H), 2.50 (t, 2H, J=6.3 Hz), 2.00 (s, 3H).ESI-MS (m/z): Calcd. for C₃₁H₄₀N₄O₉S₃: 709.2 (M+H); found: 709.2.

Example 2424-[2′-Methyl-6′-(3-phenethyl-ureido)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

To a solution of{[4-(6-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (30 mg, 0.058 mmol, as prepared in Example 25,step c) and DIEA (100 μL, 0.57 mmol) in DCM (1.5 mL) was added(2-Isocyanato-ethyl)-benzene (100 μL, 0.68 mmol) and the mixture wasstirred for 4 h at rt. The reaction mixture was diluted with EtOAc andthen washed with water and saturated NaHCO₃. The organic layer was driedover MgSO₄, filtered, and concentrated in vacuo. The resulting residuewas subjected to TFA treatment followed by C₁₈-HPLC purification asdescribed in Example 220, step c to afford 20 mg (62%) of the titlecompound as a white solid. ¹H-NMR (CD₃OD; 400 MHz) δ 8.30 (s, 1H), 8.08(ddd, 1H, J=7.9, 1.9, 1.1 Hz), 7.90 (t, 1H, J=1.6 Hz), 7.71 (t, 1H,J=7.8 Hz), 7.51–7.55 (m, 1H), 7.36–7.39 (m, 1H), 7.22–7.30 (m, 3H),7.12–7.19 (m, 2H), 7.02–7.06 (m, 2H), 3.14–3.24 (m, 2H), 2.64 (s, 3H),2.52–2.62 (m, 2H), 2.00 (s, 3H). ESI-MS (m/z): Calcd. for C₂₈H₂₈N₄O₃S₃:565.1 (M+H); found: 565.1.

Example 243{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-aceticacid ethyl ester trifluoroacetate

To a solution of{[4-(6′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (15 mg, 0.029 mmol, as prepared in Example 25,step c) and Et₃N (20 μL, 0.15 mmol) in DCM (1.0 mL) was addedisocyanato-acetic acid ethyl ester (10 μL, 0.087 mmol) and the mixturewas stirred for 4 h at rt. The reaction mixture was diluted with EtOAcand then washed with water and saturated NaHCO₃. The organic layer wasdried over MgSO₄, filtered, and concentrated in vacuo. The resultingcrude product was split in two equal portions. One portion was subjectedto TFA treatment followed by C₁₈-HPLC purification as described inExample 220, step c to afford the title compound as a white solid.¹H-NMR (CD₃OD; 400 MHz): δ 8.31 (s, 1H), 8.07 (ddd, 1H, J=7.9, 1.9, 1.2Hz), 7.90 (t, 1H, J=1.6 Hz), 7.72 (t, 1H, J=7.8 Hz), 7.56–7.60 (m, 1H),7.46–7.50 (m, 1H), 7.30 (t, 1H, J=7.8 Hz), 7.12–7.16 (m, 1H), 4.16 (q,2H, J=7.2 Hz), 3.76 (d, 2H, J=4.2 Hz), 2.72 (s, 3H), 2.01 (s, 3H), 1.26(t, 3H, J=7.2 Hz). ESI-MS (m/z): Calcd. for C₂₄H₂₆N₄O₅S₃: 547.1 (M+H);found: 547.1.

Example 244{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-aceticacid trifluoroacetate

The other portion of the crude ethyl ester obtained in Example 244 wassaponified by treatment with a mixture of MeOH/1 N NaOH (1:1, 2 mL) atrt for 4 h. The crude reaction mixture was acidified with acetic acid,concentrated in vacuo, and the residue was subjected to TFA treatmentfollowed by C₁₈-HPLC purification as described in Example 220, step c toafford the title compound as a white solid. ¹H-NMR (CD₃OD; 400 MHz): δ8.31 (s, 1H), 8.07 (ddd, 1H, J=7.9, 1.9, 1.2 Hz), 7.88 (t, 1H, J=1.8Hz), 7.72 (t, 1H, J=7.8 Hz), 7.56–7.60 (m, 1H), 7.47–7.51 (m, 1H), 7.30(t, 1H, J=7.9 Hz), 7.12–7.15 (m, 1H), 3.68–3.80 (m, 2H), 2.72 (s, 3H),2.01 (s, 3H). ESI-MS (m/z): Calcd. for C₂₂H₂₂N₄O₅S₃: 519.1 (M+H); found:519.1.

Example 245{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methoxy}-aceticacid trifluoroacetate

Following the same procedure as in Example 227, reaction of{[4-(6′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (28 mg, 0.054 mmol, as prepared in Example 25,step c), Et₃N (45 μL, 0.32 mmol), and diglycolic anhydride (20 mg, 0.16mmol) in DCM (2 mL) followed by analogous work up and purificationprovided the title compound (50% yield over two steps). ¹H-NMR (CD₃OD;400 MHz): δ 8.28 (s, 1H), 8.08 (ddd, 1H, J=7.9, 1.9, 1.2 Hz), 7.85 (t,1H, J=1.5 Hz), 7.72 (t, 1H, J=7.8 Hz), 7.56–7.60 (m, 1H), 7.53 (d, 1H,J=8.1 Hz), 7.36 (t, 1H, J=7.8 Hz), 7.26 (d, 1H, J=7.7 Hz), 3.70–3.91 (m,4H), 2.72 (s, 3H), 2.08 (s, 3H). ESI-MS (m/z): Calcd. for C₂₃H₂₃N₃O₆S₃:534.1 (M+H); found: 534.1.

Example 2462-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-acetamidetrifluoroacetate

a)({4-[6′-(2-Bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

Following the procedure described for Example 234, step a, reaction of{[4-(6′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (137 mg, 0.265 mmol, as prepared in Example 25,step c), bromoacetyl bromide (28 μL, 0.32 mmol), and DIEA (70 μL, 0.40mmol) in chloroform (3 mL) afforded 129 mg (76%) of the title compoundas a yellow foamy solid after chromatography (PTLC, 10% EtOAc in DCM,2×1500μ SiO₂ plate). ¹H-NMR (CDCl₃; 400 MHz): δ 8.05–8.10 (m, 1H),7.85–7.95 (m, 2H), 7.65–7.73 (m, 2H), 7.46–7.51 (m, 1H), 7.35 (t, 1H,J=7.9 Hz), 7.16 (d, 1H, J=7.7 Hz), 3.64 and 3.74 (AB quartet, 2H, J=14.0Hz), 2.60 (s, 3H), 2.03 (s, 3H), 1.52 (s, 9H). ESI-MS (m/z): Calcd. forC₂₆H₂₈BrN₃O₅S₃: 637.0 (M+H); found: 637.8, 639.8, 538.0, 540.0 (M−Boc).

b)2-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-acetamidetrifluoroacetate

To a solution of({4-[6′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (9 mg, 0.014 mmol, as prepared in Example 246,step a) in MeOH (0.1 mL) was added 2-mercapto acetamide (20 μL of 10%methanolic solution, Maybridge plc) and Et₃N (6 μL, 0.042 mmol). Thereaction mixture was stirred at rt for 0.5 h and then concentrated invacuo. The residue was treated with TFA as described in Example 220,step c and then purified using C₁₈-HPLC (10–60% CH₃CN in H₂O with 0.1%TFA) to afford 8.7 mg (94%) of the title compound as a clear glassysolid. ¹H-NMR (CD₃OD; 400 MHz): δ 8.30 (s, 1H), 8.09 (ddd, 1H, J=7.9,1.9, 1.2 Hz), 7.88 (t, 1H, J=1.6 Hz), 7.72 (t, 1H, J=7.9 Hz), 7.57–7.60(m, 1H), 7.35–7.40 (m, 2H), 7.27–7.31 (m, 1H), 3.05 and 3.11 (ABquartet, 2H, J=14.9 Hz), 2.78 and 2.85 (AB quartet, 2H, J=14.9 Hz), 2.74(s, 3H), 2.08 (s, 3H). ESI-MS (m/z): Calcd. for C₂₃H₂₄N₄O₄S₄: 549.1(M+H); found: 549.1.

Example 2473-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid trifluoroacetate

Following the same procedure as described in Example 246, step b,reaction of({4-[6′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (15.2 mg, 0.029 mmol, as prepared in Example 246,step a), 3-mercaptopropionate (8 μL, 0.09 mmol), Et₃N (20 μL, 0.12mmol), in MeOH (1 mL) for 1 h afforded 9 mg (56%) of the title compoundas a white solid after TFA treatment and RP-HPLC purification. ¹H-NMR(CD₃OD; 400 MHz): δ 8.28 (s, 1H), 8.06–8.09 (m, 1H), 7.88 (t, 1H, J=1.9Hz), 7.70 (t, 1H, J=7.8 Hz), 7.53–7.57 (m, 1H), 7.33–7.38 (m, 2H),7.25–7.29 (m, 1H), 2.95 and 3.04 (AB quartet, 2H, J=15.4 Hz), 2.73 (s,3H), 2.31–2.36 (m , 2H), 2.16–2.20 (m , 2H), 2.04 (s, 3H). ESI-MS (m/z):Calcd. for C₂₄H₂₅N₃O₅S₄: 564.1 (M+H); found: 564.1.

Example 2482-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-succinicacid trifluoroacetate

Following the same procedure as described in Example 246, step b,reaction of({4-[6′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (15.3 mg, 0.03 mmol, as prepared in Example 246,step a), mercaptosuccinate (14 mg, 0.09 mmol), Et₃N (20 μL, 0.12 mmol),and MeOH (1 mL) for 2 h provided 12 mg (67%) of the title compound as awhite solid after TFA treatment and RP-HPLC purification. ¹H-NMR (CD₃OD;400 MHz, (+) and (−) enantiomers appear as two distinct diastereomers onNMR presumably due to conformational restriction aroundo-methyl-biphenyl ring system): δ 8.27 (s, 1H), 8.04–8.09 (m, 1H),7.84–7.88 (m, 1H), 7.66–7.73 (m, 1H), 7.53–7.57 (m, 1H), 7.32–7.44 (m,2H), 7.27 (t, 1H, J=6.7 Hz), 3.38–3.42 (m, 0.5H), 3.09–3.29 (m, 2H),2.62–2.79 (m, 2.5H), 2.75 (s, 3H), 2.44–2.50 (m, 0.5H), 2.22–2.28 (m,0.5H), 2.06 (s, 3H). ESI-MS (m/z): Calcd. for C₂₅H₂₅N₃O₇S₄: 608.1 (M+H);found: 608.1.

Example 2492-Bromo-N-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-acetamidetrifluoroacetate

({4-[6′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (22 mg, 0.034 mmol, as prepared in Example 246,step a) was stirred in a mixture of TFA/DCM (1:1, 4 mL) for 1 h at rt.The reaction was concentrated in vacuo and the resulting residue waspurified using RP-HPLC (10–50% CH₃CN in H₂O with 0.1% TFA over 30 min)to afford 15 mg (68%) of the title compound as a clear glassy solid(purity>99.9% by analytical RP-HPLC). ESI-MS (m/z): Calcd. forC₂₁H₂₀BrN₃O₃S₃: 538.0 (M+H); found: 538.0 and 540.0

Example 2502-Acetylamino-3-{[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-3-methyl-butyricacid trifluoroacetate

N-Acetyl-penicillamine (3.0 mg, 0.0154 mmol, racemic) and DIEA (7 μL,0.04 mmol) were dissolved in DMSO (223 μL) and then transferred to asolution of2-bromo-N-[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-acetamidetrifluoroacetate (20 mM in DMSO, 230 μL, 0.0046 mmol, prepared from thetitle compound described in Example 249). The reaction was mixed on ashaker for 1 h at rt. Bromomethyl wang resin (16 mg, 1.47 mmol/gm) wasadded to scavenge the excess thiol. After 2 h of shaking, the resin wasfiltered and the filtrate was directly purified using RP-HPLC aspreviously described in Example 246, step b, to afford 1.5 mg (50%,single peak on analytical RP-HPLC) of the title compound as a glassysolid. ESI-MS (m/z): Calcd. for C₂₈H₃₂N₄O₆S₄: 649.1 (M+H); found: 649.1.

Example 2512-Acetylamino-3-{[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid trifluoroacetate

Following the same procedure as described in Example 246, step b,reaction of({4-[6′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (10 mg, 0.016 mmol, as prepared in Example 246,step a), (L)-N-acetylcysteine (22 mg, 0.135 mmol), Et₃N (50 μL, 0.12mmol), and DCM (0.5 mL) for 2 h provided 7 mg (71%) of the titlecompound as a white solid after TFA treatment and RP-HPLC purification.¹H-NMR (CD₃OD; 400 MHz): δ 8.30 (s, 1H), 8.06–8.09 (m, 1H), 7.87 (t, 1H,J=1.6 Hz), 7.68–7.73 (m, 1H), 7.54–7.59 (m, 1H), 7.34–7.39 (m, 2H),7.26–7.30 (m, 1H), 4.41–4.48 (m, 1H), 2.94–3.10 (m, 2H), 2.74 (s, 3H),2.59–2.64 (m , 1H), 2.43–2.49 (m, 1H), 2.06 (s, 3H). 2.00 (d, 3H, 2.1J=2.1 Hz). ESI-MS (m/z): Calcd. for C₂₆H₂₈N₄O₆S₄: 621.1 (M+H); found:621.1.

Example 2523-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid trifluoroacetate

a)({4-[6′-(2-Bromo-acetylamino)-4′-methoxy-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

Following the procedure described for Example 234, step a, reaction of{[4-(6′-amino-4′-methoxy-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (204 mg, 0.37 mmol, as prepared in Example 198,step e), bromoacetyl bromide (39 μL, 0.45 mmol), and Et₃N (77 μL, 0.56mmol) in DCM (5 mL) afforded 170 mg (69%) of the title compound as ayellow foamy solid after chromatography (PTLC, 50% EtOAc in hexanes,4×1000μ SiO₂ plate). ¹H-NMR (CDCl₃; 400 MHz): δ 8.02–8.05 (m, 1H), 7.91(s, 1H), 7.87 (t, 1H, J=1.6 Hz), 7.73 (br s, 1H), 7.63–7.67 (m, 2H),7.45–7.49 (m, 1H), 6.69 (d, 1H, J=2.1 Hz), 3.85 (s, 3H), 3.69 and 3.74(AB quartet, 2H, J=14.1 Hz), 2.59 (s, 3H), 2.00 (s, 3H), 1.52 (s, 9H).ESI-MS (m/z): Calcd. for C₂₇H₃₀BrN₃O₆S₃: 668.0 (M+H); found: 669.6,667.6, 570.0, 568.0 (M−Boc).

b)3-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid trifluoroacetate

Following the same procedure as described in Example 246, step b,reaction of({4-[6′-(2-bromo-acetylamino)-4′-methoxy-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (12 mg, 0.018 mmol, as prepared in Example 252,step a), 3-mercaptopropionate (8 μL, 0.09 mmol), Et₃N (20 μL, 0.12mmol), in MeOH (1 mL) for 1 h afforded 9.3 mg (62%) of the titlecompound as a white solid after TFA treatment and RP-HPLC purification.¹H-NMR (CD₃OD; 400 MHz): δ 8.29 (s, 1H), 8.07 (ddd, 1H, J=7.9, 1.9, 1.2Hz), 7.87 (t, 1H, J=1.6 Hz), 7.70 (t, 1H, J=7.8 Hz), 7.53–7.57 (m, 1H),7.05 (d, 1H, J=2.5 Hz), 6.84 (d, 1H, J=2.5 Hz), 3.83 (s, 3H), 2.98 and3.06 (AB quartet, 2H, J=15.4 Hz), 2.73 (s, 3H), 2.32–2.36 (m , 2H),2.19–2.23 (m, 2H), 2.02 (s, 3H). ESI-MS (m/z): Calcd. for C₂₅H₂₇N₃O₆S₄:594.1 (M+H); found: 594.0.

Example 2533-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid methyl ester trifluoroacetate

Following the same procedure as described in Example 246, step b,reaction of({4-[6′-(2-bromo-acetylamino)-4′-methoxy-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (22 mg, 0.04 mmol, as prepared in Example 252,step a), methyl 3-mercaptopropionate (10 μL, 0.09 mmol), Et₃N (20 μL,0.12 mmol), in MeOH (1 mL) for 1 h afforded the title compound as awhite solid after TFA treatment and RP-HPLC purification. ¹H-NMR (CD₃OD;400 MHz): δ 8.31 (s, 1H), 8.07 (ddd, 1H, J=7.9, 1.9, 1.2 Hz), 7.87 (t,1H, J=1.6 Hz), 7.70 (t, 1H, J=7.8 Hz), 7.53–7.57 (m, 1H), 7.06 (d, 1H,J=2.4 Hz), 6.85 (d, 1H, J=2.4 Hz), 3.84 (s, 3H), 3.68 (s, 3H), 3.00 and3.07 (AB quartet, 2H, J=15.4 Hz), 2.74 (s, 3H), 2.39–2.42 (m, 2H),2.23–2.27 (m, 2H), 2.03 (s, 3H). ESI-MS (m/z): Calcd. for C₂₆H₂₉N₃O₆S₄:608.1 (M+H); found: 608.1.

Example 254N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-yl]-2-methanesulfonyl-acetamidetrifluoroacetate

Following the same procedure as described in Example 257, reaction of({4-[6′-(2-bromo-acetylamino)-4′-methoxy-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (37 mg, 0.065 mmol, as prepared in Example 252,step a) and sodium methanesulfinate (25 mg, 0.195 mmol, Aldrich ChemicalCompany) in EtOH/CH₃CN (1:1, 2 mL) provided 29 mg (66%) of the titlecompound as a white solid after TFA treatment and RP-HPLC purification.¹H-NMR (CD₃OD; 400 MHz): δ 8.30 (s, 1H), 8.03 (ddd, 1H, J=7.9, 1.9, 1.2Hz), 7.84 (t, 1H, J=1.6 Hz), 7.66 (t, 1H, J=7.8 Hz), 7.51–7.54 (m, 1H),6.99 (d, 1H, J=2.6 Hz), 6.84 (d, 1H, J=2.6 Hz), 3.89 and 3.93 (ABquartet, 2H, J=14.1 Hz), 3.82 (s, 3H), 2.86 (s, 3H), 2.72 (s, 3H), 2.01(s, 3H). ESI-MS (m/z): Calcd. for C₂₃H₂₅N₃O₆S₄: 568.1 (M+H); found:568.0.

Example 255 6-Methanesulfonyl-hexanoic acid[3′-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-yl]-amidetrifluoroacetate

Following the procedure described for Example 234, step a, reaction of{[4-(6′-amino-4′-methoxy-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (60 mg, 0.11 mmol, as prepared in Example 198,step e), 6-bromo-hexanoyl chloride (26 μL, 0.17 mmol), and Et₃N (79 μL,0.55 mmol) in DCM (1 mL) afforded the title compound as a crude oilafter aqueous work up. ESI-MS (m/z): Calcd. for C₃₁H₃₈BrN₃O₆S₃: 724.1(M+H); found: 626.1, 624.1 (M−Boc). The crude bromide intermediateobtained above was suspended in a EtOH-water mixture (1:1, 3 mL) and tothe mixture was added sodium methanesulfinate (45 mg, 0.33 mmol, AldrichChemical Company). The reaction mixture was heated at 50° C. for 48 hand then concentrated in vacuo. The residue was treated with TFA asdescribed in Example 220, step c and then purified using C₁₈-HPLC(10–60% CH₃CN in H₂O with 0.1% TFA) to afford 12 mg (18% from theaniline) of the title compound as a clear glassy solid. ¹H-NMR (CD₃OD;400 MHz): δ 8.30 (s, 1H), 8.02 (ddd, 1H, J=7.9, 1.9, 1.1 Hz), 7.86 (t,1H, J=1.6 Hz), 7.67 (t, 1H, J=7.9 Hz), 7.52 (dt, 1H, J=7.7, 1.2 Hz),6.85 (d, 1H, J=2.5 Hz), 6.77 (d, 1H, J=2.5 Hz), 3.82 (s, 3H), 2.98–3.04(m, 2H), 2.96 (s, 3H), 2.72 (s, 3H), 1.99–2.04 (m, 2H), 2.03 (s, 3H),1.57–1.66 (m, 2H), 1.05–1.25 (m, 4H). ESI-MS (m/z): Calcd. forC₂₇H₃₃N₃O₆S₄: 624.1 (M+H); found: 624.1

Example 256N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-yl]-3-methanesulfonyl-propionamidetrifluoroacetate

Following the procedure described for Example 234, step a, reaction of{[4-(6′-amino-4′-methoxy-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (60 mg, 0.11 mmol, as prepared in Example 198,step e), acryloyl chloride (22 μL, 0.22 mmol), and Et₃N (80 μL, 0.55mmol) in THF (1 mL) afforded the title compound as a crude oil afteraqueous work up. ESI-MS (m/z): Calcd. for C₂₈H₃₁N₃O₆S₃: 602.1 (M+H);found: 601.9, 502.1 (M−Boc). The crude acrylamide intermediate obtainedabove was suspended in a EtOH-water mixture (1:1, 3 mL) and to themixture was added sodium methanesulfinate (45 mg, 0.33 mmol, AldrichChemical Company). The reaction mixture was heated at 50° C. for 48 hand then concentrated in vacuo. The residue was treated with TFA asdescribed in Example 220, step c and then purified using C₁₈-HPLC(10–60% CH₃CN in H₂O with 0.1% TFA) to give 15 mg (23% from the aniline)of the title compound as a white solid. ¹H-NMR (CD₃OD; 400 MHz): δ 8.30(s, 1H), 8.03 (ddd, 1H, J=7.9, 1.9, 1.1 Hz), 7.83 (t, 1H, J=1.6 Hz),7.67 (t, 1H, J=7.8 Hz), 7.54 (dt, 1H, J=7.7, 1.3 Hz), 6.84–6.87 (m, 2H),3.82 (s, 3H), 3.07 (t, 2H, J=7.8 Hz), 2.86 (s, 3H), 2.73 (s, 3H),2.44–2.51 (m, 2H), 2.06 (s, 3H). ESI-MS (m/z): Calcd. for C₂₄H₂₇N₃O₆S₄:582.1 (M+H); found: 582.1.

Example 257N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-2-methanesulfonyl-acetamidetrifluoroacetate

To a solution of({4-[6′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (8 mg, 0.0125 mmol, as prepared in Example 246,step a) in EtOH (1.0 mL) was added sodium methanesulfinate (13 mg, 0.127mmol, Aldrich Chemical Company) and the reaction was stirred overnightand monitored by MS and TLC. After ˜16 h at rt, the starting materialhad disappeared and the reaction was concentrated in vacuo to give anoil. Treatment of this intermediate with trifluoroacetic acid for 2 hfollowed by RP-HPLC purification afforded 5.2 mg (78%) of the titlecompound as a white solid. ¹H-NMR (CD₃OD; 400 MHz): δ 8.31 (s, 1H), 8.05(ddd, 1H, J=7.9, 1.9, 1.2 Hz), 7.87 (t, 1H, J=1.6 Hz), 7.68 (t, 1H,J=8.0 Hz), 7.53–7.56 (m, 1H), 7.33–7.37 (m, 2H), 7.26–7.30 (m, 1H),3.85–3.94 (m, 2H) 2.84 (s, 3H), 2.72 (s, 3H), 2.04 (s, 3H). ESI-MS(m/z): Calcd. for C₂₂H₂₃N₃O₅S₄: 538.0 (M+H); found: 538.0.

Example 258N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-2-methanesulfonyl-propionamidetrifluoroacetate

a)({4-[6′-(2-Bromo-propionylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

Following the procedure described for Example 234, step a, reaction of{[4-(6′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (65 mg, 0.126 mmol, as prepared in Example 25,step c), racemic 2-bromo-propionyl bromide (19 μL, 0.189 mmol), and Et₃N(52 μL, 0.378 mmol) in DCM (2 mL) afforded 55 mg (67%) of the titlecompound as a glassy solid after chromatography (PTLC, 10% EtOAc in DCM,2×1500μ SiO₂ plate). ESI-MS (m/z): Calcd. for C₂₇H₃₀BrN₃O₅S₃: 652.0(M+H); found: 653.6, 651.7, 553.9, 552.0 (M−Boc).

b)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-2-methanesulfonyl-propionamidetrifluoroacetate

Following the procedure described for Example 257, reaction of({4-[6′-(2-bromo-propionylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (30 mg, 0.046 mmol, as prepared in Example 258,step a) and sodium methanesulfinate (48 mg, 0.46 mmol, Aldrich ChemicalCompany) in EtOH (1 mL) provided 18 mg (72%) of the title compound as awhite solid after TFA treatment and RP-HPLC purification. ¹H-NMR (CD₃OD;400 MHz, (+) and (−) enantiomers appear as two distinct diastereomers onNMR presumably due to conformational restriction aroundo-methyl-biphenyl ring system): δ 8.32, 8.31 (2×s, 1H), 8.05–8.08 (m,1H), 7.87–7.88 (m, 1H), 7.69 (t, 1H, J=7.8 Hz), 7.52–7.55 (m, 1H),7.27–7.39 (m, 3H), 3.67–3.74 (m, 1H), 2.78, 2.724, 2.718, 2.16 (4×s,6H), 2.06, 2.03 (2×s, 3H), 1.30, 1.28, 1.17, 1.15 (4×s, 3H). ESI-MS(m/z): Calcd. for C₂₃H₂₅N₃O₅S₄: 552.1 (M+H); found: 652.0.

Example 2596-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-biphenyl-2-yl]-ureido}-hexanoicacid

a)6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-hexanoicacid ethyl ester

A solution of{2-amino-3′-[5-(imino-methoxycarbonylamino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-4-yl}-carbamicacid 2-trimethylsilanyl-ethyl ester ((Example 294: step f) 0.020 g,0.030 mmol) in dry CH₂Cl₂ (3 mL) was treated with 6-isocyanato-hexanoicacid ethyl ester (5.30 μL, 0.030 mmol) and stirred at room temperature40 min. The reaction mixture was diluted with CH₂Cl₂ and washed withwater (1×15 mL). The organic layer was dried over MgSO₄ and concentratedin vacuo to afford the product6-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-hexanoicacid ethyl ester (0.025 g, 98%) as an off-white solid. ¹H NMR (CD₃OD): δ8.217 (s, 1H), 8.062 (d, 1H, J=8.0 Hz), 7.920 (t, 1H, J=1.6 Hz), 7.718(t, 1H, J=8.0 Hz), 7.647 (d, 1H, J=1.6 Hz), 7.556 (d, 1H, J=7.6 Hz),7.282 (s, 1H), 4.292 (dd, 2H, J=8.4 Hz, J=1.6 Hz), 3.063–3.002 (m, 2H),2.699 (s, 3H), 2.327 (t, 2H, J=7.2 Hz), 2.011 (s, 3H), 1.604 (quint, 2H,J=7.2 Hz), 1.538 (s, 9H), 1.403–1.362 (m, 2H), 1.124 (dd, 2H, J=7.2 Hz,J=1.6 Hz), 1.281 (t, 3H, J=7.2 Hz). ESI-MS (m/z): Calcd. forC₃₉H₅₅N₅O₉S₃Si (M+H): 862.3; found 861.90.

b)6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-hexanoicacid

A solution of6-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-hexanoicacid ethyl ester ((Example 259: step a) 0.437 g, 0.507 mmol) inTHF:water (2:1, 15 mL) was treated with solid LiOH (0.097 g, 4.06 mmol)and stirred at room temperature 18.5 h. The THF was removed in vacuo,and the remaining aqueous solution was acidified to pH 5 with glacialacetic acid. The solution was extracted with CH₂Cl₂ (3×50 mL). Thecombined organic layers were dried over MgSO₄ and concentrated in vacuoto afford the title compound (0.4222 g, 99%) as an off-white solid.ESI-MS (m/z): Calcd. for C₃₇H₅₁N₅O₉S₃Si (M+H): 834.3; 834.2.

c)6-(3-{4-Amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-hexanoicacid

A solution of6-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-hexanoicacid ((Example 259: step b) 0.422 g, 0.506 mmol) in dry THF (20 mL) wastreated with tetrabutylammonium fluoride (1 M in hexanes, 3.39 mL, 3.39mmol) and stirred at 40° C. 4 h. Solvents were evaporated in vacuo. Theresidue was taken up in CH₂Cl₂ and washed with water (4×50 mL). Theorganic layer was dried over MgSO₄ and concentrated in vacuo. Silica gelchromatography (4% MeOH in CH₂Cl₂) afforded the product6-(3-{4-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-hexanoicacid (0.200 g, 57%) as an off-white solid. The material was combinedwith 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (0.252 g,0.870 mmol) and acetic acid (0.5 mL) in MeOH (10 mL) and was stirred at40° C. 2 h. The solvent was removed in vacuo. Silica gel chromatography(4% MeOH in CH₂Cl₂ then 10% MeOH in CH₂Cl₂) afforded the title compound(0.215 g, 80%) as a white solid. ¹H-NMR (CD₃OD): δ 8.22 (s, 1H), 8.06(m, 1H), 7.89 (m, 1H), 7.72 (m, 1H), 7.69 (m, 1H), 7.53 (m, 1H), 7.32(m, 1H), 3.01 (m, 2H), 2.66 (s, 3H), 2.27 (t, 2H, 7.4 Hz), 1.97 (s, 3H),1.57 (m, 2H), 1.54 (s, 18H), 1.51 (s, 9H), 1.37 (m, 2H), 1.27 (m, 2H).

d)6-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-biphenyl-2-yl]-ureido}-hexanoicacid bis-trifluoroacetate

The reaction conditions used in Example 1: step d were followed using6-(3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-(N′,N″-bis-tert-butoxycarbonyl-guanidino)-6-methyl-biphenyl-2-yl}-ureido)-hexanoicacid ((Example 259: step c) 80 mg, 0.086 mmol). Analogous purificationby HPLC yielded the title compound as a white solid (70 mg, 95%). ¹H-NMR(CD₃CN/D₂O): δ 8.23 (s, 1H), 8.04 (m, 1H), 7.83 (m, 1H), 7.74 (m, 1H),7.55 (m, 1H), 7.48 (m, 1H), 6.99 (m, 1H), 2.92 (m, 2H), 2.66 (s, 3H),2.24 (t, 2H, 7.4 Hz), 1.95 (s, 3H), 1.48 (m, 2H), 1.27 (m, 2H), 1.25 (m,2H). ESI-MS (m/z): Calcd. for C₂₇H₃₃N₇O₅S₃ (M+H): 632.2; found: 632.1.

Example 260N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidebis-trifluoroacetate

a)({4-[4′-Amino-6′-(4-methanesulfonyl-butyrylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

The procedure in Example 261: step b was followed using4-methanesulfonyl-butyryl chloride (Example 209: step a (53 mg, 0.29)),{[4-(6′-amino-2′-methyl-4′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 295: step h) 130 mg, 0.23 mmol), andEt₃N (192 μL, 1.38 mmol) in DCM (5 mL). After stirring for 1 h, startingmaterial remained and an additional 20 mg of acid chloride was added.The solution was partitioned between EtOAc (70 mL) and aq NH₄Cl (30 mL)and the layers were separated. The organic layer was washed with NaHCO₃(20 mL) and brine (30 mL) and was dried over sodium sulfate. Thesolution was concentrated and the residue was purified by SiO₂ flashcolumn chromatography to yield 126 mg of the amide product. The residuedissolved in EtOH (5 mL). Saturated aqueous NH₄Cl (1.5 mL) was addedfollowed by iron powder (110 mg, 2 mmol). The mixture was vigorouslystirred at 80° C. for 30 min. The solution was filtered through a 0.22μm filter and was then partitioned between EtOAc (70 mL) and water (20mL). The layers were separated, the organic solution was dried oversodium sulfate, and the solution was concentrated to give the crudetitle compound which was used without further purification. ¹H-NMR(CDCl₃): δ 7.99 (s, 1H), 7.96 (m, 2H), 7.77 (s, 1H), 7.57 (t, 1H, J=7.9Hz), 7.43 (dt, 1H, J=1.3, 7.7 Hz), 7.10 (br s, 1H), 7.04 (br s, 1H),6.43 (br s, 1H), 3.85 (br s, 2H), 2.92 (m, 2H), 2.88 (s, 3H), 2.56 (s,3H), 2.20 (t, 2H, J=6.7 Hz), 1.98 (m, 2H), 1.90 (s, 3H), 1.50 (s, 9H).

b)N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidebis-trifluoroacetate

Acetic acid (500 μL) was added to a solution of({4-[4′-amino-6′-(4-methanesulfonyl-butyrylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester ((Example 260: step a) 136 mg, 0.2 mmol) and1,3-bis-(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (145 mg, 0.5mmol) in MeOH (10 mL). The solution was stirred for 16 h at 40° C., thenwas partitioned between EtOAc (80 mL) and water (40 mL). The layers wereseparated and the organic layer was washed with aq NaHCO₃ (2×30 mL) andbrine (30 mL) and was dried over sodium sulfate. After concentration,the residue was purified by preparative TLC. The residue was treatedwith 1:1 TFA/DCM as in Example 1: step d and analogously purified byHPLC to yield the title compound (47 mg, 23%) as a white solid. ¹H-NMR(CD₃OD): δ 8.39 (s, 1H), 8.09 (ddd, 1H, J=0.9, 1.9, 8.1 Hz), 7.92 (t,1H, J=1.6 Hz), 7.74 (t, 1H, J=7.7 Hz) 7.58 (m, 1H), 7.24 (m, 2H), 2.94(s, 3H), 2.86 (t, 2H, J=7.7 Hz), 2.76 (s, 3H), 2.24 (m, 2H), 2.12 (s,3H), 1.80 (m, 2H). ESI-MS (m/z): Calcd. for C₂₅H₃₀N₆O₅S₄ (M+H): 623.1;found: 623.1.

Example 2615-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-pentanoicacid bis-trifluoroacetate

a)5-{4-Amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-pentanoicacid methyl ester

To a solution of{[4-(6′-amino-2′-methyl-4′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 295: step h) 130 mg, 0.23 mmol), andEt₃N (192 μL, 1.38 mmol) in DCM (5 mL) at 0° C. was added5-chlorocarbonyl-pentanoic acid methyl ester (53 mg, 0.29). Afterstirring for 1 h, the solution was partitioned between EtOAc (70 mL) andaq NH₄Cl (30 mL) and the layers were separated. The organic layer waswashed with NaHCO₃ (20 mL) and brine (30 mL) and was dried over sodiumsulfate. The solution was concentrated and the residue was purified bySiO₂ flash column chromatography to yield 36 mg of the amide product.The residue dissolved in EtOH (5 mL). Saturated aqueous NH₄Cl (1.5 mL)was added followed by iron powder (110 mg, 2 mmol). The mixture wasvigorously stirred at 80° C. for 30 min. The solution was filteredthrough a 0.22 μm filter and was then partitioned between EtOAc (70 mL)and water (20 mL). The layers were separated, the organic solution wasdried over sodium sulfate, and the solution was concentrated to give thecrude title compound which was used without further purification. ¹H-NMR(CDCl₃): δ 8.0 (m, 2H), 7.84 (s, 1H), 7.96 (m, 2H), 7.59 (t, 1H, J=7.7Hz), 7.43 (m, 1H), 7.23 (br s, 1H), 6.86 (br s, 1H), 6.45 (br s, 1H),3.85 (br s, 2H), 3.65 (s, 3H), 2.60 (m, 3H), 2.35 (m, 2H), 2.00 (m, 2H),1.90 (s, 3H), 1.67 (m, 2H), 1.90 (s, 3H), 1.53 (s, 9H).

b)5-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-pentanoicacid bis-trifluoroacetate

Acetic acid (500 μL) was added to a solution of5-{4-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-pentanoicacid methyl ester ((Example 260: step b) 136 mg, 0.2 mmol) and1,3-bis-(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (145 mg, 0.5mmol) in MeOH (10 mL). The solution was stirred for 16 h at 40° C., thenwas partitioned between EtOAc (80 mL) and water (40 mL). The layers wereseparated and the organic layer was washed with aq NaHCO₃ (2×30 mL) andbrine (30 mL) and was dried over sodium sulfate. After concentration,the residue was purified by preparative TLC. The residue was dissolvedin MeOH (10 mL) and 1N NaOH was added (400 μL, 0.4 mmol). After stirringfor 6 h, the solution was neutralized with AcOH (100 μL) and the solventwas removed in vacuo. The residue was treated with 1:1 TFA/DCM as inExample 1: step d and analogously purified by HPLC to yield the titlecompound (12 mg, 19%) as a white solid. ¹H-NMR (CD₃OD): δ 8.30 (s, 1H),8.09 (ddd, 1H, J=1.2, 2.1, 7.9 Hz), 7.88 (t, 1H, J=1.6 Hz), 7.70 (t, 1H,J=7.7 Hz) 7.52 (m, 1H), 7.22 (m, 1H), 7.17 (m, 1H), 2.72 (s, 3H), 2.12(m, 2H), 2.08 (s, 3H), 2.02 (m, 2H), 1.25 (m, 2H). ESI-MS (m/z): Calcd.for C₂₆H₃₀N₆O₅S₃ (M+H): 603.1; found: 603.2.

Example 2624-[2′-Methyl-4′-(N-methyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a) (4-Bromo-3-methyl-phenyl)-methyl-amine

A solution of 4-bromo-3-methylaniline (3.72 g, 20 mmol) in formic acid(15 mL) was heated at 100° C. for 8 h. The solvent was removed in vacuoand the residue was partitioned between EtOAc (100 mL) and aq NaHCO₃ (50mL). The layers were separated and the organic layers was dried (Na₂SO₄)and concentrated. The residue was dissolved in THF (80 mL) and cooled to0° C. Lithium aluminum hydride (1.52 g, 40 mmol) was added portionwiseover 10 min. The mixture was stirred at rt for 8 h and an additionalequivalent (750 mg) of LAH was added. After 16 h, the mixture wasquenched with EtOAc and MeOH and the solids were filtered. The materialwas purified by SiO₂ flash column chromatography to yield the titlecompound (2.56 g, 64%) as a colorless oil. ¹H-NMR (CDCl₃): δ 7.29 (d,1H, J=8.6 Hz), 6.33 (dd, 1H, J=2.8 Hz), 7.29 (d, 1H, J=2.8, 8.6 Hz),3.66 (s, 2H), 2.81 (d, 1H, J=5.4 Hz), 2.33 (s, 3H).

b){Imino-[4-(2′-methyl-4′-methylamino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

The procedure in Example 294: step e was followed using(4-bromo-3-methyl-phenyl)-methyl-amine ((Example 262: step a) 600 mg, 3mmol), palladium acetate (34 mg, 0.15 mmol), and2-(dicyclohexylphosphino)biphenyl (210 mg, 0.6 mmol) in dioxane (20 mL).Analogous workup yielded the crude pinacolboronate ester (720 mg, 98%)which was used without further purification. Following the procedure inExample 294: step f the crude boronate (540 mg, 2.18 mmol) was reactedwith{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) 715 mg, 1.46 mmol), aqNa₂CO₃ (2M, 4.4 mL, 8.8 mL), and Pd(PPh₃)₄ (407 mg, 0.37 mmol) inethanol (4.4 mL) and toluene (8.8 mL). Analogous workup and SiO₂ flashcolumn chromatography yielded the title compound (482 mg, 62%) as ayellow glass. ¹H-NMR (CDCl₃): δ 8.0 (s, 1H), 7.95 (m, 1H), 7.90 (m, 1H),7.55 (m, 1H), 7.51 (m, 1H), 7.05 (m, 1H), 6.53 (m, 2H), 2.9 (s, 3H),2.56 (s, 3H), 2.56 (s, 3H), 2.22 (s, 3H), 1.52 (s, 9H).

c)4-[2′-Methyl-4′-(N-methyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

The procedure in Example 314 was followed using{imino-[4-(2′-methyl-4′-methylamino-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester ((Example 262: step b) 106 mg, 0.2 mmol), HgCl₂(109 mg, 0.4 mmol),1,3-bis-(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (116 mg, 0.4mmol), and DIEA (350 μL, 2 mmol) in DMF (3 mL) at 50° C. After analogousworkup and purification by SiO₂ flash column chromatography, thematerial was treated with 1:1 TFA/DCM as in Example 1: step d.Purification by HPLC yielded the title compound as a white solid. ¹H-NMR(CD₃OD): δ 8.35 (s, 1H), 8.04 (m, 2H), 7.72 (m, 2H), 7.39 (m, 2H), 7.31(m, 1H), 3.40 (s, 3H), 2.72 (s, 3H), 2.29 (s, 3H). ESI-MS (m/z): Calcd.for C₂₁H₂₃N₅O₂S₃ (M+H): 474.1; found: 474.1.

Example 2636-{N′-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-guanidino}-hexanoicacid

a)1,3-bis-(tert-butoxycarbonyl)-1-(trimethylsilylethyl-6-hexanoate)-2-methyl-2-thiopseudourea

Diisopropylcarbodiimide (1.72 mL, 11 mmol) was added dropwise to a 0° C.solution of 6-bromohexanoic acid (1.95 g, 10 mmol),trimethylsilylethanol (2.4 g, 20 mmol), and DMAP (122 mg, 1 mmol) in DCM(20 mL). The mixture warmed to rt over 1 h and was allowed to stir at rtfor 16 h. The solvent was removed in vacuo, the residue was dissolved inEtOAc (100 mL), and the solution was filtered. The solution wasextracted with 5% citric acid (3×20 mL), NaHCO₃ (3×20 mL), and brine (30mL), then was dried over sodium sulfate. Concentration of the solutionin vacuo yielded the TMSE ester as a non-viscous oil (2.25 g, 76%) whichwas used without further purification. ¹H-NMR (CDCl₃): δ 4.16 (m, 2H),2.41 (s, 3H), 3.41 (t, 2H, J=6.75 Hz), 2.30 (t, 2H, J=6.75 Hz), 1.88 (m,2H), 1.65 (m, 2H), 1.47 (m, 2H).

Sodium hydride was added to a 0° C. solution of1,3-bis-(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (581 mg, 2 mmol)in DMF (10 mL). After stirring for 30 min at 0° C., a solution of2-trimethylsilyethyl-6-bromohexanoate (738 mg, 2.5 mmol) was added andthe reaction was warmed to rt. The reaction was stirred at rt for 2 h,60° C. for 1 h, then at 80° C. for 18 h. The solution was partitionedbetween EtOAc (120 mL) and water (50 mL) and the layers were separated.The organic layer was extracted with water (8×30 mL) and brine (50 mL),then was dried over sodium sulfate. Concentration of the solutionfollowed by SiO₂ flash column chromatography yielded the title compound(526 mg, 52%). ¹H-NMR (CDCl₃): δ 4.13 (m, 2H), 2.41 (s, 3H), 2.30 (t,2H, J=7.4 Hz), 1.69 (m, 4H), 1.53 (s, 9H), 1.50 (s, 9H), 1.34 (m, 4H),1.00 (m, 2H).

b)6-{N′-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-guanidino}-hexanoicacid

Acetic acid (0.5 mL) was added to a solution of{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 220: step b) 130 mg, 0.25 mmol) and1,3-bis-(tert-butoxycarbonyl)-1-(trimethylsilylethyl-6-hexanoate)-2-methyl-2-thiopseudourea((Example 263: step a) 245 mg, 0.5 mmol) in MeOH (10 mL). The solutionwas heated at 40° C. for 24 h. The solvent was removed in vacuo and theresidue was purified by SiO₂ flash column chromatography to yield theprotected guanidine (112 mg, 46%). A portion of the material (15 mg) wastreated with 1:1 TFA/DCM as in Example 1: step d. Purification by HPLCyielded the title compound (9.3 mg, 75%) as a white solid. ¹H-NMR(CD₃OD): δ 8.36 (s, 1H), 8.04 (m, 2H), 7.71 (m, 2H), 7.35 (d, 1H, J=8.1Hz), 7.27 (d, 1H, J=1.9 Hz), 7.22 (dd, 1H, J=1.9, 8.1 Hz), 3.34 (m, 2H),2.74 (s, 3H), 2.36 (t, 2H, J=7.4 Hz), 2.29 (s, 3H), 1.70 (m, 4H), 1.48(m, 2H). ESI-MS (m/z): Calcd. for C₂₆H₃₁N₅O₄S₃ (M+H): 574.2; found:574.2.

Example 264

a)4-(4-Amino-3-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

Sodium sulfite (1.5 g, 11.9 mmol) and NaHCO₃ (1.12 g, 13.3 mmol) weredissolved in water (30 mL) and 4-acetylamino-3-nitro-benzenesulfonylchloride (1.94 g, 7 mmol) was added. Ethanol (10 mL) and the mixture wasstirred for 6 h at rt. Aqueous NaOH (10N, 6 mL, 60 mmol) was added andthe reaction was heated to 80° C. for 2 h. The solution was brought topH˜8 with conc. HCl, and the solvent was removed in vacuo. DMF (15 mL)was added, the mixture was stirred for 15 min, and the inorganic saltswere then allowed to settle. The DMF was removed via syringe, the saltswere washed with a second portion of DMF (10 mL), and the combined DMFsolution was slowly added to a 0° C. solution of4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 931 mg, 3.5 mmol) in DMF (15 mL). The solution was stirred for0° C. for 1 h then overnight at rt. The DMF was removed in vacuo and theresidue was partitioned between EtOAc (100 mL) and aq NaHCO₃ (30 mL).The layers were separated and the organic layer was washed with aqNaHCO₃ (2×20 mL), water (30 mL), and brine (30 mL), then dried oversodium sulfate. The solution was concentrated and the residue wasdissolved in THF (20 mL) and cooled to −78° C. A solution of sodiummethoxide in methanol (1M, 7 mL, 7 mmol) was added dropwise and thereaction was stirred for 30 min. Acetic acid (500 μL) was added followedby EtOAc (100 mL). The solution was washed with NaHCO₃ (3×30 mL), brine(40 mL), and was dried over sodium sulfate. Concentration andchromatography of the residue yielded the title compound (381 mg, 28%)as a yellow solid. ¹H-NMR (CDCl₃): δ 10.56 (br s, 2H), 9.04 (d, 1H,J=8.8 Hz), 8.89 (d, 1H, J=2.3 Hz), 8.22 (dd, 1H, J=2.3, 9.1 Hz), 8.04(s, 1H), 3.90 (s, 3H), 2.64 (s, 3H), 2.35 (s, 3H).

b)4-(4-Bromo-3-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure used in Example 318: part c was followed using4-(4-amino-3-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 264: step a) 100 mg, 0.26 mmol), CuBr₂ (73mg, 0.31 mmol), and tert-butylnitrite (46 μL, 0.39 mmol) in acetonitrile(8 mL total). The title compound (118 mg, 100%) was used without furtherpurification. ¹H-NMR (CDCl₃): δ 8.46 (m, 1H), 8.03 (m, 2H), 7.94 (d, 1H,J=8.4 Hz), 3.90 (s, 3H), 2.65 (s, 3H).

c)5-Methylsulfanyl-4-{3-nitro-4-[(pyridin-2-ylmethyl)-amino]-benzenesulfonyl}-thiophene-2-carboxylicacid methyl ester

Pyridin-2-yl-methylamine (60 μL), DIEA (175 μL, 1 mmol), and4-(4-bromo-3-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 264: step b) 56 mg, 0.12 mmol) were heatedat 60° C. in THF (3 mL) for 30 min. The solvent was removed in vacuo andthe residue was purified by SiO₂ flash column chromatography to yieldthe title compound (41 mg, 69%). ¹H-NMR (CDCl₃): δ 9.46 (m, 1H), 8.90(m, 1H), 8.64 (m, 1H), 8.01 (d, 1H, J=2.6 Hz), 7.94 (m, 1H), 8.03 (m,2H), 7.71 (dt, 1H, J=1.9, 7.7 Hz), 7.28 (m, 2H), 6.95 (d, 1H, J=9.0 Hz),4.67 (d, 1H, J=5.1 Hz), 3.87 (s, 3H), 2.60 (s, 3).

d)5-Methylsulfanyl-4-(1-pyridin-2-ylmethyl-1H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxylicacid methyl ester

The procedure in Example 318: part e was followed using5-methylsulfanyl-4-{3-nitro-4-[(pyridin-2-ylmethyl)-amino]-benzenesulfonyl}-thiophene-2-carboxylicacid methyl ester ((Example 264: step c) 41 mg, 0.08 mmol), iron (110mg, 2 mmol), and EtOH/aq. AcOH, followed by treatment with formic acidto yield the title compound. ¹H-NMR (CD₃OD): δ 8.50 (m, 1H), 8.42 (s,1H), 8.08 (m, 1H), 7.97 (d, 1H, J=2.5 Hz), 7.85 (m, 1H), 7.72 (m, 1H),7.71 (dt, 1H, J=1.9, 7.7 Hz), 7.57 (m, 1H), 7.29 (m, 1H), 7.22 (d, 1HJ=7.8 Hz), 6.95 (d, 1H, J=9.0 Hz), 5.57 (s, 2H), 3.82 (s, 3H), 2.56 (s,3H).

e)5-Methylsulfanyl-4-(1-pyridin-2-ylmethyl-1H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxamidinebis-trifluoroacetate

The procedure in Example 12: step f was followed using5-methylsulfanyl-4-(1-pyridin-2-ylmethyl-1H-benzoimidazole-5-sulfonyl)-thiophene-2-carboxylicacid methyl ester ((Example 264: step d) 36 mg) and 5 mL (5 mmol) ofdimethylaluminum amide solution. Analogous workup and purificationyielded the title compound (13.2 mg, 23%) as a white solid. ¹H-NMR(CD₃OD): δ 8.63 (ddd, 1H, J=0.9, 1.6, 5.35 Hz), 8.58 (m, 1H), 8.34 (s,1H), 8.19 (dt, 1H, J=1.6, 7.8 Hz), 8.08 (dd, 1H, J=1.6, 8.7 Hz), 7.85(d, 1H, J=8.7 Hz), 7.69 (m, 1H), 7.66 (m, 1H), 5.98 (s, 1H), 2.72 (s,3H). ESI-MS (m/z): Calcd. for C₁₉H₁₇N₅O₂S₃ (M+H): 444.1; found: 444.1.

Examples 265–2664-(3-Benzyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(1-Benzyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(3-Benzyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-(1-Benzyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure as in Example 39: step a was followed using4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (20 mg, 44.7 μmol, Example 38: step e), benzyl bromide(5.3 μL, 44.7 μmol), K₂CO₃ (12.4 mg, 89.4 μmol), and DMF (1.5 mL).Removal of the solvents in vacuo was followed by preparative TLC (2–4%2.0 M NH₃ in methanol/CH₂Cl₂) to afford a mixture of4-(3-benzyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-(1-benzyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester compound as a brown oil (27.7 mg, quantitative). Thismixture was used directly in the following step. ESI-MS (m/z): Calcd.for C₂₁H₁₇BrN₂O₄S₃: 536 (M+1); found: 538.9.

b)4-(3-Benzyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(1-Benzyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The mixture from Examples 265–266: step a (27.7 mg, 44.7 μmol) wasconverted to the amidine and purified as described in Examples 39–40:step a to afford the 2 regioisomers: the 3-benzyl (1.6 mg, beige solid)and the 1-benzyl (2.0 mg, white solid). ¹H-NMR (CD₃OD, 3-benzyl): δ 9.08(s, 1H), 8.27 (s, 1H), 8.23 (s, 1H), 8.10 (s, 1H), 7.35–7.45 (m, 5H),5.70 (s, 2H), 2.58 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₁₇BrN₄O₂S₃:521.0 (M+1); found: 523.0. ¹H-NMR (CD₃OD, 1-benzyl): δ 8.73 (s, 1H),8.44 (s, 1H), 8.32 (s, 1H), 8.10 (s, 1H), 7.27–7.37 (m, 3H), 7.06–7.11(m, 2H), 5.93 (s, 2H), 2.72 (s, 3H). ESI-MS (m/z): Calcd. forC₂₀H₁₇BrN₄O₂S₃: 521.0 (M+1); found: 523.0.

Example 267–2684-(3-Allyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(1-Allyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(3-Allyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-(1-Allyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure as in Example 39: step a was followed using4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (20 mg, 44.7 μmol, Example 38: step e), allyl bromide(3.9 μL, 44.7 μmol), K₂CO₃ (12.4 mg, 89.4 μmol), and DMF (1.5 mL). Thecrude was purified by preparative TLC (2–4% 2.0 M NH₃ inmethanol/CH₂Cl₂) to afford a mixture of4-(3-allyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-(1-allyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester as a brown oil (22.4 mg, quantitative). This mixturewas used directly in the following step. ESI-MS (m/z): Calcd. forC₁₇H₁₅BrN₂O₄S₃: 486.9 (M+1); found: 488.9.

b)4-(3-Allyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(3-Allyl-7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The mixture from Example 267–268: step a (22.4 mg, 44.7 μmol) wasconverted to the amidine and purified as described in Example 20: step bto afford the 2 regioisomers: the 3-allyl (1.0 mg, beige solid) and the1-allyl (2.5 mg, beige solid). ¹H-NMR (CD₃OD, 3-allyl): δ 8.54 (s, 1H),8.31–8.34 (m, 2H), 8.04–8.05 (m, 1H), 6.05–6.14 (m, 1H), 5.33–5.36 (m,1H), 5.21–5.26 (m, 1H), 5.05–5.08 (m, 2H), 2.71 (s, 3H). ESI-MS (m/z):Calcd. for C₁₆H₁₅BrN₄O₂S₃: 471.0 (M+1); found: 473.0. ¹H-NMR (CD₃OD,1-allyl): δ 8.31–8.55 (m, 3H), 8.05–8.11 (m, 1H), 6.10–6.22 (m, 1H),4.92–5.32 (m, 4H), 2.72 (s, 3H). ESI-MS (m/z): Calcd. forC₁₆H₁₅BrN₄O₂S₃: 471.0 (M+1); found: 473.0.

Example 2694-(7-Bromo-3-phenyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(7-Bromo-3-phenyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

4-(7-Bromo-3-phenyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester was prepared according to literature (Lam, P. Y. S. etal., Tetrahedron Letters, 42:3415 (2001)) using4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (20 mg, 44.7 μmol, Example 38: step e), phenylboronicacid (11.4 mg, 93.5 μmol), Cu(OAc)₂ (8.5 mg, 46.8 μmol), pyridineN-oxide (4.7 mg, 49.2 μmol), triethylamine (13 μL, 93.3 μmol), andCH₂Cl₂ (1.5 mL) in a loosely-capped, 1-dram vial. The reaction mixturewas diluted in CH₂Cl₂ and washed with water and brine. The organic layerwas dried over magnesium sulfate. Removal of solvents in vacuo followedby preparative TLC afforded the title compound as a brown oil (12 mg,51%). ESI-MS (m/z): Calcd. for C₂₀H₁₅N₂O₄S₃: 522.9 (M+1); found: 525.0.

b)4-(7-Bromo-3-phenyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

4-(7-Bromo-3-phenyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (12 mg, 22.9 μmol) was converted to the amidine andpurified as described in Example 20: step f to afford the title compoundas a beige solid (1.6 mg, 14%). ¹H-NMR (CD₃OD): δ 8.80 (s, 1H),8.13–8.32 (m, 3H), 7.63–7.74 (m, 5H), 2.73 (s, 3H). ESI-MS (m/z): Calcd.for C₁₉H₁₅BrN₄O₂S₃: 507.0 (M+1); found: 509.0.

Example 270–2714-(7-Bromo-3-cyclopropylmethyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(7-Bromo-1-cyclopropylmethyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-(7-Bromo-3-cyclopropylmethyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester

The procedure as in Example 39: step a was followed using4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester (100 mg, 0.217 mmol, Example 38: step e),(bromomethyl)cyclopropane (21 μL, 0.217 mmol), K₂CO₃ (60 mg, 0.434mmol), and DMF (3 mL). The crude was purified by preparative TLC (2–4%2.0 M NH₃ in methanol/CH₂Cl₂) to afford a mixture of4-(7-bromo-3-cyclopropylmethyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester and4-(7-bromo-1-cyclopropylmethyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester as a brown oil (72 mg, 64%). This mixture was useddirectly in the following step. ESI-MS (m/z): Calcd. for C₁₈H₁₇BrN₂O₄S₃:515 (M+1); found: 516.9.

b)4-(7-Bromo-3-cyclopropylmethyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-(7-Bromo-1-cyclopropylmethyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The mixture from Examples 270–271: step a (72 mg, 0.14 mmol) wasconverted to the amidine and purified as described in Examples 39–40:step b to afford 2 regioisomers: the 3-cyclopropylmethyl (3-CPM) (2.8mg, beige solid) and the 1-cyclopropylmethyl (1-CPM) (3.3 mg, beigesolid). ¹H-NMR (CD₃OD, 3-CPM): δ 8.63 (s, 1H), 8.40 (d, 1H, J=1.40 Hz),8.35 (s, 1H), 8.05 (d, 1H, J=1.40 Hz), 4.27 (d, 2H, J=7.21 Hz), 2.72 (s,3H), 1.35–1.42 (m, 1H), 0.68–0.73 (m, 2H), 0.5–0.54 (m, 2H). ESI-MS(m/z): Calcd. for C₁₇H₁₇BrN₄O₂S₃: 485.0 (M+1); found: 487.0. ¹H-NMR(CD₃OD, 1-CPM): δ 8.55 (s, 1H), 8.37–8.38 (m, 1H), 8.34 (s, 1H),8.10–8.11 (m, 1H), 4.52 (d, 2H, J=7.21 Hz), 2.72 (s, 3H), 1.43–1.51 (m,1H), 0.62–0.67 (m, 2H), 0.47–0.52 (m, 2H). ESI-MS (m/z): Calcd. forC₁₇H₁₇BrN₄O₂S₃: 485.0 (M+1); found: 487.0.

Examples 272–2734-[7-Bromo-3-(2,6-dichloro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-[7-Bromo-1-(2,6-Dichloro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-[7-Bromo-3-(2,6-dichloro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester and4-[7-Bromo-1-(2,6-dichloro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester

The procedure as in Example 39: step a was followed using4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester (100 mg, 0.217 mmol, Example 38: step e),2-bromomethyl-1,3-dichloro-benzene (52 mg, 0.217 mmol), K₂CO₃ (60 mg,0.434 mmol), and DMF (3 mL). The crude was purified by preparative TLC(2–4% 2.0 M NH₃ in methanol/CH₂Cl₂) to afford a mixture of4-[7-bromo-3-(2,6-dichloro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester and4-[7-bromo-1-(2,6-dichloro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester as brown oil (70 mg, 52.2%). This mixture was useddirectly in the following step. ESI-MS (m/z): Calcd. forC₂₁H₁₅BrCl₂N₂O₄S₃: 618.9 (M+1); found: 620.9.

b)4-[7-Bromo-3-(2,6-dichloro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-[7-Bromo-1-(2,6-dichloro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The mixture from Examples 272–273: step a (70 mg, 0.11 mmol) wasconverted to the amidine and purified as described in Examples 39–40:step b to afford 2 regioisomers: the 3-(2,6-dichlorobenzyl) (3-DCB) (2.5mg, beige solid) and the 1-(2,6-dichlorobenzyl) (1-DCB) (2.2 mg, beigesolid). ¹H-NMR (CD₃OD, 3-DCB): δ 8.58 (s, 1H), 8.30–8.33 (m, 2H), 8.00(d, 1H, J=1.63 Hz), 7.55–7.58 (m, 2H), 7.44–749 (m, 1H), 5.90 (s, 2H),2.64 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₁₅BrCl₂N₄O₂S₃: 588.9 (M+1);found: 590.9. ¹H-NMR (CD₃OD, 1-DCB): δ 8.34–8.40 (m, 2H), 8.16–8.18 (m,1H), 7.86–7.90 (m, 1H), 7.46–7.60 (m, 3H), 6.22 (s, 2H), 2.64 (s, 3H).ESI-MS (m/z): Calcd. for C₂₀H₁₅BrCl₂N₄O₂S₃: 588.9 (M+1); found: 590.9.

Examples 274–2754-[7-Bromo-3-(2,5-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-[7-Bromo-1-(2,5-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-[7-Bromo-3-(2,5-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester and4-[7-Bromo-1-(2,5-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester

The procedure as in Example 39: step a was followed using4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester (100 mg, 0.217 mmol, Example 38: step e),2-bromomethyl-1,4-difluoro-benzene (28 μL, 0.217 mmol), K₂CO₃ (60 mg,0.434 mmol), and DMF (3 mL). The crude was purified by preparative TLC(2–4% 2.0 M NH₃ in methanol/CH₂Cl₂) to afford a mixture of4-[7-bromo-3-(2,5-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester and4-[7-bromo-1-(2,5-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid ethyl ester as a brown oil (70 mg, 55%). This mixture was useddirectly in the next step. ESI-MS (m/z): Calcd. for C₂₁H₁₅BrF₂N₂O₄S₃:586.0 (M+1); found: 588.9.

b)4-[7-Bromo-3-(2,5-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-[7-Bromo-1-(2,5-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The mixture from Examples 274–275: step a (70 mg, 0.12 mmol) wasconverted to the amidine and purified as described in Examples 39–40:step b to afford 2 regioisomers: the 3-(2,5-difluorobenzyl) (3-DFB) (3.0mg, white solid) and the 1-(2,5-difluorobenzyl) (1-DFB) (3.2 mg, whitesolid). ¹H-NMR (CD₃OD, 3-DFB): δ 8.58 (s, 1H), 8.30–8.33 (m, 2H), 8.00(d, 1H, J=1.63 Hz), 7.55–7.58 (m, 2H), 7.44–749 (m, 1H), 5.90 (s, 2H),2.64 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₁₅BrCl₂N₄O₂S₃: 588.9 (M+1);found: 590.9. ¹H-NMR (CD₃OD, 1-DFB): δ 8.57 (s, 1H), 8.41–8.45 (m, 1H),8.32–8.36 (m, 1H), 8.07–8.11 (m, 1H), 7.05–7.27 (m, 2H), 6.43–6.54 (m,1H), 5.94 (s, 2H), 2.72 (s, 3H). ESI-MS (m/z): Calcd. forC₂₀H₁₅BrCl₂N₄O₂S₃: 588.9 (M+1); found: 590.9.

Examples 276–2774-[7-Bromo-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-[7-Bromo-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a)4-[7-Bromo-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-[7-Bromo-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

The procedure as in Example 39: step a was followed using4-(7-bromo-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (50 mg, 0.11 mmol, Example 38: step e),2-bromomethyl-1,3-difluoro-benzene (23 mg, 0.11 mmol), K₂CO₃ (31 mg,0.22 mmol), and DMF (1.5 mL). The crude was purified by preparative TLC(2–4% 2.0 M NH₃ in methanol/CH₂Cl₂) to afford a mixture of4-[7-bromo-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester and4-[7-bromo-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester as a brown oil (67 mg, quantitative). ESI-MS (m/z):Calcd. for C₂₁H₁₅BrF₂N₂O₄S₃: 572.9 (M+1); found: 574.9.

b)4-[7-Bromo-3-(2,6-difluoro-benzyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate and4-[7-Bromo-1-(2,6-difluoro-benzyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The mixture from Examples 276–277: step a (67 mg, 0.11 mmol) wasconverted to the amidine and purified as described in Example 39–40:step a to afford 2 regioisomers: the 3-(2,6-difluorobenzyl) (3-DFB) (3.5mg, beige solid) and the 1-(2,6-difluorobenzyl) (1-DFB) (1.6 mg, whitesolid). ¹H-NMR (CD₃OD, 3-DFB): δ 8.64 (s, 1H), 8.31–8.35 (m, 2H), 8.02(s, 1H), 7.45–7.54 (m, 1H), 7.08–7.14 (m, 2H), 5.74 (s, 2H), 2.65 (s,3H). ESI-MS (m/z): Calcd. for C₂₀H₁₅BrF₂N₄O₂S₃: 556.0 (M+1); found:559.0. ¹H-NMR (CD₃OD, 1-DFB): δ 8.42 (s, 1H), 8.35–8.37 (m, 1H), 8.32(s, 1H), 7.39–7.48 (m, 1H), 6.99–7.06 (m, 1H), 7.03 (t, 2H, J=8.34),6.02 (s, 2H), 2.71 (s, 3H). ESI-MS (m/z): Calcd. for C₂₀H₁₅BrF₂N₄O₂S₃:556.0 (M+1); found: 559.0.

Example 2786-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-(4-carboxy-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid trifluoroacetate

a) 6-[3-(4-Bromo-3-methyl-5-nitro-phenyl)-ureido]-hexanoic acid ethylester

6-Isocyanato-hexanoic acid ethyl ester (370 μL, 2.16 mmol) was added toa solution of 4-bromo-3-methyl-5-nitro-phenylamine (250 mg, 1.08 mmol,Example 135: step a) in CH₂Cl₂ (5 mL, anhydrous) at rt. The reactionmixture was stirred overnight, then diluted in EtOAc and washed withsaturated NH₄Cl solution, water, and brine. The organic layer was driedover magnesium sulfate. Removal of solvents in vacuo was followed byflash chromatography (50–75% EtOAc/hexanes) to afford the title compoundas a brown oil (162 mg, 36%). ¹H-NMR (CDCl₃): δ 7.59 (d, 1H, J=2.56 Hz),7.42–7.48 (m, 1H), 4.10–4.17 (m, 2H), 3.20–3.28 (m, 2H), 2.39 (s, 3H),2.29–2.35 (m, 2H), 1.47–1.68 (m, 4H), 1.23–1.41 (m, 5H).

b)6-(3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-2-nitro-biphenyl-4-yl}-ureido)-hexanoicacid ethyl ester

A 25 mL round bottom flask was charged with6-[3-(4-bromo-3-methyl-5-nitro-phenyl)-ureido]-hexanoic acid ethyl ester(110 mg, 0.264 mmol, Example 278: step a),{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (234 mg, 0.529 mmol, Example 140: step a), aqueousNa₂CO₃ (2M, 1.06 mL, 2.12 mmol), ethanol (1.06 mL, anhydrous) andtoluene (2.11 mL, anhydrous). A stir bar was added, the solution wasdegassed for 10 min, and Pd(PPh₃)₄ (76 mg, 65.8 μmol) was added. Thereaction mixture was stirred under Ar at 80° C. for 5 hrs, then cooledto rt. The solvents were removed in vacuo. The residue was diluted inEtOAc, washed with brine, and dried over magnesium sulfate. Removal ofsolvents in vacuo followed by preparative TLC (50–100% EtOAc/hexanes)afforded the title compound as a brown oil (74 mg, 37%). ESI-MS (m/z):Calcd. for C₃₃H₄₁N₅O₉S₃: 748.2 (M+1); found: 747.8.

c)6-(3-{2-Amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-4-yl}-ureido)-hexanoicacid ethyl ester

6-(3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-2-nitro-biphenyl-4-yl}-ureido)-hexanoicacid ethyl ester (74 mg, 98.9 μmol, Example 278: step b) in EtOH (5 mL)was reduced as in Example 20: step c using Fe (28 mg, 0.50 mmol) andaqueous NH₄Cl solution (50 mg, 0.93 mmol, 10 mL). The solvents wereremoved from the filtrate in vacuo. The crude was diluted in EtOAc andwashed with water and brine. The organic layer was dried over magnesiumsulfate. The solvents were removed in vacuo to yield the title compoundas a brown oil (70.8 mg, quantitative). ESI-MS (m/z): Calcd. forC₃₃H₄₃N₅O₇S₃: 718.2 (M+1); found: 718.1.

d)6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-methoxycarbonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid ethyl ester

4-Chlorocarbonyl-butyric acid methyl ester (20.4 μL, 0.148 mmol) wasadded to a solution of6-(3-{2-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-4-yl}-ureido)-hexanoicacid ethyl ester (70.8 mg, 96.4 μmol, Example 278: step c) andtriethylamine (41.2 μL, 0.296 mmol) in CH₂Cl₂ (5 mL, anhydrous) at rt.The reaction mixture was stirred overnight at rt, then diluted in EtOAc,washed with water and brine, and dried over magnesium sulfate. Removalof solvents in vacuo followed by flash chromatography (75–100%EtOAc/hexanes) yielded the title compound as a brown oil (45.5 mg,54.5%). ESI-MS (m/z): Calcd. for C₃₉H₅₁N₅O₁₀S₃: 846.3 (M+1); found:845.9.

e)6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-carboxy-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid

Lithium hydroxide (53.8 μL, 0.215 mmol, 4N aqueous) was added to asolution of6-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-methoxycarbonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid ethyl ester (45.5 mg, 53.8 μmol, Example 278: step d) in MeOH/H₂O(10 mL, 2:1) at 0° C. The reaction mixture was warmed to rt and stirredovernight. The solvents were removed in vacuo to afford the titlecompound as a yellow solid (50 mg, quantitative). ESI-MS (m/z): Calcd.for C₃₆H₄₅N₅O₁₀S₃: 804.2 (M+1); found: 803.9.

f)6-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-(4-carboxy-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid trifluoroacetate

6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-carboxy-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid (43.2 mg, 53.7 μmol, Example 278: step e) was deprotected andpurified as in Example 1: step d to afford the title compound as a whitesolid (15 mg, 40%). ¹H-NMR (CD₃OD): δ 8.27 (s, 1H), 8.00–8.04 (m, 1H),7.87–7.89 (m, 1H), 7.63–7.71 (m, 1H), 7.49–7.54 (m, 1H), 7.32–7.35 (m,1H), 7.25–7.26 (m, 1H), 3.22 (t, 2H, J=6.98 Hz), 2.73 (s, 3H), 2.34 (t,2H, J=7.44 Hz), 2.05 (s, 3H), 1.88–2.03 (m, 4H), 1.54–1.71 (m, 4H),1.34–1.48 (m, 4H). ESI-MS (m/z): Calcd. for C₃₁H₃₇N₅O₈S₃: 704.2 (M+1);found: 704.1.

Example 2796-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-(4-methanesulfonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid trifluoroacetate

a)6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-methanesulfonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid ethyl ester

The procedure as in Example 278: step d was followed using6-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-methanesulfonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid ethyl ester (39 mg, 54.3 μmol, Example 278: step b), triethylamine(22.7 μL, 0.163 mmol), 4-methanesulfonyl-butyryl chloride (15 mg, 81.5μmol, Example 209: step a), and CH₂Cl₂ (3 mL, anhydrous). The reactionmixture was diluted in EtOAc, washed with water and brine, and driedover magnesium sulfate. The solvents were removed in vacuo to afford thetitle compound as a brown oil (48 mg, quantitative). ESI-MS (m/z):Calcd. for C₃₈H₅₁N₅O₁₀S₄: 866.3 (M+1); found: 865.8.

b)6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-methanesulfonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid

The procedure as in Example 278: step e was followed using6-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-methanesulfonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid ethyl ester (48 mg, 54.3 μmol, Example 279: step a) in a MeOH/H₂O(2:1) solution and 4N LiOH (54.3 μL, 0.217 mmol). The crude was taken ondirectly to the next step. ESI-MS (m/z): Calcd. for C₃₆H₄₇N₅O₁₀S₄: 838.2(M+1); found: 837.8.

c)6-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-(4-methanesulfonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid trifluoroacetate

6-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-(4-methanesulfonyl-butyrylamino)-6-methyl-biphenyl-4-yl]-ureido}-hexanoicacid (45.5 mg, 54.3 μmol, Example 279: step b) was deprotected andpurified as in Example 1: step d to afford the title compound as a beigesolid (10 mg, 25%). ¹H-NMR (CD₃OD): δ 8.30 (s, 1H), 8.01–8.05 (m, 1H),7.86–7.89 (m, 1H), 7.68 (t, 1H, J=7.91 Hz), 7.52–7.57 (m, 1H), 7.23–7.37(m, 2H), 3.23 (t, 2H, J=6.98 Hz), 2.92. (s, 3H), 2.80 (t, 2H, J=7.68Hz), 2.74 (s, 3H), 2.34 (t, 2H, J=7.44 Hz), 2.18 (t, 2H, J=7.21 Hz),2.05 (s, 3H), 1.72–1.79 (m, 2H), 1.63–1.71 (m, 2H), 1.54–162 (m, 2H),1.39–1.47 (m, 2H). ESI-MS (m/z): Calcd. for C₃₁H₃₉N₅O₈S₄: 738.2 (M+1);found: 738.1.

Example 2804-{2′-Methyl-4′-[N′-(3-phenyl-propyl)-guanidino]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

a)1,3-bis(tert-butoxycarbonyl)-3-(3-phenylpropyl)-2-methyl-2-thiopseudourea

Sodium hydride (95.8 mg, 2.40 mmol, 60% dispersion in mineral oil) wasadded to a solution of1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (580 mg, 2.0mmol) in DMF (4 mL, anhydrous) at 0° C. in 2 portions. The reactionmixture was stirred for 10 min. at 0° C., then (3-bromo-propyl)-benzene(607 μL, 3.99 mmol) was added and the reaction mixture was heated to 60°C. for 16 hr. The reaction mixture was cooled to rt, diluted in EtOAc,and washed with water and brine. The organic layer was dried overmagnesium sulfate. Removal of solvents in vacuo was followed bypreparatory TLC (5–10% EtOAc/hexanes) to afford the title compound as apale yellow oil (310 mg, 38%). ¹H-NMR (CDCl₃): δ 7.16–7.30 (m, 5H),3.53–3.58 (m, 2H), 2.62–2.66 (m, 2H), 2.38 (s, 3H), 1.95–2.05 (m, 2H),1.5 (s, 9H), 1.46 (s, 9H).

b)4-{4′-[N′,N″-bis(tert-butoxycarbonyl)-N′-(3-phenyl-propyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-N-methyl-5-methylsulfanyl-thiophene-2-carboxamidine

{[4-(4′-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (40 mg, 77.3 μmol, Example 220: step b) and1,3-bis(tert-butoxycarbonyl)-3-(3-phenylpropyl)-2-methyl-2-thiopseudourea(63 mg, 0.154 mmol, Example 280: step a) were dissolved in 5% aceticacid/MeOH (1.5 mL) solution and heated to 40° C. overnight. The reactionmixture was cooled to rt and the solvents were removed in vacuo. Thecrude was purified by preparative TLC (5–10% EtOAc/CH₂Cl₂) to afford thetitle compound as a red oil (26.9 mg, 40%). ESI-MS (m/z): Calcd. ForC₄₄H₅₅N₅O₈S₃: 878.3 (M+1); found: 877.9.

c)4-{2′-Methyl-4′-[N′-(3-phenylpropyl)-guanidino]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

4-{4′-[N′,N″-bis(tert-Butoxycarbonyl)-N′-(3-phenyl-propyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-N-methyl-5-methylsulfanyl-thiophene-2-carboxamidine(26.9 mg, 30.6 μmol, Example 280: step b) was deprotected and purifiedas in Example 1: step d to afford the title compound as a white solid(11 mg, 62%). ¹H-NMR (CD₃OD): δ 8.34 (s, 1H), 8.00–8.04 (m, 2H),7.69–7.73 (m, 2H), 7.17–7.34 (m, 8H), 3.30–3.34 (m, 2H), 2.71–2.76 (m,5H), 2.27 (s, 3H), 1.93–2.02 (m, 2H). ESI-MS (m/z): Calcd. forC₂₉H₃₁N₅O₂S₃: 578.2 (M+1); found: 578.2.

Example 2814-[2′-Methyl-4′-(N′-phenethyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

a)1,3-bis(tert-butoxycarbonyl)-3-(3-phenylethyl)-2-methyl-2-thiopseudourea

The procedure as in Example 280: step a was followed using1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (580 mg, 2.0mmol), NaH (95.8 mg, 2.40 mmol, 60% dispersion in mineral oil),(2-iodo-ethyl)-benzene (578 μL, 3.99 mmol), and DMF (4 mL, anhydrous).The reaction mixture was cooled to rt, diluted in EtOAc, and washed withwater and brine. The organic layer was dried over magnesium sulfate.Removal of solvents in vacuo was followed by preparatory TLC (5–10%EtOAc/hexanes) to afford the title compound as a pale yellow oil (146mg, 19%). ¹H-NMR (CDCl₃): δ 7.18–7.33 (m, 5H), 3.71–3.75 (m, 2H),2.96–3.01 (m, 2H), 2.37 (s, 3H), 1.51 (s, 9H), 1.49 (s, 9H).

b)({4-[4′-(N′N″-bis(tert-butoxycarbonyl)-N′-phenethyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester

The procedure as in Example 280: step b was followed using{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (40 mg, 77.3 μmol, Example 220: step b),1,3-bis(tert-butoxycarbonyl)-3-(3-phenylethyl)-2-methyl-2-thiopseudourea(61 mg, 0.155 mmol, Example 281: step a), and 5% acetic acid/MeOH (1.5mL) solution. The reaction mixture was cooled to rt, then concentratedin vacuo. The crude was purified by preparative TLC (5–10% EtOAc/CH₂Cl₂)to afford the title compound as a red oil (31.5 mg, 47%). ESI-MS (m/z):Calcd. for C₄₃H₅₃N₅O₈S₃: 864.3 (M+1); found: 863.9.

c)4-[2′-Methyl-4′-(N′-phenethylguanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

({4-[4′-(N′,N″-bis(tert-butoxycarbonyl)-N′-phenethyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamicacid tert-butyl ester (31.5 mg, 36.5 μmol, Example 281: step b) wasdeprotected and purified as in Example 1: step d to afford the titlecompound as a white solid (14.2 mg, 68.9%). ¹H-NMR (CD₃OD): δ 8.34 (s,1H), 7.99–8.05 (m, 2H), 7.65–7.72 (m, 2H), 7.24–7.39 (m, 6H), 7.03–7.09(m, 2H), 3.60 (t, 2H, J=7.02 Hz), 2.96 (t, 2H, J=7.02 Hz), 2.72 (s, 3H),2.23 (s, 3H). ESI-MS (m/z): Calcd. for C₂₈H₂₉N₅O₂S₃: 564.2 (M+1), found:564.2.

Example 2824-{2′-Methyl-4′-[N′-(3-methyl-butyl)-guanidino]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

a)1,3-bis(tert-butoxycarbonyl)-3-(3-phenylethyl)-2-methyl-2-thiopseudourea

The procedure as in Example 280: step a was followed using1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (580 mg, 2.0mmol), NaH (95.8 mg, 2.40 mmol, 60% dispersion in mineral oil),1-iodo-3-methyl-butane (528 μL, 3.99 mmol), and DMF (4 mL, anhydrous).The reaction mixture was cooled to rt, diluted in EtOAc, and washed withwater and brine. The organic layer was dried over magnesium sulfate.Removal of solvents in vacuo was followed by preparatory TLC (5–10%EtOAc/hexanes) to afford the title compound as a pale yellow oil (235mg, 33%). ¹H-NMR (CDCl₃): δ 3.49–3.56 (m, 2H), 2.39 (s, 3H), 1.52–1.60(m, 3H), 1.51 (s, 9H), 1.48 (s, 9H), 0.89–0.94 (m, 6H).

b)4-{4′-[N′,N″-bis(tert-butoxycarbonyl)-N′-(3-methyl-butyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-N-tert-butoxycarbonyl-5-methylsulfanyl-thiophene-2-carboxamidine

The procedure as in Example 280: step b was followed using{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (40 mg, 77.3 μmol, Example 220: step b),1,3-bis(tert-butoxycarbonyl)-1-(3-methylbutyl)-2-methyl-2-thiopseudourea(56 mg, 0.155 mmol, Example 282: step a), and 5% acetic acid/MeOH (1.5mL) solution. The reaction mixture was cooled to rt, then concentratedin vacuo. The crude was purified by preparative TLC (5–10% EtOAc/CH₂Cl₂)to afford the title compound as a red oil (29.2 mg, 46%). ESI-MS (m/z):Calcd. for C₄₀H₅₅N₅O₈S₃: 830.3 (M+1); found: 829.9.

c)4-{2′-Methyl-4′-[N′-(3-phenyl-propyl)-guanidino]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate

4-{4′-[N′,N″-bis(tert-Butoxycarbonyl)-N′-(3-methyl-butyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-N-tert-butoxycarbonyl-5-methylsulfanyl-thiophene-2-carboxamidine(29.2 mg, 35.2 μmol, Example 282: step b) was deprotected and purifiedas in Example 1: step d to afford the title compound as a white solid(13.6 mg, 73%). ¹H-NMR (CD₃OD): δ 8.34 (s, 1H), 8.00–8.05 (m, 2H),7.67–7.73 (m, 2H), 7.18–7.34 (m, 3H), 3.30–3.34 (m, 2H), 2.72 (s, 3H),2.27 (s, 3H), 1.66–1.79 (m, 1H), 1.52–1.59 (m, 211, 0.99 (d, 6H, J=6.64Hz). ESI-MS (m/z): Calcd. for C₂₅H₃₁N₅O₂S₃: 530.2 (M+1); found: 530.2.

Example 2834-(5-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid bistrifluoroacetate

a) 4-[5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-pentyloxy]-benzoic acidmethyl ester

A mixture of 4-hydroxy-benzoic acid methyl ester (3.01 g, 19.8 mmol),2-(5-bromo-pentyl)-isoindole-1,3-dione (3.9 g, 13.2 mmol), and K₂CO₃(1.82 g, 13.2 mmol) in acetone (150 mL) was heated to reflux for 24 hrs.The reaction mixture was cooled to rt and the solvents were removed invacuo. The crude was diluted in EtOAc and washed with 1N NaOH and brine.The organic layer was dried over sodium sulfate. The solvents wereremoved in vacuo. The crude was recrystallized from EtOAc to afford thetitle compound as a white solid (4 g, 83%). ¹H-NMR (CDCl₃): δ 7.95–7.98(m, 2H), 7.83–7.86 (m, 2H), 7.70–7.73 (m, 2H), 6.86–6.89 (m, 2H), 4.00(t, 2H, J=6.22 Hz), 3.88 (s, 3H), 3.73 (t, 2H, J=7.29 Hz), 1.82–1.89 (m,2H), 1.73–1.81 (m, 2H), 1.50–1.57 (m, 2H).

b) 4-(5-Amino-pentyloxy)-benzoic acid methyl ester

A suspension of4-[5-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pentyloxy]-benzoic acidmethyl ester (1 g, 2.72 mmol, Example 283: step a) and hydrazine (98.4μL, 3.13 mmol) in MeOH:H2O (10 mL, 4:1) was heated to 65° C. for 2 hrs.Additional hydrazine was added (171 μL, 5.44 mmol) to the reactionmixture at rt. The reaction mixture was heated to 70° C. for 2 hrs thenstirred overnight at rt. Potassium carbonate (30 mL, 1N aqueous) andmethylene chloride (200 mL) were added to the reaction. The organiclayer was dried over magnesium sulfate. The solvents were removed invacuo to afford the title compound as a white solid (500 mg, 77%).¹H-NMR (CDCl₃): δ 7.95–8.00 (m, 2H), 6.88–6.92 (m, 2H), 4.02 (t, 2H,J=6.43 Hz), 3.88 (s, 3H), 2.71–2.76 (m, 2H), 1.79–1.86 (m, 2H),1.49–1.56 (m, 4H).

c)4-(5-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid methyl ester

4-Nitrophenyl chloroformate (99.2 mg, 0.49 mmol) was added to a solutionof{2-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-4-yl}-carbamicacid 2-trimethylsilanyl-ethyl ester (303 mg, 0.45 mmol, Example 294:step f) and pyridine (39.8 μL, 0.49 mmol) in methylene chloride (5 mL)at rt. The reaction mixture was stirred for 2 hrs at rt.4-(5-Amino-pentyloxy)-benzoic acid methyl ester (117 mg, 0.49 mmol,Example 283: step b) and triethylamine were added to the reactionmixture and stirred for 2 hrs at rt. The reaction mixture was diluted inEtOAc, washed with water and brine, and dried over magnesium sulfate.Removal of solvents in vacuo was followed by flash chromatography(50–60% EtOAc/hexanes) to afford the title compound as a yellow solid(280 mg, 66.5%). ESI-MS (m/z): Calcd. for C₄₄H₅₇N₅O₁₀S₃Si: 940.3 (M+1);found: 939.9.

d)4-(5-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid

Lithium hydroxide (45.8 mg, 2.08 mmol) was added to a solution of4-(5-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid methyl ester (280 mg, 0.298 mmol, Example 283: step c) in1,4-dioxane:water (10 mL, 2:1) over 2 days at rt. The solvents wereremoved in vacuo. The residue was diluted in water, acidified to pH˜5with acetic acid, and extracted with EtOAc. The organic layer was washedwith brine and dried over magnesium sulfate. The solvents were removedin vacuo to afford the title compound as a yellow solid (276 mg,quantitative). ¹H-NMR (CDCl₃/CD₃OD): δ 7.93–7.99 (m, 3H), 7.83–7.86 (m,2H), 7.52–7.59 (m, 2H), 7.15–7.20 (m, 2H), 6.85–6.89 (m, 2H), 4.21–4.26(m, 2H), 3.99 (t, 2H, J=6.43 Hz), 3.13–3.24 (m, 2H), 2.61 (s, 3H), 2.02(s, 3H), 1.75–1.83 (m, 2H), 1.43–1.56 (m, 13H), 1.02–1.08 (m, 2H), 0.07(s, 9H).

e)4-[5-(3-{4-Amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-pentyloxy]-benzoicacid

Tetrabutyl ammonium fluoride solution (2.38 mL, 1M in THF) was added toa solution of4-(5-{3-[3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-4-(2-trimethylsilanyl-ethoxycarbonylamino)-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid (276 mg, 0.298 mmol, Example 283: step d) in THF (10 mL) over 2days at 35° C. The solvents were removed in vacuo. The residue wasdiluted in EtOAc, washed with water and brine, and dried over magnesiumsulfate. The solvents were removed in vacuo to afford the title compoundas a brown solid (300 mg, quantitative). ESI-MS (m/z): Calcd. forC₃₇H₄₄N₅O₈S₃: 782.2 (M+1); found: 781.8.

f)4-(5-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-(N′,N″-bis(tertbutoxycarbonyl)-guanidino)-6-methyl-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid

1,3-bis(tert-Butoxycarbonyl)-2-methyl-2-thiopseudourea (433 mg, 1.49mmol) was added to a solution of4-[5-(3-{4-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-yl}-ureido)-pentyloxy]-benzoicacid (233 mg, 0.298 mmol, Example 283: step e) in 5% AcOH/MeOH (10 mL)over 2 days at 35° C. The solvents were removed in vacuo and the residuewas purified by flash chromatography (1–6% MeOH/methylene chloride) toafford the title compound as a yellow solid (70 mg, 23%). ESI-MS (m/z):Calcd. for C₄₈H₆₁N₇O₁₂S₃: 1024.4 (M+1); found: 1024.0.

g)4-(5-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid bistrifluoroacetate

4-(5-{3-[3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-(N′,N″-bis(tert-butoxycarbonyl)-guanidino)-6-methyl-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid (15 mg, 14.6 μmol, Example 283: step f) was deprotected andpurified as in Example 1: step d to afford the title compound as a whitesolid (4.2 mg, 39.6%). ¹H-NMR (CD₃CN/D₂O): δ 8.19 (s, 1H), 7.98–8.03 (m,1H), 7.90–7.95 (m, 2H), 7.80–7.83 (m, 1H), 7.69–7.74 (m, 1H), 7.49–7.55(m, 2H), 6.93–6.97 (m, 3H), 4.01 (t, 2H, J=6.43 Hz), 2.88–3.03 (m, 2H),2.64 (s, 3H), 1.94–1.97 (m, 3H), 1.66–1.73 (m, 2H), 1.29–1.37 (m, 4H).ESI-MS (m/z): Calcd. for C₃₃H₃₇N₇O₆S₃: 724.2 (M+1); found: 724.2.

Example 2844-(4-Amino-3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

The reaction conditions in Example 12: step f were followed using4-(4-amino-3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide ((Example 319: step d) 50 mg, 0.12 mmol) and dimethylaluminumamide reagent (5 mL). Analogous workup and HPLC purification yielded thetitle compound as an off-white solid (26 mg, 34%). ¹H-NMR (CD₃OD): δ8.23 (s, 1H), 7.96 (d, 1H, J=2.1 Hz), 7.67 (dd, 1H, J=2.1, 8.6 Hz), 6.85(d, 1H, J=8.6 Hz), 2.71 (s, 3H). ESI-MS (m/z): Calcd. for C₁₂H₁₂BrN₃O₂S₃(M+H): 405.9; found: 405.9, 407.9 (m+2).

Example 285[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2,6-dimethyl-biphenyl-4-yloxymethyl]-phosphonicacid

To a flask containing{[4-(4′-hydroxy-2′,6′-dimethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 224: step b) 233 mg, 0.42 mmol), Cs₂CO₃(137 mg, 0.42 mmol), DMF (2 mL), and trifluoro-methanesulfonic aciddiethoxy-phosphorylmethyl ester (200 mg, 0.67 mmol, (Xu, Y. et al J.Org. Chem. 61, 7697 (1996); Phillion, D. et al Tetrahedron Lett. 27,1477 (1986)) were added and heated to 50 C. This mixture was heated andstirred for 18 h under an Ar atmosphere. DMF was removed under vacuumand the residue was taken in EtOAc and washed with water and saturatedNaCl. The EtOAc layer was separated dried over Na₂SO₄ and evaporatedunder vacuum to give an oil. This was purified by preparative thin-layerchromatography (EtOAc/Hexane) to give 94 mg (33%) of{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2,6-dimethyl-biphenyl-4-yloxymethyl}-phosphonicacid diethyl ester as a white solid. This solid was dissolved indichloromethane (2 mL), and cooled in an ice bath. To thisiodotrimethylsilane (Aldrich Chemical Company, 60 μL) was added and themixture was stirred for 1 h at which time the dichloromethane wasremoved and the residue was taken in MeOH and treated with 6N HCl. Thismixture was stirred for 3 h and the solvents were removed under highvacuum. To this residue a 50% solution of TFA in dichloromethane wasadded and the mixture was stirred for 1 h. TFA and dichloromethane wereremoved under vacuum and the residue was purified by preparative HPLC(Rev. Phase acetonitrile/water) which yielded the title compound as awhite solid (30 mg, 33%). ¹H-NMR (CD₃OD): δ 7.8–7.7 (m, 2H), 7.62 (s,1H), 7.5–7.3 (m, 2H), 6.7 (s, 2H), 3.77 (d, 2H, J=9.8 Hz), 2.44 (s, 3H),1.74 (s, 6H). ESI-MS (m/z): Calcd. for C₂₁H₂₃N₂O₆PS₃: 527.1 (M+H);found: 527.1.

Example 2865-Methylsulfanyl-4-(3-piperidin-1-yl-benzenesulfonyl)-thiophene-2-carboxamidine

a) 4-Bromo-5-nitro-thiophene-2-carbaldehyde

A solution of potassium nitrate (110 g, 1.09 mol) in H₂SO₄ (550 mL,conc.) was added to a solution of 4-bromo-thiophene-2-carbaldehyde(207.6 g, 1.08 mol) in H₂SO₄ (1.1 L, conc.) at CH₂Cl₂ (5 mL, anhydrous)at 0° C. over a 45 minute period. The reaction mixture was stirred 0° C.for 2 hrs, then stirred overnight at rt. The reaction mixture was pouredover ice, filtered, and washed with water and hexanes. The yellow solidwas dried overnight to afford the title compound (251.4 g, 98.6%).¹H-NMR (DMSO-d₆): δ 9.90 (s, 1H), 8.56 (s, 1H).

b) 4-Bromo-5-nitro-thiophene-2-carbaldehyde oxime

Hydroxylamine hydrochloride (85 g, 1.2 mol) was added to a solution of4-bromo-5-nitro-thiophene-2-carbaldehyde (234 mg, 0.529 mmol, Example286: step a) in EtOH (7.5 mL, 200 proof—anhydrous):pyridine (100 mL,anhydrous) at rt over 5 min. The reaction mixture was heated to refluxovernight, then cooled to rt. The solvents were removed in vacuoresulting in a solid residue that was washed with water and filtered.The solid was dried overnight under high vacuum to afford the titlecompound as a yellow solid (225 g, 88%). The solid was used for the nextstep without further characterization.

c) 4-Bromo-5-nitro-thiophene-2-carbonitrile

A mixture of 4-bromo-5-nitro-thiophene-2-carbaldehyde oxime (216 g, 0.86mol, Example 286: step b) and acetic anhydride (1 L, 10.6 mol) washeated to reflux for 4 hrs. The reaction mixture was cooled to rt andthe solvents were removed in vacuo. The crude reaction mixture wasdiluted in methylene chloride and washed with water. The organic layerwas dried over magnesium sulfate and concentrated in vacuo resulting ina residue, which was stirred in diethyl ether/hexanes and filtered toafford the title compound as a yellow solid (170.2 g, 85%). ¹H-NMR(DMSO-d₆): δ 8.25 (s, 1H).

d) 4-(3-Bromo-phenylsulfanyl)-5-nitro-thiophene-2-carbonitrileTriethylamine (104 mL, 0.75 mol) was slowly added to a solution of4-bromo-5-nitro-thiophene-2-carbonitrile (165 g, 0.708 mol, Example 286:step c) and 3-bromo-benzenethiol (78 ml, 0.76 mmol) in THF (1.2 L) at rtfor 2 days. The solvents were removed in vacuo and the resulting residuewas diluted in EtOAc, washed with saturated Na₂CO₃ solution, and driedover magnesium sulfate. The solvents were removed in vacuo and theresidue was stirred in diethyl ether:hexanes (1:5) and filtered toafford the title compound as a yellow solid (232.7 g, 96%). ¹H-NMR(DMSO-d₆): δ 7.88–7.92 (m, 1H), 7.65–7.81 (m, 2H), 7.48–7.54 (m, 1H),7.22 (s, 1H).e) 4-(3-Bromo-benzenesulfonyl)-5-nitro-thiophene-2-carbonitrile

A solution of mCPBA (26.3 g, 11.7 mol, 77%) in 1,2-dichloroethane wasadded to a solution of4-(3-bromo-phenylsulfanyl)-5-nitro-thiophene-2-carbonitrile (10 g, 29.3mmol, Example 286: step d) in 1,2-dichloroethane (200 mL) at rt over 30min. The reaction mixture was heated to reflux for 2.5 hrs then cooledto rt. The reaction mixture was washed with 0.5 N NaOH and water and theorganic layers were dried over magnesium sulfate. The solvents wereremoved in vacuo. The residue was stirred in diethyl ether, filtered,and dried under high vacuum to afford the title compound as a yellowsolid (6.9 g, 63%). ¹H-NMR (DMSO-d₆): δ 8.53 (s, 1H), 8.14–8.16 (m, 1H),7.98–8.05 (m, 2H), 7.62–7.67 (m, 1H).

f) 4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carbonitrile

A solution of sodium thiomethoxide (1.87 g, 26.8 mmol) in EtOH (26.8 mL,anhydrous) was added to a suspension of4-(3-bromo-benzenesulfonyl)-5-nitro-thiophene-2-carbonitrile (10 g, 26.8mmol, Example 286: step e) in THF (67 mL, anhydrous) portionwise at −78°C. The temperature of the reaction was maintained at −78° C. withstirring for 1 hour. The reaction was quenched with acetic acid (2 mL,34.9 mmol) at −78° C. followed by warming the reaction mixture to rt andthen filtered. The yellow solids were washed with diethyl ether andsaved. The filtrate was concentrated in vacuo resulting in a residuethat was suspended in diethyl ether and stirred at rt overnight. Thesolids were filtered from the suspension. The combined yellow solidswere dried under high vacuum to afford the title compound (8.77 g,87.4%). ¹H-NMR (DMSO-d₆): δ 8.45 (s, 1H), 7.97–8.16 (m, 3H), 7.62–7.67(m, 1H), 2.71 (s, 3H).

g)5-Methylsulfanyl-4-(3-piperidin-1-yl-benzenesulfonyl)-thiophene-2-carbonitrile

A mixture of4-(3-Bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carbonitrile(Example 286: step f, 200 mg, 0.534 mmol), piperidine (56 mg, 0.64mmol), Pd(OAc)₂ (24 mg, 0.11 mmol), BINAP (100 mg, 0.16 mmol) and Cs₂CO₃in 2 mL of toluene under Ar was stirred at 150° C. for 16 h, then cooledto RT. The mixture was purified directly by PTLC (30% EtOAc/hexane) togive 20 mg of product as a light yellow oil: ¹H-NMR (CDCl₃; 400 MHz) δ7.68 (m, 1H), 7.67 (s, 1H), 7.54–7.52 (m, 1H), 7.39–7.32 (m, 2H),3.16–3.12 (m, 4H), 2.45 (s, 3H), 1.64–1.59 (m, 4H), 1.55–1.50 (m, 2H).Mass spectrum (ESI, m/z): Calcd. for C₁₇H₁₈N₂O₂S₃, 379.1 (M+H), found379.3.

h){Imino-[5-methylsulfanyl-4-(3-piperidin-1-yl-benzenesulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

To a solution of carbamic acid tert-butyl ester (8 mg, 0.069 mmol,Aldrich Chemical Company) in 1 mL of THF at −78° C. was added 35 uL ofn-BuLi under Ar. The mixture was stirred at −78° C. for 15 min. Asolution of5-methylsulfanyl-4-(3-piperidin-1-yl-benzenesulfonyl)-thiophene-2-carbonitrile(20 mg, 0.053 mmol, Example 286: step g) in 1 mL of THF was added. Theresulting mixture was stirred at RT for 5 h, then at 50° C. overnight.Cooled to RT, the mixture was purified directly by PTLC (20%EtOAc/hexane) to give 10 mg (38%) of product as colorless oil: ¹H-NMR(CDCl₃; 400 MHz) δ 8.42 (s, 1H), 7.74 (dd, 1H, J=1.6, 1.6 Hz), 7.67 (s,1H), 7.62 (ddd, 1H, J=7.5, 1.6, 1.6 Hz), 7.57 (d, 1H, J=7.5, 1.6, 1.6Hz), 7.52 (dd, 1H, J=7.5, 7.5), 3.42–3.40 (m, 4H), 2.54 (s, 3H), 1.64(br s, 6H), 1.61 (s, 9H). Mass spectrum (ESI, m/z): Calcd. forC₂₂H₂₉N₃O₄S₃, 496.1 (M+H), found 495.9.

i)5-Methylsulfanyl-4-(3-piperidin-1-yl-benzenesulfonyl)-thiophene-2-carboxamidine

To a solution of5-methylsulfanyl-4-(3-piperidin-1-yl-benzenesulfonyl)-thiophene-2-carboxamidine(10 mg, 0.020 mmol, Example 286: step h) in 1 mL of CH₂Cl₂ under Ar at0° C. was added 5 drops (˜200 ul) of TFA. The mixture was stirred at 0°C. for 1 h. Removal of the solvent under reduced pressure followed byflash chromatography of the residue on silica gel (5% MeOH/CH₂Cl₂) gave7.5 mg (77%) of product as colorless oil: ¹H-NMR (CD₃OD, 400 MHz) δ 8.25(s, 1H), 7.76 (dd, 1H, J=1.6, 1.6 Hz), 7.62 (ddd, 1H, J=7.5, 1.6, 1.6Hz), 7.56 (ddd, 1H, J=7.5, 1.6, 1.6 Hz), 7.51 (dd, 1H, J=7.5, 7.5),3.31–3.30 (m, 4H), 2.54 (s, 3H), 1.57–1.56 (m, 6H). Mass spectrum (ESI,m/z): Calcd. for C₁₇H₂₁N₃O₂S₃, 396.1 (M+H), found 396.2.

Example 2875-Methylsulfanyl-4-{3-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-4-yl]-benzenesulfonyl}-thiophen-2-carboxamidine

a) 4-Iodo-5-methyl-1H-benzoimidazole

A solution of 5-methyl-1H-benzoimidazole (132 mg, 1.0 mmol) and NIS (248mg, 1.10 mmol) in 1 mL of TFA was reflux for 1 hr and then cooled to RT.Treated with 30 mL of EtOAc, the mixture was neutralized with sat.NaHCO₃ solution. The organic layer was washed with H₂O (10 mL), brine(10 mL) and dried (Na₂SO₄). Removal of the solvent under reducedpressure followed by flash chromatography of the residue on silica gel(5% MeOH/CH₂Cl₂) gave 78 mg (30%) of product as a white solid: ¹H-NMR(CDCl₃; 400 MHz) δ 8.07 (d, 1H), 7.57 (br s, 1H), 7.22 (d, 1H, J. 8.4Hz), 2.59 (s, 3H). Mass spectrum (ESI, m/z): Calcd. for C₈H₇IN₂, 259.0(M+H), found 259.2.

b) 4-Iodo-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole

To a solution of 4-Iodo-5-methyl-1H-benzoimidazole (100 mg, 0.39 mmol,Example 287: step a) and SEMCl (71 mg 0.43 mmol) in 2 mL of DMF under Arwas added NaH (11 mg, 0.43 mmol). The mixture was stirred at RT for 4 hand purified directly by PTLC (25% EtOAc/hexane) to give 122 mg (81%) ofproduct as a colorless oil: ¹H-NMR (CDCl₃; 400 MHz) δ 7.95 (s, 1H), 7.37(d, 1H, J=8.4 Hz), 7.21 (d, 1H, J=8.4 Hz), 5.48 (s, 2H), 3.47 (t, 2H,J=8.3 Hz), 2.59 (s, 3H), 0.89 (t, 2H, J=8.3 Hz), −0.06 (s, 91H). Massspectrum (ESI, m/z): Calcd. for C₁₄H₂₁IN₂OSi, 389.1 (M+H), found 389.0.

c)[Imino-(5-methylsulfanyl-4-{3-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-4-yl]-benzenesulfonyl}-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester

A mixture of{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester. (20 mg, 0.044 mmol, Example 140: step a),4-Iodo-5-methyl-1-(2-methylsilanyl-ethoxymethyl)-1H-benzoimidazole (21mg, 0.054 mmol, Example 287: step b) and Pd(PPh₃)₄ in 1.2 ml of 1:1:2EtOH/2M Na₂CO₃/toluene was stirred at 90° C. for 5 h, the cooled to RT.Treated with 3 mL of H₂O, the mixture was extracted with EtOAc (3×5mL)/Removal of the solvent under reduced pressure followed by flashchromatography of the residue on silica gel (30% EtOAc/hexane) gave 21mg (71%) of product as a light yellow solid: ¹H-NMR (CDCl₃; 400 MHz) δ8.42 (s, 1H). 8.08 (s, 1H), 8.05 (s, 1H), 8.01 (ddd, 1H, J=7.2, 1.8, 1.7Hz), 7.71–7.67 (m, 2H), 7.57 (d, 1H, J=8.4 Hz), 7.39 (d, 1H, J=8.7 Hz),5.64 (s, 2H), 3.57 (t, 2H, J=8.3 Hz), 2.61 (s, 3H), 2.33 (s, 3H), 1.51(s, 9H), 0.95 (t, 2H, J=8.3), −0.03 (s, 9H). Mass spectrum (ESI, m/z):Calcd. for C₃₁H₄₀N₄O₅S₃Si, 673.2, (M+H), found 672.9.

d)5-Methylsulfanyl-4-{3-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazolyl]-benzenesulfonyl}-thiophen-2-carboxamidine

To a solution of[Imino-(5-methylsulfanyl-4-{3-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-4-yl]-benzenesulfonyl}-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester (7 mg, 0.01 mmol, Example 287: step c) in 0.7 mLof CH₂Cl₂ was added 0.3 mL of TFA. The resulting solution was stirred atRT for 1 h. Removal of the solvent under reduced pressure followed byflash chromatography of the residue on silica gel (5–10% MeOH/CH₂Cl₂)gave 6 mg (84%) of product as colorless oil: ¹H-NMR (CD₃OD; 400 MHz) δ8.84 (s, 1H), 8.32 (s, 1H), 8.14 (ddd, 1H, J=7.6, 1.6, 1.6 Hz). 8.08 (s,1H), 7.83–7.77 (m, 3H), 7.52 (d, 1H, J=8.4 Hz), 5.79 (s, 2H), 3.65 (t,2H, J=8.0 Hz), 2.72 (s, 3H), 2.29 (s, 3H), 0.93 (t, 2H, J=8.0 Hz), −0.04(s, 9H). Mass spectrum (ESI, m/z): Calcd. for C₂₆H₃₂N₄O₃S₃Si, 573.1,(M+H), found 573.0.

Example 2884-[3-(5-Methyl-1H-benzoimidazol-4-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

A solution of[Imino-(5-methylsulfanyl-4-{3-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-4-yl]-benzenesulfonyl}-thiophen-2-yl)-methyl]-carbamicacid tert-butyl ester (14 mg, 0.021 mmol, Example 287: step c) in 1 mLof TFA was heated at 50° C. for 2 h under Ar, cooled to RT. Removal ofthe solvent under reduced pressure followed by flash chromatography ofthe residue on silica gel (10–15% MeOH/CH₂Cl₂) gave 14 mg (100%) ofproduct as colorless oil: ¹H-NMR (CD₃OD; 400 MHz) δ 9.28 (s, 1H). 8.35(s, 1H), 8.20 (d, 1H, J=7.6 Hz). 8.11 (s, 1H), 7.86 (dd, 1H, J=7.7,7.7), 7.80 (m, 2H), 7.63 (d, 1H, J=8.6 Hz), 2.72 (s, 3H), 2.30 (s, 3H).Mass spectrum (ESI, m/z): Calcd. for C₂₀H₁₈N₄O₂S₃, 443.1.00 (M+H), found443.1.

Example 2894-[3-(3-Methyl-5-nitro-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine.TFA salt

a)(Imino-{4-[3-(3-methyl-5-nitro-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

A solution of{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.058 mmol, 40 mg, Example 140: step a),2-iodo-3-methyl-5-nitropyridine (0.08 mmol, 21.1 mg), CuI (0.01 mmol,2.2 mg) and (Ph₃P)₄Pd (0.006 mmol) in DMF (0.6 mL) was heated at 100°under Ar for 3 hr. The reaction mixture was allowed to cool to RT andpoured in to water (20 mL). The product was extracted with CH₂Cl₂ (3×10mL). CH₂Cl₂ extracts were combined, dried (Na₂SO₄) and concentrated invaccuo. The resulting residue was purified on silica (30% EtOAc:Hexane)to obtain(Imino-{4-[3-(3-methyl-5-nitro-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester. Yield: 48%; ¹H NMR (CDCl₃) δ 9.36 (br, 1H), 8.37and 8.25 (s, 1H each), 8.1 and 7.8 (d, J=2.4 Hz, 1H each), 7.93 (s, 1H),7.74 (t, J=6.8 Hz, 1H), 2.7 and 2.5 (s, 3H each), 1.35 (s, 9H)

b)4-[3-(3-Methyl-5-nitro-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine.TFA salt

(Imino-{4-[3-(3-methyl-5-nitro-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester (20 mg, Example 289: step a) was then dissolved in1:1 mixture of CH₂Cl₂ and TFA (1 mL). The resulting solution was stirredat RT for 1 hr. and concentrated in vaccuo to obtain a yellow oil whichwas dried in a high vaccum. Ether (10 mL) was then added and theprecipitate formed was collected by suction filtration to yield4-[3-(3-Methyl-5-nitro-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine.TFA salt.

Yield: 78%; ¹H NMR (DMSO) δ 9.36 (br, 2H), 9.31 (d, J=2.4 Hz, 1H), 8.75(brs, s), 8.65 (d, J=2.4 Hz, 1H), 8.45 (s, 1H), 8.20 (m, 1H), 8.13 and8.06 (d, J=6.6 Hz, 1H each), 7.84 (t, J=6.7 Hz, 1H), 2.7 and 2.4 (s, 3Heach); MS 448.03 (M⁺) calculated for C₁₈H₁₆N₄O₄S₃; found 449.1 (M⁺+1)

Example 2904-[3-(5-Amino-3-methyl-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine.TFA salt

A solution of{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (0.058 mmol, 40 mg, Example 140: step a),2-iodo-3-methyl-5-nitropyridine (0.08 mmol, 21.1 mg), CuI (0.01 mmol,2.2 mg) and (Ph₃P)₄Pd (0.006 mmol) in DMF (0.6 mL) was heated at 100°under Ar for 3 hr. The reaction mixture was allowed to cool to RT andpoured in to water (20 mL). The product was extracted with CH₂Cl₂ (3×10mL). CH₂Cl₂ extracts were combined, dried (Na₂SO₄) and concentrated invaccuo. The resulting residue was purified on silica (30% EtOAc:Hexane)to obtain the expected coupling product. The product (54.8 mg, 0.1 mmol)was suspended in EtOH:water (2:1, 10 mL) and NH₄Cl (53.5 mg, 1 mmol) andFe powder (28 mg, 0.5 mmol) were added. The resulting mixture was heatedat reflux for 2 hr. The reaction mixture was cooled to RT and poured into Std. Na₂CO₃ solution and the product was extracted with CH₂Cl₂ (3×10mL). CH₂Cl₂ extracts were combined, dried (Na₂SO₄) and concentrated invaccuo to obtain a brownish yellow oil. This compound (29 mg) was thendissolved in 1:1 mixture of CH₂Cl₂ and TFA (1 mL). The resultingsolution was stirred at RT for 1 hr. and concentrated in vaccuo toobtain a yellow oil which was dried in a high vaccum. Ether (10 mL) wasthen added and the precipitate formed was collected by suctionfiltration to yield the title compound.

Yield: 28%; ¹H NMR (DMSO) δ 9.37 (br, 2H), 9.07 (br, 2H), 8.4 (s, 1H),8.05 (s, 1H), 7.9 (d, J=2.6 Hz, 1H), 7.85 (m, 2H), 7.74 (t, J=6.7 Hz,1H), 7.1 (s, 1H), 2.6 and 2.2 (s, 3H each); MS 418.06 (M⁺) calculatedfor C₁₈H₁₆H₄O₂S₃; found 419.1 (M⁺+1)

Example 2914-[3-(3-Methyl-pyrazin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidineTFA salt

a)(Imino-{4-{3-(3-methyl-pyrazine-2-yl)-benzenesulfanyl-thiophene-2yl}-methyl)-carbamicacid tert-butyl ester

To a flask containing{Imino-[5-methylsulfanyl-4-(3-tributylstannanyl-benzenesulfonyl)-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (22.3 mg, 0.031 mmol, Example 152: step a),methyl-iodopyrazine (8.3 mg, 0.038 mmol), Pd(PPh3)4 (10 mol %, 3.6 mg),and CuI (20 mol %, 1.2 mg) was added 0.5 mL of DMF. The flask was purgedwith Ar, and then heated to 100° C. for 16 h in an oil bath. The resultwas concentrated in vacuo and purified by preparative TLC (80%EtOAc-Hexanes) to give the 7.2 mg (46%) of the product as a yellow solidcontaminated with a small amount of tin. Mass spectrum (ESI, m/z) calcd.for C₂₂H₂₄N₄O₄S3, 505.1 (M+H), found 405.1 (M+H−BOC). ¹H NMR (CDCl₃, 400MHz): d 1.53 (s, 9H), 2.60 (s, 3H), 2.65 (s, 3H), 7.70 (t, 1H, J=8.8Hz), 7.87–7.89 (m, 2H), 8.10 (d, 1H, J=8.8 Hz), 8.25 (s, 1H), 8.53 (m,2H);

b)4-[3-(3-Methyl-pyrazin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidineTFA salt

To a solution of 7 mg of(Imino-{4-{3-(3-methyl-pyrazine-2-yl)-benzenesulfanyl-thiophene-2-yl}-methyl)-carbamicacid tert-butyl ester (Example 291: step a) in 0.3 mL of CH₂Cl₂ at 0° C.was added 0.3 mL of TFA containing 10 μL H₂O. The reaction was allowedto warm to ambient temperature. After 1 h, the solution was concentratedin vacuo with azeotropic removal using toluene (2×5 mL). Theorange-brown solid was treated with 0.2 mL hexanes/0.5 mL CHCl₃ andfinely divided using sonication. The supernatant was removed viapipette. The solids were dried giving 4.8 mg (71%) of4-[3-(3-Methyl-pyrazin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidineTFA salt as a yellow film.

Mass spectrum (ESI, m/z) calcd. for C₁₇H₁₆N₄O₂S₃, 404.5. M+H), found405.1; ¹H NMR (CD₃OD, 400 MHz): d 2.62 (s, 3H), 2.74 (s, 3H), 7.79 (t,1H, J=8.9 Hz), 7.99–8.01 (m, 1H), 8.17–8.19 (m, 1H), 8.29 (t, 1H, J=1.7Hz), 8.35 (s, 1H), 8.56–8.58 (m, 2H);

Example 2924-[3-(4-Piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

a)4-[3-(4-Methyl-piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carbonitrile

To a flask containing 0.15 g (0.4 mmol) of4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carbonitrile(Example 286: step f), 44.1 μL (0.4 mmol) of N-methylpiperazine, 4.5 mg(0.02 mmol) of Pd(OAc)₂, 24.8 mg (0.04 mmol) of BINAP, and 195 mg (0.6mmol) of CsCO₃ was added 2.5 mL of toluene. The flask was purged withAr, and heated to 100° C. for 16 h. The reaction was then concentratedin vacuo and purified by preparative TLC (50%-EtOAc-Hexane), isolatingthe low R_(f) material, which was subjected to preparative TLC again(10% MeOH-CHCl₃) to give 15.5 mg (10% yield) of4-[3-(4-methyl-piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carbonitrilein greater than 98% purity.

Mass spectrum (ESI, m/z) calcd. for C₁₇H₁₉N₃O₂S₃, 394.06 (M+H), found394.1; ¹H NMR (CDCl₃, 400 MHz): d 2.36 (s, 3H), 2.57–2.59 (m, 4H), 2.62(s, 3H), 3.29 (m, 4H), 7.11–7.13 (m, 1H), 7.38–7.40 (m, 2H), 7.49 (d,1H, J=1.2 Hz), 7.84 (s, 1H);

b)4-[3-(4-Methyl-piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester

To a flask containing 15 mg (0.03 mmol) of4-[3-(4-methyl-piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carbonitrile(Example 292: step a) was added 1 mL of MeOH and the resultant solutionwas treated with 1 mL 2M NaOMe in MeOH (2 mmol) at room temperature. Thereaction was heated to 50° C. for 2 h. At this time it was cooled toroom temperature and 2 drops of H₂O was added. Concentration of themixture in vacuo 5 followed by purification by preparative TLC (5%MeOH-CHCl₃) yielded 12 mg (74%) of4-[3-(4-methyl-piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester as a yellow solid.

Mass spectrum (ESI, m/z) calcd. for C₁₈H₂₃N₃O₃S₃, 426.09 (M+H), found426.2; ¹H NMR (CDCl₃, 400 MHz): d 2.36 (s, 3H), 2.56–2.58 (m, 7H),3.27–3.30 (m, 4H), 3.88 (s, 3H), 7.09–7.11 (m, 1H), 7.35–7.43 (m, 2H),7.54 (s, 1H), 7.57 (s, 1H), 7.71 (s, 1H);

c)4-[3-(4-Piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

4-[3-(4-Methyl-piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboximidicacid methyl ester (10 mg, 0.023 mmol, Example 292: step b)), NH₄OAc (10mg, 0.6 mmol) and 1 mL of 2M NH₃ in MeOH were heated in a sealed tube at60° C. for 3 h. The reaction was then concentrated in vacuo and purifiedby preparative TLC (10% MeOH-CHCl₃-sat'd NH₃) to give 8.7 mg (94%) of4-[3-(4-Piperazin-1-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine as a yellow solid.

Mass spectrum (ESI, m/z) calcd. for C₁₈H₂₃N₃O₃S₃, 411.09 (M+H), found411.2. ¹H NMR (CD₃OD, 400 MHz): δ 2.36 (s, 3H), 2.61–2.64 (m, 4H), 2.67(s, 3H), 3.28–3.31 (m, 4H), 7.24–7.27 (m, 1H), 7.42–7.44 (m, 2H), 7.54(d, 1H, J=1.3 Hz), 8.00 (s, 1H);

Example 2934-[3-(4-Methyl-pyrimidin-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

a)(Imino-{4-[3-(4-methyl-pyrimidin-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester

To a flask with a reflux condenser under argon was added5-Bromo-4-methyl-pyrimidine (9 mg, 0.044 mmol), prepared according tothe procedure of Yamanaka, Sakamoto, Nishimura, and Sagi, Chem. Pharm.Bull. 35(8), 3119–3126 (1987).{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (20 mg, 0.044 mmol, Example 140: step a), Na₂CO₃(2M, 0.220 mL, 0.44 mmol), Pd(PPh₃)₄ (8 mg, 0.007 mmol), ethanol (0.220mL) and toluene (0.440 mL). PdCl₂(PPh₃)₂ (42 mg, 0.06 mmol), dioxane (4mL), and triethylamine (420 μL, 3 mmol) and the mixture was stirred for2 h 15 min at 90° C. After cooling to rt, EtOAc (2 mL) and NaHCO₃(saturated, 2 mL) were added and the layers were separated. The organiclayer concentrated in vacuo followed by purification of the crudematerial by preparative TLC (5% methanol in dichloromethane) to yieldthe title compound (19 mg, 87%) as a white solid. ¹H-NMR (CDCl₃): δ 9.12(s, 1H), 8.54 (s, 1H), 8.10–7.29 (m, 7H), 2.59 (s, 3H), 2.50 (s, 3H),1.51 (s, 9H). ESI-MS (m/z): Calcd. for C₂₂H₂₄N₄O₄S₃: 504.1 (M−BOC)+H;found: 405.1.

b)4-[3-(4-Methyl-pyrimidin-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

The(imino-{4-[3-(4-methyl-pyrimidin-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophen-2-yl}-methyl)-carbamicacid tert-butyl ester ((Example 293: step a) 15 mg, 0.03 mmol) wasdissolved in dichloromethane (1 mL), water (1 drop) was added, followedby trifluoroacetic acid (1 mL). The solution was stirred for 1 h 40 minat rt. The solvents were removed in vacuo, the residue was co-evaporatedwith dichloromethane and methanol, then purified by preparative TLC (10%methanol in dichloromethane) which yielded the title compound as a paleyellow glass (4 mg, 32%). ¹H-NMR (CD₃OD): δ 9.05 (s, 1H), 8.61 (s, 1H),8.13–8.08 (m, 2H), 8.04 (s, 1H), 7.78–7.76 (m, 2H), 2.66 (s, 3H), 2.49(s, 3H). ESI-MS (m/z): Calcd. for C₁₇H₁₆N₄O₂S₃: 404.5 (M+H); found:405.1.

Example 2944-{4′,6′-Bis-[3-(3-methanesulfonyl-propyl)-ureido]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 4-Bromo-5-methyl-3-nitrobenzoic acid methyl ester

4-Bromo-3-methylbenzoic acid methyl ester (10.13 g, 44 mmol) wasdissolved in a mixture of H₂SO₄ 120 mL and TFA (15 mL) at roomtemperature. The solution was cooled on an ice bath and KNO₃ (4.65 g, 46mmol) was added portionwise over 30 min. The mixture was stirred atambient temperature for 4 hours during which it warmed to rt. TLCanalysis (after mini aqueous workup) showed total disappearance ofstarting material (30% EtOAc/Hex). The solution was poured onto ice andthe aqueous slurry was extracted with EtOAc (3×150 mL). The organiclayer was washed with 5% Na₂CO₃ (3×75 mL), NaHCO₃ (3×50 mL), water(2×100 mL), brine (100 mL), then was dried over sodium sulfate.Concentration of the solution yielded a yellowish solid/gel substance(11.6 g) which was one spot by TLC. ¹H NMR analysis shows two (major)products in ˜2:1 ratio, corresponding to the o- and m-nitrobenzoatederivatives. The material was carried onto the next step without furtherpurification.

b) 4-Bromo-5-methyl-3-nitrobenzoic acid

4-Bromo-5-methyl-3-nitrobenzoic acid methyl ester ((Example 294: step a(11.6 g, 42.3 mmol) was dissolved in MeOH (400 mL) at rt and 2N NaOH (43mL) was added dropwise over 30 min via addition funnel. The solution wasstirred for 12 hr during which, precipitate appeared, and sm disappeared(TLC shows only baseline spot in 30% EtOAc). The pH was adjusted to ˜2with conc HCl and the methanol was removed in vacuo. EtOAc (300 mL) wasadded to the aqueous slurry and the layers were separated. The aqueouslayer was extracted with EtOAc (2×50 mL) and then discarded. TLCanalysis of the combined organic extracts showed two products (40% EtOAcin Hexanes, 4% AcOH). The combined organic extracts were washed with a3:1 solution of 0.5N NaH₂PO₄/0.5N NaOAc (˜30×50 mL portions) untilremoval of the o-nitrobenzoic acid (lower spot on TLC, 40% EtOAc in Hex,4% AcOH) was complete. The organic layer was then washed with brine anddried over sodium sulfate. Concentration of the solution yielded 5.4 g(47%) of a white solid. ¹H NMR (CD₃OD) δ 8.10 (m, 2H), 2.54 (s, 3H).

c) (4-Bromo-3-methyl-5-nitro-phenyl)-carbamic acid2-trimethylsilanyl-ethyl ester

Diphenylphosphorylazide (4.31 mL, 20 mmol) was added to a stirredsolution of 4-bromo-3-methyl-5-nitro-benzoic acid (Example 294: step b(5.2 g, 20 mmol)) and diisopropylethylamine (3.66 mL, 21 mmol) in1,4-dioxane (80 mL) at rt. After 30 minutes at rt, the reaction washeated to 90° C. for 5 min. Trimethylsilylethanol (5.73 mL, 40 mmol) wasadded and the solution was stirred for 16 h at 95° C. The solvents wereremoved in vacuo and the residue was partitioned between EtOAc (100 mL)and water (30 mL). The organic layer was further extracted with aqcitric acid (3×30 mL), NaHCO₃, (2×30 mL) and brine (50 mL). Purificationby column chromatography (9:1 Hex/EtOAc) yielded the title compound as ayellow solid. ¹H NMR (CDCl₃) δ 7.73 (d, 1H, J=2.4 Hz), 7.41 (br d, 1H,J=1.7 Hz), 7.01 (s, 1H), 4.24 (m, 2H), 2.43 (s, 3H), 1.02 (m, 2H), 0.04(s, 9H).

d) (3-Amino-4-bromo-5-methyl-phenyl)-carbamic acid2-trimethylsilanyl-ethyl ester

Iron powder (6.1 g, 109 mmol) was added to a suspension of(4-bromo-3-methyl-5-nitro-phenyl)-carbamic acid 2-trimethylsilanyl-ethylester (Example 294: step c (4.1 g, 10.9 mmol)) and NH₄Cl (5.84 g, 109mmol) in EtOH (27 mL) and water (54 mL). The reaction was heated at 85°C. for 14 h. The cooled mixture was filtered through celite and thesolids were washed with 1:1 EtOAc/MeOH (200 mL). The filtrate wasconcentrated in vacuo and the residue was partitioned between EtOAc (100mL) and H₂O (30 mL). The organic solution was washed with water (30 mL),and brine (50 mL). Drying and concentration of the solution yielded thetitle compound (3.24 g, 86%) as a brown solid which was used withoutfurther purification. ¹H NMR (CDCl₃) δ 6.96 (s, 1H), 6.54 (s, 1H), 6.39(s, 1H), 4.26 (m, 2H), 4.16 (s, 2H), 2.35 (s, 3H), 1.06 (m, 2H), 0.08(s, 9H).

e)[3-Amino-5-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-carbamicacid 2-trimethylsilanyl-ethyl ester

Palladium acetate (106 mg, 0.47 mmol), 2-(dicyclohexylphosphino)biphenyl(658 mg, 1.88 mmol), (3-amino-4-bromo-5-methyl-phenyl)-carbamic acid2-trimethylsilanyl-ethyl ester (Example 294: step d (3.24 g, 9.38 mmol))were combined in a flask and placed under an argon atmosphere. p-Dioxane(40 mL) was added, followed by triethylamine (5.23 mL, 38 mmol) andpinacolborane (4.08 mL, 28 mmol). The solution was stirred at 80° C. for1 h during which a precipitate appeared. The solvent was removed invacuo and the residue was partitioned between EtOAc (100 mL) and aq.NH₄Cl (50 mL). The organic layer was further extracted with NH₄Cl (2×30mL), NaHCO₃ (30 mL), and brine (50 mL). The organic layer was dried(MgSO₄), concentrated in vacuo, and the residue was purified by SiO₂flash column chromatography (8:2 Hex/EtOAc) to afford the product (2.44g, 66%) as a brown solid. ¹H NMR (CDCl₃) δ 6.77 (s, 1H), 6.38 (s, 1H),6.28 (d, 1H, J=1.9 Hz), 4.91 (s, 2H), 4.23 (m, 2H), 2.42 (s, 3H), 1.32(s, 12H), 1.03 (m, 2H), 0.05 (s, 9H).

f){6-Amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-yl}-carbamicacid 2-trimethylsilanyl-ethyl ester

A flask with a stirbar was charged with[3-amino-5-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-carbamicacid 2-trimethylsilanyl-ethyl ester ((Example 294: step e) 2.34 g, 5.96mmol),{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) 2.93 g, 5.96 mmol), aqueousNa₂CO₃ (2M, 11.9 mL, 23.8 mmol), ethanol (12 mL) and toluene (24 mL).The solution was sparged with argon for 10 min and Pd(PPh₃)₄ (689 mg,0.6 mmol) was added. The biphasic solution was vigorously stirred underinert atmosphere at 80° C. for 16 h, then was cooled to rt. EtOAc (80mL) and water (20 mL) were added and the layers were separated. Theorganic layer was washed with saturated NaHCO₃ (2×20 mL), brine (20 mL)and was dried over sodium sulfate. Removal of the solvents in vacuofollowed by column chromatography (85:15 DCM/EtOAc) of the residueyielded the title compound (2.24 g, 55%) as a light brown solid. ¹H-NMR(CDCl₃): δ 7.98 (ddd, 1H, J=1.3, 1.9, 7.8 Hz), 7.89 (m, 2H), 7.61 (t,1H, J=7.7 Hz), 7.5 (dt, 1H, J=1.3, 7.7 Hz), 6.88 (s, 1H), 6.55 (d, 1H,J=1.7 Hz), 6.47 (s, 1H), 4.26 (m, 2H), 3.42 (s, 2H), 2.56 (s, 3H), 1.9(s, 3H), 1.52 (s, 9H), 1.06 (m, 2H), 0.08 (s, 9H).

g){[4-(4′,6′-Diamino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester

A solution of tetrabutylammonium fluoride (1M in THF, 1 mL, 1 mmol) wasadded to a solution of{6-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-yl}-carbamicacid 2-trimethylsilanyl-ethyl ester ((Example 294: step f) 86 mg, 0.11mmol) in THF (1 mL). The solution was heated at 50° C. for 12 h, thenthe solution was partitioned between EtOAc (50 mL) and water (20 mL).The layers were separated and the organic layer was further extractedwith water (5×10 mL) and brine (20 mL). The solution was dried oversodium sulfate and concentrated in vacuo to yield the title compound (71mg, 84%) which was used without further purification. ESI-MS (m/z):Calcd. for C₂₄H₂₈N₄O₄S₃ (M+H): 533.1; found: 532.7.

h)4-{4′,6′-Bis-[3-(3-methanesulfonyl-propyl)-ureido]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure in Example 296 was followed using{[4-(4′,6′-diamino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (71 mg, 0.13 mmol), diphenylphosphoryl azide (250μL, 1 mmol), 4-methanesulfonyl-butyric acid (166 mg, 1 mmol), and DIEA(183 μL, 1.05 mmol) in dioxane (4 mL). Analogous treatment of the crudeintermediate with TFA/DCM and HPLC purification yielded the product (8mg, 7%). ¹H-NMR (CD₃OD): δ 8.30 (s, 1H), 8.04 (ddd, 1H, J=1.1, 2.1, 8.1Hz), 7.90 (t, 1H, J=1.6 Hz), 7.73 (t, 1H, J=7.9 Hz), 7.58 (m, 1H), 7.49(m, 1H), 7.23 (dd, 1H, J=0.6, 2.1 Hz), 3.38 (t, 2H, J=6.8 Hz), 3.20 (m,4H), 3.0 (m, 2H), 3.01 (s, 3H), 2.97 (s, 3H), 2.74 (s, 3H), 2.05 (m,2H), 2.02 (s, 3H), 1.87 (m, 2H). ESI-MS (m/z): Calcd. for C₂₇H₃₂N₄O₄S₃(M+H): 759.1; found: 759.1, 781.1 (M+Na).

Example 29511-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-undecanoicacid bis-trifluoroacetate

a) 8-Methyl-1H-benzo[d][1,3]oxazine-2,4-dione

To a solution of 2-amino-3-methylbenzoic acid (9.07 g, 60 mmol) in THF(60 mL) was added simultaneously diisopropylethylamine (20.9 mL) and asolution of triphosgene (5.94 g, 20 mmol) in dichloromethane (60 mL)over 30 minutes period. After the addition was completed, the mixturestirred at ambient temperature for 16 hours. Solid was filtered andwashed with ether (2×100 mL) and H₂O (3×50 mL), and dried in high vacuumto afford the title compound (10.02 g, 94% yield) as a white solid. ¹HNMR (DMSO) δ 11.02 (s, 1H), 7.76 (d, 1H, J=7.7 Hz), 7.57 (d, 1H, J=7.5Hz), 7.17–7.13 (m, 1H), 2.32 (s, 3H).

b) 8-Methyl-6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione

To a flask charged with 8-methyl-1H-benzo[d][1,3]oxazine-2,4-dione((Example 295: step a) 9.27 g, 52.4 mmol) in an ice-water bath was addedconcentrated H₂SO₄ (90 mL) over 5 minutes period. After stirring for 10minutes, fuming HNO₃ (2.9 mL) was added over 15 minutes. The reactionmixture was stirred for further 30 minutes in the ice-water bath, 30minutes at ambient temperature, then slowly poured into ice withstirring. The solid was collected, washed with H₂O (3×50 mL), and driedin high vacuum to give the title compound (10.4 g, 89% yield) as ayellow solid. ¹H NMR (DMSO) δ 11.65 (br s, 1H), 8.46–8.43 (m, 2H), 2.44(s, 3H).

c) 2-Amino-3-methyl-5-nitro-benzoic acid methyl ester

To a suspension of 8-methyl-6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione((Example 295: step b) 1.04 g, 4.68 mmol) in methanol (30 mL) was addeda solution of sodium methoxide (0.5 M, 0.94 mL, 4.7 mmol) in methanol.The mixture was stirred at ambient temperature for 1 hour andneutralized by addition of saturated NH₄Cl. Methanol was removed underreduced pressure and the resulting mixture was filtered. The solids werewashed with H₂O (twice), dried in high vacuum to give the product (0.97g, 99% yield) as a yellow solid. ¹H NMR (DMSO) δ 8.48 (d, 1H, J=2.7 Hz),8.02–8.01 (m, 1H), 7.75 (br s, 2H), 3.86 (s, 3H), 2.20 (s, 3H).

d) 2-Bromo-3-methyl-5-nitro-benzoic acid methyl ester

To a flask charged with copper(II) bromide (7.40 g, 33.1 mmol) was addeda solution of t-butyl nitrite (4.50 mL, 37.9 mmol) in MeCN (30 mL) atambient temperature. After stirring for 5 minutes, a suspension of2-amino-3-methyl-5-nitro-benzoic acid methyl ester ((Example 295: stepc) 4.97 g, 23.7 mmol) in MeCN (50 mL) was added. The mixture was stirredat ambient temperature for 15 minutes, 65° C. for 20 minutes, thencooled back to ambient temperature. The reaction was filtered and thefiltrate was concentrated to give a dark brown solid. The solid wastriturated with hexane, filtered off, and washed with hexane (4×50 mL).All hexane layers were combined and concentrated to give the titleproduct (5.7 g, 88% yield) as a pale yellow solid. ¹H NMR (CDCl₃) δ 8.35(d, 1H, J=2.5 Hz), 8.21 (d, 1H, J=2.9 Hz), 3.99 (s, 3H), 2.59 (s, 3H).

e) 2-Bromo-3-methyl-5-nitro-benzoic acid

To a solution of 2-bromo-3-methyl-5-nitro-benzoic acid methyl ester((Example 295: step d) 5.04 g) in ethanol (50 mL) was added a solutionof aq NaOH (4M, 1.62 g, 40.5 mmol) and stirred at ambient temperaturefor 16 h. The resulting red colored solution was concentrated todryness, dissolved in a minimum amount of H₂O, and acidified with 1 NHCl to pH 3–4. The solid was filtered, washed with H₂O (3×50 mL) driedunder high vacuum to afford the title compound (4.5 g, 94% yield) as apale yellow solid. ¹H NMR (DMSO) δ 8.36–8.35 (m, 1H), 8.24–8.23 (m, 1H),2.53 (s, 3H).

f) (2-Bromo-3-methyl-5-nitro-phenyl)-carbamic acid tert-butyl ester

Diphenylphosphorylazide (453 μL, 2.1 mmol) was added to a stirredsolution of 2-bromo-3-methyl-5-nitro-benzoic acid ((Example 295: step e)520 mg, 2 mmol) and triethylamine (1.4 mL, 2.1 mmol) in tert-butanol (25mL) at rt. After 15 minutes, the reaction was heated to 80° C. for 16 h.EtOAc (100 mL) was added and the solution was extracted with solutionsof citric acid (3×30 mL), NaHCO₃, (2×30 mL) and brine (50 mL).Purification by column chromatography yielded the title compound as awhite solid. ¹H NMR (CDCl₃) δ 8.93 (d, 1H, J=2.6 Hz), 7.77 (app dd, 1H,J=0.7, 2.8 Hz), 7.26 (br s, 1H), 2.51 (s, 3H), 1.55 (s, 9H).

g) 2-Bromo-3-methyl-5-nitro-phenylamine

2-Bromo-3-methyl-5-nitro-phenyl)-carbamic acid tert-butyl ester((Example 295: step d) 435 mg, 1.32 mmol) was dissolved in 10 mL of a1:1 mixture of trifluoroacetic acid and DCM (10 mL total). Afterstirring for 1 h, the solvent was removed in vacuo and the yellow solidresidue (306 mg) was used without further purification. ¹H NMR (CDCl₃) δ7.46 (d, 1H, J=2.8 Hz), 7.42 (d, 1H J=2.8 Hz), 6.62 (br s, 2H), 2.42 (s,3H).

h){[4-(6′-Amino-2′-methyl-4′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-yl]-imino-methyl}-carbamicadd tert-butyl ester

A flask with a stirbar was charged with{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 140: step a (752 mg, 1.65 mmol),2-bromo-3-methyl-5-nitro-phenylamine ((Example 295: step g) 306 mg, 1.32mmol), aqueous Na₂CO₃ (2M, 4 mL, 8 mmol), ethanol (4 mL) and toluene (8mL). The solution was sparged with argon for 10 min and Pd(PPh₃)₄ (294mg, 0.25 mmol) was added. The biphasic solution was vigorously stirredunder inert atmosphere at 80° C. for 16 h, then was cooled to rt. EtOAc(40 mL) and water (20 mL) were added and the layers were separated. Theorganic layer was washed with saturated NaHCO₃ (2×20 mL), brine (20 mL)and was dried over sodium sulfate. Removal of the solvents in vacuofollowed by column chromatography (10–40% EtOAc in hexanes) of theresidue yielded the title compound (245 mg, 33%) as a yellow solid.¹H-NMR (CDCl₃): δ 8.03 (ddd, 1H, J=1.2, 2.1, 8.1 Hz), 7.91 (s, 1H), 7.90(t, 1H, J=1.6 Hz), 7.69 (t, 1H, J=7.9 Hz), 7.53 (app dd, 1H, J=0.7, 2.3Hz), 7.50 (dt, 1H, J=1.4, 7.7 Hz), 7.44 (app dd, 1H, J=0.5, 2.3 Hz),3.70 (s, 2H), 2.59 (s, 3H), 2.00 (s, 3H), 1.51 (s, 9H).

i)11-{4-Amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-undecanoicacid methyl ester

Triethylamine (139 μL, 1 mmol) was added to a solution of{[4-(6′-amino-2′-methyl-4′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 295: step h) 118 mg, 0.21 mmol) in DCM(10 mL). 11-chlorocarbonyl-undecanoic acid ethyl ester (73 mg, 0.26mmol) was added dropwise over 5 min. After 30 minutes of stirring, thereaction was not complete. Additional portions of acid chloride (3×1 eq)were added in a similar manner, until the reaction was complete.Addition of EtOAc (40 mL) followed by aqueous workup with NaHCO₃ (2×20mL) and brine (30 mL) yielded the crude amide (206 mg) as a glass. Theresidue was dissolved in EtOH (5 mL) and 4M aq NH₄Cl (1 mL) was added.Iron powder (165 mg, 3 mmol) was added and the reaction was heated at75° C. for 1 h. The cooled mixture was filtered through a 0.22 μm filterand solids washed with 5 mL portions of MeOH and EtOAc. Additional EtOAc(80 mL) was added and the organic solution was washed with citric acid(2×20 mL), NaHCO₃ (2×30 mL), water (30 mL), and brine (50 mL). Dryingand concentration of the solution yielded the title compound (165 mg)which was used without further purification.

j)11-{3′-[5-tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-(N,N-bis-(tert-Butoxycarbonylamino))guanidino-6-dimethyl-biphenyl-2-ylcarbamoyl}-undecanoicacid

Sodium hydroxide (1M, 1 mL) was added to a solution of11-{4-amino-3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-6-methyl-biphenyl-2-ylcarbamoyl}-undecanoicacid methyl ester ((Example 295: step i) 122 mg, 0.16 mmol) in MeOH (10mL). The solution was stirred for 18 h at rt, the solution was quenchedwith AcOH (500 μL), and the solvent was removed in vacuo. The residuewas dissolved in MeOH (10 mL), AcOH (500 μL), andN,N-bis(tert-butoxycarbonyl)-S-methyl-isothiourea (145 mg, 0.5 mmol) wasadded. The solution was stirred at 40° C. for 16 h and the solventremoved in vacuo. The residue was partitioned between EtOAc (50 mL) andwater (20 mL) and the organic layer was washed with brine (20 mL).Drying and concentration of the solution yielded a residue which waspurified by SiO₂ flash column chromatography (6:4 Hex/EtOAc, then25:75:5 Hex/EtOAc/MeOH). The residue was further purified by RP-HPLC(C-18 column, CH₃CN/H₂O) to yield 115 mg of product). ¹H-NMR (CD₃OD): δ8.16 (s, 1H), 8.01 (ddd, 1H, J=1.2, 1.9, 7.9 Hz), 7.87 (t, 1H, J=1.6Hz), 7.65 (t, 1H, J=7.9 Hz), 7.53 (m, 1H), 7.50 (dt, 1H, J=1.4, 7.7 Hz),7.39 (m, 1H), 2.66 (s, 3H), 2.29 (t, 2H, J=7.4 Hz), 2.05 (s, 3H), 1.93(m, 2H), 1.61 (m, 2H), 1.53 (s, 18H), 1.49 (s, 9H), 1.0–1.40 (m, 12H),0.94 (m, 2H).

k)11-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-undecanoicacid bis trifluoroacetate

The procedure in Example 260: step b was followed using11-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-4-(N,N-bis-(tert-butoxycarbonylamino))guanidino-6-methyl-biphenyl-2-ylcarbamoyl}-undecanoicacid ((Example 295: step j) 15 mg, 0.015 mmol) and 1:1 TFA/DCM (10 mL).Purification by HPLC yielded the product (8.2 mg, 55%) as an opaqueglass. ¹H-NMR (CD₃CN/D₂O): δ 8.16 (s, 1H), 7.79 (ddd, J=1.2, 2.1, 7.9Hz), 7.82 (m, 1H), 7.67 (t, 1H, J=7.9 Hz), 7.49 (m, 1H), 7.18 (m, 1H),7.14 (m, 1H), 2.65 (s, 3H), 2.26 (t, 2H, J=7.4 Hz), 2.02 (s, 3H), 1.85(m, 2H), 1.55 (m, 1H), 0.9–1.3 (m, 12H), 0.80 (m, 2H). ESI-MS (m/z):Calcd. for C₃₂H₄₂N₆O₅S₃ (M+H): 687.2; found: 687.2.

Example 2964-{4′-[3-(3-Methanesulfonyl-propyl)-ureido]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Diphenylphosphoryl azide (250 μL, 1 mmol) was added to a solution of4-methanesulfonyl-butyric acid ((Example 209: part a) 166 mg, 1 mmol)and DIEA (183 μL, 1.05 mmol) in dioxane (4 mL). The solution was stirredat rt for 15 min, then stirred at 90° C. for 3 h. The solution wascooled, then an aliquot (250 μL) was added to a solution of{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 220: step b) 76 mg) in DCM (2 mL). Thereaction was stirred overnight and the solvent was removed in vacuo. Theresidue was partially purified by SiO₂ flash column chromatography. Theimpure urea was treated with 1:1 TFA/DCM as described in Example 1: stepd and was purified by HPLC to yield the title compound (31 mg, 19%).¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 8.0 (m, 1H), 7.97 (m, 1H), 7.67 (m, 2H),7.33 (m, 2H), 7.13 (d, 1H, J=8.1 Hz), 3.37 (t, 2H, J=6.8 Hz), 3.20 (m,2H), 3.0 (s, 3H), 2.73 (s, 3H), 2.22 (s, 3H), 2.05 (m, 2H). ESI-MS(m/z): Calcd. for C₂₄H₂₈N₄O₅S₄ (M+H): 581.1; found: 581.1.

Example 2974-[2′-Methyl-6′-(4-methyl-piperazin-1-ylmethyl)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

Methanesulfonyl chloride (100 μL) was added over 1 min to a 0° C.solution of{[4-(6′-hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 5: step c) (30 mg, 0.06 mmol) anddiisopropylethylamine (0.25 ml) in DCM (10 mL). The solution was stirredfor 1 h at 0° C. and warmed to rt. 1-Methylpiperazine was added (0.25mL) and the solution was stirred for 3 h at rt. The volatile componentswere removed in vacuo and the residue was treated with 1:1 TFA/DCM (10mL) for 2 h at rt. The solvent was removed in vacuo the residue waspurified via preparative HPLC (C₁₈-column, 10–70% CH₃CN over 30 min)which yielded the title compound as a opaque glass (8.2 mg). ¹H-NMR(CD₃OD): δ 8.38 (s, 1H), 8.02 (ddd, 2H, J=1.2, 1.9, 7.9 Hz), 7.98 (t,1H, J=1.6 Hz), 7.72 (t, 1H, J=7.9 Hz), 7.57 (dt, 1H, J=1.4, 7.7 Hz),7.26–7.35 (m, 3H), 3.39 (d, 1H, J=12.9 Hz), 3.21 (d, 1H, J=12.9 Hz),3.20 (br s, 4H), 2.87 (s, 3H), 2.75 (s, 3H), 2.50 (br s, 4H), 1.98 (s,3H). ESI-MS (m/z): Calcd. for C₂₅H₃₀N₄O₂S₃ (M+H): 515.2; found: 515.2.

Example 2984-(2′-Methyl-6′-morpholin-4-ylmethyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

Methanesulfonyl chloride (100 μL) was added over 1 min to a 0° C.solution of{[4-(6′-hydroxymethyl-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (Example 5: step c) (30 mg)) anddiisopropylethylamine (0.25 mL) in DCM (10 mL). The solution was stirredfor 1 h at 0° C. and warmed to rt. 4-Methylmorpholine (0.5 mL) was addedand the solution was stirred for 3 h at rt. The volatile components wereremoved in vacuo and the residue was treated with 1:1 TFA/DCM (10 mL)for 2 h at rt. The solvent was removed in vacuo and the residue waspurified by preparative HPLC (C₁₈-column, 10–70% CH₃CN over 30 min)which yielded the title compound as a opaque glass (6.8 mg). ¹H-NMR(CD₃OD): δ 8.40 (s, 1H), 8.13 (ddd, 1H, J=1.2, 1.9, 7.9 Hz), 7.97 (t,1H, J=1.6 Hz), 7.82 (t, 1H, J=7.9 Hz), 7.61 (m, 2H), 7.49 (m, 2H), 4.15(d, 1H, J=13.5 Hz), 4.07 (d, 1H, J=13.5 Hz), 3.82 (br s, 4H), 2.75 (s,3H), 2.18 (s, 2H), 2.03 (s, 3H), 1.31 (s, 2H). ESI-MS (m/z): Calcd. forC₂₄H₂₇N₃O₃S₃ (M+H): 502.1; found: 502.1.

Example 299[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylmethoxy]-aceticacid trifluoroacetate

a) (2-Iodo-3-methyl-benzyloxy)-acetic acid tert-butyl ester

Sodium hydride (53 mg, 2.2 mmol) was added to a 0° C. solution of2-iodo-3-methyl-phenyl-methanol ((Example 5: step a) 492 mg, 2 mmol) inDMF (20 mL). The solution was stirred at 0° C. for 30 min and tert-butylbromoacetate (0.4 mL, 2.5 mmol) was added. The solution was warmed to rtover 15 min and stirred for 3 h at rt. EtOAc (80 mL) and water (40 mL)were added, the layers were separated, and the organic layer was washedwith water (6×20 mL), brine (30 mL), and was dried over sodium sulfate.Concentration of the solution followed by SiO₂ flash columnchromatography (5–10% EtOAc in hexanes) yielded the title compound(0.571 g, 79%) as an oil. ¹H-NMR (CDCl₃): δ 7.36 (dd, 1H, J=1.4, 7.4Hz), 7.30 (t, 1H, 7.4 Hz), 7.24 (dd, 1H, J=1.4, 7.4 Hz), 4.72 (s, 2H),4.15 (s, 2H), 2.53 (s, 3H), 1.56 (s, 9H).

b)[3-Methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester

The procedure used in Example 3: step b was followed using(2-iodo-3-methyl-benzyloxy)-acetic acid tert-butyl ester ((Example 299:step a) 571 mg, 1.6 mmol), PdCl₂(PPh₃)₂ (55 mg, 0.08 mmol),triethylamine (1.25 mL, 9.4 mmol), and4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (0.91 mL, 6.4 mmol) in dioxane(5 mL) at a reaction temperature of 80° C. Analogous aqueous workup andpurification by SiO₂ flash column chromatography yielded the titlecompound contaminated with the product resulting from halide reduction(542 mg, 95%). The material was used without further purification.¹H-NMR (CDCl₃): δ 7.20 (t, 1H, 7.4 Hz), 7.11 (d, 1H, J=7.4 Hz), 7.07 (d,1H, J=7.4 Hz), 4.72 (s, 2H), 3.86 (s, 2H), 2.43 (s, 3H), 1.46 (s, 9H),1.39 (s, 12H).

c)[3′(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-4-ylmethoxy]-aceticacid trifluoroacetate

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) 123 mg, 0.25 mmol),[3-methyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester ((Example 299: step c) 270 mg, 0.75 mmol), Na₂CO₃(2M, 1.5 mL, 3 mmol), Pd(PPh₃)₄ (66 mg, 0.06 mmol), ethanol (1.5 mL) andtoluene (3 mL). Analogous aqueous workup yielded 417 mg of crudematerial which was treated with 1:1 TFA/DCM as described in Example 1:step d. Analogous purification by C₁₈-HPLC yielded the title compound(26.8 mg, 22%) as a white solid. ¹H-NMR (CD₃OD): δ 8.35 (s, 1H), 8.07(ddd, 1H, J=1.2, 1.9, 7.9 Hz), 7.86 (t, 1H, J=1.6 Hz), 7.71 (t, 1H,J=7.9 Hz), 7.10–7.43 (m, 3H), 4.25 (m, 2H), 4.07 (br s, 1H), 3.78 (br s,1H), 2.73 (s, 3H), 2.35 (s, 3H), 2.02 (s, 3H). ESI-MS (m/z): Calcd. forC₂₂H₂₂N₂O₅S₃ (M+H): 490.1; found: 490.1.

Example 300[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-3-ylmethoxy]-aceticacid

a) (3-Iodo-4-methyl-benzyloxy)-acetic acid tert-butyl ester

The procedure used in Example 299: step a was followed using sodiumhydride (53 mg, 2.2 mmol), 3-iodomethyl-benzyl alcohol (992 mg, 4 mmol),tert-butyl bromoacetate (0.4 mL, 2.5 mmol) in DMF (10 mL). Analogousaqueous workup and purification by SiO₂ flash column chromatographyyielded the title compound (1.30 g, 89%) as an oil. ¹H-NMR (CDCl₃): δ7.84 (d, 1H, J=1.4 Hz), 7.27 (d, 1H, J=1.4 Hz), 7.23 (d, 1H, J=7.7 Hz),4.55 (s, 2H), 3.99 (s, 2H), 2.44 (s, 3H), 1.51 (s, 9H).

b)[4-Methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester

The procedure used in Example 3: step b was followed using(3-iodo-4-methyl-benzyloxy)-acetic acid tert-butyl ester ((Example 300:step a) 600 mg, 1.65 mmol), PdCl₂(PPh₃)₂ (58 mg, 0.08 mmol),triethylamine (1.25 mL, 9.4 mmol), and4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (0.91 mL, 6.4 mmol) in dioxane(5 mL). Analogous aqueous workup and purification by SiO₂ flash columnchromatography yielded the title compound contaminated with the productresulting from halide reduction (569 mg, 95%). The material was usedwithout further purification. ¹H-NMR (CDCl₃): δ 7.73 (d, 1H, J=1.9 Hz),7.38 (dd, 1H, J=2.1, 7.9 Hz), 7.18 (d, 1H, J=7.9 Hz), 4.61 (s, 2H), 3.97(s, 2H), 2.55 (s, 3H), 1.50 (s, 9H), 1.37 (s, 9H).

c)[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylmethoxy]-aceticacid trifluoroacetate

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) (239 mg, 0.24 mmol)),[4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyloxy]-aceticacid tert-butyl ester ((Example 300: step c) 530 mg, 1.46 mmol), Na₂CO₃(2M, 3 μL, 6 mmol), Pd(PPh₃)₄ (70 mg, 0.06 mmol), ethanol (3 mL) andtoluene (6 mL). Analogous aqueous workup yielded 629 mg of crudematerial which was treated with 1:1 TFA/DCM as described in Example 1:step d. Analogous purification by C₁₈-HPLC yielded the title compound(47 mg, 38%) as a white solid. RP-HPLC (5 to 100% ACN over 8 min)analytical purity=100%. ESI-MS (m/z): Calcd. for C₂₂H₂₂N₂O₅S₃ (M+H):491.1; found: 491.1.

Example 3013′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-3-carboxylicacid (3-morpholin-4-yl-propyl)-amide bis trifluoroacetamide

a) 3-Iodo-4-methyl-N-(3-morpholin-4-yl-propyl)-benzamide

Thionyl chloride (5.6 mL) was added over 1 min to a 0° C. solution of3-iodomethyl benzoic acid (5 g, 19.1 mmol) in THF (30 mL). The solutionwas stirred for 24 h at rt and the volatile components were removed invacuo. A portion of the crude acid chloride (1 g, 3.57 mmol) wasdissolved in DCM (10 mL) and was cooled to 0° C. Diisopropylethylamine(0.78 mL, 4.46 mmol) was added followed by 3-morpholin-4-yl-propylamine(0.52 mL, 3.56 mmol) and the reaction was stirred for 1 h at rt. EtOAc(80 mL) and aq. NH₄Cl (20 mL) was added and the layers were separated.The organic layer was washed with aq NH₄Cl (2×10 mL), NaOH (1N, 3×20mL), water (20 mL), brine (50 mL) and was dried over sodium sulfate.Concentration of the solution and SiO₂ flash column chromatography ofthe residue (0–10% MeOH in DCM) yielded the product (695 mg, 50%) as ayellow glass.

b)4-Methyl-N-(3-morpholin-4-yl-propyl)-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide

The procedure used in Example 3: step b was followed using3-iodo-4-methyl-N-(3-morpholin-4-yl-propyl)-benzamide ((Example 301:step a) 695 mg, 1.79 mmol), PdCl₂(PPh₃)₂ (63 mg, 0.09 mmol),triethylamine (1.25 mL, 9.4 mmol), and4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (0.91 mL, 6.4 mmol) in dioxane(5 mL). Analogous aqueous workup and purification by SiO₂ flash columnchromatography (0–10% MeOH in DCM) yielded the title compoundcontaminated with the product resulting from halide reduction (653 mg,94%). The material was used without further purification.

c)3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-3-carboxylicacid (3-morpholin-4-yl-propyl)-amide bis trifluoroacetamide

The procedure used in Example 1: step c was followed using{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) (237 mg, 0.24 mmol)),4-methyl-N-(3-morpholin-4-yl-propyl)-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide((Example 301: step b) 563 mg, 1.45 mmol), Na₂CO₃ (2M, 3 mL, 6 mmol),Pd(PPh₃)₄ (67 mg, 0.06 mmol), ethanol (3 mL) and toluene (6 mL).Analogous aqueous workup followed by SiO₂ flash column chromatography(0–10% MeOH in DCM) yielded 605 mg of material which was treated with1:1 TFA/DCM as described in Example 1: step d. Analogous purification byC₁₈-HPLC yielded the title compound (92 mg, 48%) as a white solid.RP-HPLC (5 to 100% ACN over 8 min) analytical purity=100%. ESI-MS (m/z):Calcd. for C₂₇H₃₂N₄O₄S₃ (M+H): 573.2; found: 573.2.

Example 3023′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-carboxylicacid (3-morpholin-4-yl-propyl)-amide bis trifluoroacetamide

a) 2-Iodo-3-methyl-N-(3-morpholin-4-yl-propyl)-benzamide

The procedure and scale used in Example 301: step a was followed using2-iodo-3-methyl benzoic acid. Concentration of the solution and SiO₂flash column chromatography of the residue (0–10% MeOH in DCM) yieldedthe product (878 mg, 630%) as a yellow glass.

b)3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-carboxylicacid (3-morpholin-4-yl-propyl)-amide bis trifluoroacetamide

The procedure used in Example 295: step h was followed using2-iodo-3-methyl-N-(3-morpholin-4-yl-propyl)-benzamide ((Example 302:step a) 150 mg, 0.39 mmol),{[4-(3-dihydroxyboranyl-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 140: step a (25 mg, 0.05 mmol), Na₂CO₃(2M, 1 mL, 2 mmol), Pd(PPh₃)₄ (30 mg, 0.03 mmol), ethanol (1 mL) andtoluene (2 mL). Analogous aqueous workup followed by SiO₂ flash columnchromatography (0–10% MeOH in DCM) yielded 60 mg of material which wastreated with 1:1 TFA/DCM as described in Example 1: step d. Analogouspurification by C₁₈-HPLC yielded the title compound (22 mg, 55%) as awhite solid. ¹H-NMR (CD₃OD): δ 8.35 (s, 1H), 8.05 (ddd, 1H, J=1.2, 1.9,7.9 Hz), 7.96 (t, 1H, J=1.6 Hz), 7.72 (t, 1H, J=7.9 Hz), 7.66 (dt, 1H,1.4, 7.7 Hz), 7.46 (m, 1H), 7.40 (m, 1H), 4.06 (m, 2H), 3.73 (m, 2H),3.35 (m, 2H), 3.20 (m, 2H), 3.08 (m, 2H), 2.94 (m, 2H), 2.73 (s, 3H),2.09 (s, 3H), 1.75 (m, 2H). ESI-MS (m/z): Calcd. for C₂₇H₃₂N₄O₄S₃ (M+H):573.2; found: 573.2.

Example 3034-[3-(6-Formyl-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

a) 2-Bromo-6-dimethoxymethyl-pyridine

The procedure in Example 6: step b was followed using6-bromo-pyridine-2-carbaldehyde (600 mg, 3.23 mmol), trimethylorthoformate (8 mL), and toluenesulfonic acid (100 mg) in MeOH (50 mL).Analogous aqueous workup yielded the product (743 mg) which was usedwithout further purification.

b)4-[36-Formyl-pyridin-2-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine

To a slurry of Rieke Zinc (370 mg, 5.64 mmol) in THF (7.4 mL) was addeda solution of 2-bromo-6-dimethoxymethyl-pyridine (400 mg, 1.7 mmol) inTHF (2.6 mL). The suspension was heated to 65° C. for 2 h and thesolution was filtered through a 0.23 μm syringe filter into a THFsolution of{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) (250 mg, 0.5 mmol)) andPd(PPh₃)₄ (0.112 mg, 0.1 mmol).The reaction was heated at 80° C. for 30min, cooled, and was poured into aqueous NaHCO₃. EtOAc (70 mL) was addedand the layers were separated. The organic layer was washed with NH₄Cl(2×20 mL), NaHCO₃ (20 mL) and brine (30 mL) and was dried over sodiumsulfate. Concentration of the solution followed by SiO₂ flash columnchromatography of the residue yielded 200 mg of the title compound whichwas contaminated with 2-dimethoxymethyl-pyridine. The material wastreated with 1:1 TFA/DCM as described in Example 1: step d. Analogouspurification by C₁₈-HPLC yielded the title compound (118 mg, 38%) as awhite solid. ¹H-NMR (CD₃OD) (aldehyde exists in hydrated form (acetal))δ 8.60 (m, 2H), 8.44 (s, 1H), 8.33 (d, 1H, J=7.9), 8.27 (d, 1H, J=7.7),8.23 (d, 1H, J=7.7), 8.12 (d, 1H, J=7.9), 7.9 (t, 1H, J=7.7), 5.82 (s,1H), 2.74 (s, 3H). ESI-MS (m/z) (sample in MeOH): Calcd. forC₁₈H₁₅N₃O₃S₃ (M+H): 418.0; found: 449.9 (MeOH adduct).

Example 3044-[3-(6-Methyl-benzo[1,3]dioxol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 5-bromo-6-methyl-benzo[1,3]dioxole

Bromine (3.36 g, 21 mmol) was added to a solution of piperonal alcohol(3.0 g, 20 mmol) in chloroform (15 mL). The solution was heated to 60°C. for 12 h. After cooling, DCM (60 mL) was added and the solution wasextracted with aq NaHCO₃ (2×20 mL), brine (20 mL), and was dried oversodium sulfate. After concentration, the residue5-bromo-6-bromomethyl-benzo[1,3]dioxole (5.88 g, 100%), solidified uponstanding. A portion of the crude solid (2.44 g, 8.33 mmol) was dissolvedin THF and cooled to −78° C. Lithium aluminum hydride (348 mg, 9.16mmol) was added and the solution was stirred for 3 h. An additionalportion of LAH (80 mg, 2.03 mmol) was added and the reaction was stirredan additional hour. EtOAc was added carefully to quench the excess LAH,followed by addition of MeOH (20 mL). The salts were filtered and thefiltrate was concentrated in vacuo, to yield the title compound (1.76 g,99%) which was used without further purification. ¹H-NMR (CDCl₃): δ 7.01(s, 1H), 6.73 (s, 1H), 5.95 (s, 2H), 2.32 (s, 3H).

b)4-[3-(6-Methyl-benzo[1,3]dioxol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

Butyllithium (2.5 M, 2.4 mL, 6 mmol) was added dropwise to a −78° C.solution of 5-bromo-6-methyl-benzo[1,3]dioxole ((Example 304: step a)648 mg, 3 mmol) in Et₂O (12 mL). The solution was stirred for 4 hmaintaining the temperature between −20 and −40° C. The solution wascooled to −78° C. and trimethylborate (5 mL, 44 mmol) was quickly addedin one portion. The solution was warmed to rt over 15 min and stirredfor 1 h at rt (appearance of gelatin-like ppt). The volatile componentswere removed in vacuo to give the crude arylboronic acid as a yellowsolid. A portion of the crude arylboronic acid (99 mg, 0.4 mmol) wascombined with{[4-(3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 27: step c) (50 mg, 0.1 mmol)), aqNa₂CO₃ (2M, 0.8 mL, 1.6 mmol), ethanol (0.8 mL), and toluene (1.6 mL).The procedure used in Example 1: step c was followed, and analogousworkup yielded the product which was purified by preparative TLC. Thepurified material was treated with 1:1 TFA/DCM as described in Example1: step d. Analogous purification by C₁₈-HPLC yielded the title compound(25 mg, 45%) as a white solid. ¹H-NMR (CD₃OD): δ 8.32 (s, 1H), 7.99 (m,1H), 7.93 (m, 1H), 7.64 (m, 2H), 6.79 (s, 1H), 6.68 (s, 1H), 2.72 (s,3H), 2.12 (s, 3H),. ESI-MS (m/z): Calcd. for C₂₀H₁₈N₂O₄S₃ (M+H): 447.0;found: 447.2.

Example 305–3064-[7-Bromo-3-(3-methyl-but-2-enyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

4-[7-Bromo-1-(3-methyl-but-2-enyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

A mixture of{[4-(7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 187–188: step c) 30 mg, 0.061 mmol),K₂CO₃ (10 mg, 0.072 mmol), and 1-bromo-3-methyl-but-2-ene (60 μL, 0.5mmol) were stirred in DMF (2.5 mL for 16 h at rt. EtOAc (50 mL) wasadded and the organic solution was washed with water (8×20 mL) and brine(20 mL) and was dried over sodium sulfate. Removal of the solvent invacuo yielded 22 mg of material which was treated with 1:1 TFA/DCM asdescribed in Example 1: step d. Analogous purification by C₁₈-HPLC(10–55% CH₃CN over 30 min) yielded the title compounds as white solids.

4-[7-Bromo-3-(3-methyl-but-2-enyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate. ¹H-NMR (CDCl₃): δ 8.55 (s, 1H), 8.34 (s, 1H), 8.27(m, 1H), 8.06 (m, 1H), 5.44 (m, 1H), 5.01 (m, 2H), 2.72 (s, 3H), 1.96(s, 3H), 1.83 (s, 3H). ESI-MS (m/z): Calcd. for C₁₈H₁₉BrN₄O₂S₃ (M+H):499.0; found: 498.9, 500.9 (m+2).4-[7-Bromo-1-(3-methyl-but-2-enyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate. ¹H-NMR (CDCl₃): δ 8.50 (br s, 1H), 8.37 (br s,1H), 8.32 (s, 1H), 8.09 (s, 1H), 5.43 (m, 1H), 5.27 (m, 2H), 2.72 (s,3H), 1.85 (s, 3H), 1.77 (s, 3H). ESI-MS (m/z): Calcd. for C₁₈H₁₉BrN₄O₂S₃(M+H): 499.0; found: 498.9, 500.9 (m+2).

Example 307–3084-(3-Benzyl-3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

4-(1-Benzyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

The procedure in Example 318: step e was followed using4-(4-amino-3-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 264: step a) 40 mg, 0.1 mmol) to yield thebenzimidazole intermediate which was used without further purification.ESI-MS (m/z): Calcd. for C₁₄H₁₂N₂O₄S₃ (M+H): 369.00; found: 369.1.

The procedure in Example 305/306 was followed using4-(3H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 187–188: step c) 20 mg, 0.037 mmol), K₂CO₃(25 mg, 0.18 mmol), and benzyl bromide (30 mg, 0.175 mmol) in DMF (2.5mL). After analogous workup, the isomeric mixture of compounds wastreated with dimethylaluminum amide reagent (5 mL) following theprocedure in Example 12: step f. Analogous workup and purification byHPLC yielded the title compounds each as a white solid.

3-benzyl isomer: ¹H-NMR (CD₃OD): δ 8.80 (br s, 1H), 8.26 (s, 1H), 8.20(br s, 1H), 7.88 (s, 2H), 7.36 (m, 5H), 5.66 (s, 2H), 2.56 (s, 3H).ESI-MS (m/z): Calcd. for C₂₀H₁₈N₄O₂S₃ (M+H): 443.0; found: 443.1.

1-benzyl isomer: ¹H-NMR (CD₃OD): δ 8.62 (br s, 1H), 8.44 (s, 1H), 8.32(br s, 1H), 7.94 (dd, 1H, J=1.6, 8.8 Hz), 7.88 (s, 2H), 7.70 (d, 1H,J=8.8 Hz), 7.34 (m, 5H), 5.58 (s, 2H), 2.72 (s, 3H). ESI-MS (m/z):Calcd. for C₂₀H₁₈N₄O₂S₃ (M+H): 443.0; found: 443.1.

Example 3094-[7-Bromo-1R-(1-phenyl-ethyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

The procedures used in Example 318: parts d–f were followed using with4-(3-bromo-4-chloro-5-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 318: part c) 35 mg, 0.072 mmol),1R-phenyl-ethylamine (50 mg), and DIBA (100 uL). All other reagentamounts, reaction conditions, and purifications were identical toExample 318 d–f. ¹H-NMR (CD₃OD): δ 8.86 (s, 1H), 8.23 (s, 1H), 8.01 (d,1H, J=1.4 Hz), 7.96 (d, 1H, J=1.4 Hz), 7.35 (m, 5H), 5.95 (q, 1H, J=7.2Hz), 2.56 (s, 3H), 2.07 (d, 3H, J=7.2 Hz). ESI-MS (m/z): Calcd. forC₂₁H₁₉BrN₄O₂S₃ (M+H): 535.0; found: 534.9, 536.9 (m+2).

Example 3104-[7-Bromo-1S-(1-phenyl-ethyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

The procedures used in Example 318: parts d–f were followed using with4-(3-bromo-4-chloro-5-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 318: part c) 35 mg, 0.072 mmol),1S-phenyl-ethylamine (50 mg), and DIEA (100 uL). All other reagentamounts, reaction conditions, and purifications were identical toExample 318 d–f. ¹H-NMR (CD₃OD): δ 8.86 (s, 1H), 8.23 (s, 1H), 8.01 (d,1H, J=1.4 Hz), 7.96 (d, 1H, J=1.4 Hz), 7.35 (m, 5H), 5.95 (q, 1H, J=7.2Hz), 2.56 (s, 3H), 2.07 (d, 3H, J=7.2 Hz). ESI-MS (m/z): Calcd. forC₂₁H₁₉BrN₄O₂S₃ (M+H): 535.0; found: 534.9, 536.9 (m+2).

Example 3116-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-ureido}-hexanoicacid ethyl ester trifluoroacetate

a)6-(3-{3′-[5-(tert-Butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-yl}-ureido)-hexanoicacid ethyl ester

Diisopropylethylamine (35 μL, 0.2 mmol), 6-isocyanato-hexanoic acidethyl ester (40 μL, 0.2 mmol), and{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 220: step b) 20 mg, 0.04 mmol) werestirred for 24 h in DCM (1 mL). The solution was partitioned betweenEtOAc (40 mL) and 0.1 N HCl (10 mL) and was washed with additional 0.1NHCl (2×10 mL), NaHCO₃ (10 mL), and brine (20 mL). The solution wasdried, concentrated in vacuo, and purified by SiO₂ preparative TLC toyield the product (12 mg, 43%). ¹H-NMR (CDCl₃): δ 8.06 (s, 1H), 7.94 (m,1H), 7.81 (m, 1H), 7.46 (m, 2H), 7.23 (br t, 1H, J=5.4 Hz), 7.15 (m,1H), 7.07 (m, 2H), 6.97 (m, 1H), 5.32 (br t, 1H), 4.15 (q, 2H, J=7.2Hz), 2.40 (s, 3H), 2.30 (t, 2H, J=7.3 Hz), 2.11 (s, 3H), 1.54–1–70 (m,4H), 1.51 (s, 9H) 1.35 (m, 2H), 1.25 (t, 3H, J=7.3 Hz).

b)6-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-ureido}-hexanoicacid ethyl ester trifluoroacetate

Following the procedure in Example 1: step d,6-(3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-yl}-ureido)-hexanoicacid ethyl ester ((Example 311: step a) 12 mg) was treated with 1:1TFA/DCM. Purification by HPLC yielded the product (8.3 mg) as a whitesolid. ¹H-NMR (CD₃OD): δ 8.31 (s, 1H), 7.97 (m, 1H), 7.94 (m, 1H), 7.65(m, 2H), 7.29 (m, 2H), 7.09 (m, 1H), 4.10 (q, 2H, 7.2 Hz), 3.20 (t, 2H,7.0 Hz), 2.71 (s, 3H), 2.33 (t, 2H, J=7.3 Hz), 2.19 (s, 3H), 1.65 (m,2H), 1.55 (m, 2H), 1.40 (m, 2H), 1.23 (t, 3H, J=7.2 Hz). ESI-MS (m/z):Calcd. for C₂₈H₃₄N₄O₅S₃ (M+H): 603.2; found: 603.2.

Example 3126-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-ureido}-hexanoicacid trifluoroacetate

Aqueous sodium hydroxide (1M, 0.75 μL), was added to a solution of6-(3-{3′-[5-(tert-butoxycarbonylamino-imino-methyl)-2-methylsulfanyl-thiophene-3-sulfonyl]-2-methyl-biphenyl-4-yl}-ureido)-hexanoicacid ethyl ester (Example 311: step a) 52 mg, 0.07 mmol) in MeOH. Thesolution was stirred for 6 h at rt, AcOH was added (100 μL) and thesolvent was removed in vacuo. The residue was treated with 1:1 TFA/DCMas in Example 1: step d and analogously purified via RP-HPLC to yield awhite solid (26 mg, 54%). ¹H-NMR (CD₃OD): δ 8.34 (s, 1H), 8.00 (m, 1H),7.95 (m, 1H), 7.67 (m, 2H), 7.32 (m, 2H), 7.11 (d, 1H, J=8.4 Hz), 3.24(t, 2H, 7.0 Hz), 2.74 (s, 3H), 2.34 (t, 2H, J=7.3 Hz), 2.22 (s, 3H),1.68 (m, 2H), 1.59 (m, 2H), 1.44 (m, 2H). ESI-MS (m/z): Calcd. forC₂₆H₃₀N₄O₅S₃ (M+H): 575.1; found: 575.1.

Example 3136-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-6-methyl-biphenyl-2-yl]-ureido}-hexanoicacid ethyl ester trifluoroacetate

The procedure used in Example 311: step a was followed using{[4-(6′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 25: step c) 60 mg, 0.12 mmol),6-isocyanato-hexanoic acid ethyl ester (28 mg, 0.15 mmol), and DIEA (89μL, 0.5 mmol). After analogous workup and purification, the crudematerial was treated with 1:1 TFA/DCM as in Example 1: step d. AnalogousHPLC purification yielded the product (20 mg, 24%) as a white solid.¹H-NMR (CD₃OD): δ 8.31 (s, 1H), 8.06 (ddd, 1H, J=1.2, 1.9, 7.9 Hz), 7.90(t, 1H, J=1.6 Hz), 7.72 (t, 1H, J=7.9 Hz), 7.13 (m, 1H), 4.11 (q, 2H,7.2 Hz), 2.99 (m, 2H), 2.73 (s, 3H), 2.29 (t, 2H, J=7.4 Hz), 2.01 (s,3H), 1.65 (m, 2H), 1.55 (m, 2H), 1.35 (m, 2H), 1.23 (t, 3H, J=7.2 Hz).ESI-MS (m/z): Calcd. for C₂₈H₃₄N₄O₅S₃ (M+H): 603.2; found: 603.2.

Example 3144-(4′-Guanidino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

DIEA (89 μL, 0.5 mmol) was added to solution of{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 220: step b) 26 mg, 0.05 mmol),1,3-bis-(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (29 mg, 0.1mmol) and HgCl₂ (27 mg, 0.1 mmol) in DMF (2 mL). The solution becamehazy after stirring for 5 min at rt. The solution was stirred for 24 hat rt and then was partitioned between EtOAc (40 mL) and water (20 mL).The layers were separated and the organic layer was extracted withcitric acid (2×10 mL), NaHCO₃ (20 mL), water (6×10 mL), and brine (20mL). After drying (Na₂SO₄) and concentration in vacuo the residue waspurified by preparative TLC. The protected guanidine was treated 1:1TFA/DCM as in Example 1: step d. Analogous HPLC purification yielded theproduct (8 mg, 24%) as a white solid. ¹H-NMR (CD₃OD): δ 8.35 (s, 1H),8.04 (m, 2H), 7.71 (m, 2H), 7.35 (d, 1H, J=8.1 Hz), 7.28 (d, 1H, J=2.3Hz), 7.23 (dd, 1H, J=2.3, 8.1 Hz), 2.74 (s, 3H), 2.28 (s, 3H). ESI-MS(m/z): Calcd. for C₂₀H₂₁N₅O₂S₃ (M+H): 460.1; found: 460.2, 230.1 (m/2).

Example 3154-[2′-Methyl-4′-(N′-methoxyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

a)(Imino-[4-(4′-isothiocyanato-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester

A solution of 1,1′-thiocarbonyldi-2(1H)-pyridone in DCM (0.25 M, 300 μL,0.075 mmol) was added to{[4-(4′-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 220: step b) 26 mg, 0.05 mmol) at rt.The orange color of the thiourea dissipated as the reagent was added,and a new higher spot appeared on TLC. The solvent was removed in vacuoand the residue was purified by preparative TLC to yield 23 mg ofproduct. ¹H-NMR (CDCl₃): δ 8.01 (br s, 1H), 7.96 (d, 1H, J=7.4 Hz), 7.87(s, 1H), 7.53 (m, 2H), 7.10 (d, 1H, J=7.9 Hz), 6.93 (br s, 1H), 6.87 (d,1H, J=7.9 Hz), 2.51 (s, 3H), 2.17 (s, 3H), 1.50 (s, 9H).

b)4-[2′-Methyl-4′-(N′-methoxyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

Methoxylamine hydrochloride (30 mg, 0.36 mmol),{imino-[4-(4′-isothiocyanato-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-methyl}-carbamicacid tert-butyl ester (Example 315: step a), 21 mg, 0.038 mmol), andtriethylamine (100 μL) were stirred in DCM (2 mL)/CH₃CN (1 mL), wasstirred for 1 h at rt. The solution was partitioned between EtOAc (40mL) and water (20 mL) and the layers were separated. The organic layerwas extracted with citric acid (3×10 mL), NaHCO₃ (20 mL), and brine (20mL). After drying (Na₂SO₄) and concentration in vacuo, the residue waspurified by preparative TLC. The purified material was dissolved inammonia in MeOH (2M, 10 mL) and mercuric oxide (100 mg) was added. Themixture was stirred overnight at rt and at 40° C. for 3 h. The solutionwas filtered and the filtrate was concentrated in vacuo. The residuepurified by preparative TLC and the product was treated with 1:1 TFA/DCMas in Example 1: step d. Purification by HPLC yielded the product (6 mg,23%) as a white solid. ¹H-NMR (CD₃OD): δ 8.36 (s, 1H), 8.05 (m, 2H),7.72 (m, 2H), 7.30 (m, 1H), 7.25 (ddd, 1H, J=0.45, 2.3, 8.1 Hz), 7.36(d, 1H, J=8.1 Hz), 3.84 (s, 3H), 2.74 (s, 3H), 2.29 (s, 3H). ESI-MS(m/z): Calcd. for C₂₁H₂₃N₅O₃S₃ (M+H): 490.1; found: 490.1.

Example 3164-[7-Bromo-3-(3,5-dimethyl-isoxazol-4-ylmethyl)-3H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

Example 3174-[7-Bromo-1-(3,5-dimethyl-isoxazol-4-ylmethyl)-1H-benzoimidazole-5-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

The procedure in Example 305–306 was followed using{[4-(7-bromo-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester ((Example 187–188: step c) 20 mg, 0.037 mmol),K₂CO₃ (25 mg, 0.18 mmol), and 4-chloromethyl-3,5-dimethyl-isoxazole (25mL, 0.15 mmol) in DMF (2.5 mL). The title compounds were isolated aswhite solids.

Example 316: ¹H-NMR (CDCl₃): δ 8.69 (s, 1H), 8.33 (s, 1H), 8.10 (d, 1H,J=1.6 Hz), 7.98 (d, 1H, J=1.6 Hz), 5.52 (s, 2H), 2.67 (s, 3H), 2.55 (s,3H), 2.02 (s, 3H). ESI-MS (m/z): Calcd. for C₁₉H₁₈BrN₅O₃S₃ (M+H): 540.0;found: 540.0, 542.0 (m+2).

Example 317: ¹H-NMR (CDCl₃): δ 8.43 (br s, 1H), 8.40 (d, 1H, J=1.6 Hz),8.35 (s, 1H), 8.13 (d, 1H, J=1.6 Hz), 5.73 (s, 2H), 5.27 (m, 2H), 2.73(s, 3H), 2.19 (s, 3H), 2.03 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁₈BrN₅O₃S₃ (M+H): 540.0; found: 540.0, 542.0 (m+2).

Example 3184-(7-Bromo-1-phenyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

a) 4-Amino-3-bromo-5-nitro-benzenesulfonyl chloride

4-Amino-3-bromo-5-nitrobenzenesulfonamide ((U.S. Pat. No. 3,987,199) 1g, 3.17 mmol) was heated at 95° C. for 3 h in chlorosulfonic acid (10mL). The solution was cooled then poured onto ice and then filtered. Thesolid was redissolved in DCM and dried over sodium sulfate. Removal ofthe solvent yielded the product (960 mg) which was used without furtherpurification.

b)4-(4-Amino-3-bromo-5-nitrobenzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

Sodium sulfite (643 mg, 5.1 mmol) and NaHCO₃ (480 mg, 5.7 mmol) weredissolved in water (20 mL) and 4-amino-3-bromo-5-nitrobenzenesulfonylchloride ((Example 318: step b) 940 mg, 3 mmol) was added. Thesuspension was stirred for 1 h at rt and 5 mL of EtOH was added to aiddissolution. The mixture was stirred for 4 h at rt, during which nearlyall of the sulfonyl chloride had dissolved and the major spot on TLC wasat the baseline. The solvent was removed in vacuo and DMF was added (10mL). The mixture was stirred for 15 min and the inorganic salts wereallowed to settle. The DMF was removed via syringe, the salts werewashed with a second portion of DMF (10 mL), and the combined DMFsolution was slowly added to a 0° C. solution of4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114:step c) 800 mg, 3 mmol) in DMF (20 mL). The solution was stirred for 0°C. for 1 h then overnight at rt. The DMF was removed in vacuo and theresidue was partitioned between EtOAc (100 mL) and aq NaHCO₃ (30 mL).The layers were separated and the organic layer was washed with aqNaHCO₃ (2×20 mL), water (30 mL), and brine (30 mL), then dried oversoldium sulfate. The solution was concentrated and the residue wasdissolved in THF (20 mL) and cooled to −78° C. A solution of sodiummethoxide in methanol (1M, 3.75 mL, 3.75 mmol) was added dropwise andthe reaction was stirred for 30 min. Acetic acid (500 μL) was addedfollowed by EtOAc (100 mL). The solution was washed with NaHCO₃ (3×30mL), brine (40 mL), and was dried over sodium sulfate. Concentration andchromatography of the residue yielded the product (430 mg). ¹H-NMR(CDCl₃): δ 8.88 (d, 1H, J=2.1 Hz), 8.27 (d, 1H, J=2.1 Hz), 8.06 (s, 1H),3.93 (s, 3H), 2.67 (s, 3H).

c)4-(3-Bromo-4-chloro-5-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

To a mixture of CuCl₂ (142 mg, 1.06 mmol), and tert-butylnitrite (157μL, 1.32 mmol) in CH₃CN (10 mL) was added a solution of4-(4-amino-3-bromo-5-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 318: step b) 410 mg, 0.88 mmol) in CH₃CN (10mL), dropwise over 5 min. After 1.5 h, extra CuCl₂ (142 mg), andtert-butylnitrite (157 μL) were added and the reaction was stirred anadditional 1.5 h. The solution was cooled then partitioned between EtOAc(120 mL) and water (50 mL). The organic layer was washed with water(2×20 mL) and brine (30 mL) then was dried over sodium sulfate.Concentration of the solution followed by chromatography yielded animpure product (285 mg, 68%) that was used without further purification.¹H-NMR (CDCl₃): δ 8.43 (d, 1H, J=2.1 Hz), 8.34 (d, 1H, J=2.1 Hz), 8.02(s, 1H), 3.90 (s, 3H), 2.66 (s, 3H).

d)4-(3-Bromo-5-nitro-4-phenylamino-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

A mixture of aniline (112 mg, 1.35 mmol),4-(3-bromo-4-chloro-5-nitro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 318: step c) 53 mg, 0.11 mmol), and sodiumacetate (16.5 mg, 0.2 mmol) in dioxane (3 mL) was heated at 80° C. for24 h. The mixture was partitioned between EtOAc (50 mL) and 0.5 N HCl(10 mL) and the organic layer was further extracted with 0.5 N HCl (2×10mL), NaHCO₃ (10 mL), and brine (20 mL). Drying of the solution oversodium sulfate followed by concentration yielded the product (58 mg)which was used without further purification. ¹H-NMR (CDCl₃): δ 8.04 (s,1H), 7.64 (d, 1H, J=2.1 Hz), 7.32 (d, 1H, J=1.9 Hz), 7.25 (m, 2H), 6.95(m, 1H), 6.69 (m, 2H), 5.70) (s, 1H), 3.90 (s, 3H), 2.66 (s, 3H).

e)4-(7-Bromo-1-phenyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

Iron powder (110 mg, 2 mmol) was added to a solution of4-(3-bromo-5-nitro-4-phenylamino-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester (Example 318: step d) in EtOH (4 mL) and 50% aqueousAcOH (1 mL). The reaction was stirred for 30 min at 60° C. during whicha new lower spot became evident by TLC analysis. EtOAc (10 mL) was addedand the mixture was filtered through a 0.22 μm polypropylene syringefilter. Additional EtOAc (30 mL) was added and the solution wasextracted with aq NaHCO₃ (3×10 mL) and brine (20 mL). The solution wasdried and concentrated in vacuo. One-half of the residue (26 mg) wassuspended in formic acid (3 mL) and was heated at 95° C. for 4 h. Theformic acid was removed in vacuo and the residue was purified bychromatography to yield the product (23 mg). ¹H-NMR (CDCl₃): δ 8.56 (d,1H, J=1.6 Hz), 8.13 (s, 1H), 8.07 (d, 1H, J=1.6 Hz), 8.04 (s, 1H), 7.55(m, 3H, 7.41 (m, 2H), 3.87 (s, 3H), 2.61 (s, 3H).

f)4-(7-Bromo-1-phenyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

The procedure in Example 12: step f was followed using4-(7-bromo-1-phenyl-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 318: step e) 23 mg, 0.044 mmol) anddimethylaluminum amide reagent (5 mL). Analogous workup and purificationby HPLC yielded the title compound as a white solid (16 mg, 49%). ¹H-NMR(CD₃OD): δ 8.53 (s, 1H), 8.47 (d, 1H, J=1.6 Hz), 8.37 (s, 1H), 8.10 (d,1H, J=1.6 Hz), 7.53–7.65 (m, 5H), 2.73 (s, 3H). ESI-MS (m/z): Calcd. forC₁₉H₁₅BrN₄O₂S₃ (M+H): 507.0; found: 507.1, 509.1 (m+2).

Example 3194-(6-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidine

a) 3-Bromo-4-fluoro-phenylamine

Sodium chlorite (6.78 g, 75 mmol) and 4-fluoro-3-bromobenzaldehyde(24.63 mmol) were dissolved in 1:1 THF/water (100 mL) and stirredvigorously at 50° C. for 5 h. EtOAc (250 mL) and 1N HCl (50 mL) wasadded and the layers were separated. The organic layer was washed withwater (3×50 mL), then was extracted with 0.5M Na₂CO₃ (10×50 mL). Thecombined basic aqueous layers were slowly acidified with concentratedHCl while stirring, to precipitate the carboxylic acid product. Thesolid was collected via filtration and dried under high vacuum overnight(4.93 g, 91%). A portion of the solid carboxylic acid was dissolved inchloroform (30 mL) and concentrated sulfuric acid was added. A refluxcondenser was attached to the flask and the solution was heated to 55°C. Sodium azide (2.36 g, 36.45 mmol) was added in 3 portions over 1 h.After 4 h, additional sulfuric acid (10 mL) and sodium azide (1 g) wereadded and the reaction was stirred at 55° C. for 16 h. The mixture wastransferred to a large cooled flask and the sulfuric acid was slowlyquenched with 5N sodium hydroxide. The solution was adjusted to pH˜8 andthe aqueous solution was extracted with DCM (5×30 mL). The organicextracts were dried over sodium sulfate and concentrated in vacuo toyield a dark brown oil (2.2 g, 95%) that solidified upon standing.¹H-NMR (CDCl₃): δ 6.94 (t, 8.4 Hz), 6.88 (dd, 1H, J=2.8, 5.6 Hz), 6.58(m, 1H), 3.62 (s, 2H).

b) 3-Bromo-4-fluoro-benzenesulfonyl chloride

Concentrated HCl (1.93 mL, 23.16 mmol) was added to a solution of3-bromo-4-fluoro-phenylamine ((Example 265: part a) 2.2 g, 11.58 mmol)in 18 mL of 2:1 DCM/MeOH. A precipitate appeared and another 9 mL of 2:1DCM/MeOH was added. The solution was cooled to −5° C. andtert-butylnitrate (2.71 mL, 23.16 mmol) was added dropwise over 8 min.After stirring for 15 min, sulfur dioxide (˜5 mL) was condensed into thereaction, followed by addition of copper(II) chloride (592 mg, 3.47mmol) (gas evolution). The solvent was removed in vacuo and the residuewas purified by SiO₂ flash column chromatography to yield the titlecompound (1.9 g, 59%). ¹H-NMR (CDCl₃): δ 8.31 (dd, 1H, J=2.3, 5.8 Hz),8.04 (ddd, 1H, J=2.6, 4.1, 8.8 Hz), 7.39 (dd, 1H, J=7.7, 8.8 Hz).

c)4-(3-Bromo-4-fluoro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester

3-Bromo-4-fluoro-benzenesulfonyl chloride ((Example 319: part b) 1.9 g,6.83 mmol) and sodium bicarbonate (1.15 g, 13.66 mmol) was suspended in16 mL of water at 70° C. A solution of sodium sulfite (1.64 g, 13 mmol)in 15 mL of water was added in 3 portions over 3 h. The mixture wasstirred for 16 h, and the solvent was removed in vacuo. DMF (15 mL) wasadded, the mixture was stirred for 15 min, and the inorganic salts werethen allowed to settle. The DMF was removed via syringe, the salts werewashed with a second portion of DMF (10 mL), and the combined DMFsolution was slowly added to a 0° C. solution of4-bromo-5-nitro-thiophene-2-carboxylic acid methyl ester ((Example 114,step c) 931 mg, 3.5 mmol) in DMF (15 mL). The solution was stirred for0° C. for 1 h. The DMF was removed in vacuo and the residue waspartitioned between EtOAc (100 mL) and aq NaHCO₃ (30 mL). The layerswere separated and the organic layer was washed with aq NaHCO₃ (2×20mL), water (30 mL), and brine (30 mL), then dried over sodium sulfate.The solution was concentrated and the residue (1.42 g) was dissolved inTHF (20 mL) and cooled to −78° C. A solution of sodium methoxide inmethanol (1M, 5 mL, 5 mmol) was added dropwise and the reaction wasstirred for 30 min at −78° C. Acetic acid (500 μL) was added followed byEtOAc (100 mL). The solution was washed with NaHCO₃ (3×30 mL), brine (40mL), and was dried over sodium sulfate. Concentration and chromatographyof the residue yielded the title compound (502 mg, 17%) as a yellowsolid. ¹H-NMR (CDCl₃): δ 8.16 (dd, 1H, J=2.3, 6.3 Hz), 7.94 (s, 1H),7.91 (ddd, 1H, J=2.6, 4.4, 8.6 Hz), 7.39 (dd, 1H, J=5.3, 8.6 Hz).

d)4-(4-Amino-3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide

The procedure in Example 124: step a was followed using4-(3-bromo-4-fluoro-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid methyl ester ((Example 319: part c) 100 mg, 0.24 mmol). After 24 h,the ammonia was allowed to evaporate and the solid product was usedwithout further purification. ¹H-NMR (CDCl₃): δ 7.73 (d, 1H, J=2.1 Hz),7.69 (s, 1H), 7.42 (dd, 1H, J=2.1, 8.6 Hz), 6.57 (d, 1H), 3.14 (s, 2H),2.36 (s, 3H).

e)4-(6-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide

The procedure used in Example 1: step c was followed using4-(4-amino-3-bromo-benzenesulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide ((Example 319: part d) 44 mg, 0.11 mmol),2-methylphenylboronic acid (54 mg, 0.4 mmol), aq Na₂CO₃ (2M, 800 μL, 1.6mmol), and Pd(PPh₃)₄ (29 mg, 0.025 mmol). Analogous workup andpurification by preparative TLC yielded the title compound (24 mg, 56%).¹H-NMR (CDCl₃): δ 7.97 (s, 1H), 7.76 (dd, 1H, J=2.3, 8.6 Hz), 7.67 (d,1H, J=2.3 Hz), 7.32 (m, 2H), 7.28 (m, 1H), 7.16 (m, 1H), 6.76 (d, 1H,J=8.6 Hz), 4.11 (s, 2H), 2.58 (s, 3H), 2.13 (s, 3H).

f)4-(6-Amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate

The reaction conditions in Example 12: step f were followed using4-(6-amino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylicacid amide ((Example 319: part e) 24 mg, 0.06 mmol) and dimethylaluminumamide reagent (5 mL). Analogous workup and HPLC purification yielded thetitle compound as an off-white solid (8.8 mg, 24%). ¹H-NMR (CD₃OD): δ8.24 (s, 1H), 7.72 (dd, 1H, J=2.3, 8.8 Hz), 7.52 (d, 1H, J=2.3 Hz), 7.33(m, 2H), 7.28 (m, 1H), 7.12 (m, 1H), 6.85 (d, 1H, J=8.8 Hz), 2.71 (s,3H), 2.10 (s, 3H). ESI-MS (m/z): Calcd. for C₁₉H₁₉N₃O₂S₃ (M+H): 418.1,found: 418.1.

Example 3204-(6′-Methanesulfonylamino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate

{[4-(2′-Amino-6′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophen-2-yl]-imino-methyl}-carbamicacid tert-butyl ester (20 mg, 0.04 mmol, Example 25: step c) and methanesulphonyl chloride (5 mg, 0.04 mmol) were dissolved into toluene (1 mL)and heated to 100° C. for 48 hours. The solvents were removed in vacuoresulting in the desired product with loss of the tert-butyl protectiongroup. The resulting compound was purified as in Example 1: step d,yielding the title compound as an off-white solid (1.3 mg). ¹H-NMR(CD₃OD): δ 8.29 (s, 1H), 8.07–8.05 (d, 1H, J=7.21 Hz), 7.90 (m, 1H),7.72–7.68 (t, 1H, J=8.14 Hz, J=7.67 Hz), 7.57–7.55 (d, 1H, J=7.67 Hz)7.35 (m, 2H), 7.26 (m, 1H), 2.75 (s, 3H), 2.50 (s, 3H), 1.30 (s, 3H).ESI-MS (m/z): Calcd. for C₂₀H₂₁N₃O₃S₄: 496.0 (M+1); found: 496.1.

Examples 321–334

ESI-MS (m/z) Ex. Calcd. No. Compound Formula (M + H) Found 3214-[4-Fluoro-3-(3-methyl-pyridin-2-yl)- C₁₈H₁₆FN₃O₂S₃ 422.04 422.1benzenesulfonyl]-5-methylsulfanyl- thiophene-2-carboxamidine 3224-(3-Chloro-4-fluoro-benzenesulfonyl)- C₁₂H₁₀ClFN₂O₂S₃ 364.96  365.1,5-methylsulfanyl-thiophene-2-carboxamidine 367.1 (m + 2) 3234-(6H-Benzo[c]chromene-2-sulfonyl)-5- C₁₉H₁₆N₂O₃S₃ 417.03 417.1methylsulfanyl-thiophene-2-carboxamidine 3244-[3-(2-Methoxymethyl-6-methyl-1H- C₂₂H₂₂N₄O₃S₃ 487.09 487.1benzoimidazol-5-yl)-benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine 3254-[3-(3-Chloro-5-trifluoromethyl-pyridin-2- C₁₈H₁₃ClF₃N₃O₂S₃ 491.98492   yl)-benzenesulfonyl]-5-methylsulfanyl- thiophene-2-carboxamidine326 4-[3-(2,6-Dimethyl-1H-benzoimidazol-5-yl)- C₂₁H₂₀N₄O₂S₃ 457.07 457.1benzenesulfonyl]-5-methylsulfanyl- thiophene-2-carboxamidine 3274-[3-(1,6-Dimethyl-1H-benzoimidazol-5-yl)- C₂₁H₂₀N₄O₂S₃ 457.07 457.1benzenesulfonyl]-5-methylsulfanyl- thiophene-2-carboxamidine 3282-Bromo-N-[3′-(5-carbamimidoyl-2- C₂₁H₂₀BrN₃O₃S₃ 538.0 540.0methylsulfanyl-thiophene-3-sulfonyl)-2- methyl-biphenyl-4-yl]-acetamide329 {[3′-(5-Carbamimidoyl-2-methylsulfanyl- C₂₇H₃₅N₄O₃S₃+ 560.19 560.0thiophene-3-sulfonyl)-2-methyl-biphenyl-4-ylcarbamoyl]-methyl}-triethyl-ammonium 330{[3′-(5-Carbamimidoyl-2-methylsulfanyl- C₂₄H₂₅N₃O₆S₃ 548.09 548.1thiophene-3-sulfonyl)-6-methyl-biphenyl-2- ylcarbamoyl]-methoxy}-aceticacid methyl ester 331 4-[3-(1-Methyl-1H-benzoimidazol-5-yl)-C₂₀H₁₈N₄O₂S₃ 443.06 443.2 benzenesulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidine 332 2-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-C₂₃H₂₄N₄O₅S₃ 533.09 533.1 thiophene-3-sulfonyl)-6-methyl-biphenyl-2-ylcarbamoyl]-methoxy}-acetamide 3332-{[3′-(5-Carbamimidoyl-2-methylsulfanyl- C₂₄H₂₇N₃O₇S₅ 630.05 630.0thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}- ethanesulfonic acid 3342-Bromo-N-[3′-(5-carbamimidoyl-2- C₂₂H₂₂BrN₃O₄S₃ 568.00 568.0methylsulfanyl-thiophene-3-sulfonyl)-4-methoxy-6-methyl-biphenyl-2-yl]-acetamide

Example 335 Tablet Preparation

Tablets containing 25.0, 50.0, and 100.0 mg, respectively, of an activecompound are prepared as illustrated below:

Tablet for Doses Containing from 25–100 mg of the Active Compound

Amount-mg

Active Compound 25.0 50.0 100.00 Microcrystalline cellulose 37.25 100.0200.0 Modified food corn starch 37.25 4.25 8.5 Magnesium stearate 0.500.75 1.5

All of the active compound, cellulose, and a portion of the cornstarchare mixed and granulated to 10% corn starch paste. The resultinggranulation is sieved, dried and blended with the remainder of the cornstarch and the magnesium stearate. The resulting granulation is thencompressed into tablets containing 25.0, 50.0, and 100.0 mg,respectively, of active ingredient per tablet.

Example 336 Intravenous Solution Preparation

An intravenous dosage form of the above-indicated active compounds isprepared as follows:

Active Compound 0.5–10.0 mg Sodium Citrate 5–50 mg Citric Acid 1–15 mgSodium Chloride 1–8 mg Water for Injection (USP) q.s. to 1 ml

Utilizing the above quantities, the active compound is dissolved at roomtemperature in a previously prepared solution of sodium chloride, citricacid, and sodium citrate in Water for Injection (USP, see page 1636 ofUnited States Pharmacopeia/National Formulary for 1995, published byUnited States Pharmacopeial Convention, Inc., Rockville, Md. (1994).

Example 337 In Vitro Inhibition of C1s

Reagents: All buffer salts were obtained from Sigma Chemical Company(St. Louis, Mo.), and were of the highest purity available. DTNB waspurchased from Pierce (Rockford, Ill.). Z-Gly-Arg-S-Bzl was purchasedfrom Enzyme Systems Products (Livermore, Calif.). Activated human C1swas purchased from Calbiochem (La Jolla, Calif.).

K_(i) Determinations: All assays are based on the ability of the testcompound to inhibit the C1s-catalyzed hydrolysis of the substrateZ-Gly-Arg-S-Bzl, which is observed via a secondary reaction with5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB). In a typical K_(i)determination, substrate is prepared in DMSO, and diluted into an assaybuffer consisting of 50 mM HEPES, 200 mM NaCl, pH 7.5, 0.05%n-octyl-β-D-glucopyranoside. Substrate solutions were prepared at aconcentration of 45 μM (K_(m)=190 μM) with DTNB at a concentration of200 μM in assay buffer. Test compounds are prepared as a 10 μM solutionin DMSO. Dilutions are prepared in DMSO yielding 7 final concentrationsencompassing a 700-fold concentration range. Purified activated C1s wasdiluted into assay buffer for a working concentration of 66 nM.

In a typical K_(i) determination, into each well of a 96-well plate ispipetted 280 μL of substrate solution, 10 μL of test compound solution,and the plate allowed to thermally equilibrate at 37° C. for 15 minutes.Reactions were initiated by the addition of a 10 μL aliquot of theenzyme, and the absorbance increase at 405 nm is continuously recordedfor 15 minutes in a Molecular Devices plate reader. Final DMSOconcentration was 4.3%. Final reagent concentrations were: [C1s]=2.3 nM,[Z-Gly-Arg-S-Bzl]=45 μM, [DTNB]=200 μM. The ratio of the velocity (rateof change in absorbance as a function of time) for a sample containingno test compound is divided by the velocity of a sample containing testcompound, and is plotted as a function of test compound concentration.The data are fit to a linear regression, and the value of the slope ofthe line calculated. The inverse of the slope is the experimentallydetermined K_(i) value.

Complement Inhibition Data

The following compounds have Ki values in the range of 0.006 to 0.023micromolar (μM) for C1s: Examples 1–13, 15–20, 24–26, 28–30, 32–35, 37,41–96, 98–110, 114–119, 121, 135–136, 171, 173, 184, 192, 194–195, 203,207, 209–211, 219–220, 224, 228, 231, 233, 236–239, 240, 242, 246, 252,254–263, 275, 280, 282, 294–296 and 314–315.

The compound of Example 11 has a Ki value of 0.023 μM for C1s. Thecompound of Example 61 has a Ki value of 0.006 μM for C1s. The resultsindicate that the compounds of the present invention are inhibitors ofcomplement, specifically C1s.

Having now fully described this invention, it will be understood tothose of ordinary skill in the art that the same can be performed withina wide and equivalent range of conditions, formulations, and otherparameters without affecting the scope of the invention or anyembodiment thereof. All patents and publications cited herein are fullyincorporated by reference herein in their entirety.

Abbreviations:

-   DCM dichloromethane-   NaHCO₃ sodium bicarbonate-   NaOH sodium hydroxide-   EtOAc ethyl acetate-   THF tetrahydrofuran-   HCl hydrochloric acid-   Na₂CO₃ sodium carbonate-   Pd(PPh₃)₄ tetrakistriphenylphosphine Pd⁰-   Et₂O diethyl ether-   DMSO dimethyl sulfoxide-   MeOH methanol-   K₂CO₃ potassium carbonate-   DMAP-resin 4-dimethylaminopyridine—modified resin-   CHCl₃ chloroform-   m-CPBA m-chloroperbenzoic acid-   Boc t-butyloxycarbonyl, also tBoc-   TBAF tetrabutyl ammonium fluoride-   AlMe₃ trimethyl aluminum-   H₂SO₄ sulfuric acid-   MgSO₄ magnesium sulfate-   Cs₂CO₃ cesium carbonate

1. A compound of Formula I:

or a solvate, hydrate or pharmaceutically acceptable salt thereof;wherein: Z is —S(O)— or —S(O₂)—; R¹ is C₁₋₄ alkyl, halo, amino, C₁₋₆alkylthio, C₂₋₆ alkenylthio, C₁₋₆ alkoxy, trifluoromethyl,methylsulfonyl, or benzylthio; Ar is phenyl, naphthyl, pyridyl,imidazolyl, thiazolyl, furanyl, thienyl, benzothiazolyl, pyrazolyl,pyrimidinyl, benzimidazolyl, benzofuranyl, indolyl, benzothiophenyl orbenzo[c]chromenyl any of which is optionally substituted; R², R³ and R⁴are independently hydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl, C₁₋₄ hydroxyalkyl,C₁₋₄ aminoalkyl, mono(C₁₋₄)alkylamino(C₂₋₆)alkyl,di(C₁₋₄)alkylamino(C₂₋₆)alkyl, carboxy(C₁₋₄)alkyl, cyano, nitro, amino,C₁₋₄ alkoxy, hydroxy, or BCO₂R^(w), where R^(w) is hydrogen, hydroxy,C₁₋₄ alkoxy, cyano, C₁₋₄ alkoxycarbonyl, C₁₋₄ alkyl, C₃₋₈ cycloalkyl,phenyl, benzyl,

where R^(d) and R^(e) are independently hydrogen, C₁₋₆ alkyl, C₂₋₆alkenyl or phenyl, R^(f) is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl orphenyl, R^(g) is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl or phenyl, and R^(h)is C₆₋₁₀ ar(C₁₋₄)alkyl or C₁₋₆ alkyl; and R⁷ is hydrogen, chloro, fluoroor amino.
 2. A compound of claim 1, wherein R¹ is halo, C₁₋₄ alkylthioor C₂₋₄ alkenylthio.
 3. A compound of claim 1, wherein Ar is naphthyl orphenyl, either of which is substituted by one or two of C₁₋₆ alkyl, C₁₋₆alkoxy, C₂₋₆ alkenyl, halo, hydroxy, phenyl, phenoxy, amino orphenylamino.
 4. A compound of claim 1, wherein Ar is 2-phenylphenyl,naphth-2-yl, 2-methoxyphenyl, 4-methoxyphenyl, 4-chlorophenyl,2-bromophenyl, 3,4-dimethylphenyl, 3-methoxyphenyl, 3-bromophenyl,4-ethylphenyl, 4-bromophenyl, 4-phenylphenyl, 3,4-dimethoxyphenyl,2-isopropylphenyl, 3,5-dichlorophenyl, 3-hydroxyphenyl,2-methyl-5-t-butylphenyl, 4-t-butylphenyl, 3-bromo-5-t-butoxyphenyl,3-bromo-5-hydroxyphenyl, 3-bromo-5-methoxyphenyl,3-bromo-5-vinyloxyphenyl, 3-phenoxyphenyl, 5-bromo-3-methylphenyl or2-aminophenyl.
 5. A compound of claim 1, wherein Ar is phenylsubstituted by one or two of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl,halo, hydroxy, phenyl, phenoxy, amino, phenylamino,hydroxytetrahydropyranyl, (C₁₋₄ alkoxy)-tetrahydropyranyl,hydroxypiperidinyl, hydroxy-N-(C₁₋₄ alkyl)-piperidinyl,hydroxy-pyridinyl-(C₁₋₄)alkyl and (C₁₋₄ alkoxy)carbonyl(C₂₋₆)alkenyl. 6.A compound of claim 1, wherein Ar is 4-amino-3-bromophenyl,3-(4-hydroxytetrahydropyran-4-yl)-phenyl,3-(4-hydroxy-1-methylpiperidin-4-yl)-phenyl,3-(4-methoxytetrahydropyran-4-yl)-phenyl,3-(hydroxy-pyridin-2-yl-methyl)-phenyl,3-(1-ethoxycarbonyl-propen-2-yl)-phenyl, 3-chloro-4-fluorophenyl or3-iodophenyl.
 7. A compound of claim 1, wherein Ar is pyridyl,imidazolyl, furanyl, thienyl, thiazolyl, benzothiazolyl, benzofuranyl,benzothiophenyl, indolyl or benzimidazolyl, any of which is optionallysubstituted by one or two of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl,halo, hydroxy, phenyl, phenoxy, amino or tolyl.
 8. A compound of claim1, wherein Ar is pyrid-2-yl, pyrid-3-yl, imidazol-2-yl,1-methylimidazol-2-yl, 2-methylfuran-2-yl, thien-2-yl, thiazol-2-yl,4-phenylthiazol-2-yl, 5-ethoxybenzothiazol-2-yl, benzimidazol-2-yl,7-bromo-1-methyl-1H-benzoimidazolyl,4-bromo-1-methyl-1H-benzoimidazolyl,4-bromo-2-methyl-1H-benzoimidazolyl, 4-bromo-1H-benzoimidazolyl,6-bromo-benzimidazolyl, pyrrol-2-yl, or piperdin-2-yl.
 9. A compound ofclaim 1, wherein Ar is benzo[c]chromenyl optionally substituted by oneor two of C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, halo, hydroxy, phenyl,phenoxy or amino.
 10. A compound of claim 1, wherein Ar has the FormulaIA:

wherein: R^(x) is halo, or phenyl substituted by one or two of C₁₋₆alkyl or (C₁₋₄ alkyl)oxy(C₁₋₄)alkyl wherein one of the C₁₋₄ alkylportions is optionally substituted by carboxy; R^(y) is hydrogen, amino,halo, phenoxy or C₁₋₄ alkylamino wherein the alkyl portion is optionallysubstituted by one of phenyl, pyridyl, tetrahydrofuranyl, imidazolyl,morpholinyl, (C₁₋₄ haloalkyl)-pyridyl, sulfonamidophenyl, hydroxy, (C₁₋₄alkyl)-thienyl or aminopyrimidinyl; and R^(z) is hydrogen, halo or C₁₋₄alkyl.
 11. A compound of claim 10, wherein R^(x) is 2-methylphenyl,2-carboxymethoxymethyl-6-methylphenyl or bromo.
 12. A compound of claim10, wherein R^(y) is hydrogen, chloro, amino, phenoxy, benzylamino,isopropylamino, pyrid-3-ylmethylamino, pyrid-4-ylmethylamino,pyrid-2-ylmethylamino, tetrahydrofuran-2-ylmethyl amino,3-(imidazol-1-yl)-propylamino, 2-methyl-2-(morpholin-4-yl)-propylamino,6-trifluoromethyl-pyrid-3-ylmethylamino,2-(3H-imidazol-1-yl)-ethylamino, 4-sulfamoylbenzylamino,2,2-dimethyl-3-hydroxypropylamino, 3-methylthien-2-ylmethylamino or4-aminopyrimidin-5-ylmethylamino.
 13. A compound of claim 10, whereinR^(z) is hydrogen, methyl or ethyl.
 14. A compound of claim 1, whereinAr has the Formula IB:

wherein: R¹³ and R¹⁴ are independently hydrogen, halo or C₁₋₄ alkyl; R¹⁵is hydrogen, halo or tolyl; R¹⁷ is hydrogen or C₁₋₄ alkyl; and one ofR¹⁶ and R¹⁸ is an electron pair and the other is hydrogen, C₁₋₆ alkyl,C₂₋₆ alkenyl, cyclopropylmethyl, phenyl, benzyl, 1-phenylethyl,pyridylmethyl or isoxazolylmethyl optionally substituted with one or twomethyl groups, wherein said benzyl is unsubstituted or is substitutedwith one or two of halo, nitro, amino or(2-carboxyethyl)-sulfanylacetylamino.
 15. A compound of claim 14,wherein R¹³ and R¹⁴ are independently hydrogen, methyl or ethyl.
 16. Acompound of claim 14, wherein R¹⁵ is hydrogen, bromo, chloro or o-tolyl.17. A compound of claim 14, wherein and R¹⁷ is hydrogen, methyl orethyl.
 18. A compound of claim 14, wherein one of R¹⁶ and R¹⁸ is anelectron pair and the other is hydrogen, methyl, cyclopropylmethyl,allyl, 3-methylbut-2-enyl, pyrid-2-ylmethyl,3,5-dimethylisoxazol-4-ylmethyl, phenyl, 1-phenylethyl, benzyl,2,6-dichlorobenzyl, 2,5-difluorobenzyl, 2,6-difluorobenzyl,2-fluoro-5-nitrobenzyl, 2-fluoro-4-nitrobenzyl, 2-fluoro-5-aminobenzylor 5-[(2-carboxyethyl)-sulfanylacetylamino]-2-fluorobenzyl.
 19. Acompound of claim 1, having the general Formula II:

or a solvate, hydrate or pharmaceutically acceptable salt thereof;wherein: R¹, R², R³, R⁴, R⁷ and Z are as defined in claim 1; R⁵ isphenyl, naphthyl, thienyl, furanyl, imidazolyl, oxazolyl, isoxazolyl,pyridyl, pyrimidinyl, benzothienyl, benzofuranyl, benzimidazolyl,quinolinyl, isoquinolinyl, pyrazinyl, piperidinyl or piperazinyl, any ofwhich is optionally substituted; and R⁶ is hydrogen, C₁₋₄ alkyl,hydroxy, C₁₋₄ alkoxy, C₂₋₄ alkenyloxy, phenoxy, benzyloxy, halo, aminoor nitro.
 20. A compound of claim 19, wherein: R⁵ is naphthyl, phenyl orphenyl substituted by one to five groups independently selected from thegroup consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄haloalkyl, C₂₋₄ alkenyl, (C₁₋₄ alkyl)carbonyl, cyano, amino,mono(C₁₋₄)alkylamino, di(C₁₋₄)alkylamino, formyl, (C₁₋₄ alkoxy)carbonyl,halo(C₁₋₄ alkoxy)carbonyl, phenyl, phenoxy, phenoxyphenyl, biphenyl,halo, C₁₋₄ haloalkoxy, carboxy, nitro, methylenedioxo (—O—CH₂—O—),ethylenedioxb, C₁₋₄ alkylsulfonyl, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylthio,hydroxy, aminocarbonyl, mono(C₁₋₄ alkyl)aminocarbonyl, di(C₁₋₄alkyl)aminocarbonyl and halogenated C₁₋₄ hydroxyalkyl.
 21. A compound ofclaim 20, wherein: R⁵ is phenyl, 2-methoxyphenyl, 2-methylphenyl,2-vinylphenyl, 2-hydroxymethylphenyl, 2-(1-hydroxyethyl)phenyl,2-trifluoromethylphenyl, 2-formylphenyl, 2-hydroxyphenyl,2-chloromethylphenyl, 2-amino, 2-chlorophenyl, 3-methoxyphenyl,3-methylphenyl, 3-formylphenyl, 3-hydroxymethylphenyl, 3-aminophenyl,3-isopropylphenyl, 3-ethoxyphenyl, 3-ethoxycarbonylphenyl,3-methylcarbonylphenyl, 3-carboxyphenyl, 3-hydroxyphenyl, 3-nitrophenyl,3-dimethylaminocarbonylphenyl, 3-trifluoromethylphenyl,3-trifluoromethoxycarbonylphenyl, 4-vinylphenyl,4-trifluoromethoxyphenyl, 4-methoxycarbonylphenyl, 4-methylphenyl,4-hydroxymethylphenyl, 4-trifluoromethylphenyl, 4-cyanophenyl,4-ethoxyphenyl, 4-dimethylaminophenyl, biphenyl, 4-phenoxyphenyl,4-chloromethyl, 4-methylsulfonyl)phenyl, 4-hydroxyphenyl,4-fluorophenyl, 2,5-dimethylphenyl, 2,3-dichlorophenyl,2,3-dimethylphenyl, 2,5-dichlorophenyl, 3,5-dichlorophenyl,3-hydroxy-4-phenylphenyl, 3,5-bistrifluoromethylphenyl,2-hydroxy-5-phenylphenyl, 4-methyl-3-nitrophenyl,3,4-methylenedioxophenyl, 3,5-dimethylphenyl, 2,4-dimethoxyphenyl,2-ethoxy-6-methylphenyl, 3-isopropoxycarbonyl-2-methylphenyl,3-fluoro-4-phenylphenyl, 4-formylphenyl, 2-carboxy-6-methylphenyl,3-formyl-2-methylphenyl, 3-hydroxy-6-methylphenyl,3-formyl-6-methylphenyl, 3-formyl-6-hydroxyphenyl,3-formyl-6-methoxyphenyl, 2-amino-6-methylphenyl, 3,4-dimethoxyphenyl,3-[(2,2,2-trifluoro-1-hydroxy)ethyl]phenyl, 4-nitrophenyl,2-fluoro-4-phenylphenyl, 2,4-dimethoxyphenyl, 4-hydroxy-3-formylphenyl,2-tolyl-5-morpholinephenyl, 4-methoxyphenyl, 3-hydroxyaminomethylphenyl, 4-phenyl-acetamide, 4-benzamide, 2,6-dimethylphenyl,phenoxyphenyl, 2-methyl-6-hydroxymethyl phenyl, 2-methyl-5-hydroxymethylphenyl, 2-hydroxy-3-phenylphenyl, naphthyl, or 4-ethoxycarbonylphenyl.22. A compound of claim 19, wherein R⁵ is phenyl substituted by one tothree groups independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxyalkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl,(C₁₋₄ alkyl)carbonyl, cyano, amino, mono(C₁₋₄)alkylamino,di(C₁₋₄)alkylamino, formyl, (C₁₋₄ alkoxy)carbonyl, halo(C₁₋₄alkoxy)carbonyl, phenyl, phenoxy, phenoxyphenyl, biphenyl, halo, C₁₋₄haloalkoxy, carboxy, nitro, methylenedioxo (—O—CH₂—O—), ethylenedioxo,C₁₋₄ alkylsulfonyl, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylthio, hydroxy,aminocarbonyl, mono(C₁₋₄ alkyl)aminocarbonyl, di(C₁₋₄alkyl)aminocarbonyl, halogenated C₁₋₄ hydroxyalkyl,carboxy(C₁₋₄)alkoxy(C₁₋₄)alkyl, carboxy(C₁₋₄)alkoxy, C₁₋₄alkylthio(C₁₋₄)alkyl wherein the alkyl portion of C₁₋₄ alkylthio isoptionally substituted with one or two carboxy groups,phosphono(C₂₋₄)alkenyl, phosphono(C₁₋₄)alkylamino, C₁₋₄haloalkylsulfonylamino, phosphono(C₁₋₄)alkoxy, C₁₋₄ alkylsulfonylamino,carboxy(C₁₋₄)alkylamino, morpholinyl(C₁₋₄)alkyl, morpholinyl,morpholinyl(C₁₋₄)alkylaminocarbonyl, piperazinyl(C₁₋₄)alkyl orpiperazinyl wherein either of said piperazinyl(C₁₋₄)alkyl or piperazinylis optionally N-substituted with methyl or ethyl, formylamino,morpholinyl(C₁₋₄)alkylamino, optionally-substituted alkylcarbonylamino,optionally-substituted ureido and optionally-substituted guanidino,wherein said optionally-substituted alkylcarbonylamino has the formula—N(H)—C(O)—C(H)(W¹)—Y^(1a)—X¹—Y^(1a)-Z¹, wherein: W¹ is hydrogen oramino; Y^(1a) is a direct covalent bond or an α,β-diradical of a C₁₋₁₀straight or branched alkane; X¹ is O or S, or a direct covalent bond;Y^(1b) is an α,β-diradical of a C₁₋₁₀ straight or branched alkane,optionally substituted with a carboxy group or an amino group; and Z¹ iscarbamoyl, carboxy, C₁₋₆ alkylsulfonyl, (C₁₋₆ alkoxy)carbonyl, C₂₋₆alkanoylamino, sulfo, phosphono, phenyl, aminosulfonyl, amino, C₁₋₆haloalkylsulfonylamino, formylamino, C₁₋₆ alkylamino, C₁₋₆alkylaminosulfonyl, C₁₋₆ alkylsulfonylamino or2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl-(C₁₋₆ alkyl)carbonylamino;or, W¹ is hydrogen and Y^(1a)—X¹—Y^(1a)-Z¹ represents hydrogen, halo,amino or tri(C₁₋₄ alkyl)ammonio; provided that, if Y^(1a) is a directcovalent bond and X is O or S, then W¹ is hydrogen; wherein saidoptionally-substituted ureido has the formula—N(L¹)-C(O)—N(L²)-Y^(2a)—X²—Y^(2a)-Z² wherein: L¹ and L² are bothhydrogen, or L¹ and L² together represent ethylene or trimethylene;Y^(2a) is a direct covalent bond or an α,β-diradical of a C₁₋₁₀ straightor branched alkane; X² is O or S, or a direct covalent bond; Y^(2b) isan α,β-diradical of a C₁₋₁₀ straight or branched alkane, optionallysubstituted with a carboxy group; and Z² is carboxy, (C₁₋₆alkoxy)carbonyl, phenoxy, carboxyphenoxy, C₁₋₆ alkylsulfonyl, phenyl,benzyloxycarbonylamino, amino, C₁₋₄ alkylamino, halophenyl, indolyl,diphenylmethyl, phenylsulfonylamino, N′-(carboxy(C₁₋₄)alkyl)ureido,tetrazolyl, phosphono or phenylamino; or, Y^(2a)—X²—Y^(2b)-Z² representsC₁₋₄ alkylsulfonyl or —(CH₂CH₂—O—)_(m)—(CH₂)_(n)—C(O)OR wherein m is aninteger from 2 to 6, n is an integer from 2 to 4, and R is hydrogen orC₁₋₄ alkyl; and wherein said optionally-substituted guanidino has theformula —N(L³)-C(═NL⁴)-N(L⁵)-Z³, wherein: L³ is hydrogen or C₁₋₄ alkyl;L⁴ and L⁵ are both hydrogen, or L⁴ and L⁵ together represent ethylene;and Z³ is hydrogen, C₁₋₆ alkyl, phenyl(C₁₋₆)alkyl, carboxy(C₁₋₆)alkyl,C₁₋₄ alkoxy, (C₁₋₄ alkyl)carbonyl or C₁₋₄ alkylsulfonyl(C₁₋₆)alkyl. 23.A compound of claim 22, wherein R⁵ is phenyl substituted at the2′-position by methyl and at the 4′-position by optionally-substitutedguanidino.
 24. A compound of claim 22, wherein R⁵ is phenyl substitutedat the 2′-position by methyl, at the 4′-position byoptionally-substituted guanidino, and at the 6′-position byoptionally-substituted alkylcarbonylamino or optionally-substitutedureido.
 25. A compound of claim 22, wherein R⁵ is phenyl substituted atthe 2′-position by methyl and at the 6′-position byoptionally-substituted alkylcarbonylamino or optionally-substitutedureido.
 26. A compound of claim 22, wherein R², R³ and R⁴ are hydrogen.27. A compound of claim 22, wherein R⁶ is hydrogen.
 28. A compound ofclaim 22, wherein R⁷ is hydrogen.
 29. A compound of claim 22, wherein Zis —SO₂—.
 30. A compound of claim 22, wherein R⁵ has the Formula IIA:

wherein: R⁸ is hydrogen or methyl; R⁹ is hydrogen, formylamino orcarbamoyl; R¹⁰ is methoxy, hydroxy, carboxymethoxy,phosphonomethylamino, trifluoromethanesulfonylamino, phosphonomethoxy,carboxymethylamino, amino, chloro, fluoro,2-(morpholin-4-yl)-ethylamino, carboxy, carbamoyl,(1,2-dicarboxyethyl)-sulfanylacetylamino, carboxymethoxyacetylamino,4-amino-4-carboxybutyrylamino,6-[5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-hexanoylamino,bromoacetylamino, 2-amino-4-carboxybutyrylamino,triethylammonioacetylamino, 2-amino-4-methanesulfonylbutyrylamino,aminoacetylamino, carbamoylmethylsulfanylacetylamino,3-phosphonopropionylamino, ureido, N′-(5-carboxypentyl)-ureido,N′-(5-ethoxycarbonylpentyl)-ureido, N′-(3-methanesulfonylpropyl)-ureido,guanidino, N′-(3-phenylpropyl)-guanidino, N′-(2-phenylethyl)-guanidino,N′-(3-methylbutyl)-guanidino, N′-acetylguanidino,N′-(4-methanesulfonylbutyl)-guanidino,N′-(3-methanesulfonylpropyl)-guanidino,N′-(6-methanesulfonylhexyl)-guanidino,N′-(5-methanesulfonylpentyl)-guanidino, N′-methoxyguanidino,N-methylguanidino, N′-hexylguanidino, N′-(5-carboxypentyl)-guanidino or4,5-dihydro-1H-imidazol-2-ylamino; R¹¹ is hydrogen,3-(morpholin-4-yl)-propylaminocarbonyl or carboxymethoxymethyl; and R¹²is carboxymethoxymethyl, 2-carboxyethoxymethyl, nitro, amino, methyl,(1,2-dicarboxyethyl)-sulfanylmethyl, 2-phosphonovinyl,morpholin-4-ylmethyl, 4-methylpiperazin-1-ylmethyl, morpholin-4-yl,formylamino, methanesulfonylamino, carboxymethylamino,3-(morpholin-4-yl)-propylaminocarbonyl, chloro, acetylamino,carbamoylmethylsulfanylacetylamino,(2-carboxyethyl)-sulfanylacetylamino, 4-methanesulfonylbutyrylamino,(1,2-dicarboxyethyl)-sulfanylacetylamino,methoxycarbonylmethoxyacetylamino, carboxymethoxyacetylamino,bromoacetylamino, 4-carboxybutyrylamino, carbamoylmethoxyacetylamino,(2-acetylamino-2-carboxy-1,1-dimethylethyl)-sulfanylacetylamino,(2-sulfoethyl)-sulfanylacetyl amino,(2-methoxycarbonylethyl)-sulfanylacetylamino,(2-acetylamino-2-carboxyethyl)-sulfanylacetylamino,methanesulfonylacetylamino, 6-methanesulfonylhexanoylamino,3-methanesulfonylpropionylamino, 2-methanesulfonylpropionylamino,benzylsulfanylacetylamino, 4-aminosulfonylbutyrylamino,11-aminoundecanoylamino, 4-trifluoromethanesulfonylaminobutyrylamino,5-carboxyvalerylamino, carboxyacetylamino, 3-carboxypropionylamino,11-carboxyundecanoylamino, 5-methoxycarbonylvalerylamino,N′-ethoxycarbonylmethylureido, N′-carboxymethylureido,N′-[5-(4-carboxyphenoxy)-pentyl]-ureido,N′-(2-methanesulfonylethyl)-ureido, N′-(5-carboxypentyl)-ureido,N′-(2-[2-{2-(2-carboxyethoxy)-ethoxy}-ethoxy]-ethoxyethyl)-ureido,N′-methanesulfonylureido, N′-(4-methanesulfonylbutyl)-ureido,N′-(3-phenylpropyl)-ureido, N′-benzylureido,N′-(1-carboxy-2-phenylethyl)-ureido,N′-(5-benzyloxycarbonylamino-5-carboxypentyl)-ureido,N′-(2-phenylethyl)-ureido, N′-(5-amino-5-carboxypentyl)-ureido,N′-[2-(4-bromophenyl)-ethyl]-ureido, N′-[2-(indol-3-yl)-ethyl]-ureido,N′-(3,3-diphenylpropyl)-ureido, N′-(2-phenylsulfonylaminoethyl)-ureido,N′-(2-methanesulfonylaminoethyl)-ureido,N′-[2-(N′-carboxymethylureido)-ethyl]-ureido,N′-[2-(2H-tetrazol-5-yl)-ethyl]-ureido,N′-[4-(2H-tetrazol-5-yl)-butyl]-ureido,N′-[5-(2H-tetrazol-5-yl)-pentyl]-ureido, N′-(5-phosphonopentyl)-ureido,N′-(5-ethoxycarbonylpentyl)-ureido, N′-(3-methanesulfonylpropyl)-ureido,N′-(2-phenylaminoethyl)-ureido or 2-oxo-imidazolidin-1-yl.
 31. Acompound of claim 19, wherein: R⁵ is thienyl, furanyl, imidazolyl,oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, benzothienyl, benzofuranyl,dibenzofuranyl, benzimidazolyl, quinolinyl, isoquinolinyl, indolyl orpyrazinyl, optionally substituted by one or two groups independentlyselected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, formyl, (C₁₋₄alkoxy)carbonyl, phenyl, C₁₋₄ alkylphenyl, phenoxy, halo, C₁₋₄haloalkoxy, carboxy, hydroxy, nitro, amino, C₁₋₄ alkylsulfonyl(C₁₋₄alkyl)ureido, sulfo(C₁₋₄)alkyl, trimethylsilanyl(C₁₋₄)alkoxy(C₁₋₄)alkyland C₁₋₄ alkoxy(C₁₋₄)alkyl.
 32. A compound of claim 31, wherein R⁵ isthien-3-yl, quinolin-7-yl, 3,5-dimethylisoxazol-4-yl,5-chlorothien-2-yl, pyrid-3-yl, pyrimidin-4-yl, quinolin-3-yl,benzothien-2-yl, benzofuran-2-yl, furan-2-yl, furan-3-yl,4-methylpyrid-3-yl, 3-methyl-pyrid-2-yl, 6-methylbenzimidazol-5-yl,benzimidazol-6-yl, 1-methyl-4-(2′-methylphenyl)benzimidazol-6-yl,2-methyl-4-(2′-methylphenyl)benzimidazol-6-yl, dibenzofuran-2-yl,2-methylimidazolyl, 6-ethoxy-benzothiazolyl, 6-methyl-pyrid-3-yl,6-chloro-pyrid-3-yl or 3-chloro-pyrid-2-yl.
 33. A compound of claim 31,wherein R⁵ is 3-methyl-5-nitropyrid-2-yl, 5-amino-3-methylpyrid-2-yl,4-methylpyrimidin-5-yl, 3-methylpyrid-2-yl, 2-chloropyrid-3-yl,6-formylpyrid-2-yl,3-methyl-5-[N′-(3-methanesulfonylprop-1-yl)]-ureidopyrid-2-yl,3-methyl-pyrid-4-yl, 3-amino-5-methyl-pyrid-4-yl,3-chloro-5-trifluoromethylpyrid-2-yl, 1H-benzimidazol-2-yl,1-methyl-1H-benzimidazol-2-yl, 3-methyl-3H-imidazol-4-yl,1H-imidazol-2-yl, 1-methyl-1H-imidazol-2-yl,1-ethyl-1H-benzimidazol-2-yl, 2,5-dimethyl-1H-imidazol-4-yl,1-(3-sulfoprop-1-yl)-1H-benzimidazol-2-yl, 3-methylpyrazin-2-yl,5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-4-yl,5-methyl-1H-benzimidazol-4-yl, 1-methyl-1H-benzimidazol-5-yl,2-methoxymethyl-6-methyl-1H-benzimidazol-5-yl,2,6-dimethyl-1H-benzimidazol-5-yl or 1,6-dimethyl-1H-benzimidazol-5-yl.34. A compound of claim 19, wherein R⁵ is —NR^(a)R^(b), wherein R^(a)and R^(b) are independently C₁₋₆ alkyl, or R^(a) and R^(b) together withthe nitrogen atom to which they are attached form a ring selected fromthe group consisting of piperidinyl, pyrroldinyl, piperazinyl,imidazolidinyl, pyrazolidinyl and morpholinyl, wherein said ring isoptionally substituted by one or two C₁₋₄ alkyl groups.
 35. A compoundof claim 34, wherein R⁵ is piperidin-1-yl or 4-methylpiperazin-1-yl. 36.A compound of claim 1, wherein R⁶ is hydrogen, methyl, halo, amino,methoxy, ethoxy, vinyloxy, hydroxy or benzyloxy.
 37. A compound of claim1, wherein R¹ is bromo, methylthio, ethylthio or prop-2-en-1-ylthio. 38.A compound of claim 37, wherein R¹ is bromo or methylthio.
 39. Acompound of claim 38, wherein R¹ is methylthio.
 40. A compound of claim1, wherein Z is SO₂.
 41. A compound of claim 1, wherein Z is SO.
 42. Acompound of claim 1, wherein R², R³ and R⁴ are independently hydrogen,C₁₋₆ alkyl, amino, cyano, nitro, C₁₋₄ alkoxy or hydroxy.
 43. A compoundof claim 42, wherein R², R³ and R⁴ are all hydrogen.
 44. A compound ofclaim 42, wherein R², R³ and R⁴ are independently hydrogen, methyl,ethyl, propyl, n-butyl, hydroxy, methoxy, or ethoxy.
 45. A compound ofclaim 1, wherein R², R³ and R⁴ are BCO₂R^(w), where R^(w), in eachinstance, is preferably one of C₁₋₄alkyl, C₄₋₇cycloalkyl or benzyl. 46.A compound of claim 45, wherein R², R³ and R⁴ are independentlyhydrogen, methyl, ethyl, propyl, n-butyl, hydroxy, methoxy, ethoxy,cyano, BCO₂CH₃, BCO₂CH₂CH₃ or BCO₂CH₂CH₂CH₃.
 47. A compound of claim 1,wherein R⁷ is hydrogen.
 48. A compound selected from the groupconsisting of:4-[4′-(N′-Hexyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-{4′-[N′-(4-Methanesulfonyl-butyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-{4′-[N′-(3-Methanesulfonyl-propyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-{4′-[N′-(6-Methanesulfonyl-hexyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-{4′-[N′-(5-Methanesulfonyl-pentyl)-guanidino]-2′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[4′-(N′-Acetyl-guanidino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-{4′-Guanidino-2′-[3-(4-methanesulfonyl-butyl)-ureido]-6′-methyl-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinetrifluoroacetate;4-[4′-(4,5-Dihydro-1H-imidazol-2-ylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate;4-(4′-Guanidino-2′-methyl-6′-nitro-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate;4-(6′-Amino-4′-guanidino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate;3-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid methyl ester bis-trifluoroacetate;3-{[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-methylsulfanyl}-propionicacid bis-trifluoroacetate;6-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-biphenyl-2-yl]-ureido}-hexanoicacid;N-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-yl]-4-methanesulfonyl-butyramidebis-trifluoroacetate;5-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-pentanoicacid bis-trifluoroacetate;4-[2′-Methyl-4′-(N-methyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate;6-{N′-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-2-methyl-biphenyl-4-yl]-guanidino}-hexanoicacid;4-{2′-Methyl-4′-[N′-(3-phenyl-propyl)-guanidino]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate;4-[2′-Methyl-4′-(N′-phenethyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate;4-{2′-Methyl-4′-[N′-(3-methyl-butyl)-guanidino]-biphenyl-3-sulfonyl}-5-methylsulfanyl-thiophene-2-carboxamidinebistrifluoroacetate;4-(5-{3-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-yl]-ureido}-pentyloxy)-benzoicacid bistrifluoroacetate;11-[3′-(5-Carbamimidoyl-2-methylsulfanyl-thiophene-3-sulfonyl)-4-guanidino-6-methyl-biphenyl-2-ylcarbamoyl]-undecanoicacid bis-trifluoroacetate;4-(4′-Guanidino-2′-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate;4-[2′-Methyl-4′-(N′-methoxyl-guanidino)-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophene-2-carboxamidinebis-trifluoroacetate; and pharmaceutically-acceptable salts or prodrugsthereof.